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ABSTRACT	  
The	   HIV-­‐1	   pandemic	   continues	   unabated.	   Although	   treatments	   exist	   that	   can	  
substantially	   alleviate	   the	  morbidity	   and	  mortality	   associated	  with	  HIV,	   there	   is	   still	   a	   need	   for	  
improved	   anti-­‐HIV	   treatments	   that	   reduce	   toxicities	   and	   administration	   frequency	   and	  mediate	  
sustained	   inhibition	   of	   viral	   replication.	  Given	   the	   high	  mutability	   and	   variability	   of	   the	   virus,	   a	  
strategy	  that	  is	  garnering	  increasing	  focus	  is	  the	  targeting	  of	  host	  factors	  that	  the	  virus	  requires	  to	  
replicate,	  so-­‐called	  HIV-­‐dependency	  factors	  (HDFs).	  It	  is	  hoped	  this	  will	  reduce	  the	  emergence	  of	  
viral	  drug	  resistance.	  A	  number	  of	  genome-­‐wide	  screens	  have	  been	  performed	  to	  identify	  HDFs,	  
although	  many	  remain	  to	  be	  validated,	  particularly	  in	  relevant	  cells	  lines.	  
An	   objective	   of	   this	   thesis	  was	   to	   validate	   three	   host	   factors	   as	   HDFs,	   in	   both	   TZM-­‐bl	  
reporter	   and	   T	   cell-­‐derived	   cell	   lines,	   and	   to	   examine	   their	   potential	   as	   anti-­‐HIV-­‐1	   therapeutic	  
targets	   through	   exploitation	   of	   the	   cellular	   gene	   silencing	   pathway,	   RNA	   interference	   (RNAi).	  
These	  were	  HIV-­‐1	  Tat	  specific	   factor	  1	   (HTATSF1),	  DEAD	  (Asp-­‐Glu-­‐Ala-­‐Asp)	  box	  polypeptide	  3,	  X-­‐
linked	  (DDX3X)	  and	  SWI/SNF	  related,	  matrix	  associated,	  actin	  dependent	  regulator	  of	  chromatin,	  
subfamily	  b,	  member	  1	  (SMARCB1),	  selected	  because	  they	  had	  been	  previously	  implicated	  in	  HIV-­‐
1	   pathogenesis.	   The	   well-­‐characterised	   HDF,	   PC4	   and	   SFRS1	   interacting	   protein	   1	   (PSIP1)/lens	  
epithelium-­‐derived	   growth	   factor	   (LEDGF)/p75,	  was	   included	   in	   the	   study	   as	   a	   positive	   control.	  
Cassettes	   expressing	   short	   hairpin	   RNAs	   (shRNAs)	   targeting	   the	   four	   host	   proteins	   were	  
generated,	   although	   shRNAs	   did	   not	   suppress	   endogenous	   ddx3x	   mRNA	   levels.	   The	   ability	   of	  
shRNAs	  to	   inhibit	  HIV-­‐1	  replication	   in	   the	  reporter	  cell	   line,	  TZM-­‐bl,	  was	  examined.	  These	  HeLa-­‐
derived	   cells	   are	   permissive	   for	   R5-­‐tropic	   HIV-­‐1	   infection	   and	   contain	   an	   integrated	   luciferase	  
gene	   driven	   by	   the	   viral	   promoter.	   shRNAs	  mediated	   a	   dose-­‐dependent	   inhibition	   of	   luciferase	  
activity	  in	  cells	  infected	  with	  a	  HIV-­‐1	  subtype	  B	  molecular	  clone	  and,	  although	  production	  of	  the	  
viral	  protein	  p24	  was	  unaltered,	  infectious	  particle	  production	  was	  decreased	  in	  cells	  treated	  with	  
a	   shRNA	   suppressing	   HTATSF1.	   Little	   effect	   was	   observed	   with	   a	   shRNA	   targeting	   SMARCB1,	  
suggesting	  that	  this	  may	  not	  function	  as	  an	  HDF	  under	  these	  conditions.	  No	  effect	  on	   infectious	  
particle	  production	  was	  seen	  with	  the	  shRNA	  targeting	  PSIP1,	  which	  was	  a	  result	  of	  the	  long	  half-­‐
life	   of	   this	   protein,	   highlighting	   a	   limitation	   of	   using	   such	   reporter	   systems	   for	   HDF	   validation.	  
Importantly,	  shRNAs	  were	  not	  associated	  with	  any	  cytotoxic	  effects	  in	  TZM-­‐bl	  cells.	  
Whether	  HTATSF1	  is	  a	  potential	  therapeutic	  target	  was	  interrogated	  further	  in	  the	  more	  
relevant	   T	   cell-­‐derived	   SupT1	   cell	   line.	   Lentiviruses	   were	   used	   to	   generate	   populations	   where	  
>90%	   had	   one	   copy	   of	   the	   integrated	   shRNA	   expression	   cassette.	   Replication	   of	   the	   subtype	   B	  
molecular	  clone	  p81A-­‐4	  was	  significantly	   inhibited	   in	   the	  shH1-­‐expressing	  SupT1	  cell	   line,	  which	  
targets	  HTATSF1,	   for	  over	  14	  days	  post-­‐infection,	  although	   inhibition	  was	  not	  as	  pronounced	  as	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that	  observed	  in	  the	  shP1-­‐expressing	  SupT1	  cell	  line,	  which	  targets	  PSIP1.	  In	  contrast	  to	  a	  previous	  
report,	   no	   change	   in	   the	   ratio	   of	   unspliced	   to	   singly-­‐	   or	  multiply-­‐spliced	  HIV-­‐1	   transcripts	  were	  
detected	  in	  shH1-­‐expressing	  SupT1	  cells,	  suggesting	  that	  HTATSF1	  does	  not	  function	  as	  a	  splicing	  
cofactor	  in	  this	  system.	  A	  slight	  rebound	  in	  p24	  levels	  at	  14	  days	  post-­‐infection	  was	  accompanied	  
by	   increased	   HTATSF1	   expression	   and	   a	   decrease	   in	   the	   percentage	   of	   cells	   with	   transgene	  
expression	  in	  the	  population.	  In	  addition,	  there	  was	  a	  slight	  decrease	  in	  shH1-­‐derived	  guide	  strand	  
expression,	  but	  no	  change	  in	  transcription	  rates	  of	  the	  htatsf1	  gene,	  suggesting	  that	  cells	  within	  
the	  population	  with	  shH1	  expression	  and	  HTATSF1	  suppression	  may	  have	  a	  growth	  disadvantage.	  
Thus,	  although	  this	  work	  demonstrates	   for	   the	  first	   time	  that	  HTATSF1	  functions	  as	  an	  HDF	   in	  T	  
cell-­‐derived	  SupT1	  cells,	  it	  may	  not	  constitute	  a	  viable	  therapeutic	  target.	  
A	   second	   objective	   of	   this	   thesis	   was	   to	   examine	   the	   feasibility	   of	   transcriptional	   gene	  
silencing	   (TGS)	   of	   HDFs	   as	   an	   anti-­‐HIV	   strategy.	   TGS	   is	   a	   small	   RNA-­‐induced	   gene	   silencing	  
pathway	   that	  operates	   through	  chromatin	   remodelling	  with	   the	  potential	   to	  mediate	   long-­‐term	  
silencing	   of	   gene	   expression.	   Thus,	   its	   application	   may	   reduce	   the	   frequency	   of	   drug	  
administration	   and	   associated	   toxicities.	   Short	   interfering	   RNAs	   (siRNAs)	   targeting	   the	   htatsf1	  
promoter	  were	   able	   to	   reduce	   target	  mRNA	   expression,	  which	  was	   accompanied	   by	   decreased	  
htatsf1	  transcription	  rates	  in	  HEK293T	  cells,	  suggesting	  silencing	  via	  a	  TGS	  mechanism.	  The	  htatsf1	  
silencing	   inhibited	   infectious	   HIV-­‐1	   particle	   production	   from	   TZM-­‐bl	   cells.	   This	   work	   provides	  
proof	  of	  principle	  that	  TGS	  induction	  at	  a	  HDF	  may	  inhibit	  HIV-­‐1	  replication.	  
siRNAs	   targeting	   the	   ddx3x	   promoter	   did	   not	   induce	   TGS.	   To	   examine	   whether	   gene	  
susceptibility	   to	   TGS	  may	   be	   influenced	   by	   promoter	   architectures,	   49	   promoter	   features	  were	  
examined	  for	  enrichment	   in	  genes	  at	  which	  small	  RNA-­‐induced	  TGS	  has	  been	  reported.	   Initially,	  
the	  TGS	  group	  was	  compared	  to	  a	  random	  set	  of	  2,000	  promoters	  and	  then	  all	  other	  promoters	  in	  
the	  genome.	  To	  control	  for	  gene	  activation,	  two	  further	  analyses	  were	  performed	  comparing	  the	  
TGS	  group	  features	  to	  those	  from	  promoters	  active	  in	  the	  THP-­‐1	  cell	  line	  and	  housekeeping	  genes.	  
Whilst	  difficult	  to	  ascribe	  differences	  between	  the	  TGS	  group	  and	  the	  control	  groups	  to	  anything	  
beyond	  a	  variation	  in	  the	  proportion	  of	  active	  genes	  within	  each	  group,	  there	  was	  enrichment	  for	  
certain	  promoter	   features	  that	  are	   independent	  of	  activity;	   the	  TGS	  group	  was	  characterised	  by	  
broad	  transcription	  start	  regions,	  high	  CpG	  content	  and	  a	  single	  expression	  profile.	  Moreover,	  the	  
fraction	  of	  promoters	  with	  reported	  non-­‐coding	  RNA	  overlap	  was	  greater	   in	  the	  TGS	  group	  than	  
the	   control	   groups.	   Thus,	   there	   is	   some	   evidence	   that	   a	   number	   of	   promoter	   features	   are	  
associated	  with	  TGS	  susceptibility.	  It	  is	  hoped	  this	  novel	  analysis	  will	  facilitate	  selection	  of	  future	  
TGS	   targets,	   including	   HDFs.	   In	   summary,	   the	   work	   presented	   in	   this	   thesis	   paves	   the	   way	   for	  
development	   of	   improved	   anti-­‐HIV	   therapies	   involving	   HDF-­‐targeted	   TGS-­‐based	   gene	   therapies	  
that	  mediate	  sustained	  inhibition	  of	  the	  virus.	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Human	   immunodeficiency	   virus	   (HIV)	   is	   the	   aetiological	   agent	   of	   acquired	   immune	  
deficiency	   syndrome	   (AIDS),	   which	   is	   characterised	   by	   immune	   dysfunction	   and	   death	  
approximately	   11	   years	   post-­‐infection	   in	   the	   absence	   of	   treatment	   (UNAIDS/WHO	   2009).	   It	   is	  
currently	   estimated	   that	   33.3	   million	   people	   are	   infected	   worldwide,	   with	   2.6	   million	   new	  
infections	   and	   1.8	   million	   AIDS-­‐related	   deaths	   in	   2009	   (www.unaids.org/globalreport/).	   Sub-­‐
Saharan	  Africa	  bears	   an	   inordinate	   share	  of	   the	  global	  HIV	  burden	  with	  68%	  of	   infections,	  with	  
South	  Africa	  housing	  the	  largest	  epidemic	  of	  any	  country	  –	  5.6	  million	  in	  2009.	  Although	  HIV	  has	  
been	  the	  most	  intensely	  studied	  infectious	  agent	  since	  its	  identification	  in	  1983	  (Gallo	  et	  al.	  1983),	  
a	  preventative	   vaccine	  or	  post-­‐infection	   cure	   remains	  elusive.	   This	  may	  be	   largely	   attributed	   to	  
the	   high	   variability	   of	  HIV	   –	   not	   only	   does	   this	   facilitate	   the	   emergence	   of	   drug	   resistance	   and	  
escape	  from	  the	  immune	  system,	  but	  it	  also	  hampers	  the	  design	  of	  treatments/vaccines	  that	  are	  
effective	  against	  all	  circulating	  viruses.	  
Although	  currently	  available	  drugs	   to	   treat	   the	   infection	  are	  highly	  effective	  at	   reducing	  
HIV-­‐related	  deaths,	  they	  require	  chronic,	  daily	  administration	  to	  be	  effective.	  Treatment	  success	  
is	  tightly	  correlated	  with	  patient	  compliance,	  which	  can	  be	  poor	  as	  a	  result	  of	  toxic	  side	  effects	  of	  
the	  drugs	  and	  accessibility	  of	  chronic	  treatment.	  This	  could	  be	  dramatically	  improved	  through	  the	  
use	   of	   a	   single	   intervention	   therapy	   that	   would	   aid	   the	   patient	   for	   life.	   Gene	   therapy	   has	   the	  
potential	   to	   provide	   a	   solution,	   although	   existing	   single-­‐intervention	   anti-­‐HIV	   gene	   therapy	  
strategies	   require	  complex	  and	  expensive	  engraftments.	  Those	  not	  delivered	  by	   transplantation	  
are	   subject	   to	   concerns	   with	   respect	   to	   chronic	   administration	   and	   toxicity.	   However,	   a	  
mammalian	  pathway,	  small	  RNA-­‐induced	  transcriptional	  gene	  silencing	  (TGS),	  has	  the	  potential	  to	  
mediate	   durable	   target	   silencing.	   Gene	   therapies	   based	   on	   TGS	   may,	   therefore,	   reduce	  
administration	   frequency	  and	   toxicity	  without	   the	  need	   for	  expensive	  procedures,	  which	  would	  
be	  of	  particular	  benefit	  to	  resource-­‐poor	  settings.	  
Reduction	   in	   the	   emergence	   of	   viral	   resistance	   would	   also	   improve	   current	   treatment	  
regimens.	   Inhibitors	  of	   cellular	   factors	   that	  HIV	   requires	   for	   replication	  will	   increase	   the	  genetic	  
barrier	  to	  viral	  escape,	  and	  so	  may	  provide	  a	  powerful	  addition	  to	  existing	  antiviral	  therapeutics.	  
To	  this	  end,	  there	  are	  substantial	  efforts	  being	  employed	  to	  identify	  host	  factors	  involved	  in	  HIV-­‐1	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replication	  and	   validate	   them	  as	   therapeutic	   targets,	   by	   showing	   that	   their	   suppression	   inhibits	  
viral	  replication	  without	  toxic	  side	  effects	  to	  the	  host.	  
The	   ultimate	   goal	   of	   the	   work	   described	   in	   this	   thesis	   was	   to	   contribute	   to	   the	  
development	  of	   improved	  HIV	   therapeutics	  with	   reduced	   toxicity,	  administration	   frequency	  and	  
viral	   resistance.	  This	  was	  accomplished	  through	  validating	  the	  therapeutic	  potential	  of	   targeting	  
host	   factors,	   by	   assessing	   how	   their	   suppression	   affects	   viral	   replication	   and	   cytotoxicity,	   and	  
examination	  of	   their	   susceptibility	   to	   suppression	  by	   small	  RNA-­‐induced	  TGS.	   Thus,	   this	   general	  
introduction	  will	  examine	  how	  the	  variability	  of	  HIV	  impedes	  clearance	  of	  the	  virus,	  emphasising	  
the	  rationale	  behind	  therapies	  designed	  to	  target	  cellular	  factors	  involved	  in	  viral	  replication.	  The	  
RNA	   interference	   (RNAi)	   pathway	  will	   be	  described	  and	  how	  exploitation	  of	   this	   powerful	   gene	  
silencing	  mechanism	  can	   facilitate	   identification	  of	  host	  proteins	   required	   for	  completion	  of	   the	  
HIV	  life	  cycle	  and	  interrogate	  their	  therapeutic	  potential.	  The	  capacity	  of	  TGS	  to	  provide	  a	  durable	  
gene	   therapy	   will	   be	   discussed	   and,	   finally,	   the	   putative	   roles	   in	   HIV-­‐1	   replication	   of	   various	  
cellular	  factors	  and	  their	  potential	  as	  anti-­‐HIV	  therapeutic	  targets.	  
	  
1.2	  Human	  immunodeficiency	  virus	  
	  
1.2.1	  HIV	  origins	  
	  
HIV	   is	   a	   member	   of	   the	   Lentivirus	   genus	   and	   the	   Retroviridae	   family	   and	   isolates	   are	  
currently	  grouped	  into	  two	  types,	  HIV-­‐type	  1	  (HIV-­‐1)	  and	  -­‐type	  2	  (HIV-­‐2).	  HIV-­‐2	  is	  largely	  restricted	  
to	  Western	  and	  Central	  Africa,	   reflecting	   the	  geographical	  distribution	  of	   the	  primate	   reservoir,	  
the	  sooty	  mangabey	  (Van	  Heuverswyn	  and	  Peeters	  2007;	  Wain	  et	  al.	  2007).	  In	  contrast,	  the	  HIV-­‐1	  
primate	   reservoir	   was	   a	   great	   ape,	   the	   chimpanzee,	   not	   a	   monkey	   (Wain	   et	   al.	   2007).	   HIV-­‐1	  
dominates	   the	  global	  epidemic,	  which	  may	   relate	   to	   the	  apparent	  decreased	  virulence	  of	  HIV-­‐2	  
(Whittle	  et	  al.	  1994).	  
HIV-­‐1	  is	  further	  subdivided	  into	  three	  major	  groups,	  which	  arose	  from	  three	  independent	  
ape-­‐to-­‐human	  transmissions:	  major	  (M),	  outlier	  (O)	  and	  non-­‐M/non-­‐O	  (N).	  These	  three	  groups	  are	  
as	   distinct	   from	   each	   other	   as	   they	   are	   from	   the	   lentivirus	   causing	   immunodeficiency	   in	  
chimpanzees,	   termed	  simian	   immunodeficiency	  virus	  of	  chimpanzees	   (SIVcpz)	   (Gao	  et	  al.	  1999).	  
Group	   M	   includes	   nine	   subtypes,	   or	   clades,	   designated	   A	   to	   K	   based	   on	   genomic	   sequence	  
homology.	  In	  Southern	  and	  East	  Africa,	  HIV-­‐1	  subtype	  C	  is	  the	  most	  prevalent	  virus,	  accounting	  for	  
48%	   of	   global	   infections,	   whilst	   subtype	   B	   is	   the	   most	   represented	   virus	   in	   North	   and	   South	  
America,	   Central	   and	   Western	   Europe	   and	   Australia,	   accounting	   for	   15%	   of	   global	   infections	  
(UNAIDS	  2008).	  Viruses	  of	  different	  subtypes	  may	  infect	  the	  same	  cell	  and	  share	  genetic	  material	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resulting	   in	   recombinant	   forms.	   Those	  mosaic	   viruses	   able	   to	   replicate	   and	   be	   transmitted	   are	  
termed	   circulating	   recombinant	   forms	   (CRFs),	   and	   those	   that	   do	   not	   spread	   from	   their	   original	  
location,	  unique	  recombinant	  forms	  (URFs)	  (Carr	  et	  al.	  2001).	  
	  
1.2.2	  HIV	  genome	  organisation	  
	  
The	   HIV	   genome	   encodes	   structural	   proteins	   and	   enzymes	   common	   to	   retroviruses.	   In	  
addition,	  lentiviruses,	  such	  as	  HIV,	  encode	  a	  number	  of	  regulatory	  and	  accessory	  proteins.	  The	  HIV	  
virion	  contains	  two	  identical	  copies	  of	  positive	  single-­‐stranded	  (ss)	  RNA	  molecules	  containing	  the	  
genes	   gag	   (group-­‐specific	   antigen),	   pol	   (polymerase)	   and	   env	   (envelope)	   (Figure	   1.1A).	   These	  
encode	   structural	   proteins	   of	   the	   core	   and	   matrix,	   enzymes	   critical	   for	   replication	   and	   viral	  
envelope	  glycoproteins,	   respectively.	  Along	  with	  host-­‐derived	   lipoprotein-­‐rich	  membrane,	   these	  
components	  form	  enveloped	  viral	  particles	  with	  a	  diameter	  of	  ~120	  nm	  (Figure	  1.1B).	  
The	  gag	  gene	  encodes	  Pr55Gag,	  a	  polyprotein	  precursor	  that	  is	  cleaved	  by	  the	  intrinsic	  viral	  
protease	  (PR)	  to	  produce	  proteins	  matrix	  (MA/p17),	  capsid	  (CA/p24)	  and	  nucleocapsid	  (NC/p6	  &	  
p7)	   (Ganser-­‐Pornillos	   et	   al.	   2008).	   The	   pol	   gene	   products	   are	   also	   initially	   synthesised	   as	   a	  
polyprotein	  precursor,	  Pr160GagPol	  that,	  as	  the	  name	  implies,	  includes	  both	  translated	  gag	  and	  pol	  
regions	  following	  a	  rare	  frameshift	  event	  during	  Pr55Gag	  translation.	  PR	  again	  releases	  the	  mature	  
proteins,	   resulting	   in	   the	  enzymes	  PR,	   reverse	   transcriptase	   (RT;	   p66	  and	  p51	   subdomains)	   and	  
integrase	  (IN)	  (Moulard	  and	  Decroly	  2000;	  Hill	  et	  al.	  2005).	  Unlike	  the	  Gag	  and	  Pol	  precursors,	  the	  
polyprotein	   encoded	   by	   the	   env	   gene,	   gp160,	   is	   processed	   by	   cellular	   proteases	   (Moulard	   and	  
Decroly	  2000;	  Hill	  et	  al.	  2005).	  This	  occurs	  during	  trafficking	  of	  gp160	  to	  the	  cell	  surface,	  forming	  
gp120,	   which	   is	   exposed	   on	   the	   virion	   surface	   and	   interacts	   with	   receptors,	   and	   gp41,	   which	  
constitutes	  the	  transmembrane	  domain	  and	  contains	  elements	  that	  are	  important	  for	  membrane	  
fusion.	  gp120	  and	  gp41	  both	  form	  trimers	  that	  associate	  non-­‐covalently	  to	  form	  heterodimers.	  
Reverse	   transcription	   of	   the	   RNA	   genome	   generates	   proviral	   DNA	   with	   long	   terminal	  
repeats	   (LTRs)	   flanking	   the	  coding	   region.	  These	  LTRs	  are	  divided	   into	  3	   regions:	  unique,	  3’	  end	  
(U3),	  repeated	  (R)	  and	  unique,	  5’	  end	  (U5).	  Incomplete	  LTRs,	  composed	  of	  just	  R/U5	  and	  U3/R	  are	  
present	   at	   the	   5’	   and	   3’	   ends	   of	   the	   RNA	   genome,	   respectively	   (Figure	   1.1A).	   Transcription	  
predominantly	   initiates	   from	   the	   provirus	   5’	   U3/R	   junction	   and,	   consequently,	   the	   U3	   region	  
contains	  a	  number	  of	  enhancer	  elements,	  including	  transcription	  factor	  binding	  sites	  and	  a	  TATA	  
box	   (Patarca	  et	  al.	  1987;	  Roebuck	  and	  Saifuddin	  1999).	  Basal	   transcriptional	  activity	   is	  very	   low,	  
however,	   but	   is	   increased	  by	  more	   than	   two	   logs	   in	   the	  presence	  of	   the	   regulatory	  protein	  Tat	  
(transcriptional	  transactivator)	  (Dayton	  et	  al.	  1986;	  Fisher	  et	  al.	  1986),	  which	  is	  encoded	  by	  a	  two-­‐
exon	  RNA	  (Figure	  1.1A).	  Tat	  acts	  upon	  the	  transactivation	  response	  region	  (TAR)	  (Berkhout	  et	  al.	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1989),	  a	  stem-­‐loop	  structure	  encoded	  in	  the	  R	  region	  and	  present	  at	  the	  5’	  end	  of	  all	  viral	  RNAs.	  
Another	   regulatory	  gene,	   rev	   (regulator	  of	  viral	  gene	  expression),	  encodes	  a	  protein	   involved	   in	  
the	  nuclear	   export	   of	   unspliced	   and	  partially	   spliced	   viral	   transcripts	   that	   characterise	   the	   later	  
stages	  of	  viral	  gene	  expression	  (Jeang	  et	  al.	  1991).	  
	  
	  
Figure	   1.1:	   HIV-­‐1	   genome	   organisation.	   A.	   The	   HIV-­‐1	   genome	   is	   composed	   of	   nine	   genes,	   three	   of	   which	   encode	  
polyprotein	  precursors.	  Pr55Gag	  and	  Pr160GagPol	  are	  processed	  by	  the	  viral	  protease	  (PR)	  to	  produce	  structural	  proteins	  
and	  enzymes,	   respectively.	   The	  polyprotein	   product	   of	   the	  env	   gene,	   gp160,	   is	   cleaved	  by	  host	   cellular	   proteases	   to	  
produce	  envelope	  glycoproteins	  gp120	  and	  gp41.	  The	  genome	  includes	  genes	  encoding	  two	  regulatory	  proteins	  tat	  and	  
rev,	  and	  four	  accessory	  proteins	  vif,	  vpr,	  vpu	  and	  nef.	  LTRs	  are	  not	  present	  in	  the	  RNA	  genome	  and	  only	  in	  the	  proviral	  
DNA	   following	   duplication	   of	   U3	   and	   U5	   sequences	   during	   the	   reverse	   transcription	   process.	  B.	   Schematic	   of	   a	   HIV	  
virion,	  an	  enveloped	  lentivirus	  of	  ~120	  nm	  in	  diameter.	  
	  
Four	   accessory	   proteins	   are	   encoded	   in	   the	   HIV-­‐1	   genome,	   including	   Nef	   (negative	  
effector/necessary	  factor),	  Vif	  (viral	  infectivity	  factor),	  Vpr	  and	  Vpu	  (viral	  proteins	  R	  and	  U)	  (Figure	  
1.1A).	   These	   proteins	   carry	   out	   various	   functions	   that	   enhance	   infectivity,	   in	   particular	   Nef	  
[reviewed	  in	  (Emerman	  and	  Malim	  1998;	  Arhel	  and	  Kirchhoff	  2009;	  Nomaguchi	  and	  Adachi	  2009;	  
Dube	  et	  al.	  2010a;	  Jere	  et	  al.	  2010)].	  Of	  note,	  Vpr	  is	  involved	  in	  cell	  cycle	  arrest	  and	  enables	  the	  
reverse	   transcribed	   viral	   DNA	   to	   access	   the	   nucleus,	   resulting	   in	   productive	   infection,	   in	   non-­‐
dividing	  cells	  such	  as	  macrophages	  (Andersen	  et	  al.	  2008).	  Neither	  mature	  regulatory	  or	  accessory	  
proteins	  require	  proteolytic	  cleavage	  for	  their	  production.	  
	  
1.2.3	  HIV	  life	  cycle	  
	  
HIV	   infects	   and	   replicates	   in	   human	   CD4+	   T	   cells	   and	   macrophages	   (Figure	   1.2).	   Viral	  
particles	   bind	   to	   surface	   CD4,	   a	   58	   kDa	   type	   I	   integral	   cell	   surface	   glycoprotein,	   triggering	   a	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conformational	  change	  that	  exposes	  a	  binding	  surface	  on	  gp120	  for	  chemokine	  receptors	  (Liu	  et	  
al.	  2008).	  At	  least	  17	  chemokine	  receptors	  have	  been	  identified	  as	  functioning	  as	  HIV	  coreceptors	  
(Alkhatib	   and	   Berger	   2007),	   although	   the	   α-­‐chemokine	   receptor,	   chemokine	   (C-­‐X-­‐C	   motif)	  
receptor	   type	  4	   (CXCR4),	  and	  the	  β-­‐chemokine	  receptor,	  chemokine	   (C-­‐C	  motif)	   receptor	   type	  5	  
(CCR5),	  appear	  to	  predominate	   in	  vivo.	  CCR5	  is	  expressed	  on	  macrophages,	  dendritic	  cells	  (DCs),	  
brain	  cells	  and	  activated	  lymphocytes,	  while	  CXCR4	  is	  expressed	  in	  resting	  T	  cells	  and	  monocytes	  
(Lusso	  2000).	  This	  differential	  distribution	  of	  coreceptors	   is	   important	   in	  determining	  tropism	  of	  
viruses:	  those	  preferentially	  using	  CCR5	  are	  termed	  M	  (for	  macrophage)-­‐tropic,	  or	  R5	  viruses,	  and	  
those	  preferentially	  using	  CXCR4,	  T	  (for	  T	  lymphocyte)-­‐tropic,	  or	  X4	  viruses	  (Agrawal	  et	  al.	  2009).	  
Viruses	  able	  to	  use	  both	  CCR5	  and	  CXCR4	  for	  entry	  are	  termed	  dual	  tropic,	  or	  R5X4	  viruses.	  
gp120	   interaction	   with	   a	   chemokine	   receptor	   causes	   conformational	   changes	   allowing	  
gp41	  to	  insert	  itself	  into	  the	  host	  cell	  membrane,	  effecting	  membrane	  fusion	  (Campbell	  and	  Hope	  
2008).	  About	  four	  to	  six	  CCR5	  coreceptors	  are	  required	  for	  viral	  fusion	  to	  occur	  (Kuhmann	  et	  al.	  
2000).	  The	  capsid	  is	  then	  injected	  into	  the	  cytoplasm	  and	  shuttles	  toward	  the	  nuclear	  membrane,	  
during	  which	  time	  reverse	  transcription	  takes	  place	  (Arhel	  et	  al.	  2007).	  Reverse	  transcription	  is	  a	  
complex	  process	   catalysed	  by	   the	   viral	   RT,	   a	  heterodimer	  of	   two	   subunits,	   p51	  and	  p66.	  p51	   is	  
encoded	   by	   the	   same	   sequence	   as	   p66	   but	   lacks	   the	   C-­‐terminal	   RNaseH	   domain	   (through	   PR	  
activity),	  yet	  adopts	  a	  very	  different	  structure	  to	  p66	  (Seckler	  et	  al.	  2009).	  Reverse	  transcription	  is	  
initiated	   by	   a	   transfer	   RNA	   (tRNA)	   primer	   and	   proceeds	   in	   a	   series	   of	   steps	   including	   DNA	  
synthesis	  and	  RNA	  degradation	  that	  utilise	  a	  number	  of	  cis-­‐elements	  in	  the	  viral	  genome.	  A	  ~100	  
nt	   DNA	   ‘flap’	   within	   the	   plus-­‐strand	   DNA	   is	   generated	   during	   the	   final	   stage	   of	   reverse	  
transcription	   which	   is	   critical	   for	   uncoating	   and	   nuclear	   import	   of	   the	   viral	   pre-­‐integration	  
complex	  (PIC)	  (Arhel	  et	  al.	  2007).	  
The	  mechanism	  by	  which	  HIV	  overcomes	  the	  nuclear	  pore	  diffusion	  size	  limit	  and	  the	  DNA	  
concentration	   gradient	   to	   import	   the	   PIC	   into	   the	   nucleus	   remains	   unclear.	   Nevertheless,	   the	  
central	   polypurine	   tract	   (cPPT),	   IN,	   Vpr	   and	   a	   nuclear	   localisation	   signal	   in	   MA,	   have	   all	   been	  
shown	  to	  play	   roles	   in	   import.	   Importin	  7	  has	  been	  shown	  to	  mediate	  PIC	   import	   (Fassati	   et	  al.	  
2003)	  in	  a	  HIV-­‐specific	  manner	  that	  is	  dependent	  on	  IN	  binding	  (Zaitseva	  et	  al.	  2009).	  In	  addition,	  
tRNAs	  were	   shown	   to	   promote	  nuclear	   import	   (Zaitseva	   et	   al.	   2006),	   although	   the	  host	   factors	  
involved	  in	  this	  process	  have	  yet	  to	  be	  identified.	  
Once	  the	  PIC	  reaches	  the	  nucleus,	  with	  the	  aid	  of	  the	  viral	  enzyme	  IN,	  the	  DNA	  molecule	  
is	   incorporated	   into	   human	  DNA	   (Figure	   1.3).	   The	  main	  DNA	   cleaving	   and	   joining	   steps	   are	   the	  
initial	   removal	   of	   a	   terminal	   dinucleotide	   from	   each	   end	   of	   the	   reverse	   transcribed	   cDNA	   (3’	  
processing)	  and	  strand	  transfer.	  The	  latter	  is	  a	  single-­‐step	  transesterification	  reaction	  in	  which	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Figure	  1.2:	  The	  basic	  steps	  of	  the	  HIV	  life	  cycle.	  Following	  binding	  (1)	  of	  the	  virus	  to	  the	  cell	  surface	  via	  its	  receptor	  CD4,	  association	  with	  a	  coreceptor,	  typically	  CCR5	  or	  CXCR4,	  leads	  to	  virus	  
and	  host	  cell	  membrane	  fusion	  (2).	  Uncoating	  (3)	  and	  reverse	  transcription	  (4)	  of	  the	  RNA	  genome	  precedes	  nuclear	  import	  of	  a	  dsDNA	  molecule	  that	  is	  integrated	  (5)	  into	  the	  host	  genomic	  
DNA.	  The	  integrated	  proviral	  DNA	  then	  hijacks	  the	  host	  cellular	  transcription	  machinery	  for	  expression	  of	  different	  classes	  of	  RNA	  transcripts,	  determined	  by	  the	  degree	  of	  splicing	  (6).	  Nuclear	  
export	  (7)	  of	  these	  transcripts	  allow	  their	  translation	  (8)	  and,	  where	  required,	  protease	  cleavage	  (9).	  Unspliced	  transcripts	  are	  combined	  with	  viral	  proteins	  in	  virus	  assembly	  at	  the	  host	  cell	  
membrane	  with	  subsequent	  budding	  (10)	  of	  new	  virions	  from	  the	  cell	  surface.	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staggered	  cleavage	  of	  opposite	  target	  DNA	  strands	  provides	  the	  energy	  to	  join	  the	  newly	  recessed	  
viral	  3’	  ends	  to	  them	  (Brown	  et	  al.	  1987).	   In	  the	  third	  main	  step	  of	  integration,	  gap	  repair,	  extra	  
nucleotides	  are	  trimmed	  from	  the	  5’	  ends	  of	  the	  viral	  cDNA	  and	  these	  are	  joined	  to	  host	  DNA	  3’	  
ends.	  This	  step	   involves	  host	  cell	  DNA	  repair	  enzymes	  (Skalka	  and	  Katz	  2005).	   In	  addition	  to	  the	  
integration	   reaction,	   non-­‐homologous	   end	   joining	   and	   homologous	   recombination	   cellular	  
pathways	  are	  involved	  in	  the	  formation	  of	  1-­‐	  and	  2-­‐LTR	  circles	  that	  are	  detected	  in	  the	  nuclei	  of	  
infected	  cells	  (Li	  et	  al.	  2001).	  
	  
Figure	   1.3:	   The	   HIV	   integrase	   reaction.	  A	   blunt-­‐ended,	   linear	   viral	   genome	   cDNA	   is	   the	   precursor	   to	   integration.	   3’	  
processing	  generates	  a	   recessed	  CA	  at	   the	  3’	  end.	  Binding	   to	  host	  DNA	   is	   followed	  by	  a	   concerted	   transesterifcation	  
reaction.	  The	  process	   is	  completed	  by	  the	  third	  main	  step,	  gap	  repair,	  yielding	  a	  duplication	  of	  host	  DNA	  flanking	  the	  
provirus	  (ie	  five	  bases,	  shown	  here	  by	  circles).	  Host	  cell	  DNA	  repair	  enzymes	  are	  involved	  in	  this	  step.	  
	  
Proviral	   DNA	   can	   remain	   quiescent	   for	   extended	   periods	   or	   become	   transcriptionally	  
active,	  particularly	  where	  there	  is	   inflammation	  (Staal	  et	  al.	  1990).	  As	  previously	  mentioned,	  Tat	  
regulates	  proviral	  transcription.	  In	  the	  absence	  of	  Tat,	  RNA	  polymerase	  (Pol)	  II	  is	  recruited	  to	  the	  
LTR	  through	  TATA-­‐binding	  protein	  (TBP)	  but	  productive	  elongation	  is	  largely	  absent	  because	  of	  a	  
lack	  of	  RNA	  Pol	   II	   C-­‐terminal	  domain	   (CTD)	  phosphorylation.	   The	   few	  protein-­‐coding	   transcripts	  
that	   are	   produced	   during	   this	   Tat-­‐independent	   phase	   result	   in	   sufficient	   Tat	   to	   activate	  
transcription.	   Tat	   binds	   to	   the	   TAR	   loop	   and	   recruits	   positive	   transcription	   elongation	   factor	   b	  
(pTEF-­‐b)	   through	   an	   association	   with	   the	   cyclin	   T1	   subunit	   (Richter	   et	   al.	   2002).	   The	   cyclin-­‐
dependent	  kinase	  9	  (CDK9)	  catalytic	  domain	  of	  pTEF-­‐b	  is	  then	  brought	  into	  proximity	  with	  RNA	  Pol	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II	   and	   can	   phosphorylate	   serines	   2	   and	   5	   of	   the	   RNA	   Pol	   II	   CTD	   (Parada	   and	   Roeder	   1996),	  
alleviating	  the	  elongation	  stall.	  HIV-­‐1	  transcription	  is	  further	  regulated	  through	  the	  interaction	  of	  
transcription	  factors,	  including	  nuclear	  factor	  (NF)-­‐κB,	  with	  binding	  sites	  in	  the	  LTR	  (Williams	  et	  al.	  
2007).	   Binding	   of	   such	   host	   factors	   promotes	   transcription	   through	   induction	   of	   nucleosome	  
remodelling	  (He	  et	  al.	  2002).	  
There	   are	   three	   classes	   of	   protein-­‐coding	   HIV-­‐1	   transcripts:	   (1)	   ~9	   kb	   unspliced,	   which	  
function	   as	   Pr55Gag	   and	   Pr160GagPol	   precursors	   and	   virion	   genomes;	   (2)	   ~4	   kb	   partially	   spliced,	  
termed	   singly	   spliced,	   which	   encode	   Env,	   Vif,	   Vpr	   and	   Vpu;	   and,	   (3)	   ~2	   kb	   abundantly	   spliced,	  
often	  termed	  fully	  spliced,	  which	  encode	  Tat,	  Rev	  and	  Nef.	  The	  prevailing	  view	  is	  that	  Rev	  binding	  
to	  the	  Rev	  responsive	  element	  (RRE)	  shepherds	  intron-­‐containing	  unspliced	  and	  singly	  spliced	  HIV	  
transcripts	   from	  the	  nucleus	   to	   the	  cytoplasm,	  which	  would	  normally	  be	  degraded.	   In	  doing	  so,	  
Rev	   interacts	   with	   chromosome	  maintenance	   region	   1	   (CRM1)	   (Bogerd	   et	   al.	   1998),	   utilising	   a	  
shuttling	   pathway	   normally	   employed	   for	   export	   of	   proteins,	   small	   nuclear	   RNAs	   (snRNAs)	   and	  
ribosomal	  RNAs	  (rRNAs)	  (Fornerod	  et	  al.	  1997).	  The	  Rev-­‐CRM1	  pathway	  is	  distinct	  from	  that	  used	  
to	  export	  fully	  spliced	  HIV-­‐1	  messenger	  RNAs	  (mRNAs)	  and	  cellular	  mRNAs	  (Clouse	  et	  al.	  2001).	  In	  
this	  way,	  Rev	  regulates	  a	  key	  switch	  between	  the	  early	  pattern	  of	  HIV	  gene	  expression,	  in	  which	  
short,	  multiply-­‐spliced	  mRNAs	  encoding	  the	  viral	  regulatory	  genes	  Tat,	  Rev	  and	  Nef	  are	  exported	  
from	   the	   nucleus,	   and	   the	   late	   pattern,	   in	   which	   larger,	   singly	   spliced	   and	   unspliced	   RNAs	  
encoding	  the	  viral	  structural	  proteins	  and	  the	  RNA	  genomes	  of	  progeny	  virions	  are	  exported.	  
Following	  translation	  of	  HIV	  transcripts	  in	  the	  cytoplasm,	  viral	  proteins	  accumulate	  at	  the	  
cell	   surface.	   Genomic	   RNA	   encapsidation	   is	   directed	   by	   a	   cis-­‐acting	   sequence	   known	   as	   the	  
packaging	   signal,	   or	  Ψ-­‐site	   (Berkowitz	   et	   al.	   1996),	  which	   interacts	  with	  NC.	   Initially,	   immature	  
virions	   are	   formed,	   characterised	  by	   incomplete	   spherical	   capsids	   composed	  of	   the	  polyprotein	  
Gag	  in	  a	  hexagonal	  lattice	  (Briggs	  et	  al.	  2009).	  Virion	  maturation	  results	  from	  sequential	  cleavage	  
of	  Gag	  by	  PR,	  which	  causes	  a	  rearrangement	  of	  the	  capsid	  to	  a	  conical	  structure,	  composed	  solely	  
of	  CA	  (Wiegers	  et	  al.	  1998;	  Briggs	  et	  al.	  2003).	  Prior	  to	  formation	  of	  complete	  Gag	  spheres,	  cellular	  
factors,	   including	   the	   endosomal	   sorting	   complex	   required	   for	   transport	   (ESCRT)	   machinery,	  
promote	   HIV-­‐1	   virion	   budding	   (Carlson	   et	   al.	   2008)	   whilst	   restriction	   of	   budding	   by	  
CD137/tetherin	   is	  antagonised	  by	  Vpu	  (Neil	  et	  al.	  2008;	  Dube	  et	  al.	  2010b).	  Virion	  maturation	   is	  
thought	  to	  occur	  during	  or	  shortly	  after	  particle	  release	  from	  the	  plasma	  membrane.	  
	  
1.2.4	  HIV	  pathogenesis	  
	  
Within	  a	  few	  weeks	  of	  infection,	  there	  is	  a	  high	  level	  of	  HIV	  replication	  in	  the	  blood	  that	  
can	  exceed	  ten	  million	  viral	  particles	  per	  microlitre	  of	  plasma	  (Simon	  and	  Ho	  2003).	  Concomitant	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with	   this	   is	   a	   decline	   in	   the	   numbers	   of	   CD4+	   T	   lymphocytes.	  However,	  within	   a	   few	  weeks	   an	  
immune	  response	  to	  HIV	  develops	  that	  curtails	  viral	  replication,	  resulting	  in	  a	  decline	  in	  the	  viral	  
load	  and	  a	  return	  of	  CD4+	  T	  cell	  numbers	  to	  near	  normal	  levels	  [reviewed	  in	  (Fanales-­‐Belasio	  et	  al.	  
2010)].	   The	   control	   of	   viraemia	   has	   largely	   been	   attributed	   to	   the	   emergence	   of	   cytotoxic	   T	  
lymphocytes	   (CTL)	  and,	   to	  a	   lesser	  extent,	   the	  development	  of	  a	  neutralising	  antibody	  response	  
(Streeck	   and	   Nixon	   2010).	   As	   a	   result	   of	   these	   immune	   responses,	   individuals	   can	   remain	  
asymptomatic	  for	  many	  years.	  Kinetic	  studies	  have	  shown	  that,	  during	  the	  asymptomatic	  period,	  
up	   to	   a	   billion	  HIV	  particles	   and	   two	  billion	  CD4+	  T	   cells	   are	  destroyed	  and	  produced	  each	  day	  
(Simon	  and	  Ho	  2003).	  Thus,	  the	  virus	  continues	  to	  replicate,	  causing	  a	  gradual	  drop	  in	  CD4+	  T	  cell	  
numbers	   (Mellors	   et	   al.	   1996)	   resulting	   in	   individuals	   becoming	   susceptible	   to	   various	  
opportunistic	   infections	   (Brooks	   et	  al.	   2009)	  and	  aggressive	  neoplasms	   (Broder	  2010),	   signalling	  
the	  onset	  of	  AIDS.	  
There	  are	  several	  reasons	  why	  antiviral	  immunity	  is	  unable	  to	  eradicate	  the	  HIV	  infection.	  
A	  functional	  impairment	  of	  immune	  responses	  can	  be	  detected,	  indicating	  that	  the	  virus	  induces	  a	  
dysfunction	  of	  immune	  cells	  very	  early	  after	  infection	  (Rosenberg	  et	  al.	  1998;	  Douek	  2003;	  Lange	  
et	   al.	   2003;	   Lichterfeld	   et	   al.	   2004).	   Disease	   progression	   is	   accompanied	   by	   destruction	   of	   the	  
lymphoid	   tissue	   architecture,	   which	   further	   hampers	   immune	   responses.	   Circulating	   viruses	  
display	   a	   high	   degree	   of	   variability,	   which	   enables	   escape	   from	   immune	   recognition.	   This	   is	  
facilitated	   by	   the	   persistence	   of	   integrated	   virus	   in,	   amongst	   others,	   macrophage	   and	   resting	  
CD4+	  T	  cell	  reservoirs.	  Such	  latent	  infections	  are	  characterised	  by	  low	  expression	  of	  viral	  antigens	  
preventing	  eradication	  even	  in	  the	  presence	  of	  effective	  antiviral	  treatment.	  
Some	  individuals	  display	  efficient	  control	  of	  HIV	  infection	  –	  so-­‐called	  ‘elite	  controllers’	  or	  
‘long-­‐term	   non-­‐progressors’.	   Despite	   extensive	   study	   of	   these	   cohorts,	   no	   correlates	   or	  
mechanism	   of	   protection	   against	   HIV	   infection	   have	   been	   definitively	   identified.	   Vaccine	  
development	  has	  been	  further	  hampered	  by	  the	  extreme	  variability	  of	  HIV,	  both	  within	  the	  host	  
and	  between	  clades,	  groups	  and	  types.	  
	  
1.2.5	  HIV	  variability	  and	  treatment	  
	  
Variability	   underscores	   the	   ability	   of	   HIV	   to	   escape	   host	   immunity	   and	   restricts	  
development	   of	   a	   vaccine	   that	   can	   elicit	   cross-­‐clade	   protection.	   Variability	  within	   the	   host	   is	   a	  
product	   of	   at	   least	   three	   features:	   (1)	   a	   highly	   erroneous	   reverse	   transcription	   process	   that	  
introduces,	  on	  average,	  one	  substitution	  per	  genome	  per	  replication	  (Sarafianos	  et	  al.	  2009);	  (2)	  
rapid	   viral	   replication	   that	   generates	   around	   1010	   virions	   per	   day	   in	   an	   infected	   individual	   (Ho	  
1997);	  and,	  (3)	  recombination	  of	  HIV	  strains	  in	  an	  individual.	  Consequently,	  envelope	  proteins,	  the	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major	  targets	  of	  vaccine-­‐induced	  antibodies,	  can	  differ	  in	  sequence	  by	  up	  to	  38%	  within	  the	  same	  
HIV-­‐1	   subtype	   (Korber	   and	   Gnanakaran	   2009).	   Vaccines	   designed	   to	   elicit	   CTL	   responses	  
encounter	   the	   same	   difficulties,	   as	   viruses	  within	   the	   same	   HIV-­‐1	   subtype	   differ	   by	   up	   to	   20%	  
(McMichael	  et	  al.	  2002).	  
Although	   an	   effective	   vaccine	   has	   remained	   elusive,	   a	   range	   of	   antiretroviral	   small	  
molecule	   drugs	   has	   brought	   about	   a	   substantial	   decrease	   in	   HIV-­‐associated	  mortality.	  Most	   of	  
these	  target	  the	  HIV	  enzymes	  RT,	  PR	  and	  IN,	  and	  in	  combination	  form	  highly	  active	  antiretroviral	  
therapy	   (HAART)	   that	   has	   changed	   HIV	   infection	   from	   a	   rapidly	   lethal	   disease	   to	   a	   chronic,	  
manageable	   condition.	   More	   specifically,	   antiretroviral	   intervention	   extends	   the	   life	   span	   of	   a	  
typical	  HIV-­‐1-­‐infected	  patient	  in	  the	  USA	  by	  about	  14	  years	  (Walensky	  et	  al.	  2006).	  
The	  HIV/AIDS	  pandemic	   is	  still	   far	   from	  stabilised,	  however.	  HAART	  must	  be	  undertaken	  
for	  a	  lifetime	  as	  its	  discontinuance	  is	  accompanied	  by	  viral	  rebound	  (Mata	  et	  al.	  2005;	  Chun	  et	  al.	  
2010),	  yet	  chronic	  antiretroviral	  therapy	  can	  bring	  about	  cardiac	  and	  metabolic	  side-­‐effects,	  which	  
increase	  the	  risk	  of	  developing	  heart	  disease	  and	  type	  2	  diabetes	  (Filardi	  et	  al.	  2008;	  Sabin	  et	  al.	  
2008;	  Silverberg	  et	  al.	  2009;	  Williams	  et	  al.	  2009).	  In	  addition,	  Sub-­‐Saharan	  Africa	  is	  the	  epicentre	  
of	  the	  pandemic	  but	  antiretroviral	  therapy	  is	  available	  for	  too	  few,	  or	  reaches	  those	  who	  need	  it	  
too	  late,	  in	  this	  resource-­‐poor	  region.	  Other	  limitations	  of	  HAART	  include	  an	  inability	  to	  eradicate	  
the	  virus	  because	  of	  the	  inducible	  retroviral	  reservoir	  present	   in	  memory	  T	  cells	  that	  can	  persist	  
for	  long	  periods	  (Marcello	  2006).	  HAART	  ultimately	  drives	  the	  emergence	  of	  drug-­‐resistance	  and	  
regimen	  selection	  is	  complicated	  by	  the	  ability	  of	  new	  HIV-­‐1	  strains	  to	  emerge	  and	  migrate	  quickly	  
(Taylor	  et	  al.	  2008).	  This	  is	  of	  particular	  relevance	  to	  the	  use	  of	  drug-­‐resistance	  algorithms,	  which	  
employ	  subtype	  B	  as	  the	  consensus	  sequence	  (Hirsch	  et	  al.	  2008).	  Of	  concern	  is	  that	  there	  is	  some	  
indication	  that	  the	  prevalence	  of	  CRFs	  and	  URFs	  is	  growing	  rapidly	   (Taylor	  et	  al.	  2008),	  although	  
the	   implications	   of	   this	   trend	   are	   unknown.	   New	   cross-­‐species	   transmissions	   from	   established	  
retroviral	   reservoirs	   in	  apes	  and	  Old	  World	  monkeys	  are	  also	  possible,	  particularly	  as	   logging	   in	  
previously	   inaccessible	   forests	   and	   the	   demand	   for	   bushmeat	   continues	   [reviewed	   in	   (Broder	  
2010)].	   Indeed,	  a	  Cameroonian	   living	   in	  Paris	  was	  recently	  documented	  as	  being	   infected	  with	  a	  
HIV	  strain	  originating	   in	  gorillas	   (SIVgor),	  designated	  group	  P	   (Plantier	  et	  al.	  2009).	  Whether	  new	  
viruses	   that	   arise	   from	   recombination	  or	   transpeciation	  events	  will	   be	   eminently	   susceptible	   to	  
current	   antiretroviral	   therapies	   is	   unknown.	   Therefore,	   the	   search	   for	   safer	   and	  more	   effective	  
therapies	  remains	  of	  critical	  importance.	  
Ideally,	  novel	  HIV	  therapies	  will	  present	  a	  high	  genetic	  barrier	  to	  the	  development	  of	  drug	  
resistance	  and	  fit	  with	  the	  realities	  of	  resource-­‐poor	  nations.	  Targeting	  host	  proteins	  required	  for	  
replication,	   so-­‐called	  HIV-­‐dependency	   factors	   (HDFs),	  would	   increase	   the	  genetic	  barrier	   to	  viral	  
escape.	   Cellular	   targets	   are	   virtually	   constant	   relative	   to	   the	   variability	   of	   viral	   targets	  within	   a	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patient	  and	  across	  the	  pandemic.	  Moreover,	  viral	  escape	  would	  require	  adaptation	  to	  the	  use	  of	  a	  
different	   cofactor	   (Zhou	   et	   al.	   2004b;	   Nair	   et	   al.	   2005).	   Although	   this	   is	   possible	   in	   principle,	  
particularly	   given	   the	   redundancy	   typical	   of	   cellular	   pathways,	   it	   has	   not	   been	   observed	  
experimentally.	  Thus,	  a	  low-­‐intervention	  gene	  therapy	  targeting	  a	  HDF	  presents	  an	  attractive	  anti-­‐
HIV	  therapeutic	  strategy.	  
The	  major	   concern	  with	   HDF-­‐targeting	   is	   the	   potential	   for	   adverse	   effects	   on	   the	   host.	  
Nonetheless,	   a	   naturally	   occurring	   32-­‐base	   pair	   (bp)	   deletion	   (Δ32)	   in	   the	   CCR5	   gene	   was	  
discovered	  that	  renders	  homozygous	  individuals	  resistant	  to	  R5	  virus	  infection	  (Huang	  et	  al.	  1996;	  
Liu	  et	  al.	  1996).	  The	  deletion	  results	  in	  premature	  truncation	  and	  a	  lack	  of	  CCR5	  expression	  on	  the	  
cell	  surface	  (Samson	  et	  al.	  1996),	  yet	  no	  associated	  physiological	  problems	  have	  been	  described.	  
Indeed,	   some	   of	   the	   most	   promising	   anti-­‐HIV	   treatments	   already	   approved	   or	   in	   clinical	   trials	  
target,	   not	   a	   viral	   protein,	   but	   CCR5.	   Individuals	   heterozygous	   for	   the	   Δ32	   allele	   progress	   to	  
disease	  more	  slowly	  and	  have	  lower	  viral	  loads.	  Thus,	  complete	  abolition	  of	  HDF	  gene	  expression	  
may	   not	   be	   necessary	   for	   inhibition	   of	   viral	   replication.	   Additional	   HDFs	   may	   exist,	   therefore,	  
whose	   depletion	   would	   be	   detrimental	   to	   the	   virus	   without	   compromising	   host	   fitness.	  
Consequently,	   the	   identification	  of	  such	  HDFs	  has	  become	  a	   focus	   in	   recent	  years.	  A	  number	  of	  
groups	   has	   performed	   genome-­‐wide	   screens	   to	   this	   end	   [reviewed	   in	   (An	   and	  Winkler	   2010)],	  
although	  most	  of	  the	  novel	  HDFs	   identified	  have	  yet	  to	  be	  confirmed.	  The	  validation	  of	  HDFs	  as	  
potential	   therapeutic	   targets	   is,	   therefore,	   a	   major	   objective	   of	   this	   thesis.	   Genome-­‐wide	  
identification	   of	   HDFs	   and	   their	   subsequent	   validation	   often	   exploits	   the	   cellular	   pathway	   RNA	  
interference	  (RNAi)	  for	  specific	  inhibition	  of	  host	  gene	  expression.	  
	  
1.3	  RNA	  interference	  
	  
RNAi	   is	   a	   process	   conserved	   throughout	   eukaryotes	   involving	   small	   non-­‐coding	   RNAs	  
(ncRNAs)	   that	   suppress	   gene	  expression	   through	  an	  association	  with	  mRNAs	  of	   complementary	  
sequence.	  The	  first	  small	  RNA,	  lin-­‐4,	  was	  identified	  through	  genetic	  screens	  in	  nematodes	  (Lee	  et	  
al.	  1993;	  Wightman	  et	  al.	  1993),	  and	  it	  was	  subsequently	  shown	  that	  double-­‐stranded	  (ds)	  RNAs	  
were	  the	  precursors	  to	  such	  silencing	  events	  (Fire	  et	  al.	  1998).	  Since	  these	  seminal	  findings,	  RNAi	  
has	  proved	  an	  indispensible	  cellular	  pathway	  and	  a	  powerful	  experimental	  technique.	  
The	   number	   of	   eukaryotic	   silencing	   small	   RNA	   classes	   continues	   to	   expand	   with	  
improvements	   in	   next	   generation	   sequencing	   technologies	   [reviewed	   in	   (Ghildiyal	   and	   Zamore	  
2009)].	  Although	  it	  is	  becoming	  increasingly	  apparent	  that	  different	  small	  RNA-­‐mediated	  silencing	  
pathways	   are	   intertwined	   [reviewed	   in	   (Siomi	   and	   Siomi	   2009)],	   two	   classes	   fall	   under	   the	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umbrella	   of	   RNAi	   in	   humans	   as	   both	   originate	   from	   dsRNA	   precursors	   that	   are	   processed	   by	  
RNase	   III	   enzymes:	  microRNAs	   (miRNAs)	  and	  endogenous	   small	   interfering	  RNAs	   (endo-­‐siRNAs).	  
Both	   are	   involved	   in	   post-­‐transcriptional	   regulation	   of	   RNAs	   and	   associate	   with	   the	   Argonaute	  
(Ago)	   subfamily	   of	   the	   Ago	   family	   of	   proteins.	   They	   differ	   in	   their	   biogenesis,	   however,	   with	  
miRNAs	   originating	   from	   hairpin	   precursors	   and	   endo-­‐siRNAs	   from	   long,	   dsRNA	   precursors.	  
miRNA	   biogenesis	   is	   the	   best	   understood	   and	   exploited	   RNAi	   pathway,	   perhaps	   reflecting	   the	  
ubiquitous	  expression	  of	  miRNAs	  and	  their	   importance	  in	  regulating	  specific	  biological	  processes	  
in	  specific	  tissues	  at	  specific	  times.	  
	  
1.3.1	  miRNA	  biogenesis	  in	  mammals	  
	  
The	  transcription	  of	  miRNA	  genes	  is	  typically	  mediated	  by	  RNA	  Pol	  II	  (Cai	  et	  al.	  2004;	  Lee	  
et	   al.	   2004),	   although	   some	   associated	   with	   Alu	   repeats	   may	   be	   transcribed	   by	   RNA	   Pol	   III	  
(Borchert	  et	  al.	  2006).	  About	  half	  of	  mammalian	  miRNA	  loci	  are	  clustered	  and	  transcribed	  from	  a	  
polycistronic	   unit	   (Lee	   et	   al.	   2002).	   Their	   genomic	   location	   can	   be	  within	   both	   non-­‐coding	   and	  
coding	  transcripts.	  In	  the	  latter,	  the	  majority	  are	  intronic,	  although	  miRNAs	  have	  been	  reported	  in	  
protein-­‐coding	   exons	   that	   are	   subject	   to	   alternative	   splicing	   (Kim	   et	   al.	   2009).	   The	   primary	  
transcripts	  (pri-­‐miRNAs)	  generated	  contain	  hairpin	  motifs	  composed	  of	  an	  ~33	  bp	  stem	  region,	  a	  
flexible	   terminal	   loop	   and	   flanking	   single-­‐stranded	   (ss)	   sequences.	   Processing	   of	   pri-­‐miRNAs,	  
termed	  cropping,	  is	  carried	  out	  by	  the	  microprocessor	  complex	  in	  the	  nucleus	  cotranscriptionally	  
and	   pre-­‐splicing	   (Kim	   and	   Kim	   2007;	   Morlando	   et	   al.	   2008;	   Pawlicki	   and	   Steitz	   2008).	   The	  
microprocessor	   complex	   contains	   the	   RNase	   III	   enzyme	   Drosha	   and	   the	   RNA-­‐binding	   cofactor	  
DiGeorge	   syndrome	  critical	   region	  8	   (DGCR8)	   (Denli	   et	   al.	   2004;	  Gregory	   et	   al.	   2004;	  Han	   et	   al.	  
2004;	  Landthaler	  et	  al.	  2004).	  Recognition	  of	  the	  pri-­‐miRNA	  leads	  to	  its	  cleavage	  ~11	  bp	  from	  the	  
junction	   between	   the	   stem	   and	   flanking	   ss	   regions	   (Zeng	   and	   Cullen	   2005;	   Han	   et	   al.	   2006),	  
releasing	  a	  short	  hairpin	  termed	  the	  precursor	  miRNA	  (pre-­‐miRNA)	  (Lee	  et	  al.	  2002).	  
The	  60-­‐70	  nt	  pre-­‐miRNA	  contains	  an	  ~16-­‐18	  bp	  stem	  and	  an	  ~2	  nt	  3’	  overhang	  that	  are	  
recognised	  by	  exportin	  5	  (Zeng	  and	  Cullen	  2004),	  through	  which	  the	  pre-­‐miRNA	  is	  shuttled	  to	  the	  
cytoplasm	   (Yi	   et	  al.	  2003).	  Here,	   the	  hairpins	  are	  processed	  again	  by	  another	  RNase	   III	  enzyme,	  
Dicer,	  near	  the	  terminal	  loop	  releasing	  ~22	  nt	  miRNA	  duplexes	  (Hutvagner	  et	  al.	  2001;	  Lee	  et	  al.	  
2002).	  These	  duplexes	  are	   loaded	  onto	  one	  of	   four	  Ago	  proteins	   (Ago1-­‐4),	   generating	   the	  RNA-­‐
induced	   silencing	   complex	   (RISC)	   (MacRae	   et	   al.	   2008).	   Dicer	   interacts	   with	   two	   proteins,	   TAR	  
RNA-­‐binding	   protein	   (TRBP)	   and	   PACT,	   which	   may	   contribute	   to	   the	   formation	   of	   RISC	  
(Chendrimada	  et	  al.	  2005;	  Lee	  et	  al.	  2006).	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One	  strand	  remains	  associated	  with	  Ago	  as	  a	  mature	  miRNA,	  or	  guide	  strand,	  whilst	  the	  
other,	   miRNA*	   or	   passenger	   strand,	   is	   degraded.	   Strand	   selection	   is	   determined	   by	   relative	  
thermodynamic	  stabilities	  at	  the	  ends	  of	  the	  miRNA	  duplexes	  –	  the	  strand	  with	  the	  most	  unstable	  
5’	  end	  is	  preferentially	  retained	  (Schwarz	  et	  al.	  2003;	  Ma	  et	  al.	  2005;	  Parker	  et	  al.	  2005),	  although	  
some	   pre-­‐miRNAs	   may	   produce	   miRNAs	   from	   both	   strands	   at	   similar	   frequencies	   (Wei	   et	   al.	  
2009).	   Ago2	   has	   endonuclease,	   or	   slicer,	   activity	   and	   thus	   can	   cleave	   the	   passenger	   strand	  
(Matranga	   et	   al.	   2005;	   Rand	   et	   al.	   2005).	  However,	  most	  miRNA	  duplexes	   contain	  mismatches,	  
which	  prevent	  cleavage	  of	  the	  passenger	  strand.	  Similar	  to	  Ago2,	  Ago1	  also	  mediates	  passenger	  
strand	  cleavage	  of	  perfect	  dsRNA	  duplexes	  but	  only	  strand	  dissociation	  activity	  of	  miRNA	  duplexes	  
(Wang	   et	   al.	   2009a).	   Ago3	   and	   Ago4	   are	   capable	   of	   neither	   strand-­‐dissociation	   nor	   cleavage	  
activities.	   In	   the	   absence	   of	   passenger	   strand	   cleavage,	   a	   RNA	   helicase	   activity	   may	   facilitate	  
unwinding	  of	  the	  duplex	  and	  passenger	  strand	  removal	  (Kim	  et	  al.	  2009).	  
An	  Ago-­‐sorting	  mechanism	  based	  on	  the	  duplex	  structure	  exists	  in	  Caenorhabditis	  elegans	  
(Jannot	   et	   al.	   2008)	   and	   in	   Drosophila	   melanogaster	   (Tomari	   et	   al.	   2007),	   the	   latter	   also	  
dependent	  on	  the	   identity	  of	   the	  guide	  strand’s	   first	  nucleotide	   (Ghildiyal	  and	  Zamore	  2009).	   In	  
humans,	   there	   is	   little	   difference	   between	   the	   identity	   of	   miRNAs	   bound	   to	   each	   Ago	   protein	  
(Czech	   and	   Hannon	   2011),	   although	   there	   is	   some	   evidence	   that	   mismatched	   duplexes	   are	  
preferentially	  loaded	  into	  Ago1	  and	  perfect	  dsRNA	  duplexes	  into	  Ago2	  (Gonzalez	  et	  al.	  2008).	  The	  
mechanism	  by	  which	  a	  miRNA	  regulates	  its	  target	  depends	  on	  the	  Ago	  into	  which	  a	  small	  RNA	  is	  
loaded	  and	  the	  degree	  of	  complementarity	  between	  the	  guide	  strand	  and	  its	  target	  mRNA,	  usually	  
in	  the	  3’	  untranslated	  region	  (UTR).	  Those	  few	  miRNAs	  fully	  complementary	  to	  their	  targets	  direct	  
Ago2-­‐mediated	   endonucleolytic	   cleavage	  of	   the	  mRNA	   (Figure	   1.4A).	  Unlike	  Ago2,	  Ago1	   cannot	  
cleave	  target	  mRNAs,	  indicating	  that	  the	  slicer	  activity	  of	  passenger	  strands	  and	  target	  mRNAs	  is	  
mechanistically	   distinct	   (Wang	   et	   al.	   2009a).	   The	   most	   common	   mechanism	   of	   target	   mRNA	  
suppression	  is	  translational	  suppression	  and	  target	  degradation	  in	  P	  bodies	  (Figure	  1.4B)	  (Guo	  et	  
al.	   2010).	   This	   is	   directed	   by	   miRNAs	   pairing	   with	   their	   targets	   only	   through	   a	   region	  
corresponding	  to	  nucleotides	  2-­‐8	  at	   the	  5’	  end,	   termed	  the	  seed	  region	  (Bartel	  2009;	  Guo	  et	  al.	  
2010).	  The	  small	   size	  of	   the	  seed	  means	  that	  one	  miRNA	  can	  regulate	  the	  expression	  of	  several	  
hundred	  genes	  simultaneously.	  
	  
1.3.2	  Endo-­‐siRNA	  and	  non-­‐canonical	  miRNA	  biogenesis	  
	  
Endo-­‐siRNAs	  are	  ~21	  nt	  and,	   in	  mammals,	  have	  so	   far	  been	   identified	   in	  mouse	  oocytes	  
(Tam	  et	  al.	  2008;	  Watanabe	  et	  al.	  2008)	  and	  adult	  mouse	  hippocampus	  (Smalheiser	  et	  al.	  2011).	  
They	  originate	  from	  transcription	  of	  intergenic	  repetitive	  elements,	  pseudogenes	  and	  endo-­‐siRNA	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clusters.	  The	  resulting	  long,	  dsRNA	  precursors	  are	  processed	  in	  a	  manner	  dependent	  on	  Dicer,	  but	  
not	  Drosha	  (Tam	  et	  al.	  2008;	  Watanabe	  et	  al.	  2008).	  The	  endo-­‐siRNAs	  identified	  in	  mouse	  oocytes	  
associated	  with	  Ago2,	  suggesting	  that	  they	  may	  inhibit	  gene	  expression	  through	  target	  cleavage.	  
Other	  Drosha-­‐independent	  mechanisms	  for	  the	  production	  of	  Dicer	  substrates	  that	   feed	  
into	  the	  standard	  miRNA	  pathway	  have	  been	  described,	  including	  mirtrons	  (Berezikov	  et	  al.	  2007;	  
Okamura	  et	  al.	  2007;	  Ruby	  et	  al.	  2007),	  small	  nucleolar	  RNAs	  (snoRNAs)	  (Ender	  et	  al.	  2008)	  and	  
tRNA	   fragments	   (Cole	   et	   al.	   2009;	   Lee	   et	   al.	   2009;	   Bogerd	   et	   al.	   2010).	   In	   addition,	   a	   Dicer-­‐
independent	   mechanism	   for	   the	   production	   of	   miRNAs	   has	   been	   identified	   that	   relies	   on	   the	  
catalytic	  activity	  of	  Ago2	  (Cifuentes	  et	  al.	  2010;	  Yang	  and	  Lai	  2010;	  Yang	  et	  al.	  2010).	  
	  
1.3.3	  RNAi	  mimics	  
	  
Given	   that	   the	   endogenous	   miRNA	   pathway	   accommodates	   intermediates	   from	  
numerous	  sources,	  it	  is	  unsurprising	  that	  the	  introduction	  of	  exogenous	  RNAi	  mimics	  into	  cells	  has	  
proved	   so	   successful	   at	   suppressing	   gene	   expression.	   Small	   interfering	   RNAs	   (siRNAs)	  were	   the	  
first	   RNAi	   mimics	   shown	   to	   be	   capable	   of	   mediating	   suppression	   of	   target	   gene	   expression	  
(Elbashir	  et	  al.	  2001).	  siRNAs	  are	  duplexes,	  typically	  21-­‐23	  bp	  in	  length	  with	  2	  nt	  3’	  overhangs	  that	  
resemble	   miRNA	   duplexes	   (Figure	   1.4C).	   siRNAs	   may	   be	   readily	   purchased	   pre-­‐synthesised	   or	  
generated	  by	  in	  vitro	  transcription.	  They	  can	  be	  transfected	  into	  cells	  for	  direct	  incorporation	  into	  
RISC.	  Whilst	  highly	  effective,	  siRNAs	  induce	  silencing	  only	  transiently:	  up	  to	  seven	  days	  in	  cultured	  
cells	   with	   a	   rapid	   turnover	   rate,	   which	   is	   a	   result	   of	   their	   dilution	   or	   degradation	   over	   time	  
(Bartlett	  and	  Davis	  2006).	  
The	  use	  of	  expressed	  RNAi	  mimics	  provides	  an	  option	  for	  more	  prolonged	  gene	  silencing.	  
These	  may	  be	  designed	  to	  enter	  the	  pathway	  as	  Drosha	  or	  Dicer	  substrates.	  Short	  hairpin	  RNAs	  
(shRNAs)	  with	  stems	  ≥20	  bp	  mimic	  pre-­‐miRNAs	  (Harborth	  et	  al.	  2003;	  Ge	  et	  al.	  2010)	  and	  so	  enter	  
the	   pathway	   at	   the	   level	   of	   Dicer	   processing	   (Figure	   1.4D).	   These	   siRNA	   precursors	   comprise	   a	  
sense	   region	   that	   generates	   a	   passenger	   strand,	   a	   loop	   sequence,	   an	   antisense	   region	   that	  
generates	  the	  guide	  strand	  and	  a	  2	  nt	  3’	  overhang	  to	  permit	  recognition	  by	  exportin	  5	  and	  Dicer	  
(Zeng	   et	   al.	   2002;	   Boden	   et	   al.	   2004;	   Liu	   et	   al.	   2007).	   shRNAs	   may	   be	   transcribed	   from	   DNA	  
plasmids	   or	   genome-­‐integrated	   expression	   cassettes	   for	   more	   prolonged	   expression.	   Although	  
RNA	  Pol	  II	  promoters	  were	  investigated	  (Ren	  et	  al.	  2007;	  Giering	  et	  al.	  2008),	  shRNA	  transcription	  
is	   typically	   from	   RNA	   Pol	   III	   promoters,	  which	   generates	   the	   defined	   5’	   and	   3’	   ends	   critical	   for	  
shRNA	   efficacy	   (Paul	   et	   al.	   2002;	   Tuschl	   and	   Borkhardt	   2002;	   Yu	   et	   al.	   2002;	   Cheng	   and	   Chang	  
2007).	  RNA	  Pol	  III	  promoters,	  such	  as	  U6	  and	  H1,	  are	  constitutively	  active	  leading	  to	  high	  levels	  of	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Figure	   1.4:	   miRNA	   biogenesis	   in	   mammals	   and	   RNAi	   mimics.	  miRNA	   genes	   are	   typically	   transcribed	   by	   RNA	   Pol	   II	  
generating	  pri-­‐miRNAs	  that	  are	  processed	   in	   the	  nucleus	  by	   the	  microprocessor	  complex,	  which	  contains	  Drosha	  and	  
DGCR8.	   The	   resulting	   pre-­‐miRNA	   is	   exported	   to	   the	   cytoplasm	   by	   exportin	   5	   where	   Dicer-­‐mediated	   processing	  
generates	  miRNA	   duplexes.	   Duplexes	   are	   loaded	   into	   Ago	   proteins,	   which	  may	   be	   facilitated	   by	   TRBP	   and/or	   PACT.	  
Functional	  RISC	  is	  formed	  on	  removal	  of	  the	  passenger	  strand,	  which	  can	  mediate	  mRNA	  cleavage	  where	  miRNAs	  are	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perfectly	   complementary	   to	   their	   targets	   (A).	  More	   commonly,	   miRNAs	  mediate	   translational	   suppression	   of	   target	  
mRNAs	  (B)	  and	  their	  degradation	  in	  P	  bodies.	  Exogenous	  siRNAs	  can	  be	  introduced	  into	  cells	  that	  may	  be	  incorporated	  
into	  RISC	  (C).	  DNA	  plasmids	  may	  also	  be	  introduced	  resulting	  in	  the	  expression	  of	  shRNAs,	  which	  imitate	  pre-­‐miRNAs,	  
entering	  the	  pathway	  at	  the	  level	  of	  Dicer	  processing	  (D).	  
	  
shRNA	  expression	  (Geiduschek	  and	  Kassavetis	  2001;	  Schramm	  and	  Hernandez	  2002;	  Boudreau	  et	  
al.	  2008).	  RNA	  Pol	  II	  promoters	  have	  the	  advantage	  of	  conferring	  greater	  transcriptional	  control,	  
with	  the	  option	  of	  introducing	  tissue-­‐specific	  and	  inducible	  systems.	  They	  are	  more	  amenable	  to	  
the	  production	  of	  pri-­‐miRNA	  mimics,	  where	  the	  length	  of	  ss	  sequences	  flanking	  the	  hairpin	  does	  
not	  need	  to	  be	  precise,	  but	  >40	  bp	  (McManus	  et	  al.	  2002;	  Zeng	  et	  al.	  2002).	  
The	  small	  size	  of	  the	  seed	  region	  means	  that	  RNAi	  mimics	  require	  careful	  design	  to	  avoid	  
off-­‐target	   effects.	   G:U	  wobbles	  may	   be	   introduced	   to	   increase	   the	   likelihood	   of	   desired	   strand	  
selection	  (Khvorova	  et	  al.	  2003;	  Schwarz	  et	  al.	  2003).	  Both	  siRNAs	  and	  shRNAs	  are	  designed	  to	  be	  
perfectly	  complementary	  to	  their	  targets	  and	  so	  typically	  are	  loaded	  into	  Ago2	  and	  mediate	  target	  
mRNA	  cleavage.	  Substrate	  requirements	  must	  be	  met	  and,	  for	  this	  reason,	  shRNAs	  and	  pri-­‐miRNA	  
mimics	  are	  usually	  designed	  by	  using	  endogenous	  pre-­‐	  or	  pri-­‐miRNAs	  as	  scaffolds,	   replacing	  the	  
guide	   strand	   sequences	  with	  an	  artificial	   sequence	   that	   is	   complementary	   to	   the	  desired	   target	  
(McManus	  et	  al.	  2002;	  Zeng	  et	  al.	  2002).	  
Although	  RNA	  Pol	   II	  promoters	  offer	  the	  most	  control	  and	  generate	  mimics	   less	   likely	  to	  
saturate	   the	   endogenous	   RNAi	   pathway	   from	   those	   produced	   from	   RNA	   Pol	   III	   U6	   and	   H1	  
promoters	  (Grimm	  et	  al.	  2006),	  their	  successful	  design	  requires	  more	  knowledge	  of	  endogenous	  
sequences	  and	  good	  predictions	  of	  the	  RNA	  mimic’s	  folding.	  Thus,	  although	  RNA	  Pol	  II-­‐driven	  pri-­‐
miRNA	  mimics	  offer	  great	  therapeutic	  potential	  as	  a	  gene	  therapy,	  RNA	  Pol	  III-­‐driven	  shRNAs	  and	  
siRNAs	   remain	   the	   preferred	   mimics	   for	   potent	   gene	   silencing	   and	   therefore,	   in	   determining	  
protein	  function.	  Consequently,	  validation	  of	  a	  role	  for	  a	  protein	  in	  HIV-­‐1	  replication	  typically	  uses	  
siRNAs	  or	   shRNAs,	  and	   these	  mimics	  have	  also	  been	  employed	   in	  genome-­‐wide	   screens	   for	   the	  
identification	  of	  HDFs	  (Brass	  et	  al.	  2008;	  Konig	  et	  al.	  2008;	  Zhou	  et	  al.	  2008;	  Yeung	  et	  al.	  2009b).	  
	  
1.3.4	  RNAi	  screens	  for	  the	  identification	  of	  HDFs	  
	  
A	   number	   of	   approaches	   for	   the	   identification	   of	   host	   factors	   required	   for	   HIV-­‐1	  
replication	   is	   available.	   However,	   candidate	   gene	   association	   studies	   are	   limited	   by	   what	   is	  
known,	   genome-­‐wide	   association	   studies	   by	   the	   requirement	   for	   large	   sample	   sizes,	   and	  
immunoprecipitations	   coupled	   to	   mass	   spectrometry	   by	   the	   difficulty	   in	   obtaining	   quality	  
preparations	   for	  every	  HIV-­‐1	  protein	   (An	  and	  Winkler	  2010;	  Raghavendra	  et	  al.	  2010).	  Genome-­‐
wide	  RNAi	  screens	  are	  not	  necessarily	  hypothesis-­‐driven	  and	  do	  not	  require	  genetic	  variation	  for	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HDF	  detection.	  Together	  with	  the	  availability	  of	  genome-­‐wide	  si/shRNA	  libraries	  and	  advances	  in	  
high-­‐throughput	  screening	  technologies,	  genome-­‐wide	  reverse	  genetics	  approaches	  have	  become	  
increasingly	  widespread	  in	  the	  investigation	  of	  host-­‐virus	  interactions	  [reviewed	  in	  (Hirsch	  2010)].	  
Four	   genome-­‐wide	   RNAi-­‐based	   screens	   for	   the	   identification	   of	   host	   factors	   of	   critical	  
importance	  for	  the	  replication	  of	  HIV-­‐1	  were	  reported	  (Brass	  et	  al.	  2008;	  Konig	  et	  al.	  2008;	  Zhou	  
et	  al.	  2008;	  Yeung	  et	  al.	  2009b)	  as	  well	  as	  a	  meta-­‐analysis	  of	  the	  first	  three	  screens	  (Bushman	  et	  
al.	  2009).	  The	  screens	  differed	  in	  their	  approach	  (Table	  1.1),	  in	  particular	  with	  respect	  to	  cell	  lines,	  
virus,	  RNAi	  library,	  assay	  length	  and	  readout,	  and	  filtering	  criteria.	  
Surprisingly,	   little	   overlap	  was	  observed	  between	   these	   first	   three	   studies	   (<7%	   for	   any	  
pairwise	   combination)	   (Bushman	   et	   al.	   2009).	   Bushman	   et	   al.	   attributed	   the	   lack	   of	   overlap	   to	  
experimental	  noise,	  differences	  in	  timing	  of	  sampling	  and	  in	  the	  hit	  filtering	  criteria.	  Analysis	  of	  a	  
screen	  duplicate	  (Konig	  et	  al.	  2008)	  revealed	  that	  experimental	  variance	  was	  such	  that	  only	  150	  of	  
300	  hits	  would	  be	  expected	  if	  the	  screen	  were	  repeated	  under	  identical	  experimental	  conditions.	  
It	   is	   perhaps	   unsurprising,	   therefore,	   that	   the	   overlap	   was	   small	   given	   that	   the	   screens	   used	  
different,	   albeit	   at	   times	   similar,	   conditions.	   Indeed,	   the	   small	   overlap	   was	   shown	   to	   be	  
statistically	  significant	  (Goff	  2008;	  Bushman	  et	  al.	  2009).	  Bushman	  et	  al.	  also	  demonstrated	  that	  
the	  screens	  were	  more	  robust	  at	  identifying	  enriched	  networks	  than	  individual	  proteins	  involved	  
in	   HIV-­‐1	   replication.	   Using	   the	   Database	   for	   Annotation,	   Visualisation	   and	   Integrated	  Discovery	  
(DAVID)	  (Huang	  da	  et	  al.	  2009)	  they	  identified	  gene	  ontology	  groups	  enriched	  in	  all	  three	  screens,	  
including	   the	   nuclear	   pore,	   ubiquitin/proteasome,	   mediator	   complex,	   transcription	   and	  
transcriptional	  elongation,	  RNA	  binding/splicing,	  mitochondrial	  function	  and	  chaperones.	  
These	  first	  three	  screens	  used	  cells	  chosen	  for	  experimental	  convenience	  and	  are	  not	  the	  
natural	  targets	  of	  the	  virus.	  Thus,	  genes	  required	  for	  replication	  in	  T	  cells	  but	  not	  in	  the	  cells	  used	  
in	  the	  screens	  would	  be	  missed.	  Conversely,	  genes	  found	  to	  be	  significant	  in	  the	  screens	  may	  be	  
of	   little	   import	   in	  T	  cells.	  The	  first	   three	  screens	  also	  all	  employed	  transfection	  of	  siRNAs	  as	   the	  
mechanism	  of	  gene	  silencing.	  Given	  the	  time	  frame	  of	  the	  assays	  used,	  this	  approach	  may	  have	  
been	  insufficient	  to	  decrease	  stable	  targets.	  This	  is	  likely	  to	  account	  for	  the	  notable	  absence	  of	  a	  
well-­‐characterised	   partner	   of	   HIV-­‐1	   IN,	   PC4	   and	   SFRS1	   interacting	   protein	   1	   (PSIP1)/lens	  
epithelium-­‐derived	  growth	  factor	  (LEDGF)/p75,	  from	  all	  three	  screens.	  The	  fourth	  study	  by	  Yeung	  
et	  al.	   attempted	   to	  address	   these	   issues	  by	  performing	  a	   screen	   in	   Jurkat	   cells,	   a	   T	   cell-­‐derived	  
line,	  with	  stable	  expression	  of	  RNA	  Pol	  III-­‐driven	  shRNAs	  delivered	  by	  lentiviral	  vector	  (Table	  1.1).	  
252	   genes	   were	   identified	   as	   putative	   HDFs,	   again	   displaying	   little	   overlap	   with	   the	   first	   three	  
screens	  at	  the	  level	  of	  individual	  proteins	  but	  enrichment	  for	  similar	  cellular	  processes	  (Yeung	  et	  
al.	  2009b).	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Table	  1.1:	  Overview	  of	  experimental	  details	  of	  four	  genome-­‐wide	  RNAi	  screens	  for	  the	  identification	  of	  HDFs.	  
	   Brass	  et	  al.	  (2008)	   König	  et	  al.	  (2008)	   Zhou	  et	  al.	  (2008)	   Yeung	  et	  al.	  (2009)	  
Scope	   Early	  and	  late	  stage	   Early	  stage	  (following	  entry)	   Early	  and	  late	  stage	   Early	  and	  late	  stage	  
RNAi	  library	   siRNA	  targeting	  21,121	  genes	  
4	  siRNAs/gene,	  4	  siRNAs/well	  
siRNA	  targeting	  19,628	  genes	  
4-­‐6	  siRNAs/gene,	  2	  siRNAs/well	  
siRNA	  targeting	  19,709	  genes	  
3	  siRNAs/gene,	  3	  siRNAs/well	  
shRNA	  targeting	  54,509	  transcripts	  
lentivirus	  delivery,	  pooled	  library	  
Replicates	   Duplicates	   Duplicates,	  triplicates	   Single	  values	   n/a	  
Virus	   HIV-­‐IIIB	   HIV	  NL4-­‐3Δenv-­‐Δnef	   HIV-­‐HXB2	   HIV	  NL4-­‐3	  
Cells	   TZM-­‐bl	  (HeLa-­‐derived)	   HEK293T	   P4/R5	  (HeLa-­‐derived)	   Jurkat	  
siRNA	  concentration	   50	  nM/well,	  12.5	  nM/siRNA	   25	  nM/well,	  12.5	  nM/siRNA	   53	  nM/well,	  17.6	  nM/siRNA	   n/a	  
Assay	  length	  (transfection	  to	  
readout)	  
120/144	  h	   72	  h	   72/120	  h	   3	  weeks	  selection	  +	  1/4	  weeks	  
infection	  
Assay	  readout	   Tat-­‐dependent	  β-­‐gal	  reporter	  cell	  
line,	  %	  p24+	  cells	  
Luciferase	  reporter	  virus	   Tat-­‐dependent	  β-­‐gal	  reporter	  cell	  
line	  
Barcoded	  shRNAs	  by	  microarray	  
Normalisation	   Plate	  mean	   Plate	  mean	   Negative	  control	   n/a	  
Hit	  selection	   ≥2	  x	  SD	  below	  plate	  mean	   Redundant	  siRNA	  analysis,	  decision	  
matrix	  
≥2	  x	  SD	  below	  negative	  control	   n/a	  
Toxicity	  assay	   Cell	  count	   ATP	  content	   Reducing	  capacity	   n/a	  
Validation	  criteria	   ≥1	  siRNA/gene	  confirmed	   ≥2	  siRNA/gene	  confirmed	   ≥2	  siRNA/gene	  confirmed	   n/a	  
#	  of	  filtered	  hits	   273	   295	   224	   252	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Another	  screen	  used	  an	  approach	  similar	  to	  that	  of	  Yeung	  et	  al.,	  in	  that	  Jurkat	  cells	  were	  
screened	  using	  stably	  expressed	  shRNAs.	  However,	  this	  screen	  was	  not	  genome-­‐wide,	  but	  rather	  
the	   library	  of	   shRNAs	  was	  enriched	   for	   those	   targeting	  human	  kinases	   and	  phosphatases,	   since	  
these	   are	   druggable	   proteins	   with	   critical	   roles	   in	   the	   regulation	   of	   eukaryotic	   cell	   signalling	  
pathways	  (Rato	  et	  al.	  2010).	  By	  reducing	  the	  scope	  of	  the	  screen,	  this	  study	  successfully	  reduced	  
the	  information	  load	  whilst	  increasing	  information	  density	  as	  experimental	  noise	  was	  decreased.	  
However,	  reducing	  the	  scope	  was	  also	  the	  source	  of	  this	  study’s	  greatest	  limitation.	  
Since	   experimental	   differences	   have	   such	   an	   important	   influence	   on	   screen	   results,	  
guidelines	  have	  been	  produced	  by	  different	  groups,	  in	  accordance	  with	  the	  Minimum	  Information	  
About	  an	  RNAi	  Experiment	  (MIARE)	  guidelines	  (www.miare.sourceforge.net),	  to	  aid	  researchers	  in	  
designing	   RNAi	   screens	   for	   the	   identification	   of	   HDFs	   (Borner	   et	   al.	   2010;	   Pache	   et	   al.	   2010).	  
Nevertheless,	  RNAi	  screens	  are	  always	  going	  to	  have	  their	  limitations.	  The	  cells	  used	  are	  not	  the	  
natural	   targets	  of	  HIV-­‐1	   replication.	   This	   is	  of	  particular	   importance	  when	   it	   is	   appreciated	   that	  
enhanced	   expression	   of	   HDFs	   augments	   HIV-­‐1	   replication	   in	   neonatal	   mononuclear	   cells	  
(Sundaravaradan	   et	  al.	   2010).	  Thus,	  differences	   in	  gene	  expression	  between	  different	   cell	   types	  
will	   affect	   HIV-­‐1	   replication	   kinetics	   and,	   possibly,	   the	   relative	   import	   of	   HDFs.	   Although	   some	  
success	   has	   been	   obtained	   with	   in	   vivo	   virogenomics	   studies	   (Aich	   et	   al.	   2007;	   Cogburn	   et	   al.	  
2007),	  this	  is	  not	  readily	  applicable	  to	  HIV-­‐1.	  Other	  limitations	  of	  RNAi	  screens	  include	  that	  HDFs	  
with	   redundant	   functions	   will	   be	   overlooked,	   as	   may	   those	   with	   a	   long	   half-­‐life,	   such	   as	  
PSIP1/LEDGF/p75	   (Llano	   et	   al.	   2006a).	   In	   addition,	   current	   RNAi	   libraries	   do	   not	   interrogate	  
ncRNAs.	  Off-­‐target	  effects	  of	  siRNAs	  may	  give	  rise	  to	  false	  positives	  and	  where	  the	  RNAi	  mimics	  
do	  not	   induce	   sufficient	   suppression,	   false	   negatives.	   Additional	   false	   negatives	  may	   arise	   from	  
filtering	  processes	  discarding	  HDFs	  whose	  depletion	  is	  toxic	  and	  an	  inability	  to	  identify	  HDFs	  with	  
purely	  an	  extracellular	  role	  in	  HIV-­‐1	  replication.	  Moreover,	  RNAi	  screens	  provide	  no	  quantification	  
of	   the	   population	   variation	   in	   HDF	   gene	   expression.	   This	   is	   notable	   given	   that	   genes	   with	   the	  
greatest	  within-­‐population	  expression	  variability	  are	  enriched	  for	  chemokine	  signalling	  and	  HIV-­‐1	  
interacting	   proteins,	   suggesting	   that	   variations	   in	   the	   expression	   of	   HDFs	   may	   account	   for	  
differential	  HIV-­‐1	  susceptibility	  (Li	  et	  al.	  2010).	  The	  complexity	  of	  virus-­‐host	  interactions	  suggests	  
a	   combination	   of	   platforms	   may	   need	   to	   be	   exploited	   for	   greater	   clarification	   of	   the	   role	   of	  
individual	  cellular	  factors.	  Despite	  these	  limitations,	  RNAi	  screens	  offer	  huge	  promise	  when	  used	  
as	   a	   primary	   genetic	   screen	   and	   when	   it	   is	   acknowledged	   that	   the	   design	   of	   specific	   sets	   of	  
experiments	  are	  crucial	  to	  translating	  the	  collected	  genomics	  data	  into	  palatable	  knowledge.	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Clearly,	  hits	   generated	   in	  RNAi	   screens	   for	   the	   identification	  of	  HDFs	   require	   validation.	  
Brass	   et	   al.	   were	   aware	   of	   this	   and	   so	   confirmed	   the	   requirement	   for	   four	   of	   their	   hits,	   Rab6,	  
Vps53,	  TNPO3	  and	  Med28,	  in	  HIV-­‐1	  replication	  by	  generating	  cells	  with	  stable	  shRNA	  expression	  
and	   performing	   additional	   experiments	   (Brass	   et	   al.	   2008).	   Admittedly,	   validation	   would	   have	  
been	  preferable	  in	  cell	  types	  that	  more	  closely	  resemble	  the	  natural	  targets	  of	  HIV-­‐1	  infection.	  
RNAi	  has	  been	  used	   for	  some	  time	  to	  validate	  HDF	  roles	   for	  cellular	   factors.	  One	  of	   the	  
first	   host	   factors	   shown	   to	   inhibit	   HIV-­‐1	   replication	   on	   siRNA-­‐mediated	   suppression	   was	   CD4	  
(Novina	   et	  al.	   2002).	  Numerous	   studies	  have	  demonstrated	  a	   resistance	   to	  HIV-­‐1	   replication	  on	  
RNAi-­‐mediated	  suppression	  of	  coreceptors	  CCR5	  and	  CXCR4	  (Martinez	  et	  al.	  2002;	  Anderson	  et	  al.	  
2003a;	   Anderson	   et	   al.	   2003b;	   Qin	   et	   al.	   2003;	   Song	   et	   al.	   2003;	   Anderson	   and	   Akkina	   2005a;	  
Anderson	  and	  Akkina	  2005b;	   Shimizu	   et	  al.	   2009;	   Shimizu	   et	  al.	   2010).	  RNAi-­‐mediated	   silencing	  
has	   confirmed	  many	  other	   cofactors,	   including	   those	   involved	   in	   integration,	   such	   as	   barrier	   to	  
auto-­‐integration	   factor	   1	   (BAF1),	   emerin	   (Jacque	   and	   Stevenson	   2006)	   and	   PSIP1/LEDGF/p75	  
(Maertens	   et	   al.	   2003;	   Llano	   et	   al.	   2006a),	   transcription,	   such	   as	   NF-­‐κB	   (Surabhi	   and	   Gaynor	  
2002),	   p21-­‐activated	   kinase	   (PAK1)	   (Nguyen	   et	   al.	   2006),	   cyclin	   T1	  and	  CDK9	   (Chiu	   et	   al.	   2004),	  
and	  envelope	  protein	  maturation,	  such	  as	  furin	  (Nguyen	  et	  al.	  2006).	  The	  examples	  given	  have	  all	  
been	  well-­‐characterised	  HDFs	   for	   some	   time.	   Few	  of	   the	   novel	  HDFs	   identified	   in	   screens	   have	  
been	  validated	  and	   those	   studies	  which	  do	  attempt	   to	  do	   so	   rarely	  progress	   to	  a	  T	   cell-­‐derived	  
line,	   presumably	   because	   of	   the	   technical	   difficulties	   associated	   with	   their	   transfection	  
necessitating	   the	  generation	  of	   stable	   lines	   through	   lentiviral	  delivery	  of	  RNAi	  mimic	  expression	  
cassettes.	  One	  notable	   exception	   emerged	   recently	   from	   the	  Berkhout	   group:	   they	   selected	   30	  
putative	  HDFs	  and	  examined	   their	   ability	   to	   inhibit	  HIV-­‐1	   replication	   in	   T	   cell-­‐derived	   lines	  with	  
stable	   shRNA	  expression	   (Eekels	   et	  al.	   2011).	  Only	  half	  were	   less	   susceptible	   to	  HIV-­‐1	   infection,	  
determined	  by	  CA/p24	   levels	  7	  days	  post-­‐infection,	  demonstrating	   the	   importance	  of	   screen	  hit	  
validation.	  The	  anticipated	  flurry	  of	  publications	  on	  HDF	  confirmation	  following	  the	  publication	  by	  
Brass	  et	  al.	   (Brass	   et	  al.	   2008)	  has	  not	  materialised,	  with	   instead	   the	  global	   focus	   seemingly	  on	  
refining	  RNAi-­‐based	  genome-­‐wide	  screens	  for	  HDF	  identification.	  Clearly,	  there	  is	  still	  a	  great	  deal	  
of	  work	   for	  molecular	   biologists	   as	   other	   host	   factor	   targets	   as	   promising	   as	   CCR5	  may	   still	   be	  
awaiting	  discovery.	  Validation	  of	  HDFs	  and	  examination	  of	   their	  potential	  as	   therapeutic	   targets	  
was,	  therefore,	  examined	  in	  this	  thesis	  through	  exploitation	  of	  the	  RNAi	  pathway	  in	  T	  cell-­‐derived	  
lines.	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As	  well	  as	  the	  identification	  and	  validation	  of	  HDFs,	  exploitation	  of	  the	  RNAi	  pathway	  has	  
been	  used	  as	  a	  mode	  of	  gene	  therapy.	  The	  majority	  of	  anti-­‐HIV	  RNAi-­‐based	  gene	  therapies	  have	  
been	   directed	   against	   the	   virus	   itself	   [reviewed	   in	   (Barichievy	   et	   al.	   2009;	   Berkhout	   2009)].	  
Unfortunately,	  virus-­‐targeted	  RNAi	  is	  likely	  to	  be	  hampered	  by	  the	  same	  obstacle	  as	  HAART,	  that	  
of	  viral	  escape.	  Furthermore,	  the	  sequence	  specificity	  of	  RNAi	  may	  favour	  more	  rapid	  viral	  escape	  
than	   treatment	  with	   small	  molecule	   enzyme	   inhibitors	   (Boden	   et	   al.	   2003),	   the	   latter	   requiring	  
several	   mutations	   to	   confer	   amino	   acid	   changes	   that	   result	   in	   drug	   resistance.	   Consequently,	  
there	   has	   been	   a	  movement	   toward	   combinatorial	   RNAi	   gene	   therapies,	   with	   estimations	   that	  
simultaneous	  targeting	  of	  four	  viral	  targets	   is	  necessary	  to	  severely	  delay	  viral	  escape	  (Berkhout	  
2004;	   Ter	   Brake	   and	   Berkhout	   2005).	   A	   number	   of	   combinatorial	   RNAi	   approaches	   has	   been	  
developed,	   including	   shRNA	   multimers,	   polycistronic	   miRNA	   shuttles,	   bifunctional	   shRNAs	   and	  
long	  hairpin	  RNAs	  (lhRNAs),	  which	  aim	  to	  produce	  more	  than	  one	  siRNA	  from	  a	  single	  expression	  
cassette	  [reviewed	  in	  (Grimm	  and	  Kay	  2007)].	  However,	  therapies	  may	  be	  simplified	  and	  reduce	  
viral	  escape	  still	  further	  by	  introduction	  of	  an	  element	  targeting	  a	  HDF.	  
The	   potential	   of	   HDF-­‐targeting	   gene	   therapy	   was	   dramatically	   demonstrated	   by	   the	  
apparent	   cure	   of	   a	   HIV-­‐infected	   patient	   who	   had	   leukaemia	   in	   addition	   to	   AIDS.	   This	   patient	  
received	  a	  bone	  marrow	  transplant	  in	  which	  donor	  stem	  cells	  were	  homozygous	  for	  the	  CCR5	  Δ32	  
allele.	  CD4+	  T	  cells	  were	  successfully	  reconstituted	  in	  the	  patient	  without	  signs	  of	  HIV-­‐1	  infection,	  
despite	   discontinuation	   of	   antiretroviral	   therapy	   (Hutter	   et	   al.	   2009;	   Allers	   et	   al.	   2010).	   This	  
approach	   is	   certainly	   not	   applicable	   to	   all	   HIV-­‐infected	   individuals,	   however,	   as	   bone	   marrow	  
transplantation	  is	  a	  high-­‐risk	  treatment	  (ie	  only	  10-­‐30%	  of	  recipients	  survive).	  
Engraftment	   of	   autologous	   cells	   treated	   ex	   vivo	   with	   an	   HDF-­‐targeting	   RNAi	   mimic	  
introduced	  by	  a	  viral	  vector	  may	  be	  a	  more	  broadly	  applicable	  strategy.	  This	  may	  be	  possible	  with	  
isolated	  peripheral	  blood	  mononuclear	   cells	   (PBMCs),	   although	   in	   this	   case	   the	  modified	  T	   cells	  
would	  have	  a	  limited	  life	  span,	  such	  that	  repeat	  infusions	  would	  be	  necessary.	  The	  modification	  of	  
haematopoietic	  stem	  cells	  would	  be	  more	  durable,	  though	  more	  complicated,	   leading	  to	  T	  cells,	  
monocytes,	  macrophages	  and	  DCs	  less	  susceptible	  to	  HIV	  infection.	  The	  presence	  of	  an	  anti-­‐HDF	  
RNAi	   mimic	   would	   be	   expected	   to	   confer	   a	   survival	   advantage	   to	   modified	   cells	   over	   those	  
unmodified	   in	  HIV-­‐infected	   individuals.	  Proof	  of	  principle	  has	  been	  demonstrated	   in	  non-­‐human	  
primates	  that	  received	  blood	  stem	  cells	  treated	  with	  an	  SIV	   lentiviral	  vector	  expressing	  a	  shRNA	  
against	   CCR5	   (An	   et	   al.	   2007).	   These	   primates	   exhibited	   normal	   haematopoietic	   reconstitution	  
and	  T	  cells	  were	  more	  resistant	   to	  SIV	   infection.	  A	  similar	  approach	  was	  used	   in	   the	  humanised	  
bone	  marrow/liver/thymus	  (BLT)	  mouse	  model,	  which	  received	  human	  haematopoietic	  stem	  cells	  
modified	   by	   lentiviral	   delivery	   of	   anti-­‐CCR5	   shRNA.	   These	   mice	   showed	   decreased	   HIV-­‐1	  
replication	  and	  no	  defects	   in	  T	  cell	  development	  (Shimizu	  et	  al.	  2010).	  Another	  approach,	  which	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avoids	   technically	   difficult	   engraftments,	   is	   the	   delivery	   of	   RNAi	  mimics	   in	   vivo.	  Obtaining	   RNAi	  
mimic	  delivery	  is	  an	  ongoing	  focus	  of	  research	  in	  the	  field	  of	  gene	  therapy	  with	  many	  approaches	  
being	  developed,	  many	  of	  which	  address	  the	  issue	  of	  tissue-­‐specificity	  [reviewed	  in	  (Tiemann	  and	  
Rossi	  2009;	  Lares	  et	  al.	  2010)].	  
Even	   if	   delivery	   problems	   are	   solved,	   there	   are	   a	   number	   of	   concerns	   related	   to	   RNAi-­‐
based	  gene	  therapies,	  whether	  targeting	  viral	  or	  HDF	  transcripts.	  Exogenous	  siRNAs	  and	  shRNAs	  
produce	  guide	  strands	  similar	  to	  miRNAs	  and,	  therefore,	  have	  the	  potential	  to	  silence	  hundreds	  of	  
off-­‐target	  genes	  through	  their	  seed	  regions	  (Jackson	  et	  al.	  2003;	  Jackson	  and	  Linsley	  2004;	  Jackson	  
et	  al.	  2006).	  Although	  alignment	  algorithms	  and	  microarray	  analyses	  can	  be	  used	  to	  predict	  and	  
monitor	  off-­‐target	  effects,	  respectively,	  this	   is	  hampered	  by	  continued	  expansion	   in	  the	  number	  
of	  known	  functional	  ncRNAs.	  
High	   levels	   of	   shRNA	   expression	   from	   RNA	   Pol	   III	   promoters	   can	   lead	   to	   toxic	   effects	  
through	   competition	   with	   endogenous	   miRNAs	   and	   saturation	   of	   the	   RNAi	   pathway	   (An	   et	   al.	  
2006;	  Grimm	  et	  al.	  2006;	  Castanotto	  et	  al.	  2007).	  The	  fatal	  side	  effects	  observed	  in	  mice	  treated	  in	  
vivo	  with	  shRNAs	  were	  attributed	  to	  saturation	  of	  exportin	  5	  (Grimm	  et	  al.	  2006).	  Saturation	  has	  
also	  been	  observed	  at	  the	  level	  of	  Ago	  proteins	  (Grimm	  et	  al.	  2010),	  suggesting	  that	  siRNAs	  could	  
also	  mediate	  toxicity	  through	  competition	  with	  the	  endogenous	  pathway.	  
RNAi-­‐based	  gene	  therapies	  are	  also	  complicated	  by	  the	  potential	  for	  mimics	  to	  activate	  an	  
immune	   response.	   Exogenous	   RNAs	   may	   stimulate	   Toll-­‐like	   receptors	   (TLRs),	   leading	   to	   a	  
signalling	  cascade	  that	  activates	  the	  interferon	  pathway	  (Takeda	  and	  Akira	  2005).	  Indeed,	  a	  major	  
setback	  to	  the	  field	  of	  RNAi	  was	  the	  discovery	  that	  vascular	  endothelial	  growth	  factor	  A	  (VEGF-­‐A)-­‐
targeting	   siRNAs	   alleviated	   macular	   degeneration	   through	   sequence-­‐	   and	   target-­‐independent	  
effects	  on	  TLR3	  (Kleinman	  et	  al.	  2008).	  Admittedly,	  this	  raises	  the	  issue	  of	  whether	  innate	  immune	  
activation	  by	  RNAi	  mimics	   is	   good	  or	  bad.	   In	   some	   settings	   it	   is	   certainly	   favourable:	   interferon	  
induction	  has	  been	  used	  synergistically	  with	  siRNAs	  for	  the	  destruction	  of	  tumour	  cells	  (Pastor	  et	  
al.	   2010).	   However,	   in	   the	   context	   of	   HIV-­‐1	   infection,	   destruction	   of	   cells	   expressing	   anti-­‐HDF	  
RNAi	  mimics	  would	  be	  an	  unwanted	   side	  effect.	   Expressed	   shRNAs	  are	   less	  prone	   to	   interferon	  
pathway	  activation	  as	  they	  are	  not	  detected	  by	  cell	  surface	  receptors	  [reviewed	  in	  (Marques	  and	  
Williams	   2005)].	   Nevertheless,	   these	   may	   activate	   a	   type	   I	   interferon	   response	   through	  
cytoplasmic	  receptors	  dsRNA-­‐dependent	  protein	  kinase	   (PKR)	  and	  retinoic	  acid-­‐inducible	  gene	  1	  
(RIG-­‐1),	  which	  can	  lead	  to	  apoptosis	  (Karpala	  et	  al.	  2005;	  Garcia-­‐Sastre	  and	  Biron	  2006;	  Hornung	  
et	  al.	  2006;	  Nallagatla	  et	  al.	  2007).	  Some	  sequence	  motifs	  have	  been	  implicated	  (Pebernard	  and	  
Iggo	  2004),	  and	  thus	  this	  innate	  response	  may	  be	  prevented	  if	  these	  are	  avoided,	  along	  with	  PKR	  
and	  RIG-­‐1-­‐activating	  5’	   triphosphates,	  which	  are	  present	   in	  RNA	  Pol	   III-­‐derived	   shRNAs.	  Capped	  
RNA	   Pol	   II-­‐derived	   transcripts	   and	   tRNA-­‐shRNA	   fusions	   offer	   safer	   alternatives	   in	   this	   regard	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[reviewed	  in	  (Rossi	  2008)],	  but	  their	  use	  is	  limited	  by	  the	  difficulty	  associated	  with	  their	  successful	  
design.	  Expression	  of	  shRNAs	  in	  haematopoietic	  stem	  cells	  does	  not	  induce	  interferon	  responses	  
(Robbins	  et	  al.	  2006),	  although	  this	  returns	  to	  the	  difficulties	  associated	  with	  modified	  stem	  cell	  
introduction	  (see	  above).	  
One	  of	  the	  major	  drawbacks	  of	  RNAi-­‐based	  gene	  therapy	  is	  the	  requirement	  for	  continual	  
administration/expression	  of	  the	  RNAi	  mimic	  for	  sustained	  target	  suppression.	  This	   is	  a	  result	  of	  
the	  targets	  being	  mRNAs	  whose	  transcription	  is	  unaffected	  by	  the	  mechanism	  of	  gene	  silencing.	  
Continuous	   administration	   of	   RNAi	   mimics	   and	   complex	   engraftments	   are	   not	   conducive	   to	  
resource-­‐poor	   regions,	   however.	   Thus,	   a	   more	   favourable	   gene	   therapy	   regimen	   would	   entail	  
reduced	  intervention	  frequency,	  which	  would	  be	  practically	  easier	  to	  administer	  to	  patients	  on	  a	  
large	   scale.	   In	   addition,	   reduced	   intervention	  would	  decrease	   the	  exposure	  of	   cells	   to	   toxicities	  
associated	  with	   off-­‐target	   effects,	   pathway	   saturation	   and	   innate	   immune	   response	   activation.	  
Fortunately,	   another	   arm	   of	   the	   RNAi	   pathway	   has	   become	   evident	   in	   mammals	   with	   the	  
potential	  to	  mediate	  long-­‐term	  gene	  silencing	  through	  modulation	  of	  transcription.	  
	  
1.4	  Transcriptional	  gene	  silencing	  
	  
Small	   RNA	  molecules	   bound	   to	  Ago	  proteins	   have	  been	   shown	   to	  modulate	   chromatin	   and	  
affect	   gene	   expression	   by	   TGS.	   First	   described	   in	   plants	   and	   yeast	   [reviewed	   in	   (Matzke	   and	  
Birchler	   2005;	   Buhler	   and	  Moazed	   2007;	  Grewal	   and	   Elgin	   2007)],	   TGS	   in	  mammalian	   cells	  was	  
initially	  met	  with	   controversy;	   partly	   a	   result	   of	   the	  paucity	  of	   endogenous	  effectors	   identified.	  
Guide	  strands	  may	  be	  loaded	  into	  a	  nuclear	  form	  of	  RISC,	  termed	  the	  RNA-­‐induced	  transcriptional	  
silencing	  complex	  (RITS)	  (Verdel	  et	  al.	  2004).	  Like	  RISC,	  Ago	  proteins	  are	  the	  core	  components	  of	  
the	  complex	  and	  targeting	  is	  mediated	  by	  complementary	  base-­‐pairing	  of	  the	  RNA	  guide	  strand.	  
Except	   for	   budding	   yeast,	   small	   RNA-­‐mediated	   heterochromatin	   regulation	   is	   conserved	  
throughout	  eukaryotes.	  	  
The	   first	   report	   of	   mammalian	   TGS	   utilised	   exogenous	   siRNAs	   to	   silence	   expression	   of	   an	  
integrated	   GFP	   reporter	   driven	   by	   the	   eukaryotic	   translation	   elongation	   factor	   1	   alpha	   (EF-­‐1α)	  
promoter	   (Morris	   et	   al.	   2004).	  Morris	   et	   al.	   confirmed	   silencing	   at	   the	   transcriptional	   level	   by	  
performing	   nuclear	   run-­‐on	   analysis,	   the	   gold	   standard	   for	   differentiating	   silencing	   effects	  
mediated	  by	   TGS	   from	   those	  of	   the	   canonical	   RNAi	   pathway	   that	   involves	  mRNA	   targeting	   and	  
post-­‐transcriptional	  gene	  silencing	  (PTGS).	  The	  same	  strategy	  was	  employed	  to	  obtain	  TGS	  at	  the	  
endogenous	  E-­‐cadherin	  promoter	  a	  year	  later	  (Ting	  et	  al.	  2005).	  Both	  reports	  implicated	  a	  role	  for	  
epigenetic	   changes	   in	   RNA-­‐induced	   gene	   silencing,	   which	   have	   the	   capacity	   to	   be	   inherited	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through	  multiple	   rounds	   of	   cell	   division,	   underscoring	   the	   potential	   of	   TGS	   to	   induce	   sustained	  
target	  suppression.	  
	  
1.4.1	  Epigenetic	  changes	  associated	  with	  TGS	  
	  
The	  formation	  of	  chromatin	  through	  the	  binding	  of	  histones	  to	  DNA	  both	  restricts	  access	  
to	  the	  genetic	  code	  and	  creates	  a	  mechanism	  by	  which	  access	  is	  regulated.	  The	  nucleosome	  is	  the	  
basic	  unit	  of	  chromatin,	  around	  which	  DNA	  is	  coiled	  (Kornberg	  and	  Klug	  1981).	  Each	  nucleosome	  
consists	  of	  a	  core	  of	  two	  copies	  of	  histones	  H2A,	  H2B,	  H3	  and	  H4.	  Approximately	  147	  bp	  of	  DNA	  is	  
wrapped	  around	  each	  nucleosome	  (Luger	  et	  al.	  1997).	  Between	  core	  units	  lies	  the	  linker	  histone,	  
H1,	  which	  may	  be	  involved	  in	  higher-­‐order	  compaction	  of	  DNA.	  The	  histones	  are	  subject	  to	  post-­‐
translational	  modifications,	  including	  acetylation	  and	  methylation,	  particularly	  on	  N-­‐terminal	  tails	  
that	   protrude	   from	   the	   core,	   mediated	   by	   histone	   acetylases/deacetylases	   (HATs/HDACs)	   and	  
histone	   methyltransferases/demethylases	   (HMTs/HDMTs),	   respectively	   (Strahl	   and	   Allis	   2000).	  
Histone	  variants,	  such	  as	  H2A.Z	  and	  H3.3,	  provide	  additional	  variety	  to	  the	  nucleosome	  (Verdel	  et	  
al.	  2004).	  These	  modifications	  and	  variants	  can	  recruit	  specific	  proteins	  and	  also	  alter	  the	  binding	  
affinity	   between	   histones	   and	   DNA.	   Binding	   affinities	   affect	   chromatin	   compaction	   and,	   thus,	  
access	   of	   the	   transcription	   machinery	   to	   the	   DNA.	   Therefore,	   histone	   modifications	   mediate	  
epigenetic	   regulation	   of	   transcription	   and	   may	   be	   silencing	   and	   activating,	   depending	   on	   the	  
residue	  and	  type	  of	  modification.	  
Another	  common	  type	  of	  epigenetic	  regulation	  involves	  DNA	  methylation,	  particularly	  at	  
CpG	   dinucleotides.	   Most	   CpG-­‐rich	   regions	   (CpG	   islands)	   overlap	   promoters,	   where	   DNA	  
methylation	   is	  associated	  with	  gene	  silencing	   (Suzuki	  and	  Bird	  2008).	  Whilst	  DNA	  methylation	   is	  
largely	  maintained	  by	  DNA	  methyltransferase	  (DNMT)	  1	  (Weber	  et	  al.	  2007),	  a	  number	  of	  proteins	  
mediate	  de	  novo	  DNA	  methylation,	  including	  DNMT3A	  and	  DNMT3B	  (Okano	  et	  al.	  1999).	  
Identification	   of	   the	   protein	   complexes	   involved	   in	   the	   epigenetic	   changes	   that	  
accompany	  mammalian	  TGS	  is	  ongoing.	  In	  the	  seminal	  TGS	  article	  (Morris	  et	  al.	  2004),	  the	  ability	  
of	  a	  promoter-­‐targeted	  siRNA	  to	  induce	  TGS	  was	  reversed	  by	  treatment	  with	  trichostatin	  A	  (TSA)	  
or	   5-­‐azacytidine	   (5-­‐azaC),	   implicating	   roles	   for	   histone	   deacetylation	   and	   DNA	   methylation,	  
respectively.	  Ting	  et	  al	  went	  further	  by	  demonstrating	  that	  TGS	  was	  accompanied	  by	  enrichment	  
for	  histone	  3	  lysine	  9	  (H3K9)	  dimethylation	  (Ting	  et	  al.	  2005),	  a	  chromatin	  modification	  associated	  
with	   inactive	   promoters.	   Many	   studies	   have	   shown	   a	   role	   of	   core	   histone	   post-­‐translational	  
modifications	   in	   TGS	   (Ting	   et	   al.	   2005;	   Kim	   et	   al.	   2006;	  Weinberg	   et	   al.	   2006;	   Han	   et	   al.	   2007;	  
Wang	   et	  al.	   2007;	  Weinberg	   et	  al.	   2007;	  Gonzalez	   et	  al.	   2008;	  Kim	   et	  al.	   2008;	   Lim	   et	  al.	   2008;	  
Morris	   et	   al.	   2008;	   Suzuki	   et	   al.	   2008;	  Hawkins	   et	   al.	   2009;	  Hong	   et	   al.	   2009;	   Tan	   et	   al.	   2009b;	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Turunen	   et	  al.	   2009;	  Palanichamy	   et	  al.	   2010;	  Yue	   et	  al.	   2010).	  Enzymes	   responsible	  have	  been	  
elucidated	   over	   the	   years	   through	   their	   enrichment	   at	   targeted	   promoters,	   as	   determined	   by	  
chromatin	   immunoprecipitation	  (ChIP).	  These	   include	  the	  Polycomb	  Group	  Protein	  EZH2	  (Kim	  et	  
al.	  2006;	  Kim	  et	  al.	  2008;	  Hawkins	  et	  al.	  2009),	  which	  trimethylates	  histone	  3	   lysine	  27	  (H3K27),	  
HDAC1	   (Suzuki	   et	   al.	   2008;	   Hawkins	   et	   al.	   2009)	   and	   possibly	   the	   H3K9	  methyltransferase	   G9a	  
(Hawkins	  et	  al.	  2009).	  Such	  experiments	  have	  also	  shown	  that	  the	  roles	  of	  proteins	  differ	   in	  the	  
establishment	  and	  maintenance	  of	  TGS	  (Hawkins	  et	  al.	  2009).	  
Although	  Ting	  and	  coworkers	  observed	  induction	  of	  silent-­‐state	  histone	  modifications	  at	  
the	  targeted	  E-­‐cadherin	  promoter,	  DNA	  methylation	  was	  not	  found	  at	  the	  targeted	  region	  (Ting	  et	  
al.	   2005).	   Thus,	   it	  was	   surprising	   that	   the	   first	   epigenetic	  modifier	   described	   associating	  with	   a	  
TGS-­‐inducing	  RNA	  was	   flag-­‐tagged	  DNMT3A	   (Weinberg	   et	  al.	   2006).	  The	  controversy	  associated	  
with	  the	  requirement	  for	  DNA	  methylation	  in	  TGS	  has	  been	  fuelled	  by	  several	  conflicting	  reports	  
(Castanotto	   et	   al.	   2005;	   Janowski	   et	   al.	   2005;	   Pulukuri	   and	   Rao	   2007;	   Napoli	   et	   al.	   2009).	   An	  
appealing	  hypothesis,	   suggested	  by	   two	  studies	   that	  employed	  stable	   shRNA	  expression,	   is	   that	  
DNA	  methylation	  follows	  histone	  modifications	  where	  guide	  strand	  expression	   is	  sustained	   (Kim	  
et	   al.	   2007;	   Hawkins	   et	   al.	   2009).	   Given	   that	  most	   TGS	   studies	   employ	   transient	   expression	   of	  
siRNAs,	   it	   is	   not	   surprising	   that	  DNA	  methylation	   is	   not	   always	   observed.	  Nevertheless,	   several	  
observations	  question	   the	   importance	  of	  DNA	  methylation	   in	   small	  RNA-­‐induced	   transcriptional	  
regulation:	   (1)	   a	   DNMT3A	   association	   with	   endogenous	   short	   RNA	   guides	   has	   not	   been	  
demonstrated	   using	   immunoprecipitation	   techniques	   (Park	   et	   al.	   2010);	   (2)	   periodic,	   strand-­‐
specific	  cyclical	  DNA	  methylation	  at	  active	  promoters	  has	  been	  described,	  which	  might	  introduce	  
artifactual	   observations	   (Metivier	   et	   al.	   2008);	   and,	   (3)	   it	   is	   possible	   to	   reactivate	   aberrantly	  
silenced	   tumour	   suppressor	   genes	   without	   loss	   of	   DNA	   hypermethylation	   (Pruitt	   et	   al.	   2006).	  
These	  findings	  bring	  into	  question	  the	  role	  of	  DNA	  methylation	  as	  a	  ‘marker’	  of	  sustained	  TGS.	  
Despite	   the	   controversies	   surrounding	   the	   role	   of	   DNA	   methylation,	   the	   epigenetic	  
changes	   that	   accompany	   TGS	   underlie	   one	   of	   the	   advantages	   of	   this	   approach	   over	   PTGS	   as	   a	  
therapeutic	   strategy	   –	   it	   may	   preserve	   silencing	   even	   after	   removal	   of	   the	   promoter-­‐targeted	  
small	  RNA.	  Hawkins	  et	  al	  have	  shown	  that	  only	  3	  days	  of	  promoter-­‐targeting	  shRNA	  induction	  in	  
dividing	   cells,	   and	   2	   days	   in	   serum-­‐starved,	   non-­‐dividing	   cells,	   is	   required	   to	   achieve	   long-­‐term	  
silencing	   of	   ubiquitin	   C	   (>30	   days),	   in	   a	   manner	   dependent	   on	   DNA	   and	   histone	   methylation	  
(Hawkins	  et	  al.	  2009).	  Thus,	  providing	  silent-­‐state	  chromatin	  is	  attained	  at	  the	  targeted	  promoter,	  
small	  RNAs	  can	  induce	  sustained	  target	  suppression.	  
	  
1.4.2	  Mechanism	  of	  small	  RNA-­‐induced	  TGS	  in	  mammals	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The	  observation	  that	  siRNA-­‐induced	  silencing	  at	  the	  EF-­‐1α	  promoter	  was	  sensitive	  to	  the	  
RNA	   Pol	   II	   inhibitor	  α-­‐amanitin	   (Weinberg	   et	   al.	   2006),	   led	   to	   the	   proposal	   of	   two	   models	   to	  
explain	  the	  mechanism	  of	  TGS:	  (1)	  the	  siRNA	  binds	  to	  DNA,	  facilitated	  by	  the	  opening	  of	  the	  DNA	  
duplex	  by	  the	  transcription	  machinery;	  and,	  (2)	  the	  siRNA	  binds	  to	  nascent	  promoter-­‐associated	  
RNA.	   Work	   by	   Han	   et	   al	   favoured	   the	   latter	   after	   revealing	   a	   requirement	   for	   a	   promoter-­‐
associated	  transcript	  (Han	  et	  al.	  2007).	  The	  antisense	  strand	  of	  the	  siRNA	  was	  shown	  to	  associate	  
with	  a	  low-­‐copy	  EF-­‐1α-­‐coding	  transcript	  with	  an	  extended	  5’	  UTR.	  In	  addition,	  the	  association	  was	  
inhibited	  by	  RNase	  A	  but	  resistant	  to	  RNase	  H	  treatment,	   implicating	  an	  RNA-­‐RNA	  interaction	  in	  
TGS.	  
Other	  studies	  have	  also	  demonstrated	  a	  requirement	  for	  promoter-­‐associated	  transcripts	  
for	   small	   RNA-­‐mediated	   gene	   silencing.	   Some	   of	   these	   studies	   have	   shown,	   as	   at	   the	   EF-­‐1α	  
promoter,	  that	  silencing	  requires	  sense	  transcripts	  (Hawkins	  et	  al.	  2009;	  Tan	  et	  al.	  2009b;	  Yue	  et	  
al.	   2010),	   whilst	   others	   have	   found	   antisense	   transcription	   through	   the	   targeted	   region	   is	  
necessary	  (Gonzalez	  et	  al.	  2008;	  Schwartz	  et	  al.	  2008).	  Several	  reports	  have	  shown	  the	  presence	  
of	   both	   sense	   and	   antisense	   promoter	   transcripts	   (Gonzalez	   et	   al.	   2008;	   Napoli	   et	   al.	   2009),	  
although	  their	  detection	  is	  not	  always	  accompanied	  by	  confirmation	  of	  their	  necessity	  in	  TGS	  (Kim	  
et	  al.	  2008;	  Napoli	  et	  al.	  2009;	  Palanichamy	  et	  al.	  2010).	  The	  relative	  contributions	  of	  sense	  and	  
antisense	  promoter	   transcripts	   to	  RNA-­‐induced	  TGS	   requires	   further	  clarity,	  particularly	  as	   their	  
relative	  levels	  may	  affect	  outcome	  (Morris	  et	  al.	  2008;	  Schwartz	  et	  al.	  2008).	  
Despite	  these	  complications,	  the	  findings	  support	  a	  model	  for	  TGS	  in	  which	  small	  RNA	  and	  
Ago-­‐containing	  RITS	   complexes	  are	  guided	   to	   their	   targets	  by	   complementary	  base	  pairing	  with	  
low-­‐copy,	  promoter-­‐associated	  RNA	  Pol	  II	  transcripts.	  This	  serves	  as	  a	  scaffold	  for	  the	  recruitment	  
of	   epigenetic-­‐modifying	   protein	   complexes	   that	   favour	   heterochromatin	   formation	   and,	  
therefore,	   decreased	   transcription	   of	   the	   targeted	   gene	   (Figure	   1.5).	   Experiments	   in	  
Schizosaccharomyces	   pombe	   support	   the	   ability	   of	   nascent	   RNA	   transcripts	   to	   direct	  
heterochromatin	   formation;	   remodelling	   occurred	   where	   RNAi-­‐associated	   protein	   complexes	  
were	  tethered	  artificially	  to	  nascent	  transcripts	  (Buhler	  et	  al.	  2006).	  The	  model	  has	  gained	  general	  
acceptance,	   facilitated	  by	   characterisation	  of	   endogenous	  miRNA	  TGS	  effectors	   (Gonzalez	   et	   al.	  
2008;	  Kim	  et	  al.	  2008;	  Tan	  et	  al.	  2009b).	  However,	  a	  different	  mechanism	  for	  TGS	  has	  also	  been	  
proposed	  that	  does	  not	  involve	  any	  epigenetic	  modifications	  at	  all	  (Janowski	  et	  al.	  2005;	  Janowski	  
et	  al.	  2006;	  Schwartz	  et	  al.	  2008;	  Napoli	  et	  al.	  2009).	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Figure	   1.5:	   Proposed	   mechanism	   of	   TGS.	   siRNA	   or	   miRNA	   duplexes	   are	   loaded	   into	   Ago-­‐containing	   RITS.	   These	  
complexes	  are	  directed	  to	   low-­‐copy	  promoter-­‐associated	  RNA	  Pol	   II	   transcripts	   through	  complementary	  base	  pairing,	  
leading	   to	   the	   recruitment	   of	   epigenetic	   modifying	   proteins.	   These	   increase	   silent-­‐state	   histone	   modifications	   and,	  
where	   long-­‐term	   silencing	   is	   established,	   DNA	   methylation.	   The	   resulting	   increase	   in	   nucleosome	   occupancy	   and	  
chromatin	   compaction	   reduces	   the	   accessibility	   of	   the	   promoter	   to	   the	   transcription	  machinery	   and,	   consequently,	  
gene	  transcription.	  
	  
1.4.3	  Transcriptional	  interference	  
	  
The	  Corey	  group	  has	  focused	  on	  targeting	  the	  region	  surrounding	  the	  transcription	  start	  
site	   (TSS),	   as	   opposed	   to	   upstream	   regions,	   which	   were	   targeted	   in	   preceding	   descriptions	   of	  
mammalian	   TGS	   (Morris	   et	   al.	   2004;	   Ting	   et	   al.	   2005).	   They	   reasoned	   that	   an	   open	   complex	   is	  
generated	  at	  the	  TSS	  by	  the	  binding	  of	  RNA	  Pol	  II,	  rendering	  it	  more	  susceptible	  to	  hybridisation	  
with	  oligonucleotides	  (Milne	  et	  al.	  2000).	  The	  TSS-­‐targeting	  small	  duplex	  RNAs	  were	  referred	  to	  as	  
antigene	  RNAs	  (agRNAs),	   rather	  than	  siRNAs,	  to	  differentiate	  them	  from	  those	  targeting	  mRNAs	  
(Janowski	  et	  al.	  2006).	  Corey’s	  group	  designed	  agRNAs	  targeting	  the	  progesterone	  receptor	  (PGR)	  
TSS	   (Janowski	   et	   al.	   2005).	   Surprisingly,	   the	   observed	   silencing	   in	   T47D	   breast	   cancer	   cells	  was	  
potent	   and	   not	   sensitive	   to	   either	   5-­‐azaC	   (Janowski	   et	   al.	   2005)	   or	   TSA	   (Janowski	   et	   al.	   2006),	  
suggesting	  that	   the	   inhibition	  obtained	  was	  mediated	  by	  a	  mechanism	  that	  was	   independent	  of	  
epigenetic	  changes,	  since	  termed	  transcriptional	  interference	  (TI).	  The	  mechanism	  of	  TI	  is	  unclear	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but	   some	   studies	   have	   implicated	   RNA	   Pol	   II	   occlusion	   mediated	   by	   RNA-­‐DNA-­‐DNA	   triplex	  
formation	  (Martianov	  et	  al.	  2007;	  Jain	  et	  al.	  2010).	  
Variations	   in	   epigenetic	   outcome	   between	   classical	   TGS	   (ie	   accompanied	   by	   epigenetic	  
changes)	  and	  TI	  may	  depend	  on	  the	  Ago	  protein	  involved.	  However,	  this	  seems	  unlikely	  given	  that	  
Ago1-­‐3	  have	  been	  associated	  with	  small	  RNA-­‐induced	  heterochromatin	  formation	  (Gonzalez	  et	  al.	  
2008;	  Hawkins	  et	  al.	  2009;	  Tan	  et	  al.	  2009b;	  Turner	  et	  al.	  2009;	  Turunen	  et	  al.	  2009;	  Giles	  et	  al.	  
2010;	  Hawkins	  and	  Morris	  2010),	  and	  Ago1	  and	  Ago2	  also	  with	  TI	  (Janowski	  et	  al.	  2006;	  Napoli	  et	  
al.	   2009;	   Chu	   et	   al.	   2010).	   Indeed,	   whether	   a	   distinct	   TI	   mechanism	   exists	   is	   still	   debateable,	  
particularly	  as	  the	  most	  recent	  report	  from	  the	  Corey	  group	  does	  demonstrate	  increased	  H3K27	  
trimethylation	  at	  the	  PGR	  promoter	  (Yue	  et	  al.	  2010),	  in	  contrast	  to	  their	  previous	  work,	  despite	  
using	   the	   same	   TSS-­‐targeting	   agRNA	   and	   cell	   line.	   Further	   studies	   are	   required	   to	   elucidate	  
whether	   there	   is	  a	  universal	  TGS	  mechanism	  and,	   if	  not,	  how	  RITS	   recruits	  different	  proteins	   to	  
initiate	  different	  events	  and	  their	  functional	  consequence.	  Regardless,	  therapeutic	  application	  of	  
TGS	  is	  likely	  to	  focus	  on	  mechanisms	  that	  result	  in	  heterochromatin	  formation	  since	  the	  potential	  
for	  long-­‐term	  silencing	  with	  TI	  is	  unknown.	  
	  
1.4.4	  Transcriptional	  gene	  activation	  
	  
The	  apparent	  ability	  of	  promoter-­‐targeting	  small	  duplex	  RNAs	  to	  associate	  with	  different	  
proteins	  may	   underlie	   the	   observation	   that	   they	   can	   also	   direct	   transcriptional	   gene	   activation	  
(TGA).	  The	   initial	   report	  of	  TGA	  showed	   increased	  expression	  of	  E-­‐cadherin,	  p21	  and	  VEGF-­‐A	  on	  
transfection	   of	   promoter-­‐targeting	   siRNAs	   into	   cultured	   cells	   (Li	   et	   al.	   2006),	   which	   could	   be	  
prevented	   by	   suppressing	   Ago2	   expression.	   However,	   these	   findings	   require	   further	   validation,	  
since	   gene	   activation	   may	   also	   be	   the	   result	   of	   an	   off-­‐target	   PTGS	   effect	   on	   a	   transcriptional	  
repressor,	   a	   phenomenon	   first	   described	   by	  Weinberg	   et	   al.	   In	   this	   study,	   microarray	   analysis	  
demonstrated	   that	   transcriptional	   activation	   with	   an	   antisense	   RNA	   targeting	   the	   HIV-­‐1	   LTR	  
promoter	  was	  accompanied	  by	  decreased	  expression	  of	  a	  transcript	  that	  functioned	  indirectly	  in	  
its	  regulation	  (Weinberg	  et	  al.	  2007).	  
A	  different	  PTGS	  off-­‐target	  effect	  was	  shown	  to	  cause	  the	  previously	  observed	  TGA	  at	  the	  
p21	  gene	  (Li	  et	  al.	  2006).	  In	  this	  case,	  a	  suppressive	  antisense	  transcript	  overlapping	  the	  promoter	  
was	  the	  unintended	  target	  of	  the	  TGA-­‐inducing	  siRNAs	  (Morris	  et	  al.	  2008).	  Whether	  the	  PTGS	  of	  
the	  suppressive	  ncRNA	  occurred	  in	  the	  nucleus	  or	  cytoplasm	  is	  unknown,	  but	  it	  is	  interesting	  that	  
nuclear	   PTGS	   has	   been	   confirmed	   in	   plants	   (Hoffer	   et	   al.	   2011).	   Despite	   these	   controversies,	  
reports	   of	   TGA	   continued,	   including	   identification	   of	   endogenous	   small	   RNA	   activators;	  
transcriptional	  activation	  of	  E-­‐cadherin	  and	  cold-­‐shock	  domain-­‐containing	  protein	  2	  (CSDC2)	  was	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observed	   following	   over-­‐expression	   of	   miR-­‐373	   (Place	   et	   al.	   2008).	   However,	   there	   was	   no	  
reciprocal	   E-­‐cadherin	   and	   CSDC2	   silencing	   on	   endogenous	   miR-­‐373	   knockdown.	   In	   addition,	  
computational	  analysis	  revealed	  miR-­‐373	  targets	  within	  1	  kb	  of	  the	  TSS	  in	  >372	  genes,	  but	  not	  all	  
responded	   to	   miR-­‐373	   over-­‐expression.	   Although	   the	   miR-­‐373-­‐mediated	   TGA	   may	   function	  
through	  a	  direct	  interaction	  of	  the	  miRNA	  with	  the	  promoter	  leading	  to	  recruitment	  of	  epigenetic	  
modifying	  complexes,	  such	  as	  HATs	  and	  HDMTs	  (Figure	  1.6A),	  further	  experimentation	  is	  required	  
to	   exclude	   off-­‐target	   PTGS	   effects	   on	   a	   regulatory	   ncRNA	   (Figure	   1.6B).	   Recently,	  miR-­‐205	  was	  
shown	   to	   induce	   TGA	   of	   interleukin-­‐24	   (IL24)	   and	   -­‐32	   (IL32)	   (Majid	   et	   al.	   2010).	   In	   this	   case,	   a	  
luciferase	   reporter	   assay	   demonstrated	   that	   direct	   promoter	   targeting	   mediated	   the	   miRNA-­‐
induced	   TGA.	   It	   is	   unknown,	   however,	   whether	   this	   TGA	   occurs	   through	   direct	   recruitment	   of	  
epigenetic	   modifying	   complexes	   (Figure	   1.6A)	   or	   steric	   hindrance	   of	   transcriptional	   repressor	  
docking	  with	  its	  cognate	  binding	  site	  in	  an	  enhancer	  region	  (Figure	  1.6C),	  as	  has	  been	  described	  at	  
the	  IL-­‐10	  gene	  (Matilainen	  et	  al.	  2010).	  Further	  studies	  are	  required	  to	  examine	  the	  mechanisms	  
of	  TGA	  and	  their	  significance	  to	  gene	  regulation	  in	  vivo.	  
	  
Figure	   1.6:	   Potential	  mechanisms	   of	   TGA.	   Several	  mechanisms	   for	   the	   induction	   of	   TGA	   have	   been	   described.	   Ago-­‐
bound	  promoter-­‐targeted	  small	  RNAs	  may	  induce	  TGA	  through	  direct	  recruitment	  of	  epigenetic	  modifying	  proteins	  (A)	  
or	   through	   PTGS	   of	   a	   ncRNA	   that	   has	   an	   endogenous	   TGS	   function	   (B).	   Alternatively,	   TGA	  may	   be	   a	   result	   of	   steric	  
hindrance	  of	  a	  repressor	  binding	  site	  in	  an	  enhancer	  region	  (C).	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Given	  the	  number	  of	  long	  ncRNA-­‐mediated	  gene	  regulatory	  pathways	  already	  identified,	  
it	  is	  perhaps	  not	  surprising	  that	  different	  small	  RNA-­‐mediated	  transcription	  modulation	  pathways	  
exist,	  particularly	  as	  the	  short	  RNA	  transcriptome	  is	  probably	  at	  least	  as	  complex,	  if	  not	  more	  so,	  
than	   that	   of	   long	  RNAs	   (Kapranov	   et	   al.	   2007a).	  However,	   it	   remains	   unclear	   how	   similar	   small	  
RNAs	  can	  induce	  TGS	  in	  one	  context	  and	  TGA	  in	  another,	  particularly	  as	  Turunen	  et	  al.	  were	  able	  
to	   induce	   TGS	   and	   TGA	   of	   VEGF-­‐A	   with	   promoter-­‐targeting	   shRNAs	   within	   the	   same	   cell	   line.	  
Therapeutic	  application	  of	  TGS	  and	  TGA	  will	  require	  a	  greater	  understanding	  of	  the	  potential	  for	  
promoter-­‐targeting	  RNAs	  to	  mediate	  opposing	  effects.	  
	  
1.4.5	  TGS-­‐based	  gene	  therapy	  
	  
Although	  the	  durability	  of	  TGS	  will	  vary	  between	  genes,	  the	  promoter-­‐targeted	  small	  RNA	  
will	   not	   require	   continual	   administration/expression	   if	   stable	   epigenetic	   changes	   are	   induced.	  
Consequently,	  there	  is	  less	  likelihood	  of	  toxicity	  associated	  with	  saturation	  of	  the	  RNAi	  pathway,	  a	  
concern	  with	  the	  PTGS	  strategy	  (Grimm	  et	  al.	  2006;	  Grimm	  et	  al.	  2010).	  In	  combination	  with	  the	  
fact	  that	  targets	  are	  in	  limited	  numbers,	  as	  opposed	  to	  many	  copies	  of	  mRNA,	  TGS	  may	  provide	  a	  
more	  efficient	  silencing	  strategy	  than	  PTGS.	  
The	  therapeutic	  application	  of	  small	  RNA-­‐induced	  gene	  silencing	  has	  followed	  two	  distinct	  
strategies:	   introduction	   of	   synthetic	   siRNAs/agRNAs	   and,	   secondly,	   use	   of	   gene	   expression	  
cassettes	   whose	   transcription	   produces	   RNAi	   precursors	   or	   antisense	   RNAs.	   Synthetic	   agRNAs	  
were	   recently	   shown	   to	   retain	   their	   activity,	   either	   silencing	   or	   activating	   transcription,	   despite	  
introduction	   of	   chemical	  modifications,	   which	  may	   increase	   their	   stability	   and	   facilitate	   in	   vivo	  
applications	   (Watts	   et	   al.	   2010).	   In	   contrast	   to	   PTGS,	   siRNAs	   inducing	   TGS	   need	   to	   access	   the	  
nucleus.	   Some	   studies	   suggest	   that	   efficient	   nuclear	   localisation	   of	   exogenous	   siRNAs	   requires	  
administration	   at	   a	   high	   concentration	   	   –	   up	   to	   ten	   times	   that	   typically	   used	   to	   obtain	   PTGS	  
(Janowski	   et	   al.	   2005;	   Han	   et	   al.	   2007;	   Hawkins	   et	   al.	   2009).	   However,	   the	   reason	   for	   this	   is	  
unclear,	   particularly	   as	   others	   have	  obtained	  TGS	  with	   comparable	   concentrations	  of	   siRNAs	   to	  
that	   commonly	   used	   for	   PTGS	   induction	   (Janowski	   et	   al.	   2006;	   Schwartz	   et	   al.	   2008;	   Yue	   et	   al.	  
2010).	  
Using	  expressed	  TGS-­‐inducing	   small	  RNAs	  ensures	  nuclear	  delivery.	  U6	  promoter-­‐driven	  
expression	  of	  the	  antisense	  strand	  of	  a	  siRNA	  alone	  was	  sufficient	  to	  mediate	  TGS	  at	  the	  HIV-­‐1	  LTR	  
(Weinberg	  et	  al.	  2006).	  Although	  the	  antisense	  effector	  was	  able	  to	   increase	  Ago1	  at	   the	  target	  
site	  (Turner	  et	  al.	  2009),	  dsRNAs	  that	  resemble	  RNAi	  pathway	  precursors	  may	  provide	  increased	  
silencing	  because	  of	  more	  efficient	  incorporation	  into	  RITS	  than	  small	  antisense	  RNA	  alone.	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Several	   groups	   have	   induced	   TGS	   through	   expression	   of	   RNAi	   mimics.	   shRNAs	   have	  
successfully	  been	  used	  to	  transcriptionally	  silence	  human	  RASSF1A	  (Castanotto	  et	  al.	  2005;	  Kim	  et	  
al.	  2006),	   IL2	   (Murayama	  et	  al.	  2006),	  ubiquitin	  C	   (Hawkins	  et	  al.	  2009),	  VEGF-­‐A	   (Turunen	  et	  al.	  
2009)	  and	  the	  HIV-­‐1	  LTR	   (Yamagishi	  et	  al.	  2009).	   It	   is	  currently	  unknown	  exactly	  how	  expressed	  
shRNAs	   are	   processed:	   if	   Dicer	   processing	   and	   Ago	   loading	   occurs	   in	   the	   cytoplasm,	   RITS	  must	  
undergo	  nuclear	   import.	  Although	   such	   import	  has	  been	  described	   in	  Tetrahymena	   (Noto	   et	  al.	  
2010)	   and	   Caenorhabditis	   elegans	   (Guang	   et	   al.	   2008),	   in	   humans	   the	   pathway	   has	   yet	   to	   be	  
identified,	  although	  may	  involve	  importin	  8	  (Weinmann	  et	  al.	  2009).	  Alternatively,	  processing	  and	  
loading	  may	  occur	  within	  the	  nucleus	  itself.	  Ago	  proteins	  are	  present	  in	  human	  nuclei	  (Tan	  et	  al.	  
2009a;	   Weinmann	   et	   al.	   2009)	   and	   nuclear	   Dicer	   activity	   was	   proposed	   (Lee	   et	   al.	   2008).	   In	  
addition,	  Dicer	  has	  been	   shown	   to	   shuttle	  between	   the	  nucleus	   and	   cytoplasm	   in	   fission	   yeast,	  
with	  absence	  from	  the	  former	  preventing	  heterochromatin	  assembly	  (Emmerth	  et	  al.	  2010)	  and	  
its	  association	  with	  chromatin	  mediating	  gene	  silencing	  (Woolcock	  et	  al.	  2011).	  Moreover,	  shRNA	  
processing	  may	  not	  be	  required	  for	  TGS	  given	  that	  Ago2	  has	  been	  shown	  to	  form	  an	  active	  RISC	  
with	   pre-­‐miRNAs	   in	   the	   nucleus	   (Tan	   et	   al.	   2009a).	   Clarification	   on	   the	   cellular	  
compartmentalisation	   of	   RNAi	   pathway	   components	   will	   enhance	   our	   ability	   to	   design	   TGS-­‐
inducing	   small	  RNAs	  and	  understand	   their	   relative	  potencies.	  More	   information	  on	  endogenous	  
pathways	  that	  allow	  some	  miRNAs	  to	  modulate	  chromatin	  but	  restrict	  others	  to	  mRNA	  regulation	  
in	  the	  cytoplasm	  will,	  hopefully,	  facilitate	  this.	  
	  
1.4.6	  TGS-­‐based	  modulation	  of	  viruses	  
	  
TGS	  has	  therapeutic	  potential	  in	  a	  number	  of	  diseases,	  including	  cancer	  (Pulukuri	  and	  Rao	  
2007)	  and	  those	  characterised	  by	  dysregulated	  hetrochromatin	  [reviewed	  in	  (Hahn	  et	  al.	  2010)].	  A	  
number	  of	   studies	   have	   also	   shown	   its	   use	   in	   the	   transcriptional	   regulation	  of	   viruses.	   TGS	  has	  
been	   induced	  with	   siRNAs	   at	   both	   the	   Human	   papilloma	   virus	   (HPV)-­‐16	   promoter	   (Hong	   et	   al.	  
2009)	  and	  enhancer	  (Palanichamy	  et	  al.	  2010),	  leading	  to	  decreased	  production	  of	  the	  oncogenic	  
E6	  and	  E7	  viral	  proteins	  and	  increased	  cell	  death	  and	  senescence.	  In	  addition,	  TGS	  has	  successfully	  
been	  induced	  at	  both	  the	  SIV	  (Lim	  et	  al.	  2008)	  and	  HIV-­‐1	  (Suzuki	  et	  al.	  2008;	  Turner	  et	  al.	  2009;	  
Yamagishi	  et	  al.	  2009)	  LTRs.	  However,	  similar	  to	  RNA-­‐induced	  TGS	  at	  the	  viral	  LTR,	  latent	  provirus	  
exhibits	   suppressed	   expression	   through	   heterochromatin	   formation	   and	   associations	   with	  
heterochromatic	   chromosome	   regions	   in	   trans	   (Dieudonne	   et	  al.	   2009;	  Tyagi	   et	  al.	   2010).	  Thus,	  
despite	  stable	  expression	  of	  LTR-­‐targeted	  shRNA	  sustaining	  suppressed	  HIV-­‐1	  gene	  expression	  for	  
>1	  year	  in	  a	  CD4+	  T	  cell	  line	  (Yamagishi	  et	  al.	  2009),	  concerns	  persist	  over	  whether	  TGS	  of	  the	  HIV-­‐
1	  promoter	  would	   in	   fact	  be	  detrimental	   to	  patients	  by	   increasing	   the	   latent	   reservoir	   of	   virus.	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TGA	  may	  offer	  greater	  therapeutic	  benefit	  than	  TGS	  at	  the	  HIV-­‐1	  LTR	  through	  reversing	   latency,	  
rendering	   replicating	   virus	   susceptible	   to	   antiviral	   drugs.	  Modulation	   of	   chromatin	   to	   eradicate	  
latent	   viral	   reservoirs	   is	   not	   a	   new	   idea;	   an	   HDAC	   inhibitor,	   in	   combination	   with	   intensified	  
antiviral	  drugs,	  has	  been	  used	  to	  deplete	  latent	  virus	  and	  accelerate	  clearance	  of	  HIV	  in	  patients	  
(Lehrman	  et	  al.	  2005).	  Small	  RNA-­‐induced	  TGA	  may	  prove	  more	  practical	   than	  a	  HDAC	   inhibitor	  
since	  effects	  would	  be	  specific	  to	  the	  viral	  promoter.	  However,	  TGA	  of	  the	  viral	  promoter	  has	  not	  
yet	  been	  reported,	  except	  when	  inadvertently	  induced	  by	  off-­‐target	  PTGS	  (Weinberg	  et	  al.	  2007).	  
Given	  these	  difficulties,	  transcriptional	  modulation	  may	  be	  better	  employed	  at	  promoters	  
of	   host	   factors	   required	   for	   HIV-­‐1	   replication,	   rather	   than	   at	   the	   viral	   promoter	   itself.	   TGS	   has	  
been	   reportedly	   induced	   at	   CCR5	   (Kim	   et	   al.	   2006;	   Han	   et	   al.	   2007),	   although	   the	   ability	   of	  
silencing	  this	  coreceptor,	  or	  any	  other	  HDF,	  by	  this	  mechanism	  to	  inhibit	  HIV-­‐1	  replication	  has	  not	  
been	   examined.	   Certainly,	   TGS	   of	   HDFs	   presents	   an	   exciting	   anti-­‐HIV	   therapeutic	   strategy;	   it	  
simultaneously	   presents	   a	   high	   genetic	   barrier	   to	   the	   development	   of	   drug-­‐resistance	   and,	  
providing	  sustained	  silent-­‐state	  chromatin	  is	  achieved,	  reduces	  therapy	  administration,	  which	  fits	  
with	  the	  realities	  of	  resource-­‐poor	  nations	  and	  may	  reduce	  the	  toxicities	  typically	  associated	  with	  
RNAi.	  However,	  the	  susceptibility	  of	  HDFs,	  other	  than	  CCR5,	  to	  TGS	  has	  not	  been	  investigated,	  nor	  
the	   therapeutic	  potential	   of	   silencing	  HDFs	  by	   this	  mechanism.	  This	   thesis,	   therefore,	   examines	  
whether	  HDF-­‐targeted	  TGS	  is	  sufficiently	  potent	  to	  inhibit	  viral	  replication	  and	  identifies	  promoter	  
features	  associated	  with	  TGS	  susceptibility.	  
	  
1.5	  HIV-­‐dependency	  factors	  
	  
Four	  cellular	  factors	  were	  selected	  for	  inclusion	  in	  this	  study,	  for	  validation	  as	  HDFs	  in	  a	  T	  
cell-­‐derived	   line	   and/or	   examination	   of	   their	   susceptibility	   to	   TGS.	   They	   were	   selected	   for	  
different	  reasons,	  described	  in	  detail	  below	  (see	  1.5.1-­‐4).	  Briefly,	  both	  HIV-­‐1	  Tat	  specific	  factor	  1	  
(HTATSF1)	  and	  DEAD	  (Asp-­‐Glu-­‐Ala-­‐Asp)	  box	  polypeptide	  3,	  X-­‐linked	  (DDX3X)	  were	  hits	  in	  genome-­‐
wide	   screens	   (Brass	   et	   al.	   2008;	   Zhou	   et	   al.	   2008)	   and,	   although	   their	   roles	   as	   HDFs	   were	  
confirmed	   in	   subsequent	   studies	   (Ishaq	   et	   al.	   2008;	   Miller	   et	   al.	   2009),	   these	   also	   employed	  
reporter	   cell	   lines	   and	   their	   potential	   as	   therapeutic	   targets	   has	   not	   been	   examined	   in	   T	   cell-­‐
derived	   lines.	   Controversy	   surrounds	   the	   requirement	   in	  HIV-­‐1	   replication	   for	   SWI/SNF	   related,	  
matrix	   associated,	   actin	   dependent	   regulator	   of	   chromatin,	   subfamily	   b,	  member	   1	   (SMARCB1)	  
(Bukrinsky	   2006)	   and	   so	   this	   was	   selected	   to	   clarify	   whether	   this	   is	   a	   HDF.	   The	   fourth	   cellular	  
factor,	   PSIP1/LEDGF/p75,	   is	   a	   well-­‐characterised	   HDF	  with	   a	   role	   in	   integration	   of	   the	   provirus	  
(Llano	  et	  al.	  2006a).	  This	  was	  included	  in	  the	  study	  to	  serve	  as	  a	  positive	  control	  for	  effects	  of	  HDF	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suppression	  on	  HIV-­‐1	  replication.	  None	  of	  the	  four	  cellular	  factors	  had	  been	  previously	  examined	  
for	  their	  susceptibility	  to	  TGS.	  
	  
1.5.1	  HTATSF1	  	  
Transcription	  in	  eukaryotic	  cells	  requires	  the	  assembly	  of	  an	  elaborate	  multi-­‐subunit	  pre-­‐
initiation	  complex,	  followed	  by	  initiation,	  elongation	  and	  termination.	  Activators	  of	  transcription	  
conventionally	  mediate	  their	  regulation	  by	  increasing	  the	  rate	  of	  initiation.	  In	  contrast,	  based	  on	  
in	   vivo	   and	   in	   vitro	   evidence,	   the	   HIV	   regulatory	   protein	   Tat	   predominantly	   stimulates	  
transcription	  at	  the	  level	  of	  elongation	  (Kao	  et	  al.	  1987;	  Laspia	  et	  al.	  1989;	  Marciniak	  et	  al.	  1990;	  
Feinberg	  et	  al.	  1991)	  on	  binding	  the	  TAR	  element	  (Berkhout	  et	  al.	  1989;	  Cullen	  1993).	  
Zhou	   and	   Sharp	   originally	   identified	   HTATSF1	   as	   a	   requirement	   for	   Tat	   activation	   of	  
elongation	   in	   a	   partially	   reconstituted	   transcription	   reaction	   isolated	   from	  HeLa	  nuclear	   extract	  
(Zhou	  and	  Sharp	  1996).	  These	  observations	  were	  confirmed	  by	  several	  studies:	  immunodepletion	  
of	   HTATSF1	   from	   nuclear	   extracts	   inactivated	   Tat	   stimulation	   of	   transcription	   and	  
complementation	  with	  recombinant	  HTATSF1	  restored	  transactivation	  (Li	  and	  Green	  1998;	  Kim	  et	  
al.	  1999;	  Parada	  and	  Roeder	  1999).	  HTATSF1	  is	  a	  component	  of	  an	  RNA	  Pol	  II-­‐containing	  complex	  
that	  includes	  other	  elongation	  factors	  hSPT5	  and	  pTEF-­‐b	  (Parada	  and	  Roeder	  1999).	  CDK9	  of	  pTEF-­‐
b,	  along	  with	  phosphorylating	  RNA	  Pol	  II	  CTD,	  phosphorylates	  HTATSF1	  (Zhou	  et	  al.	  1998;	  Zhou	  et	  
al.	  2004a),	  although	  the	  functional	  significance	  of	  this	   is	  unknown.	  HTATSF1	  also	  associates	  with	  
the	  RAP30	  subunit	  of	  TFIIF	  (Kim	  et	  al.	  1999),	  which	  is	  tightly	  bound	  to	  elongating	  RNA	  Pol	  II.	  Since	  
HTATSF1	   also	   binds	   hSPT5,	   which	   associates	   with	   RNA	   Pol	   II,	   HTATSF1	  may	   contribute	   toward	  
stabilisation	   of	   the	   elongation	   complex.	  HTATSF1	   is	   a	   general	   transcription	   elongation	   factor	   of	  
cellular	  genes	  (Li	  and	  Green	  1998;	  Chen	  et	  al.	  2009).	  Thus,	  Tat	  takes	  advantage	  of	  an	  existing	  RNA	  
Pol	  II	  complex	  to	  relieve	  the	  elongation	  block	  imposed	  on	  HIV-­‐1	  transcription,	  although	  it	  should	  
be	  noted	  that	  the	  contribution	  afforded	  by	  HTATSF1	  is	  not	  completely	  understood.	  
Sequence	   analysis	   of	   HTATSF1	   revealed	   a	   highly	   acidic	   carboxyl-­‐terminal	   half	   and	   an	  
amino-­‐terminal	  half	  containing	  two	  RNA	  recognition	  motifs	  (RRMs)	  (Zhou	  and	  Sharp	  1996).	  In	  the	  
former,	   48%	   of	   the	   last	   245	   residues	   consist	   of	   glutamate	   or	   aspartate.	   This	   half	   also	   contains	  
many	  serine	  residues	  that	  are	  arranged	  in	  a	  short	  peptide	  sequence	  matching	  consensus	  sites	  for	  
phosphorylation,	   which	   may	   contribute	   additional	   negative	   charges	   to	   this	   region.	   The	   acidic	  
carboxyl-­‐terminal	  of	  HTATSF1	  is	  required	  for	  Tat	  transactivation	  through	  an	  interaction	  with	  pTEF-­‐
b	  (Zhou	  et	  al.	  1998).	  
Primarily	   through	   the	   first	   RRM	   domain,	   HTATSF1	   has	   been	   shown	   to	   interact	   with	  
spliceosomal	  U	  small	  nuclear	  ribonucleoproteins	  (snRNPs),	  an	  association	  that	  strongly	  stimulates	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Tat	   transactivation	   and	  HIV-­‐1	   transcription	   elongation	   (Fong	   and	   Zhou	  2001).	   This	   supports	   the	  
notion	   that	   the	   recruitment	   of	   U	   snRNPs	   near	   the	   elongating	   polymerase	   is	   important	   for	  
transcription.	  As	   the	  HTATSF1-­‐U	  snRNP	  complex	  also	  stimulates	  splicing	   in	  vitro	   (Fong	  and	  Zhou	  
2001),	   HTATSF1	   may	   serve	   as	   a	   dual-­‐function	   factor	   to	   facilitate	   reciprocal	   activation	   of	  
transcription	   and	   splicing	   –	   a	   putative	   mechanism	   for	   the	   requirement	   of	   HTATSF1	   in	   HIV-­‐1	  
transcription	   elongation.	   It	   has	   also	   been	   suggested,	   in	   contrast	   to	  most	   studies,	   that	  HTATSF1	  
functions	  solely	  in	  splicing,	  not	  elongation	  (Miller	  et	  al.	  2009).	  
	  
	  
Figure	  1.7:	  Domains	  of	  HTATSF1.	  The	  amino-­‐terminal	  half	  contains	  two	  RRMs	  (light	  blue)	  and	  the	  carboxyl-­‐terminal	  half	  
a	  highly	  acidic	  domain	  (residues	  420-­‐754,	  dark	  blue).	  
	  
HTATSF1	  was	  a	  hit	  in	  one	  of	  four	  genome-­‐wide	  RNAi	  screens	  for	  the	  identification	  of	  HDFs	  
–	  siRNA	  knockdown	  of	  HTATSF1	  resulted	  in	  a	  69%	  decrease	  in	  p24	  production	  (Brass	  et	  al.	  2008).	  
Together	  the	  evidence	  suggests	  a	  requirement	  for	  HTATSF1	  in	  HIV-­‐1	  replication.	  However,	  much	  
of	  the	  previous	  work	  has	  focused	  on	  immunodepletion	  in	  vitro	  and	  the	  siRNA	  screen	  results,	  not	  
recapitulated	   in	   other	   screens,	   have	   yet	   to	   be	   verified	   in	   a	   relevant	   cell	   line.	   Moreover,	   the	  
potential	   toxicity	   of	   suppressing	   this	   general	   transcription	   elongation	   factor	   has	   yet	   to	   be	  




HIV-­‐1	   gene	   expression	   is	   substantially	   governed	   post-­‐transcriptionally	   by	   Rev-­‐regulated	  
export	   of	   unspliced/partially	   spliced	   viral	   RNAs	   from	   the	   nucleus	   to	   the	   cytoplasm	   (see	   1.2.3)	  
(Harris	  and	  Hope	  2000).	  DDX3X	  was	  first	  in	  the	  family	  of	  DEAD	  box	  helicases	  found	  to	  play	  a	  role	  
in	  HIV-­‐1	  replication	  through	  its	  function	  in	  the	  Rev/RRE-­‐CRM1	  export	  pathway.	  DEAD	  box	  proteins	  
are	   superfamily	   2	   RNA	   helicases	   involved	   in	   many	   aspects	   of	   RNA	   metabolism,	   including	  
transcription,	   mRNA	   splicing	   and	   RNA	   export	   [reviewed	   in	   (Rajkowitsch	   et	   al.	   2007;	   Pan	   and	  
Russell	  2010)].	  Some,	  such	  as	  DDX3X,	  use	  an	  ATP-­‐dependent	  cycle	  of	  conformational	  changes	  to	  
disrupt	   RNA	   structure,	   accelerating	   structural	   transitions	   of	   RNAs	   and	   RNPs,	   in	   a	   manner	   that	  
bears	   a	   strong	   resemblance	   to	   the	   activities	   of	   certain	   protein	   chaperones.	   Consequently,	   a	  
number	  of	  functions	  have	  been	  ascribed	  to	  DDX3X	  in	  both	  the	  nucleus	  and	  cytoplasm	  [reviewed	  
in	  (Schroder	  2010)],	   including	  regulation	  of	  cell	  growth	  through	  translational	  control	  of	  cyclin	  E1	  
(Lai	  et	  al.	  2010).	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HIV-­‐1	  does	  not	  encode	  a	  RNA	  helicase	  and,	  thus,	  hijacks	  an	  array	  of	  cellular	  RNA	  helicases.	  
Studies	   have	  previously	   shown	   that	   suppression	  of	  DDX3X	   leads	   to	   decreased	  HIV-­‐1	   replication	  
accompanied	  by	  a	  decrease	  in	  cytoplasmic	  RRE-­‐containing	  viral	  transcripts	  (Yedavalli	  et	  al.	  2004).	  
Interestingly,	  DDX3X	  may	  be	  limiting	  for	  HIV-­‐1	  replication;	  CA/p24	  production	  is	  slightly	  increased	  
in	   Jurkat	   cells	   infected	   with	   a	   HIV-­‐1	   molecular	   clone	   in	   which	   Nef	   is	   replaced	   with	   DDX3X	  
(Yedavalli	   et	   al.	   2004).	   Furthermore,	   HIV-­‐1	   appears	   to	   modulate	   expression	   levels	   of	   DDX3X;	  
expression	  is	  enhanced	  in	  Tat-­‐expressing	  samples	  (Yedavalli	  et	  al.	  2004)	  and	  varies	  between	  cells	  
with	  latent	  and	  actively-­‐replicating	  virus	  (Krishnan	  and	  Zeichner	  2004).	  Upregulation	  of	  DDX3X	  for	  
efficient	   HIV-­‐1	   replication	   suggests	   this	   protein	   is	   a	   good	   therapeutic	   target,	   since	   moderate	  
suppression	  may	  not	  interfere	  with	  endogenous	  cellular	  pathways,	  thus	  minimising	  toxicity,	  whilst	  
simultaneously	  inhibiting	  viral	  pathways.	  
DDX3X	  was	   identified	  as	  a	  HDF	  by	   two	  genome-­‐wide	  siRNA	  screens	  performed	   in	  HeLa-­‐
derived	   cells	   (Brass	   et	   al.	   2008;	   Zhou	   et	   al.	   2008).	   Screen	   results	   were	   recently	   validated	   on	  
demonstration	   that	   shRNA-­‐mediated	   knockdown	   of	   DDX3X	   suppressed	   replication	   of	   an	   HIV-­‐1	  
molecular	  clone	  without	  effecting	  cell	  viability	  (Ishaq	  et	  al.	  2008).	  This	  supports	  that	  DDX3X	  may	  
not	   be	   essential	   to	   the	   cell	   or,	   alternatively,	   that	   low	   level	   DDX3X	   is	   sufficient	   to	   maintain	   its	  
putative	  function	  for	  cellular	  mRNA	  metabolism	  while	  higher	  levels	  are	  required	  for	  its	  function	  in	  
HIV-­‐1	  RNA	  nuclear	  export.	  Unfortunately,	  this	  validation	  was	  conducted	  in	  HEK293T-­‐derived	  cells.	  
This	  is	  of	  particular	  importance	  when	  the	  multi-­‐functionality	  of	  DDX3X	  is	  considered	  [reviewed	  in	  
(Schroder	  2010)].	  At	   least	  four	  different	  viruses,	  namely	  hepatitis	  B	  virus	  (HBV),	  hepatitis	  C	  virus	  
(HCV),	   HIV	   and	   poxviruses,	   encode	   proteins	   that	   interact	   with	   DDX3X.	   It	   is	   required	   for	   HCV	  
replication	   (Angus	   et	   al.	   2010;	   Sun	   et	   al.	   2010)	   but,	   conversely,	   displays	   antiviral	   properties;	  
DDX3X	  may	  function	  as	  a	  RIG-­‐1-­‐like	  receptor	  in	  the	  cytoplasm	  on	  recognition	  of	  viral	  RNAs,	  which	  
leads	   to	   a	   type	   I	   interferon	   response	   (Mulhern	   and	   Bowie	   2010;	   Oshiumi	   et	   al.	   2010b).	   These	  
antiviral	  effects	  are	  such	  that	  both	  HBV	  and	  poxvirus	  express	  proteins	  that	   interact	  with	  DDX3X,	  
abolishing	  its	  ability	  to	  induce	  an	  innate	  immune	  response	  (Kalverda	  et	  al.	  2009;	  Oda	  et	  al.	  2009;	  
Wang	   and	   Ryu	   2010).	   Thus,	   although	   DDX3X	   has	   proved	   a	   prime	   target	   for	   viral	   manipulation	  
because	   of	   it	   multi-­‐functionality,	   its	   suppression	   may	   have	   positive	   or	   negative	   effects	   on	   cell	  
proliferation	   and	   viral	   replication	   depending	   on	   the	   cell	   type	   and	   environmental	   conditions.	  
Confirmation	   is	   required,	   therefore,	   of	   whether	   RNAi-­‐mediated	   DDX3X	   suppression	   will	   be	  
effective	   at	   inhibiting	   HIV-­‐1	   replication	   in	   a	   T	   cell-­‐derived	   line,	   a	   model	   that	   more	   closely	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SMARCB1	   is	   one	   of	   four	   core	   components	   of	   the	  mammalian	   SWI/SNF	   complex	   that	   is	  
involved	   in	  ATP-­‐dependent	  chromatin	   remodelling	  during	   transcriptional	  activation	   (Wang	   et	  al.	  
1996)	   and	   nucleotide	   excision	   repair	   (Ray	   et	   al.	   2009).	   SMARCB1	   is	   also	   known	   as	   SNF5	   and	  
integrase	   interactor	   1	   (INI1),	   the	   latter	   because	   it	   was	   the	   first	   host	   protein	   shown	   to	   directly	  
interact	  with	  HIV-­‐1	  IN	  (Kalpana	  et	  al.	  1994),	  an	  interaction	  that	  is	  HIV-­‐specific	  among	  retroviruses	  
(Yung	   et	   al.	   2004;	   Rain	   et	   al.	   2009).	   SMARCB1	   contains	   three	   conserved	   regions	   including	   two	  
imperfect	  repeats,	  Rpt1	  and	  Rpt2,	  and	  a	  C-­‐terminal	  coiled-­‐coil	  domain	  (Morozov	  et	  al.	  1998).	  The	  
Rpt	  domains	  are	  involved	  in	  protein-­‐protein	  interactions	  with	  both	  viral	  and	  cellular	  proteins	  and	  
Rpt1	  is	  necessary	  and	  sufficient	  to	  bind	  to	  HIV-­‐1	  IN	  (Wu	  et	  al.	  1996;	  Morozov	  et	  al.	  1998;	  Cheng	  et	  
al.	  1999;	  Lee	  et	  al.	  1999).	  Residues	  106-­‐183	  bind	  DNA	  non-­‐specifically,	  whereas	  residues	  183-­‐243	  
comprise	  the	  IN	  binding	  domain	  (IBD),	  with	  T213,	  D224,	  D226	  and	  S246	  critical	  for	  IN	  interaction	  
(Figure	  1.8)	  (Yung	  et	  al.	  2001).	  A	  masked	  nuclear	  export	  sequence	  (residues	  266-­‐276)	  within	  Rpt2	  
becomes	   functional	   when	   the	   C-­‐terminal	   domain	   is	   deleted	   (Craig	   et	   al.	   2002),	   facilitating	  
SMARCB1	  CRM1-­‐dependent	  export.	  
Despite	   the	   early	   discovery	   of	   a	   SMARCB1-­‐IN	   association,	   there	   is	   still	   controversy	  
regarding	   the	   role	   of	   SMARCB1	   in	   HIV-­‐1	   replication.	   Considerable	   evidence	   supports	   that	   the	  
SWI/SNF	   complex	   is	   directly	   involved	   in	   Tat-­‐mediated	   activation	   of	   HIV-­‐1	   transcription	   through	  
remodelling	  of	  the	  +1	  nucleosome	  (Ariumi	  et	  al.	  2006;	  Mahmoudi	  et	  al.	  2006;	  Treand	  et	  al.	  2006),	  
which	   is	   positioned	   immediately	   downstream	   of	   the	   transcription	   start	   site	   at	   the	   viral	   LTR.	  
SMARCB1	   has	   also	   been	   shown	   to	   interact	   with	   HIV-­‐1	   PICs	   (Turelli	   et	   al.	   2001),	   RT	   complexes	  
(Iordanskiy	   et	   al.	   2006)	   and	   Pr160GagPol	   (Yung	   et	   al.	   2001),	   and	   to	   be	   incorporated	   into	   HIV-­‐1	  
virions	   (Yung	   et	   al.	   2004;	   Sorin	   et	   al.	   2009),	   although	   the	   functional	   significance	   of	   these	  
associations,	   as	   well	   as	   the	   interaction	   with	   IN,	   is	   unclear.	   Recent	   evidence	   suggests	   that	  
SMARCB1	  association	  with	  the	  IN	  portion	  of	  Pr160GagPol	  is	  necessary	  for	  trafficking	  of	  the	  latter	  and	  
HIV-­‐1	  particle	  assembly	  and	  budding	  (Cano	  and	  Kalpana	  2010),	  and	  with	  IN	  as	  part	  of	  the	  PIC	  to	  
facilitate	  initiation	  of	  latent	  or	  productive	  transcription	  programmes	  soon	  after	  integration	  (Boese	  
et	  al.	  2009).	  
Suppression	   of	   SMARCB1,	   or	   expression	   of	   mutants,	   has	   been	   shown	   to	   inhibit	   HIV-­‐1	  
replication	   (Yung	   et	   al.	   2001;	   Ariumi	   et	   al.	   2006;	   Boese	   et	   al.	   2009)	   and	   infectious	   particle	  
production	  (Sorin	  et	  al.	  2006;	  Cano	  and	  Kalpana	  2010).	  In	  contrast,	  it	  has	  also	  been	  suggested	  that	  
SMARCB1	  interferes	  with	  early	  steps	  of	  HIV-­‐1	  replication	  (Maroun	  et	  al.	  2006;	  Sorin	  et	  al.	  2006).	  
Such	  studies,	  along	  with	  the	  multiple	  interactions	  in	  which	  SMARCB1	  engages,	  have	  compounded	  
efforts	  to	  determine	  the	  therapeutic	  potential	  of	  targeting	  this	  cellular	  factor.	  In	  support	  of	  a	  HDF	  
role,	  gene	  expression	  analyses	  reveal	  that,	  similar	  to	  DDX3X,	  SMARCB1	  is	  up-­‐regulated	  in	  actively-­‐	  
versus	  latently-­‐infected	  cells	  (Krishnan	  and	  Zeichner	  2004).	  However,	  several	  genome-­‐wide	  RNAi	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screens	  to	  detect	  HDFs	  did	  not	  identify	  SMARCB1	  (Brass	  et	  al.	  2008;	  Konig	  et	  al.	  2008;	  Zhou	  et	  al.	  
2008;	  Yeung	  et	  al.	  2009b).	  Given	  these	  conflicting	  reports	  and	  the	  fact	  that,	  with	  the	  exception	  of	  
Yeung	  et	  al.,	  studies	  examining	  the	  role	  of	  SMARCB1	  in	  HIV-­‐1	  replication	  have	  not	  used	  a	  T	  cell-­‐




PSIP1/LEDGF/p75	   is	   a	   well-­‐characterised	   HDF	   involved	   in	   HIV-­‐1	   integration.	   PSIP1	   is	  
neither	  lens-­‐specific	  nor	  a	  growth	  factor	  but,	  rather,	  an	  ubiquitously	  expressed	  and	  constitutively	  
nuclear	  transcription	  factor-­‐type	  protein.	  Two	  splice	  variants,	  530	  amino	  acid	  p75	  and	  333	  amino	  
acid	   p52,	   possess	   unique	   C-­‐termini	   (Figure	   1.8)	   (Ge	   et	   al.	   1998).	   Both	   isoforms	   function	   as	  
transcriptional	  coactivators	   (Ge	  et	  al.	  1998),	  although	  only	  p75	  associates	  with	  HIV-­‐1	   IN	  directly	  
(Cherepanov	  et	  al.	  2003;	  Rain	  et	  al.	  2009;	  Raghavendra	  et	  al.	  2010).	  
A	  number	  of	  groups	  established	  the	  role	  of	  p75	  in	  chromatin	  tethering	  and	  demonstrated	  
that	   lentiviral	   IN	   proteins	   are	   cytoplasmic	   in	   the	   absence	   of	   p75	   (Cherepanov	   et	   al.	   2003;	  
Maertens	  et	  al.	  2003;	  Llano	  et	  al.	  2004;	  Komano	  et	  al.	  2005).	  Discrete	  functional	  modules	  govern	  
various	   activities	   (Figure	   1.8);	   nuclear	   localisation	   of	   p75	   is	   the	   outcome	  of	   both	  NLS-­‐mediated	  
nuclear	   import	   (Maertens	   et	   al.	   2003)	   and	   a	   dynamic	   scan-­‐and-­‐lock	   mechanism	   for	   chromatin	  
trapping	  (Hendrix	  et	  al.	  2010).	  Chromatin	  linkage	  of	  IN	  is	  mediated	  by	  specific	  domains	  located	  at	  
opposite	   ends	   of	   p75,	   hence	   the	   tether	   metaphor.	   The	   first	   198	   amino	   acids	   of	   PSIP1/LEDGF	  
contain	  a	  modular	  chromatin-­‐binding	  ensemble	  containing	  charged	  regions	  1,	  2	  and	  3	  (CR1,	  CR2	  
and	  CR3)	  that	  enhance	  the	  dominant	  chromatin-­‐binding	  activities	  of	  the	  PWWP	  (Pro-­‐Trp-­‐Trp-­‐Pro)	  
domain	  and	  an	  AT-­‐Hook	  pair	  (Figure	  1.8).	  The	  C-­‐terminal	  IBD	  (residues	  347-­‐429)	  interacts	  with	  the	  
IN	   catalytic	   core	   domain	   (CCD)	   (Cherepanov	   et	   al.	   2003).	   The	   functional	   unit	   comprises	   two	  
asymmetric	   integrase	   dimers	   and	   two	   p75	   molecules	   (Michel	   et	   al.	   2009).	   IN	   subunit-­‐subunit	  
interactions	  are	  highly	  dynamic,	  with	  p75	   strongly	   stabilising	   interactions	  and	  promoting	   the	   IN	  
tetramer,	  the	  interface	  of	  which	  is	  important	  for	  enzymatic	  activities	  and	  high	  affinity	  p75	  binding	  
(McKee	  et	  al.	  2008;	  Michel	  et	  al.	  2009).	  
Suppression	  of	  p75	  alters	   the	  genomic	  distribution	  of	  HIV-­‐1	   integration	  with	   three	  main	  
effects:	   (1)	   the	   lentiviral	   bias	   for	   integrating	   into	   active	   genes	   was	   reduced;	   (2)	   AT-­‐rich	   DNA	  
targeting	  decreased;	  and,	  (3)	  p75-­‐regulated	  genes	  were	  relatively	  disfavoured	  (Ciuffi	  et	  al.	  2005).	  
These	   integration	  pattern	  results	  have	  been	  confirmed	  and	  extended	   in	  two	  subsequent	  studies	  
(Marshall	  et	  al.	  2007;	  Shun	  et	  al.	  2007).	  Recent	  profiling	  of	  the	  p75	  chromatin	  interaction	  in	  the	  
region	   analysed	   by	   the	   ENCODE	   project	   reveals	   associations	  with	   active	   chromatin	  markers,	   as	  
expected.	   However,	   some	   associations	   did	   not	   correlate	   with	   preferred	   HIV-­‐1	   integration	   sites	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indicating	  that	  not	  all	  p75	  complexes	  on	  the	  chromosome	  are	  amenable	  to	  HIV-­‐1	  integration	  (De	  
Rijck	  et	  al.	  2010).	  p75	  also	  associates	  with	  HIV-­‐1	  Rev,	  which	  is	  accompanied	  by	  loss	  of	  association	  
with	   IN	   (Levin	   et	   al.	   2010a;	   Levin	   et	   al.	   2010b),	   which	   may	   serve	   to	   regulate	   proviral	   DNA	  
integration	  and	  prevent	  super-­‐infection.	  
	  
	  
Figure	  1.8:	  Domain	   structure	  of	  PSIP1/LEDGF/p75	  and	  SMARCB1/INI1/SNF5	  and	   interactions	  with	  HIV-­‐1	   IN.	  Amino	  
acids	   at	   the	   interfaces	   between	   IN	   and	   p75	   and	   SMARCB1	   are	   indicated	   in	   green	   and	   red,	   respectively.	  A.	   The	   N-­‐
terminal	  domain	  ensemble	  participating	  in	  chromatin	  binding	  is	  primarily	  the	  PWWP	  domain	  (brown)	  and	  the	  AT	  Hook	  
domain	   (yellow),	   with	   CR1-­‐3	   (green)	   being	   relatively	   charged	   regions	   that	   influence	   chromatin	   binding	   to	   a	   lesser	  
extent.	  In	  cells,	  p75	  binds	  tetrameric	  IN	  via	  its	  IBD	  (residues	  347-­‐429,	  blue).	  The	  nuclear	  localisation	  signal	  is	  depicted	  in	  
pink.	  Alternative	   splicing	   can	   generate	   a	  C-­‐termini	   variant,	   p52.	  B.	   IN	   is	   generated	   from	  Pr160GagPol	   by	   viral	   protease	  
cleavage.	   IN	   associates	   with	   both	   p75	   and	   SMARCB1	   through	   its	   CCD	   (residues	   51-­‐212,	   purple).	   The	   catalytically	  
essential	  DDE	  motif	  of	  the	  CCD	  is	  depicted	  in	  purple.	  C.	  For	  SMARCB1,	  yellow	  denotes	  the	  DNA-­‐binding	  region,	  blue	  the	  
IBD	  and	  pink	  the	  masked	  nuclear	  export	  sequence.	  
	  
Several	   approaches	   have	   shown	   that	   for	   HIV-­‐1,	   p75	   is	   functionally	   super-­‐abundant	   and	  
must	   be	   stripped	   from	   the	   DNase-­‐	   and	   salt-­‐extractable	   chromatin	   fraction	   to	   produce	   a	  
substantial	   block	   to	  HIV-­‐1	   integration	   (Llano	   et	   al.	   2006a;	   Llano	   et	   al.	   2006b;	  Hombrouck	   et	   al.	  
2007;	  Shun	  et	  al.	  2007).	  Nevertheless,	  mouse	  knockouts	  reveal	  that	  p75	  is	  not	  essential	  for	  cell	  or	  
organism	   survival	   (Sutherland	   et	   al.	   2006),	   suggesting	   that	   p75	   is	   a	   good	   anti-­‐HIV	   therapeutic	  
target.	   Indeed,	   a	   number	   of	   approaches	   are	   being	   pursued	   for	   the	   inhibition	   of	   the	   p75-­‐IN	  
interaction,	   including	   small-­‐molecule	   inhibitors	   (Christ	   et	   al.	   2010;	   De	   Luca	   et	   al.	   2010)	   and	  
inhibitory	  peptides	  based	  on	  the	  IBD	  (Hayouka	  et	  al.	  2010a;	  Hayouka	  et	  al.	  2010b).	  
There	  are	  concerns	  over	  p75-­‐IN	  targeting	   inducing	  a	  shift	   toward	   integration	  sites	  more	  
typical	  of	  γ-­‐retroviruses,	  which	  may	   increase	  cancer	   incidence.	   In	  addition,	  a	   shift	   in	   integration	  
may	  have	  consequences	   for	   the	   frequency	  of	  post-­‐integration	   latency,	  as	   the	   integration	  site	  of	  
the	  HIV-­‐1	  promoter	  primarily	  modulates	  transcriptional	  burst	  size,	  rather	  than	  frequency	  (Skupsky	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et	  al.	  2010).	  Regardless,	  shRNA-­‐mediated	  p75	  knockdown	  in	  T	  cell-­‐derived	  SupT1	  cells	  was	  shown	  
to	  inhibit	  HIV-­‐1	  replication	  for	  over	  30	  days	  (Llano	  et	  al.	  2006a).	  Consequently,	  p75-­‐targeting	  was	  
performed	  in	  this	  study	  as	  a	  positive	  control	  for	  HDF	  suppression	  inhibiting	  HIV-­‐1	  replication.	  
	  
1.6	  Thesis	  objectives	  
	  
Sustained	   inhibition	   of	   HIV-­‐1	   replication	   may	   be	   achieved	   by	   targeting	   cellular	   factors	  
required	  for	  productive	  completion	  of	  the	  viral	  life	  cycle.	  This	  is	  likely	  to	  present	  a	  higher	  genetic	  
barrier	  to	  viral	  escape	  than	  targeting	  the	  virus	  directly,	  although	  care	  must	  be	  taken	  to	  avoid	  toxic	  
side	  effects.	  A	  number	  of	  putative	  HDFs	  require	  validation,	  particularly	  in	  cells	  that	  are	  the	  natural	  
substrates	  of	  HIV-­‐1,	  to	  provide	  a	  clear	  indication	  of	  whether	  these	  cellular	  factors	  warrant	  further	  
investigation	  as	  anti-­‐HIV	   therapeutic	   targets.	   Strategies	   that	  do	  not	   require	  daily	  administration	  
will	  be	  more	  practical	  in	  resource-­‐poor	  settings	  and	  may	  also	  reduce	  therapy-­‐associated	  toxicities.	  
The	  application	  of	  TGS,	  which	  has	  the	  potential	  to	  induce	  long-­‐term	  gene	  silencing,	  is	  an	  attractive	  
therapeutic	  option.	  However,	  this	  approach	  has	  rarely	  been	  explored	  at	  HDF	  gene	  promoters	  and	  
the	  ability	  of	  TGS	  at	  HDFs	  to	  inhibit	  HIV-­‐1	  replication	  has	  not	  been	  characterised.	  In	  addition,	  it	  is	  
currently	  unknown	  whether	  all	  RNA	  Pol	  II-­‐transcribed	  genes	  are	  susceptible	  to	  small	  RNA-­‐induced	  
TGS,	  which	  hampers	  target	  selection.	  Therefore,	  the	  overall	  aims	  of	  this	  thesis	  were:	  
1. To	   characterise	  whether	   the	   host	   factors	   HTATSF1,	   DDX3X	   and	   SMARCB1	   are	   HDFs	  
and	  potential	  anti-­‐HIV	  therapeutic	  targets.	  
a. A	   panel	   of	   shRNAs,	   designed	   to	   target	   the	   four	   cellular	   factors	   HTATSF1,	  
DDX3X,	   SMARCB1	  and	  PSIP1,	  were	   tested	   for	   their	   ability	   to	  mediate	   target	  
suppression	  in	  vitro.	  
b. The	   ability	   of	   these	   shRNAs	   to	   inhibit	   HIV-­‐1	   replication	   was	   assessed	   in	  
reporter	  cell	   lines,	   to	   indicate	  whether	   the	   targeted	  host	   factors	   function	  as	  
HDFs.	  
c. The	  cytotoxic	  effects	  accompanying	  shRNA-­‐mediated	  target	  suppression	  were	  
examined.	  
d. To	   further	   validate	   the	   therapeutic	   potential	   of	   targeting	   these	   cellular	  
factors,	   T	   cell-­‐derived	   lines	   with	   stable	   shRNA	   expression	   were	   generated.	  
These	  were	  tested	  for	  their	  ability	  to	  support	  HIV-­‐1	  replication.	  
e. Proliferation	   rates	   of	   the	   T	   cell-­‐derived	   lines	   with	   suppressed	   host	   factor	  
expression	  were	  determined.	  
2. To	  characterise	  whether	  TGS	  could	  be	  induced	  at	  various	  HDF	  promoters	  and	  describe	  
promoter	  features	  associated	  with	  TGS	  susceptibility.	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a. A	  panel	  of	   siRNAs,	  designed	   to	   target	  HDF	  promoters,	  were	   tested	   for	   their	  
ability	  to	  mediate	  target	  suppression	  in	  vitro.	  
b. The	   mechanism	   of	   siRNA-­‐mediated	   target	   silencing	   was	   characterised,	   to	  
discriminate	  between	  PTGS	  and	  TGS.	  
c. The	   ability	   of	   TGS	   at	   HDF	   promoters	   to	   inhibit	   HIV-­‐1	   infectious	   particle	  
production	  was	  determined	  in	  reporter	  cell	  lines.	  
d. A	   genome-­‐wide	   analysis	   of	   promoter	   features	   was	   performed	   to	   identify	  
those	  associated	  with	  TGS	  susceptibility.	  
Achieving	  these	  objectives	  contributes	  to	  the	  field	  of	  HIV	  therapy	  development	  by:	  (1)	  validating	  
HDFs	  and	   confirming	   their	  potential	   as	  drug	   targets;	   (2)	  demonstrating	  whether	  TGS	  of	  HDFs	   is	  
sufficiently	  potent	  to	  inhibit	  viral	  replication;	  and,	  (3)	  facilitating	  the	  ability	  of	  future	  researchers	  
to	   select	   TGS	   target	   genes	   and,	   therefore,	   novel	   HDF	   targets.	   Together,	   completion	   of	   these	  
objectives	   contributes	   to	   the	   development	   of	   improved	  HIV	   therapeutics	  with	   reduced	   toxicity,	  
administration	  frequency	  and	  viral	  resistance.	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CHAPTER	  2	  





Viruses,	   by	   definition,	   are	   obligate	   parasites.	   Encoding	   only	   15	   proteins	   (Frankel	   and	  
Young	   1998),	   HIV	   exploits	   cellular	   functions	   of	   its	   host	   to	   facilitate	   replication.	   Given	   the	   high	  
mutability	  of	  HIV,	  the	  targeting	  of	  cellular	  factors	  required	  for	  HIV	  replication	  is	  an	  attractive	  anti-­‐
HIV	   therapy	   since	   the	   genetic	   barrier	   for	   viral	   escape	   should	   be	   significantly	   higher	   than	  when	  
targeting	  the	  virus	  itself	  (see	  1.2.5).	  
RNAi	   is	   a	   useful	   method	   for	   gene	   silencing	   in	   which	   dsRNAs	   induce	   sequence-­‐specific	  
degradation	  of	  homologous	  mRNAs	   in	  plants	  and	  animals	  (Fire	  et	  al.	  1998;	  Chiu	  and	  Rana	  2002;	  
McManus	   and	   Sharp	   2002)	   (see	   1.3.1).	   Indeed,	   RNAi	   has	   become	   the	   method	   of	   choice	   for	  
genome-­‐wide	   screens	   for	   the	   identification	   of	   factors	   involved	   in	   processes,	   including	   viral	  
replication	   (see	   1.3.5).	   Four	   genome-­‐wide	   RNAi	   screens	   have	   been	   performed	   to	   identify	   host	  
proteins	  involved	  in	  HIV-­‐1	  replication	  (Brass	  et	  al.	  2008;	  Konig	  et	  al.	  2008;	  Zhou	  et	  al.	  2008;	  Yeung	  
et	  al.	  2009b),	  so-­‐called	  HIV-­‐dependency	  factors	  (HDFs)	  (Brass	  et	  al.	  2008)	  (see	  1.3.4).	  Little	  overlap	  
was	   observed	   between	   these	   studies,	  which	   is	   unsurprising	   given	   the	   different	   conditions	   used	  
and	   the	  variation	  between	   identical	   screens	   (Bushman	  et	  al.	  2009).	  An	  elegant	  meta-­‐analysis	  of	  
the	  first	  three	  screens	  demonstrated	  that	  the	  analysis	  of	  enriched	  networks	  was	  more	  robust	  than	  
identification	  of	  individual	  proteins	  involved	  in	  HIV-­‐1	  replication	  (Bushman	  et	  al.	  2009).	  Thus,	  the	  
individual	  proteins	  identified	  in	  these	  screens	  require	  further	  experimental	  validation	  of	  their	  role	  
in	  HIV-­‐1	  replication.	  
HTATSF1	  was	  a	  hit	  in	  the	  first	  genome-­‐wide	  RNAi	  screen	  for	  HDFs	  (Brass	  et	  al.	  2008)	  and	  
was	  previously	   implicated	   in	  HIV	  pathogenesis	  as	  an	  elongation	   factor	   (Zhou	  and	  Sharp	  1996;	  Li	  
and	   Green	   1998;	   Kim	   et	   al.	   1999;	   Parada	   and	   Roeder	   1999;	   Zhou	   et	   al.	   2004a)	   (see	   1.5.1).	  
Increasing	  evidence	  supports	  a	  general	  elongation	  factor	  role	  that	  is	  not	  HIV-­‐specific	  (Li	  and	  Green	  
1998;	  Parada	  and	  Roeder	  1999;	  Chen	   et	  al.	   2009).	  DDX3X	  was	  a	  hit	   in	   two	  screens	   (Brass	   et	  al.	  
2008;	   Zhou	   et	   al.	   2008).	   An	   RNA	   helicase,	   DDX3X	   is	   involved	   in	   the	   Rev-­‐CRM1	   nuclear	   export	  
pathway	  of	  singly	  spliced	  and	  unspliced	  HIV	  transcripts	   (Yedavalli	  et	  al.	  2004)	  but	  has	  also	  been	  
implicated	  in	  regulation	  of	  cell	  cycle	  progression	  (Lai	  et	  al.	  2010)	  and	  an	  antiviral	  innate	  immune	  
response	  (Oshiumi	  et	  al.	  2010a)	  (see	  1.5.2).	  At	  the	  outset	  of	  this	  work,	  no	  study	  had	  validated	  the	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screen	   results	   to	   show	   that	   RNAi-­‐mediated	   depletion	   of	   HTATSF1	   and	   DDX3X	   in	   cell	   culture	  
inhibits	  HIV-­‐1	  replication.	  
SMARCB1	   is	   one	   of	   four	   core	   components	   of	   the	  mammalian	   SWI/SNF	   complex	   that	   is	  
involved	   in	  ATP-­‐dependent	  chromatin	   remodelling	  during	   transcriptional	  activation	   (Wang	   et	  al.	  
1996)	   (see	   1.5.3).	   SMARCB1	  was	   the	   first	   host	   protein	   shown	   to	   directly	   interact	  with	  HIV-­‐1	   IN	  
(Kalpana	  et	  al.	  1994;	  Rain	  et	  al.	  2009),	  yet	  there	  is	  considerable	  controversy	  regarding	  the	  role	  of	  
SMARCB1	  in	  HIV-­‐1	  replication.	  The	  majority	  of	  evidence	  points	  to	  SMARCB1	  as	  an	  HDF,	  with	  roles	  
both	  early	  and	  late	  in	  the	  HIV-­‐1	  replication	  cycle.	  However,	  the	  lack	  of	  identification	  of	  SMARCB1	  
in	  several	  large-­‐scale	  RNAi	  screens	  to	  detect	  HDFs	  (Brass	  et	  al.	  2008;	  Konig	  et	  al.	  2008;	  Zhou	  et	  al.	  
2008;	  Yeung	  et	  al.	  2009b),	  and	  the	  numerous	  conflicting	  results,	  necessitate	  further	  investigation	  
into	  the	  requirement	  for	  this	  protein	  in	  viral	  replication.	  
The	   75	   kDa	   isoform	   of	   PSIP1,	   p75,	   has	   a	   well-­‐characterised	   role	   in	   HIV-­‐1	   integration	  
(Llano	   et	   al.	   2006a;	   Vandekerckhove	   et	   al.	   2006)	   (see	   1.5.4).	   PSIP1	   is	   believed	   to	   function	   as	   a	  
general	   adaptor	   between	   chromatin	   and	   proteins	   that	   must	   be	   brought	   into	   the	   proximity	   of	  
chromatin	   to	   function,	   such	   as	   those	   involved	   in	   transcription	   (Bartholomeeusen	   et	   al.	   2007;	  
Bartholomeeusen	   et	   al.	   2009)	   and	   integration.	   p75	   mouse	   knockouts	   reveal	   that	   p75	   is	   not	  
essential	   for	   cell	   or	  organism	  survival	   (Sutherland	   et	  al.	   2006).	   In	  addition,	   stable	   knockdown	   is	  
well	   tolerated	   in	   human	   cell	   lines,	   producing	   no	   discernible	   differences	   in	   growth	   rates,	  
morphology	  or	  phenotypes	  other	  than	  lentivirus	  susceptibility	  (Llano	  et	  al.	  2004;	  Ciuffi	  et	  al.	  2005;	  
Llano	  et	  al.	  2006a;	  Vandekerckhove	  et	  al.	  2006;	  Marshall	  et	  al.	  2007).	  This	   implicates	  PSIP1	  as	  a	  
good	  antiviral	  therapeutic	  target	  and,	  indeed,	  shRNA-­‐targeting	  of	  PSIP1	  was	  shown	  to	  effectively	  
inhibit	  HIV-­‐1	  replication	  in	  SupT1	  cells	  (Llano	  et	  al.	  2006a).	  
In	  this	  chapter,	  RNAi	  was	  exploited	  to	  determine	  whether	  three	  host	  proteins,	  HTATSF1,	  
DDX3X	   and	   SMARCB1,	   have	   potential	   as	   novel	   anti-­‐HIV	   therapeutic	   targets.	   PSIP1	   was	   also	  
included	  in	  this	  study	  as	  a	  positive	  control	  for	  host	  factor	  suppression-­‐mediated	  inhibition	  of	  HIV-­‐
1	   replication.	   To	   this	   end,	   shRNAs	   targeting	   these	   host	   factors	  were	   expressed	   from	  U6-­‐driven	  
cassettes.	  shRNA-­‐mediated	  suppression	  was	  used	  to	  examine	  the	  requirement	  of	  targeted	  cellular	  
factors	   for	  HIV-­‐1	   replication	   in	   a	   reporter	   cell	   line.	   In	   addition,	  whether	   target	   suppression	  was	  
accompanied	  by	  cytotoxicity	  was	  assessed.	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2.2	  Materials	  and	  methods	  
	  
2.2.1	  Design	  of	  cellular	  factor-­‐targeting	  shRNAs	  
	  
shRNAs	  were	  designed	  to	  target	  htatsf1	  (Entrez	  gene	  ID	  27336)	  transcript	  NM_014500.3,	  
ddx3x	   (Entrez	   gene	   ID	   1654)	   transcript	   NM_001356.3,	   psip1	   (Entrez	   gene	   ID	   11168)	   transcript	  
NM_033222.2	  and	  smarcb1	  (Entrez	  gene	  ID	  6598)	  transcript	  NM_003073.3	  (Table	  2.1).	  
	  
Table	  2.1:	  Regions	  within	  host	  factor	  transcripts	  targeted	  by	  shRNAs.	  
Target	   shRNA	   Target	  region	   Target	  length	  (nt)	  
shH1	   378-­‐398	   21	  
shH2	   415-­‐435	   21	  HTATSF1	  
shH3	   1416-­‐1438	   23	  
shD1	   1940-­‐1960	   21	  
shD2	   1154-­‐1175	   22	  DDX3X	  
shD3	   1285-­‐1305	   21	  
shP1	   1652-­‐1671	   20	  
PSIP1	  
shP2	   860-­‐880	   21	  
shS1	   342-­‐361	   20	  
SMARCB1	  
shS2	   1052-­‐1072	   21	  
	  
shP2	  targets	  a	  region	  common	  to	  both	  the	  p52	  (NM_021144.3)	  and	  p75	  (NM_033222.2)	  
isoforms	   whilst	   shP1	   is	   p75-­‐specific.	   The	   shP1	   guide	   sequence	   has	   been	   shown	   previously	   to	  
inhibit	   p75	  expression	   (Llano	   et	   al.	   2006a).	   Similarly,	   shS1	  was	  adapted	   from	  a	   siRNA	   sequence	  
shown	   to	   suppress	  SMARCB1	  expression	   (Maroun	   et	  al.	   2006).	  Other	   target	   sites	  were	  selected	  
from	   sequences	   suggested	   by	   an	   algorithm	   developed	   by	   The	   RNAi	   Consortium,	   The	   Broad	  
Institute,	   (www.broad.mit.edu/genome_bio/trc/rnai.html)	   that	   predicts	   si/shRNA-­‐susceptible	  
sites	   in	   all	   human	   and	  mouse	   RefSeq	   transcripts	   based	   on	   predicted	   knockdown	   efficiency	   and	  
specificity.	  All	  shRNAs	  were	  designed	  to	  contain	  a	  loop	  sequence	  derived	  from	  miR-­‐31	  (Table	  2.2).	  
In	  some	  shRNAs,	  G:U	  mismatches	  were	  incorporated	  at	  the	  3’	  end	  of	  the	  sense	  strand	  to	  decrease	  
thermodynamic	  stability	  and	  favour	  antisense	  strand	  selection	  as	  the	  guide	  (Table	  2.2)	  (Schwarz	  
et	  al.	  2003).	  
	  
2.2.2	  Cloning	  expressed	  shRNAs	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Generation	  of	  Pol	  III	  U6	  shRNA	  expression	  cassettes	  has	  been	  described	  (Castanotto	  et	  al.	  
2002)	  and	  a	  similar	  two-­‐step	  PCR	  approach	  was	  used	  here	  (Figure	  2.1).	  The	  first	  amplification	  was	  
carried	   out	   with	   a	   universal	   U6	   forward	   primer	   and	   the	   first	   shRNA	   reverse	   primer	   (R1)	   that	  
contained	  sequences	  complementary	  to	  the	  3’	  end	  of	   the	  U6	  promoter	  and	  encoding	  the	  sense	  
and	   loop	   regions	   of	   the	   short	   hairpin	   (Table	   2.2).	   The	   DNA	   plasmid	   pTZU6+1	   (Bertrand	   et	   al.	  
1997),	  which	  contains	  the	  human	  U6	  small	  nuclear	  RNA	  promoter	  (GenBank®	  accession	  number	  
X59362),	  was	  used	  as	  a	  template.	  PCR	  was	  performed	  on	  a	  Mastercycler®	  (BioRad,	  CA,	  USA)	  using	  
Expand	   High	   FidelityPLUS	   PCR	   System	   reagents	   (Roche,	  Mannheim,	   Germany).	   The	   PCR	   reaction	  
included	  10	  ng	  template,	  Expand	  HiFiPLUS	  reaction	  buffer	  (proprietary	  information),	  1.5	  mM	  MgCl2,	  
200	  µM	   dNTP	  mix,	   2.5	   U	   of	   Expand	   HiFiPLUS	   Taq	   polymerase	   and	   10	   pmol	   of	   each	   primer	   in	   a	  
volume	   of	   50	   µl.	   Thermocycling	   conditions	   were	   95	   °C	   for	   10	   minutes	   (min),	   30	   cycles	   of	  
denaturation	   at	   95	   °C,	   annealing	   at	   55	   °C	   and	   extension	   at	   72	   °C,	   each	   for	   30	   seconds	   (sec),	  
followed	   by	   a	   final	   extension	   at	   72	   °C	   for	   10	   min.	   Amplification	   specificity	   was	   confirmed	   by	  
resolution	  of	  PCR	  products	  on	  a	  2%	  agarose	  gel	  (see	  A1.2.3).	  
	  
	  
Figure	  2.1:	  Schematic	  demonstrating	  the	  two-­‐step	  PCR	  approach	  used	  to	  generate	  shRNA	  expression	  cassettes.	  The	  
first	  round	  of	  PCR	  generates	  an	  amplicon	  encoding	  the	  sense	  strand	  as	  well	  as	  the	  loop	  of	  the	  shRNA.	  The	  second	  round	  
amplicon	  encodes	  the	  sense,	  loop	  and	  antisense	  sequences	  and	  is	  cloned	  directly	  into	  the	  TA	  cloning	  vector	  pTZ57R/T.	  
	  
Step	  one	  PCR	  products	  were	  diluted	  500-­‐fold	  and	  used	  as	  template	  (~10	  pg)	  in	  a	  second	  
PCR	  reaction.	  Primers	  used	  in	  the	  second	  step	  were	  the	  universal	  U6	  forward	  primer	  and	  a	  second	  
shRNA	  reverse	  primer	   (R2)	   that	  contained	  sequences	  complementary	   to	   the	   loop	  and	  antisense	  
strand	  of	  the	  shRNA	  expression	  cassette,	  as	  well	  as	  a	  Pol	  III	  termination	  signal	  (Table	  2.2).	  Other	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reaction	  conditions,	  including	  thermocycling	  parameters,	  were	  the	  same	  as	  those	  used	  in	  the	  first	  
PCR	  step.	  
PCR	   products	   of	   the	   appropriate	  molecular	   weight	   were	   ligated	   directly	   into	   pTZ57R/T	  
(Fermentas,	  WI,	  USA),	   a	   TA	   cloning	   vector.	   The	   ligation	   reaction	   contained	   a	   3:1	  molar	   ratio	   of	  
insert	  to	  vector	  (180	  fmol	  insert	  to	  60	  fmol	  vector)	  and	  20	  U	  T4	  DNA	  ligase	  (New	  England	  Biolabs®,	  
Inc.,	  MA,	  USA)	   in	   a	   volume	  of	  20	  µl,	  which	  was	   incubated	  at	   room	   temperature	  overnight.	   Ten	  
microlitres	  of	  the	  ligation	  reaction	  mixture	  was	  used	  to	  transform	  100	  µl	  of	  chemically	  competent	  
Escherichia	   coli	  DH5α	   (Invitrogen,	   CA,	   USA)	   (see	   A1.1.1,	   A1.1.2	   and	   A1.1.3).	   Transformed	   cells	  
were	  plated	  on	  Luria	  Bertani	   (LB)	  agar	  plates	  containing	  ampicillin	   (Gibco,	  BRL,	  UK),	  5-­‐bromo-­‐4-­‐
chloro-­‐3-­‐indoyl-­‐β-­‐D-­‐galactopyranoside	   (X-­‐gal)	   (Sigma,	   MO,	   USA)	   and	   isopropyl-­‐β-­‐D-­‐1-­‐
thiogalactopyranoside	  (IPTG)	  (Roche,	  Mannheim,	  Germany)	  and	  incubated	  at	  37	  °C	  overnight	  (see	  
A1.1.1).	  
	  
Table	  2.2:	  Oligonucleotide	  primers	  used	  to	  generate	  shRNAs	  targeting	  cellular	  factors.	  
Primer	   Sequence	  (5’-­‐3’)	  
U6	  forward	   CTAACTAGTGGCGCGCCAAGGTCGGGCAGGAAGAGGG	  
shH1	  R1	   TTATTGGGTCAGGATAATTGGCCTGATATGTAGCGGTGTTTCGTCCTTTCCACAA	  
shH1	  R2	   AAAAAAGCTACATATCAGGCCAATTATTGGGTCAGGATAA	  
shH2	  R1	   GCAATGGGTCAGGTTÂCGGTAGAACTAGATGCGCGGTGTTTCGTCCTTTCCACAA	  
shH2	  R2	   AAAAAAGCGCATCTAGTTCTACCGCAATGGGTCAGGTTÂC	  
shH3	  R1	   CGTTTGGGTCAGGAACÂCCATTCCAGTTGCAGTGGTGTTTCGTCCTTTCCACAA	  
shH3	  R2	   AAAAAACTGCAACTGGAATGGCGTTTGGGTCAGGAACÂ	  
shD1	  R1	   GATATGGGTCAGGTATCTTGTTCGACTATTCTACGGTGTTTCGTCCTTTCCACAA	  
shD1	  R2	   AAAAAAGTAGAATAGTCGAACAAGATATGGGTCAGGTATC	  
shD2	  R1	   ACTCTGGGTCAGGAAGTTCCTGTTCCAAGCGTTCGGTGTTTCGTCCTTCCACAA	  
shD2	  R2	   AAAAAAGACGGAGTGATTACGATGGCATTGGGTCAGGATGC	  
shD3	  R1	   ACTCTGGGTCAGGÂAGTTCCTGTTCCAAGCGTTCGGTGTTTCGTCCTTCCACAA	  
shD3	  R2	   AAAAAAGAACGCTTGGAACAGGAACTCTGGGTCAGGÂAGT	  
shP1	  R1	   CGAATGGGTCAGGTTCÂCTTCCTCATGCTGTCTGGTGTTTCGTCCTTTCCACAA	  
shP1	  R2	   AAAAAAGACAGCATGAGGAAGCGAATGGGTCAGGTTC	  
shP2	  R1	   CATTTGGGTCAGGAATCTTGACTTCTGTAGCTGCGGTGTTTCGTCCTTTCCACAA	  
shP2	  R2	   AAAAAAGCAGCTACAGAAGTCAAGATTTGGGTCAGGAATC	  
shS1	  R1	   GGAATGGGTCAGGTTCCAGAGTGAGGGGTATCTCGGTGTTTCGTCCTTTCCACAA	  
shS1	  R2	   AAAAAAGAGATACCCCTCACTCTGGAATGGGTCAGGTCC	  
shS2	  R1	   AACTTGGGTCAGGAGTTCTCCTTCTCTGACATGTGGTGTTTCGTCCTTTCCACAA	  
shS2	  R2	   AAAAAACATGTCAGAGAAGGAGAACTTGGGTCAGGAGTT	  
Sequences	   complementary	   to	   the	   3’	   end	   of	   the	   U6	   promoter	   are	   underlined	   and	   to	   a	   Pol	   III	   termination	   signal	   are	  
shaded	   grey.	   Those	   complementary	   to	   the	   antisense	   guide	   strand	   are	   in	   bold	   and	   to	   the	   loop	   sequence	   in	   italics.	  
Introduced	  G:U	  mismatches	  in	  the	  sense	  strand	  are	  indicated	  by	  a	  circumflex.	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White	   colonies	   were	   screened	   for	   the	   presence	   of	   shRNA	   expression	   cassettes	   by	  
culturing	   in	   4	   ml	   LB	   broth	   supplemented	   with	   ampicillin	   overnight	   at	   37	   °C	   with	   shaking	   (see	  
A1.1.1).	   Plasmids	   were	   prepared	   using	   the	   High	   Pure	   Plasmid	   Isolation	   Kit	   (Roche,	  Mannheim,	  
Germany)	  (see	  A1.2.1)	  and	  5	  µg	  digested	  with	  5	  U	  XbaI	  and	  5	  U	  HindIII	  (Fermentas,	  WI,	  USA)	  for	  I	  
hour	   at	   37	   °C	   in	   a	   20	   µl	   reaction	   containing	   Tango	   Buffer	   (Fermentas,	   WI,	   USA).	   Digestion	  
reactions	   were	   resolved	   on	   a	   2%	   agarose	   gel	   (see	   A1.2.3).	   Clones	   that	   exhibited	   the	   desired	  
digestion	   products	   were	   sequenced	   with	   M13	   forward	   (5’	   GTA	   AAA	   CGA	   CGG	   CCA	   G	   3’)	   and	  
reverse	   (5’	   CAG	   GAA	   ACA	   GCT	   ATG	   AC	   3’)	   primers	   using	   automated	   cycle	   sequencing	   (Inqaba	  
Biotec,	   Pretoria,	   South	   Africa).	   Those	   containing	   correct	   shRNA	   expression	   cassettes	   were	  
cultured	  in	  300	  ml	  ampicillin-­‐supplemented	  LB	  overnight	  at	  37	  °C	  (see	  A1.1.1)	  with	  shaking	  prior	  
to	   bulk	   plasmid	   DNA	   preparation	   using	   the	   QIAGEN	   Plasmid	   Maxi	   Kit	   (QIAGEN,	   CA,	   USA)	   (see	  
A1.2.2).	  
Several	   previously	   developed	   constructs	  were	   used	   as	   controls	   in	   experiments:	   a	  mock	  
pTZU6+1	   construct	   with	   no	   shRNA	   sequence	   (Bertrand	   et	   al.	   1997);	   a	   shRNA	   negative	   control,	  
shHBVx,	  which	  targets	  an	  irrelevant	  site	  in	  hepatitis	  B	  virus	  (HBV)	  X	  protein	  (Carmona	  et	  al.	  2006);	  
and,	   two	  positive	   controls,	   shU5	  and	   shTAT,	  which	  are	  named	  after	   the	   location	  of	   their	   target	  
sequences	  within	   HIV-­‐1	   transcripts	   and	  were	   initially	   developed	   based	   on	   subtype	   B	  molecular	  
clone	  HXB2,	  GenBank®	  accession	  number	  K03455	  (Barichievy	  et	  al.	  2007).	  
	  
2.2.3	  Cloning	  luciferase	  reporter	  vectors	  
	  
To	   assess	   knockdown	   by	   shRNAs,	   four	   reporter	   constructs	   were	   generated,	   each	  
containing	   the	  multiple	   shRNA	   targets	   for	   a	   cellular	   factor	   (Figure	   2.2).	   Target	   sequences	  were	  
generated	  from	  complementary	  oligonucleotides	  (target	  F1	  and	  target	  R1)	  that	  also	  contained	  an	  
XhoI	  site	  at	  the	  5’	  end	  and	  a	  NotI	  site	  at	  the	  3’	  end	  to	  facilitate	  cloning.	  In	  addition,	  an	  EcoRV	  site	  
was	  incorporated	  to	  enable	  screening	  for	  positive	  clones.	  HTATSF1	  and	  DDX3X	  target	  sequences,	  
where	  three	  shRNA	  targets	  were	  needed	  (Figure	  2.2),	  were	  generated	  from	  four	  oligonucleotides	  
(target	  F1,	  target	  F2,	  target	  R1	  and	  target	  R2;	  Table	  2.3).	  
To	  enhance	  ligation,	  200	  pmol	  of	  target	  F2	  and	  R1	  oligonucleotides	  were	  treated	  with	  2	  U	  
polynucleotide	  kinase	   (Promega,	  WI,	  USA)	   in	  a	  20	  µl	   volume	  that	  also	  contained	  polynucleotide	  
kinase	  buffer	   (Promega,	  WI,	  USA)	   and	  1	  mM	  ATP	   at	   37	   °C	   for	   1	   hr.	  One	  hundred	  picomoles	   of	  
complementary	  oligonucleotides	  were	  annealed	  in	  a	  volume	  of	  20	  µl	  by	  heating	  at	  80	  °C	  for	  5	  min	  
and	  then	  allowing	  the	  samples	  to	  slowly	  cool	  to	  room	  temperature.	  The	  resulting	  dsDNA	  inserts	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were	   used	   in	   either	   two-­‐	   (PSIP1	   and	   SMARCB1	   reporters)	   or	   three-­‐way	   (HTATSF1	   and	   DDX3X	  
reporters)	   ligations	   with	   psiCheck™-­‐2	   (Promega,	   WI,	   USA).	   This	   plasmid	   contains	   a	   multiple	  
cloning	  site	  within	  the	  3’	  UTR	  of	  a	  SV40	  promoter-­‐driven	  Renilla	   luciferase,	  as	  well	  as	  a	  HSV	  TK-­‐
driven	  firefly	  luciferase	  cassette.	  
	  
	  
Figure	  2.2:	  Schematic	  of	  generated	  reporter	  constructs	  containing	  cognate	  shRNA	  target	  sequences	  for	  each	  cellular	  
factor.	   Complementary	   oligonucleotides	   were	   annealed	   and	   cloned	   into	   psiCheck™-­‐2	   such	   that	   each	   cellular	   factor	  
shRNA	   target	   sequence	   is	   present	   sequentially	   within	   the	   3’	   UTR	   of	   the	   Renilla	   luciferase	   gene.	   Renilla	   luciferase	  
expression	   reflects,	   therefore,	   the	   ability	   of	   a	   shRNA	   to	   inhibit	   its	   cognate	   target.	   The	   construct	   also	   contains	   an	  
independently-­‐expressed	  firefly	  luciferase	  gene,	  whose	  expression	  is	  unaffected	  by	  the	  presence	  of	  shRNAs.	  
	  
Table	  2.3:	  Oligonucleotides	  used	  to	  generate	  shRNA	  target	  sequences	  in	  the	  reporter	  constructs.	  
Target	  oligonucleotide	   Sequence	  (5’-­‐3’)	  
HTATSF1	  F1	   TCGAGATATCGCTACATATCAGGCCAATTATGCGCA	  
HTATSF1	  F2	   TCTAGTTCTACCGCAAACTGCAACTGGAATGGCGTTGC	  
HTATSF1	  R1	   CTAGATGCGCATAATTGGCCTGATATGTAGCGATATC	  
HTATSF1	  R2	   GGCCGCAACGCCATTCCAGTTGCAGTTTGCGGTAGAA	  
DDX3X	  F1	   TCGAGATATCGTAGAATAGTCGAACAAGATAGACGG	  
DDX3X	  F2	   AGTGATTACGATGGCATGAACGCTTGGAACAGGAACTCGC	  
DDX3X	  R1	   TCACTCCGTCTATCTTGTTCGACTATTCTACGATATC	  
DDX3X	  R2	   GGCCGCGAGTTCCTGTTCCAAGCGTTCATGCCATCGTAA	  
PSIP1	  F1	   TCGAGATATCAGACAGCATGAGGAAGCGAAGCAGCTACAGAAGTCAAGATTGC	  
PSIP1	  R1	   GGCCGCAATCTTGACTTCTGTAGCTGCTTCGCTTCCTCATGCTGTCTGATATC	  
SMARCB1	  F1	   TCGAGATATCGAGATACCCCTCACTCTGGAAACATGTCAGAGAAGGAGAACTGC	  
SMARCB1	  R1	   GGCCGCAGTTCTCCTTCTCTGACATGTTTCCAGAGTGAGGGGTATCTCGATATC	  
XhoI	  target	  sites	  are	  underlined,	  EcoRV	  target	  sites	  in	  bold	  and	  NotI	  target	  sites	  in	  italics.	  
	  
Prior	  to	  ligation,	  9	  µg	  of	  the	  plasmid	  was	  digested	  in	  three	  separate	  40	  µl	  reactions,	  each	  
containing	  15	  U	  XhoI	  and	  15	  U	  NotI	  and	  Orange	  buffer	   (Fermentas,	  WI,	  USA),	  at	  37	  °C	   for	  1	  hr.	  
Digestion	  products	  were	   resolved	  on	   a	   1%	  agarose	   gel	   (see	  A1.2.3)	   and	   the	  digested	  backbone	  
excised	  and	  purified	  using	  the	  MinElute™	  Gel	  Extraction	  Kit	  (QIAGEN,	  CA,	  USA)	  (see	  A1.2.4).	  Three	  
micrograms	  of	  the	  purified	  backbone	  was	  treated	  with	  5	  U	  Antarctic	  phosphatase	  (New	  England	  
Biolabs®,	  Inc.,	  MA,	  USA)	  in	  a	  10	  µl	  reaction	  containing	  Antarctic	  phosphatase	  buffer	  (New	  England	  
Biolabs®,	   Inc.,	  MA,	  USA)	  at	  37	  °C	  for	  1	  hr,	   followed	  by	   inactivation	  of	  the	  enzyme	  at	  65	  °C	  for	  5	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min.	  Sixty	  femtomoles	  of	  the	  dephosphorylated	  backbone	  was	  used	  in	  ligation	  reactions	  with	  180	  
fmol	  of	  insert(s)	  at	  16	  °C	  overnight.	  Transformation,	  colony	  screening	  and	  bulk	  vector	  preparation	  
were	  as	  described	  in	  2.2.2,	  with	  the	  exception	  that	  colonies	  were	  screened	  by	  EcoRV	  (Fermentas,	  
WI,	  USA)	  digestion.	  
	  
2.2.4	  Mammalian	  cell	  culture	  
	  
Cells	   of	   the	   human	   embryonic	   kidney	   (HEK)	   cell	   line,	   HEK293,	   were	   maintained	   in	  
Dulbecco’s	  Modified	  Eagle’s	  Medium	  (DMEM)	  (BioWhittaker,	  MD,	  USA)	  supplemented	  with	  10%	  
heat-­‐inactivated	  fetal	  calf	  serum	  (FCS)	  (Delta	  Bioproducts,	  Johannesburg,	  SA)	  at	  37	  °C	  and	  5%	  CO2	  
in	   a	   Forma	   Series	   II	   3110	   water-­‐jacketed	   incubator	   (Thermo	   Fisher	   Scientific,	   Inc.,	   MA,	   USA).	  
Cervical	  cancer	  Henrietta	  Lacks	  (HeLa)	  cells	  were	  maintained	  as	  HEK293	  cells.	  HeLa-­‐derived	  TZM-­‐
bl	   cells	   (NIH	   AIDS	   Research	   and	   Reference	   Reagent	   Program,	   DC,	   USA),	   which	   express	   the	   HIV	  
receptor	  CD4	  and	  coreceptor	  CCR5	  and	  contain	  a	  luciferase	  reporter	  driven	  by	  a	  Tat-­‐inducible	  LTR	  
promoter	  derived	  from	  pSG3.1	  (GenBank®	  accession	  number	  L02317)	  (Platt	  et	  al.	  1998;	  Derdeyn	  
et	  al.	  2000;	  Wei	  et	  al.	  2002),	  were	  also	  maintained	  as	  HEK293	  cells.	  All	  cells	  were	  propagated	  in	  75	  
cm2	  flasks	  and	  seeded	  into	  plates	  of	  different	  well	  sizes	  for	  experiments	   (Nunc™,	  Thermo	  Fisher	  
Scientific,	   Inc.,	   MA,	   USA).	   To	   determine	   the	   correct	   number	   of	   cells	   for	   seeding,	   cells	   were	  
counted	  on	  a	  haemocytometer	  using	  a	  1:1	  mixture	  of	  Trypan	  Blue	  stain	  (Sigma-­‐Aldrich,	  MO,	  USA)	  
and	  cells	  that	  had	  been	  washed	  in	  phosphate	  buffered	  saline	  (PBS)	  (Gibco,	  BRL,	  UK).	  
	  
2.2.5	  DNA	  plasmid	  transfections	  
	  
Cell	  transfections	  were	  carried	  out	  using	  1	  µl	  Lipofectamine™	  2000	  (Invitrogen,	  CA,	  USA)	  
per	  1	  µg	  DNA.	  DNA	  was	  mixed	  with	  a	  volume	  of	  OptiMEM	  (Gibco,	  BRL,	  UK)	  equal	  to	  1/10th	  of	  the	  
cell	  culture	  medium	  (eg	  50	  µl	  OptiMEM	  per	  0.5	  ml	  culture	  in	  a	  24-­‐well	  plate).	  The	  same	  volume	  of	  
OptiMEM	  was	  simultaneously	  mixed	  with	  the	  appropriate	  volume	  of	  Lipofectamine™	  2000.	  Both	  
solutions	  were	   incubated	   at	   room	   temperature	   for	   10	  min	   prior	   to	  mixing	   and	   a	   further	   room	  
temperature	   incubation	  of	  20	  min.	  A	  volume	  equal	   to	  1/5th	  of	   the	  cell	   culture	  medium	  of	  DNA-­‐
Lipofectamine™	  2000-­‐OptiMEM	  mixture	  was	  slowly	  added	  to	  cells	  (eg	  100	  µl	  mixture	  per	  0.5	  ml	  
culture	   in	   a	   24-­‐well	   plate).	   Media	   was	   changed	   4-­‐5	   hours	   post-­‐transfection	   to	   minimise	  
transfection	  reagent-­‐associated	  toxicity.	  
	  
2.2.6	  Dual	  luciferase	  reporter	  assay	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To	  assess	  the	   inhibitory	  potential	  of	  the	  shRNAs,	  HEK293	  and	  HeLa	  cells	  were	  seeded	  at	  
1.2	  x	  105	  and	  5.0	  x	  104	   cells	  per	  well,	   respectively,	   in	  a	  24-­‐well	  plate	  24	  hours	  pre-­‐transfection.	  
Each	   well	   was	   transfected	   with	   1	   µg	   of	   pTZU6+1	   shRNA	   expression	   construct,	   100	   ng	   of	   the	  
appropriate	   psiCheck™-­‐2	   target	   reporter	   construct	   and	   10	   ng	   pCI-­‐eGFP,	   which	   expresses	  
enhanced	  green	  fluorescent	  protein	  (eGFP)	  from	  a	  CMV	  promoter	  (Passman	  et	  al.	  2000)	  to	  allow	  
estimation	  of	   transfection	  efficiency.	   Transfections	  were	  performed	   in	   triplicate	   as	   described	   in	  
2.2.5.	  
Forty-­‐eight	   hours	   post-­‐transfection,	   reporter	   assays	   were	   performed	   using	   the	   Dual	  
Luciferase®	  Reporter	  Assay	  System	  (Promega,	  WI,	  USA).	  Briefly,	  medium	  was	  removed	  and	  cells	  
lysed	  with	  100	  µl	  Passive	  Lysis	  Buffer	  for	  20	  min.	  Ten	  microlitres	  of	  cell	  lysate	  was	  transferred	  to	  a	  
Costar®	   96-­‐well	   flat	   bottom	   assay	   plate	   (Corning,	   Inc.,	   BY,	   USA).	   Firefly	   luciferase	   activity	   was	  
measured	   following	   the	  addition	  of	  50	  µl	   LARII	   (Figure	  2.3).	   The	   subsequent	  addition	  of	   Stop	  &	  
Glo®	   solution	   simultaneously	   inhibited	   firefly	   luciferase	   and	   permitted	   the	   quantification	   of	  
Renilla	   luciferase	   activity	   (Figure	   2.3).	   All	   luciferase	   activities	   were	   quantified	   by	   a	   Veritas™	  
Microplate	   Luminometer	   (Turner	   Biosystems,	   CA,	   USA).	   Renilla:firefly	   luciferase	   activity	   ratios	  
were	  normalised	  to	  the	  average	  expression	  ratio	  of	  mock	  (ie	  pTZU6+1)-­‐transfected	  samples.	  
	  
	  
Figure	   2.3:	   Schematic	   representation	   of	   the	   dual	   luciferase	   reporter	   assay.	   In	   the	   absence	   of	   shRNA	   expression,	  
processing	   and/or	   guide	   strand	   association	   with	   its	   target,	   there	   is	   Renilla	   luciferase	   expression.	   When	   the	   shRNA	  
successfully	   mediates	   inhibition	   of	   its	   target,	   Renilla	   luciferase	   expression	   is	   decreased	   whilst	   firefly	   luciferase	  
expression	  is	  unaffected.	  This	  results	  in	  a	  reduced	  Renilla:	  firefly	  luciferase	  activity	  ratio.	  
	  
2.2.7	  Quantitative	  reverse	  transcription	  polymerase	  chain	  reaction	  (qRT-­‐PCR)	  measurement	  of	  
mRNA	  concentrations	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To	   assess	   the	   suppression	   of	   endogenous	  mRNA	   targets	  mediated	   by	   shRNAs,	   HEK293	  
and	  TZM-­‐bl	  cells	  were	  seeded	  at	  1.2	  x	  105	  and	  5.0	  x	  104	  cells	  per	  well,	   respectively,	   in	  a	  24-­‐well	  
plate	  24	  hours	  pre-­‐transfection.	  Cells	  of	  each	  well	  were	  transfected	  with	  1	  µg	  of	  pTZU6+1	  shRNA	  
expression	   construct	   and	   10	   ng	   pCI-­‐eGFP	   in	   triplicate,	   as	   described	   in	   2.2.5.	   Forty-­‐eight	   hours	  
post-­‐transfection,	  medium	  was	  removed	  and	  total	  RNA	  extracted	  using	  TriReagent™	  (Sigma,	  MO,	  
USA)	  (see	  A1.3.1).	  Total	  RNA	  (100-­‐200	  ng)	  was	  subjected	  to	  deoxyribonuclease	  (DNase)	  treatment	  
and	   random-­‐primed	   reverse	   transcription	   (RT)	   using	   the	   QuantiTect	   Reverse	   Transcription	   Kit	  
(QIAGEN,	  CA,	  USA)	  (see	  A1.3.2).	  
	  
Table	  2.4:	  Primers	  used	  in	  qPCR	  to	  determine	  cellular	  factor	  cDNA	  levels.	  	  
Primer	   Sequence	  (5’-­‐3’)	   Amplicon	  length	  (bp)	  
HTATSF1	  forward	   AGTGGGACCTGGACAAAAAGG	  
HTATSF1	  reverse	   GTTCCGGGGCTTTTTCTTGTG	  
171	  
DDX3X	  forward	   CGTGGAAGTGGATCAAGGGGAA	  
DDX3X	  reverse	   TTGGTGGGAGTGGTTTTGACCA	  
144	  
PSIP1	  (p75	  specific)	  forward	   GCTGAACAAAGACAGCATGAGGA	  
PSIP1	  (p75	  specific)	  reverse	   ATTGCTCTCCCCGTTATGTTGTG	  
146	  
SMARCB1	  forward	   ATCAGACAGCAGATCGAGTCCTA	  
SMARCB1	  reverse	   TCAGGGCAAACTTCTCTGGTGA	  
144	  
ACTB	  forward	   AGGTCATCACCATTGGCAATGAG	  
ACTB	  reverse	   TCTTTGCGGATGTCCACGTCA	  
118	  
	  
One	  microlitre	  of	  complementary	  DNA	  (cDNA)	  was	  analysed	  for	  target	  mRNA	  expression	  
relative	  to	  beta-­‐actin	  (actb)	  mRNA	  (Entrez	  Gene	  ID	  60,	  transcript	  NM_01101.2)	  expression	  using	  
the	  Lightcycler®	  FastStart	  DNA	  MasterPLUS	  SYBR	  Green	  I	  Kit	  (Roche,	  Mannheim,	  Germany)	  in	  a	  20	  
µl	   reaction	   (see	   A1.3.4).	   Primers	   were	   designed	   to	   produce	   specific	   100-­‐200	   bp	   amplicons	  
spanning	  splice	   junctions	   (Table	  2.4).	  The	  qPCR	  was	  performed	   in	  a	  Carousel-­‐Based	  Lightcycler®	  
V.2	  System	   (Roche,	  Mannheim,	  Germany)	  with	   the	   following	  parameters:	  denaturation	  at	  95	   °C	  
for	  10	  min,	  50	  cycles	  of	  denaturation	  at	  95	  °C,	  annealing	  at	  60	  °C	  and	  extension	  at	  72	  °C,	  each	  for	  
10	  sec.	  Amplification	  cycles	  were	  followed	  by	  melting	  curve	  analysis	  to	  verify	  the	  specificity	  of	  the	  
PCR	   products.	   No	   RT	   controls	   were	   included	   for	   each	   sample	   and	   no	   cDNA	   controls	   for	   each	  
primer	   set.	   Target:actb	   mRNA	   concentration	   ratios	   were	   determined	   by	   the	   Lightcycler®	   V.2	  
software	  (Roche,	  Mannheim,	  Germany)	  and	  normalised	  to	  the	  average	  expression	  ratio	  of	  mock-­‐
transfected	  samples.	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2.2.8	  Challenge	  with	  HIV-­‐1	  molecular	  clone	  pNL4-­‐3.Luc.R-­‐.E-­‐	  
	  
To	   assess	   the	   ability	   of	   shRNAs	   targeting	   cellular	   factors	   to	   inhibit	   HIV-­‐1	   replication,	  
HEK293	  cells,	  seeded	  at	  1.2	  x	  105	  cells	  per	  well	   in	  a	  24-­‐well	  plate,	  were	  transfected	  with	  900	  ng	  
shRNA	   expression	   construct,	   10	   ng	   of	   pRSV-­‐RLuc	   (gift	   from	   J.	   J.	   Rossi),	   which	   encodes	   a	   CMV-­‐
driven	  Renilla	  luciferase	  gene	  and	  90	  ng	  pNL4-­‐3.Luc.R-­‐.E-­‐,	  a	  HIV-­‐1	  subtype	  B	  molecular	  clone	  (NIH	  
AIDS	  Research	  &	  Reference	  Reagent	  Program,	  MD,	  USA)	  (Connor	  et	  al.	  1995;	  He	  et	  al.	  1995).	  This	  
clone	  consists	  of	  pNL4-­‐3	  (GenBank®	  accession	  number	  M19921)	  with	  a	  firefly	  luciferase	  reporter	  
gene	   fused	   to	   the	   5’	   end	   of	   the	  nef	   coding	   region	   using	  NotI	   and	  XhoI	   sites.	   Two	   frame	   shifts	  
render	  this	  clone	  Vpr-­‐	  and	  Env-­‐	  and,	  therefore,	  competent	  for	  a	  single	  round	  of	  replication	  only.	  
Forty-­‐eight	   hours	   post-­‐transfection,	   cells	  were	   assayed	   for	   dual	   luciferase	   activity	   using	  
the	   Dual	   Luciferase®	   Reporter	   Assay	   System	   (Promega,	  WI,	   USA),	   as	   described	   in	   2.2.6.	   Firefly	  
luciferase	   activities	  were	   normalised	   to	  Renilla	   luciferase	   activities	   and	   then	   normalised	   to	   the	  
average	  firefly:Renilla	  luciferase	  expression	  ratio	  of	  the	  mock-­‐transfected	  samples.	  
	  
2.2.9	   Detection	   of	   processed	   shRNA	   guide	   strands	   using	   polyacrylamide	   gel	   electrophoresis	  
(PAGE)	  and	  Northern	  blot	  analysis	  
	  
TZM-­‐bl	  cells	  were	  seeded	  at	  2	  x	  106	  cells	  per	  60	  cm2	  Costar®	  dish	  (Corning,	  Inc.,	  NY,	  USA)	  
and	   each	   dish	   transfected	   24	   hours	   later	   with	   20	   µg	   shRNA	   expression	   constructs	   using	   the	  
calcium	  chloride	  method	  (see	  A1.2.5).	  Forty-­‐eight	  hours	  post-­‐transfection,	  total	  RNA	  was	  isolated	  
using	  TriReagent™	  (Sigma,	  MO,	  USA)	  (see	  A1.3.1).	  Thirty	  micrograms	  of	  RNA	  and	  a	  radiolabelled	  
RNA	  molecular	  weight	  Decade™	  Marker	   (Ambion,	  TX,	  USA)	   (see	  A1.3.3)	  were	  combined	  with	  an	  
equal	  volume	  of	  RNA	  loading	  dye	  (Ambion,	  TX,	  USA)	  and	  denatured	  at	  80	  °C	  for	  5	  min.	  Samples	  
were	   resolved	  on	  a	  15%	  polyacrylamide	  gel	  with	  a	  1:19	   ratio	  of	  bis-­‐acrylamide:acrylamide,	  8	  M	  
urea	  and	  TBE	  buffer	  (890	  mM	  Tris	  base,	  890	  mM	  boric	  acid	  and	  32	  mM	  EDTA,	  pH	  8.0).	  The	  gel	  was	  
stained	  with	  10	  mg/ml	  ethidium	  bromide	  and	  visualised	  on	  a	  UV	  transilluminator	  (Kodak	  Gel	  Logic	  
200	  Imaging	  System)	  to	  check	  RNA	  quality	  and	  equal	  loading	  of	  samples.	  
RNA	   underwent	   transfer	   to	   Hybond-­‐N+	   positively	   charged	   nylon	   membrane	   (GE	  
Healthcare,	  NJ,	  USA)	  using	   the	  Hybaid	   semi-­‐dry	  blotter	   (Amersham	  Biosciences,	  CT,	  USA)	  at	  3.3	  
mA/cm2	  (not	  exceeding	  400	  mA)	  for	  one	  hour.	  RNA	  was	  cross-­‐linked	  to	  the	  membrane	  at	  2000	  x	  
100	  μJ/cm2	  in	  a	  UV	  cross-­‐linker	  (UVP,	  Inc.,	  CA,	  USA)	  and	  the	  membrane	  then	  baked	  at	  80	  °C	  for	  1	  
hour	  in	  a	  vacuum	  oven	  (Thermo	  Fisher	  Scientific,	  Inc.,	  MA,	  USA).	  
DNA	  oligonucleotide	  probes	  complementary	  to	  the	  processed	  shRNA	  guide	  strands	  (Table	  
2.5)	  were	  labelled	  with	  γ-­‐32P-­‐ATP	  (6000	  ci/mmol)	  (Perkin	  Elmer,	  MA,	  USA)	  using	  T4	  polynucleotide	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kinase	   (Promega,	  WI,	  USA).	   The	   20	  µl	   reactions,	   composed	  of	   Reaction	  Buffer	  A	   (Promega,	  WI,	  
USA)	  (50	  mM	  Tris-­‐HCl,	  pH	  7.6,	  10	  mM	  MgCl2,	  5	  mM	  dithiothreitol	  (DTT),	  0.1	  mM	  spermidine	  and	  
0.1	  mM	  EDTA),	   20	   pmol	   probe,	   20	   pmol	   γ-­‐32P-­‐ATP	   and	   10	  U	   of	   T4	   polynucleotide	   kinase,	  were	  
incubated	  for	  20	  min	  at	  37	  °C.	  Addition	  of	  1	  µl	  of	  0.5	  M	  EDTA,	  pH	  8.0,	  and	  incubation	  at	  75	  °C	  for	  
10	  min,	  terminated	  the	  labelling	  reaction.	  Labelled	  probes	  were	  purified	  by	  centrifugation	  at	  200	  x	  
g	   for	  2	  min	  through	  Sephadex®	  G-­‐25	  columns	  (Sigma,	  MO,	  USA)	  and	  then	  added	  to	  membranes	  
pre-­‐hybridised	  with	  10	  ml	  Rapid	  Hyb	  solution	  (Amersham	  Biosciences,	  CT,	  USA)	  in	  a	  rotating	  oven	  
(Thermo	  Fisher	  Scientific,	  Inc.,	  MA,	  USA).	  Hybridisation	  was	  permitted	  overnight	  at	  42	  °C.	  
	  
Table	  2.5:	  Sequences	  of	  DNA	  oligonucleotide	  probes	  used	  in	  Northern	  blots.	  
Oligonucleotide	  probe	   Sequence	  (5’-­‐3’)	  
Anti-­‐shH1	   GCTACATATCAGGCCAATTAT	  
Anti-­‐shH2	   GCGCATCTAGTTCTACCGCAA	  
Anti-­‐shH3	   ACTGCAACTGGAATGGCGTT	  
Anti-­‐shP1	   AGACAGCATGAGGAAGCGAA	  
Anti-­‐shP2	   GCAGCTACAGAAGTCAAGATT	  
Anti-­‐shS1	   GAGATACCCCTCACTCTGGAA	  
Anti-­‐shS2	   ACATGTCAGAGAAGGAGAACT	  
Anti-­‐U6	  snRNA	   TAGTATATGTGCTGCCGAAGCGAGCA	  
Probes	  were	  labelled	  with	  γ-­‐32P-­‐ATP	  prior	  to	  hybridisation	  with	  membrane-­‐bound	  RNA.	  
	  
Membranes	  were	  subject	  to	  a	   low	  stringency	  washes	   in	  50	  ml	  5x	  SSC	  (750	  mM	  NaCl,	  65	  
mM	  disodium	  citrate,	  pH	  7.0)	  and	  0.1%	  sodium	  dodecylsulphate	   (SDS)	   (Sigma,	  MO,	  USA)	   for	  20	  
min	  at	  room	  temperature.	  Two	  high	  stringency	  washes	  were	  then	  performed	  at	  42	  °C,	  each	  with	  
50	  ml	  1x	  SSC	  (150	  mM	  NaCl,	  13	  mM	  disodium	  citrate,	  pH	  7.0)	  and	  0.1%	  SDS	  for	  15	  min.	  Following	  
a	  48	  hour	  exposure	  to	  an	  imaging	  plate	  (Fujifilm,	  Tokyo,	  Japan),	  blots	  were	  viewed	  on	  a	  FLA-­‐7000	  
phosphorimager	   (Fujifilm,	  Tokyo,	   Japan).	  Blots	  were	  stripped	  with	  50	  ml	  1%	  SDS	  at	  80	  °C	   for	  30	  
min	  prior	  to	  reprobing.	  A	  probe	  complementary	  to	  U6	  small	  nuclear	  RNA	  was	  used	  to	  verify	  equal	  
loading	  of	  RNA	  samples	  (Table	  2.5).	  
	  
2.2.10	  HIV-­‐1	  reporter	  assay	  in	  TZM-­‐bl	  cells	  
	  
TZM-­‐bl	   cells	  were	   seeded	   at	   5	   x	   104	   cells	   per	  well	   in	   a	   24-­‐well	   plate.	   Cells	   of	   each	  well	  
were	   transfected	   24	   hours	   later	  with	   various	   amounts	   of	   pTZU6+1	   shRNA	   expression	   construct	  
and	   10	   ng	   pCI-­‐eGFP	   in	   triplicate,	   as	   described	   in	   2.2.5.	   When	   shRNA	   dose-­‐effects	   were	   being	  
	   53	  
assessed,	  the	  stuffer	  DNA	  pUC19	  (NEB,	  MA,	  USA)	  was	  also	  included	  in	  transfections	  such	  that	  the	  
total	  amount	  of	  transfected	  DNA	  was	  constant	  for	  all	  samples	  at	  1.01	  µg.	  
Cells	  were	   infected	  with	   various	  R5-­‐tropic	  HIV-­‐1	   at	   a	   TCID50	   (see	  A1.4.3)	   of	   1000/ml	   24	  
hours	   post-­‐transfection	   (primary	   infection):	   subtype	   C	   envelope-­‐pseudotyped	   subtype	   B	  
molecular	  clone	  pSG3Δenv.ZM53M	  (a	  gift	  from	  M.	  Papathanasopoulos)	  (Wei	  et	  al.	  2002;	  Derdeyn	  et	  
al.	  2004);	  subtype	  B	  molecular	  clone	  p81A-­‐4	  (NIH	  AIDS	  Research	  &	  Reference	  Reagent	  Program,	  
MD,	  USA)	  (Chesebro	  et	  al.	  1992;	  Walter	  et	  al.	  2005)	  (see	  A1.4.2);	  and,	  subtype	  C	  FV5	  (GenBank®	  
accession	   number	   DQ382363),	   propagated	   from	   a	   primary	   isolate	   originally	   isolated	   in	   1998	   at	  
Johannesburg	  General	  Hospital	  (a	  gift	  from	  M.	  Papathanasopoulos)	  (see	  A1.4.1).	  Infections	  were	  
carried	  out	  in	  the	  presence	  of	  15	  µg/ml	  diethylaminoethyl	  dextran	  (DEAE-­‐D)	  to	  enhance	  infection	  
efficiencies.	  
Cells	  were	  washed	  three	  times	  with	  PBS	  (Gibco,	  BRL,	  UK)	  24	  hours	  post-­‐infection.	  In	  some	  
experiments,	  200	  µl	  of	  culture	  supernatant	  was	  removed	  48	  hours	  post-­‐infection	  and	  stored	  at	  -­‐
80	   °C	   for	   subsequent	   analysis	   of	   HIV-­‐1	   p24	   content	   by	   enzyme-­‐linked	   immunosorbent	   assay	  
(ELISA)	   (Murex	   Biotech	   Ltd,	   Kent,	   UK)	   (see	   A1.4.4).	   Another	   100	  µl	   of	   culture	   supernatant	  was	  
used	  to	   infect	  additional	  TZM-­‐bl	  cells	   (secondary	   infection),	  seeded	  at	  5	  x	  104	  cells	  per	  well	   in	  a	  
24-­‐well	  plate	  the	  preceding	  day,	  in	  the	  presence	  of	  15	  µg/ml	  DEAE-­‐D.	  
Tat-­‐induced	  luciferase	  activity	  was	  assessed	  48	  hours	  post-­‐infection(s)	  in	  cell	  lysates	  using	  
the	  Bright-­‐Glo™	  Luciferase	  Assay	  System	  (Promega,WI,	  USA).	  Briefly,	  medium	  was	  removed	  and	  
cells	   lysed	   with	   100	   µl	   Glo	   Lysis	   Buffer	   for	   5	   min.	   Twenty-­‐five	   microlitres	   of	   cell	   lysate	   was	  
transferred	  to	  a	  Costar®	  96-­‐well	  flat	  bottom	  assay	  plate	  (Corning,	  Inc.,	  BY,	  USA).	  Luciferase	  activity	  
was	   measured	   in	   a	   Veritas™	   Microplate	   Luminometer	   (Turner	   Biosystems,	   CA,	   USA)	   before	  
(background	  reading)	  and	  after	  the	  addition	  of	  25	  µl	  Bright-­‐Glo™	  Assay	  Reagent.	  Background	  was	  
subtracted	  from	  each	  sample.	  
	  
2.2.11	  Detection	  of	  cellular	  factors	  by	  SDS-­‐PAGE	  and	  Western	  blot	  analysis	  
	  
To	  assess	  the	  kinetics	  of	  shRNA-­‐mediated	  target	  suppression,	  TZM-­‐bl	  cells	  were	  seeded	  at	  
1.5	  x	  105	  cells	  per	  well	   in	  a	  6-­‐well	  plate.	  Each	  well	  was	   transfected	  with	  2	  µg	  shRNA	  expression	  
plasmid	  and	  50	  ng	  pCI-­‐eGFP	  24	  hours	   later,	  as	  described	   in	  2.2.5.	  Twenty-­‐four,	  48	  and	  96	  hours	  
post-­‐transfection,	  media	  was	  removed	  and	  cells	  washed	  with	  PBS.	  Cells	  were	  harvested	  by	  trypsin	  
(Gibco,	  BRL,	  UK)	  treatment	  and	  centrifugation	  at	  130	  x	  g	  for	  4	  min	  and	  lysed	  by	  addition	  of	  500	  µl	  
Radio-­‐Immunoprecipitation	   Assay	   (RIPA)	   buffer	   (50	  mM	   Tris,	   pH	   8.0,	   150	  mM	  NaCl,	   0.1%	   SDS,	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0.5%	   sodium	   deoxycholate	   and	   1%	   Triton	   X-­‐100)	   containing	   1:200	   dilution	   of	   Calbiochem®	  
Protease	  Inhibitor	  Cocktail	  Set	  III	  (Merck,	  Darmstadt,	  Germany).	  
Total	  protein	  was	  quantified	  using	  the	  Pierce®	  bicinchoninic	  acid	  (BCA)	  Protein	  Assay	  Kit	  
(Thermo	  Fisher	  Scientific	  Inc,	  IL,	  USA)	  (see	  A1.5.1).	  The	  EasyWestern	  Protein	  Standard	  (GenScript	  
Corp,	  NJ,	  USA),	  composed	  of	  IgG-­‐binding	  proteins	  ranging	  from	  22	  to	  120	  kD	  in	  size,	  and	  80	  µg	  of	  
cellular	   protein	   were	   resolved	   on	   a	   12%	   polyacrylamide	   gel	   with	   a	   1:19	   ratio	   of	   bis-­‐
acrylamide:acrylamide,	   0.375	   mM	   Tris,	   pH	   8.8,	   	   and	   0.2%	   SDS.	   Protein	   was	   transferred	   to	   a	  
polyvinylidene	   fluoride	   (PVDF)	  membrane	   (Millipore,	  MA,	   USA)	   at	   35	   V	   overnight	   in	   circulating	  
transblot	   buffer	   (25	   mM	   Tris	   base,	   192	   mM	   glycine	   and	   20%	   methanol),	   pH	   8.3.	   Following	  
transfer,	   the	  membrane	  was	  rinsed	   in	  Tris	  buffered	  saline	  (TBS)	   (0.5	  M	  Tris.HCl,	  9%	  (w/v)	  NaCl),	  
pH	   7.5	   and	   then	   blocked	   for	   1	   hour	   at	   room	   temperature	  with	   blocking	   solution	   (TBS	  with	   5%	  
skimmed	  milk	  powder	  and	  0.1%	  (v/v)	  Tween	  20).	  Primary	  antibodies	  were	  added	  to	  the	  blocking	  
solution	  and	  incubated	  at	  room	  temperature	  with	  gentle	  shaking	  for	  a	  further	  hour.	  The	  dilutions	  
of	   rabbit	   polyclonal	   primary	   antibodies	   were	   as	   follows:	   anti-­‐HTATSF1	   (a	   gift	   from	   M.	   Garcia-­‐
Blanco)	  at	  1:100,	  anti-­‐PSIP1	  (GenWay	  Biotech,	  Inc.,	  CA,	  USA)	  at	  1:2,000,	  anti-­‐SMARCB1	  (GenWay	  
Biotech,	  Inc.,	  CA,	  USA)	  at	  1:500	  and	  anti-­‐β-­‐actin	  (GenWay	  Biotech,	  Inc.,	  CA,	  USA)	  at	  1:1,000.	  The	  
latter	  was	   used	   to	   verify	   equal	   loading	   of	   samples.	  Membranes	  were	  washed	   three	   times	  with	  
blocking	  solution	  for	  10	  min	  each	  before	  a	  1	  hour	  incubation	  with	  a	  horseradish	  peroxidase	  (HRP)-­‐
conjugated	   donkey	   anti-­‐rabbit	   IgG	   secondary	   antibody	   (GenWay	   Biotech,	   Inc.,	   CA,	   USA)	   at	  
1:25,000	   in	   blocking	   solution.	  Membranes	  were	  washed	   twice	  with	   blocking	   solution	   and	   once	  
with	  TBS-­‐T	  (TBS	  with	  0.1%	  (v/v)	  Tween	  20),	  each	  for	  10	  min.	  One	  millilitre	  of	  SuperSignal®	  West	  
Pico	  Chemiluminescent	  Substrate	  (Thermo	  Fisher	  Scientific,	  Inc.,	  IL,	  USA),	  composed	  of	  enhancer	  
solution	  and	  stable	  peroxide	  solution	   in	  a	  1:1	  ratio,	  was	  added	  to	  the	  membrane	  and	   incubated	  
for	  5	  min.	  Images	  were	  acquired	  with	  a	  G-­‐BOX	  (Syngene,	  MD,	  USA)	  using	  an	  exposure	  of	  up	  to	  45	  
min.	  Levels	  of	  target	  protein	  is	  reported	  relative	  to	  levels	  of	  β-­‐actin	  and	  normalised	  to	  the	  shHBVx	  
negative	  control	  at	  each	  time	  point.	  
Given	  the	  difference	  in	  molecular	  weight	  of	  some	  of	  the	  targeted	  proteins,	  HTATSF1	  (~86	  
kDa),	   PSIP1	   (~75	   kDa)	   and	  β-­‐actin	   (~42	   kDa)	   could	   be	   detected	   simultaneously.	   SMARCB1	   (~44	  
kDa)	   and	   β-­‐actin	   could	   not	   and,	   therefore,	   some	   membranes	   were	   stripped	   between	  
immunoblots.	  This	   involved	  washing	  the	  membrane	  twice	  with	  stripping	  buffer	  (20	  mM	  Tris.HCl,	  
pH	  7.5,	  6	  M	  guanidine	  hydrochloride,	  0.2%	  (v/v)	  Nonidet	  P-­‐40	  and	  0.1	  M	  β-­‐mercaptoethanol)	  for	  5	  
min	   each,	   three	   times	   with	   TBS-­‐T	   for	   3	   min	   each	   and	   once	   with	   TBS	   for	   5	   min,	   all	   at	   room	  
temperature.	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2.2.12	  Detection	  of	  early	  apoptotic	  TZM-­‐bl	  cells	  
	  
To	  examine	  whether	  target	  suppression	  is	  cytotoxic,	  TZM-­‐bl	  cells	  were	  seeded	  at	  3	  x	  104	  
cells	   per	  well	   on	   CELLocate®	  microgrid	   coverslips	   (Eppendorf,	   Hamburg,	   Germany)	   in	   a	   24-­‐well	  
plate.	  Each	  well	  was	  transfected	  with	  500	  ng	  shRNA	  expression	  plasmid,	  as	  described	  in	  2.2.5,	  in	  
duplicate.	   Seventy-­‐two	   hours	   post-­‐transfection,	   apoptosis	   was	   quantified	   using	   the	   TACS™	  
Annexin	  V-­‐FITC	  Apoptosis	  Detection	  Kit	  (R&D	  Systems,	  Inc.,	  MN,	  USA).	  Briefly,	  cells	  were	  washed	  
with	  PBS	  and	  then	  incubated	  in	  the	  dark	  for	  15	  min	  with	  100	  µl	  of	  Annexin	  V	  Incubation	  Reagent,	  
containing	  binding	  buffer	  (10	  mM	  HEPES,	  pH	  7.4,	  150	  mM	  NaCl,	  5	  mM	  KCl,	  1	  mM	  MgCl2,	  1.8	  mM	  
CaCl2)	  and	  0.5	  µl	  Annexin	  V-­‐FITC.	  Cells	  were	  then	  washed	  twice	  with	  500	  µl	  binding	  buffer	  before	  
inversion	   of	   coverslips	   onto	   slides	   with	   Calbiochem®	   FluorSave™	   Reagent	   (Merck,	   Darmstadt,	  
Germany).	   Cells	   were	   treated	  with	   500	   nM	   TSA	   16	   hours	   pre-­‐analysis	   as	   a	   positive	   control	   for	  
apoptosis	  induction.	  
Transmitted	   light	  and	  fluorescence	  images	  were	  acquired	  for	  two	  fields	  of	  view	  per	  well	  
on	  an	  Axiovert	  100	  M	  with	   image	  capture	  by	  AxioVision	  2.0.5	  software	  (Carl	  Zeiss	  Microimaging	  
GmbH,	  Germany).	  Fluorescence	  was	  quantified	  using	  ImageJ	  1.40g	  (public	  domain;	  developed	  by	  
W.	  Rasband,	  National	  Institutes	  of	  Health,	  MD,	  USA).	  
	  
2.2.13	  GFP	  splicing	  assay	  
	  
To	  examine	  whether	  suppression	  of	  HTATSF1	  affects	  splicing,	  TZM-­‐bl	  cells	  were	  seeded	  at	  
6	  x	  104	  cells	  per	  well	  in	  a	  12-­‐well	  plate.	  Twenty-­‐four	  hours	  later,	  each	  well	  was	  transfected	  with	  1	  
µg	   of	   shRNA	   expression	   plasmid,	   targeting	  HTATSF1,	   or	   HBVx	   as	   a	   negative	   control.	   Cells	  were	  
transfected	  a	  second	  time	  48	  hours	  later	  with	  either	  pEGFP-­‐C1-­‐NAD	  (a	  gift	  from	  M.	  Wood),	  which	  
contains	   a	   CMV-­‐driven	   eGFP	   ORF	   interrupted	   by	   intron	   6	   from	   NADH-­‐coenzyme	   Q	   reductase	  
(Entrez	  gene	  ID	  4719),	  or	  a	  mutant	  construct	  (a	  gift	  from	  M.	  Wood),	  which	  resembles	  pEGFP-­‐C1-­‐
NAD	   but	   for	   mutated	   splice	   sites.	   Transfections	   were	   carried	   out	   as	   described	   in	   2.2.5	   and	   in	  
triplicate.	   After	   another	   48	   hour	   incubation,	   transmitted	   light	   and	   fluorescence	   images	   were	  
acquired,	  as	  described	  in	  2.2.12.	  
Cells	  were	  then	  harvested,	  lysed	  and	  subject	  to	  protein	  quantification	  by	  the	  BCA	  method,	  
as	  described	  in	  2.2.11,	  with	  the	  exception	  that	  250	  µl	  of	  RIPA	  buffer	  was	  used	  (see	  also	  A1.5.1).	  
GFP	  fluorescence	  in	  150	  µl	  of	  cell	  lysate	  was	  quantified	  in	  a	  VersaFluor™	  fluorometer	  (BioRad,	  CA,	  
USA),	  with	  excitation	  at	  379-­‐401	  nm	  and	  emission	  at	  505-­‐515	  nm,	  and	   reported	   relative	   to	   the	  
total	  amount	  of	  protein	  in	  the	  sample.	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2.2.14	  MTT	  assay	  
	  
To	  examine	  whether	  the	  shRNAs	  were	  themselves	  cytotoxic,	  TZM-­‐bl	  cells	  were	  seeded	  at	  
1	   x	   104	   cells	   per	  well	   in	   a	   96-­‐well	   plate.	   Twenty-­‐four	   hours	   later,	  wells	  were	   either	   transfected	  
with	  100	  ng	  shRNA	  expression	  plasmid,	  as	  described	  in	  2.2.5,	  or	  treated	  with	  10,	  100	  or	  500	  nM	  
TSA,	   all	   in	   triplicate.	   Forty-­‐eight	   hours	   post-­‐transfection/-­‐TSA	   treatment,	   0.1	   mg	   of	   3-­‐(4,5-­‐
dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyltetrazolium	   bromide	   (MTT)	   was	   added	   to	   each	   well,	   which	   is	  
reduced	   by	   active	   reductase	   enzymes	   in	   living	   cells,	   such	   as	   mitochondrial	   dehydrogenases.	  
Following	   incubation	   at	   37	   °C	   for	   1	   hour,	   all	   media	   was	   removed	   and	   the	   resulting	   formazan	  
precipitates	  resuspended	  in	  200	  µl	  dimethyl	  sulfoxide	  (DMSO).	  The	  absorbance	  at	  570	  nm,	  with	  a	  
reference	  wavelength	  of	  655	  nm,	  was	  determined	  in	  a	  Model	  680	  microplate	  reader	  (BioRad,	  CA,	  
USA).	  
	  
2.2.15	  Cell	  viability	  by	  fluorescence	  microscopy	  
	  
Viability	  of	  cells	  expressing	  shRNAs	  was	  also	  assessed	  by	  fluorescence	  microscopy.	  TZM-­‐bl	  
cells	  were	  seeded	  at	  5	  x	  104	  cells	  per	  well	  in	  a	  24-­‐well	  plate	  24	  hours	  prior	  to	  transfection	  with	  500	  
ng	  of	  shRNA	  expression	  plasmid	  and	  100	  ng	  pCI-­‐eGFP	  per	  well,	  as	  described	  in	  2.2.5.	  Forty-­‐eight	  
hours	  post-­‐transfection,	  transmitted	  light	  and	  fluorescence	  images	  were	  acquired,	  as	  described	  in	  
2.2.12.	  
	  
2.2.16	  qRT-­‐PCR	  measurement	  of	  interferon-­‐β 	  mRNA	  concentrations	  
	  
Induction	   of	   interferon-­‐β	   expression	   accompanies	   an	   immune	   response	   to	   double-­‐
stranded	  RNAs.	  To	  determine	  whether	  shRNAs	   induced	  an	   immune	  response,	  TZM-­‐bl	  cells	  were	  
seeded	  at	  3	  x	  104	  cells	  per	  well	   in	  a	  24-­‐well	  plate	  and	  each	  well	   transfected	  with	  500	  ng	  shRNA	  
expression	  plasmid	  and	  10	  ng	  of	  pCI-­‐eGFP,	  as	  described	  in	  2.2.5.	  One	  microgram	  of	  polyinosinic:	  
polycytidylic	   acid	   (poly(I:C))	   (Sigma-­‐Aldrich,	   MO,	   USA),	   which	   is	   a	   dsRNA	   construct	   known	   to	  
induce	  an	  interferon	  response,	  was	  used	  as	  a	  positive	  control	  (Loseke	  et	  al.	  2006;	  Reynolds	  et	  al.	  
2006).	   Forty-­‐eight	   hours	   post-­‐transfection,	   total	   RNA	   was	   extracted	   using	   TriReagent™	   (see	  
A1.2.1)	  and	  subject	  to	  DNase	  treatment,	  reverse	  transcription	  and	  qPCR,	  as	  described	  in	  2.2.7	  (see	  
also	  A1.3.2	   and	  A1.3.4).	   Primers	   used	   to	   amplify	   interferon-­‐β	  mRNA	  were:	   forward	   5'	   TCC	  AAA	  
TTG	   CTC	   TCC	   TGT	   TGT	   GCT	   3';	   and,	   reverse	   5'	   CCA	   CAG	   GAG	   CTT	   CTG	   ACA	   CTG	   AAA	   A	   3'.	  
Expression	  was	  determined	  relative	  to	  β-­‐actin	  mRNA	  (Table	  2.4),	  as	  described	  in	  2.2.7.	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2.2.17	  Statistical	  analyses	  
	  
Data	   are	   expressed	   as	   the	   mean	   ±	   the	   standard	   error	   of	   the	   mean	   (SEM)	   and	   where	  
appropriate	  are	  normalised	  to	  a	  control	  sample	  within	  the	  experiment.	  Statistical	  difference	  was	  
considered	   to	   be	   significant	   (*)	  when	  p	   <0.05.	   Data	  was	   analysed	   using	   unpaired,	   two-­‐tailed	   t-­‐
tests,	   one-­‐way	   ANOVAs,	   followed	   by	   a	   Dunnett‘s	   multiple	   comparison	   post-­‐test,	   and	   two-­‐way	  
ANOVAs,	  followed	  by	  Bonferroni	  post-­‐tests,	  where	  appropriate,	  calculated	  using	  GraphPad	  Prism	  
4.0c	  (GraphPad	  Software,	  Inc.,	  CA,	  USA).	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2.3	  Results	  
	  
2.3.1	  shRNAs	  suppress	  cellular	  targets	  in	  HEK293	  cells	  
	  
Ten	   shRNAs	   were	   designed	   to	   target	   cellular	   factors	   HTATSF1,	   DDX3X,	   PSIP1	   and	  
SMARCB1	  (Figure	  2.4A).	  The	  loop	  sequence	  incorporated	  into	  each	  shRNA	  was	  derived	  from	  miR-­‐
31.	   Nucleotide	   substitutions	   were	   sometimes	   made	   in	   the	   passenger	   strand	   to	   create	   G:U	  
mismatches	  that	  enhanced	  thermodynamic	  asymmetry	  in	  the	  shRNAs	  and	  facilitated	  the	  desired	  
guide	   strand	   selection	   (see	   1.3.1	   and	   1.3.3).	   Sequences	   encoding	   shRNAs	   were	   cloned	  




Figure	  2.4:	  Constructed	  cellular	  factor-­‐targeting	  shRNA	  expression	  cassettes.	  A.	  The	  cellular	  factors	  htatsf1	  and	  ddx3x	  
were	   each	   targeted	   by	   three	   shRNAs	   and	   psip1	   and	   smarcb1	   by	   two	   shRNAs.	   All	   shRNAs	   contain	   a	   loop	   sequence	  
derived	  from	  miR-­‐31.	  G:U	  mismatches	  are	  indicated	  by	  a	  black	  arrowhead.	  B.	  shRNAs	  were	  cloned	  into	  Pol	  III	  expression	  
cassettes	  by	  a	  two-­‐step	  PCR	  method.	  On	  introduction	  of	  the	  shRNA	  plasmids	  into	  cells,	  RNAi	  pathway	  processing	  of	  the	  
expressed	  shRNAs	  produced	  target-­‐specific	  guide	  strands.	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RNA	  Pol	   III	   transcription	  has	   clear	   start	   and	   termination	   signals,	  producing	   shRNAs	  with	  
well-­‐defined	   ends.	   All	   shRNAs	   commence	  with	   a	   purine,	   the	   preferred	   initial	   ribonucleotide	   for	  
RNA	  Pol	  III	  transcription.	  The	  termination	  signal	  of	  >4	  thymidines	  result	  in	  a	  3’	  two	  nt	  overhang	  in	  
the	  shRNA,	  which	  is	  characteristic	  of	  Drosha	  products,	  ensuring	  shRNA	  recognition	  by	  exportin	  5	  
and	  Dicer.	  
The	   ability	   of	   shRNAs	   to	   suppress	   target	   expression	   was	   initially	   assessed	   using	   a	   dual	  
luciferase	   reporter	  assay,	   in	  which	  shRNA	  target	   sequences	  are	  within	   the	  3’	  UTR	  of	   the	  Renilla	  
luciferase	   gene.	   Following	   cotransfection	   of	   HEK293	   cells	   with	   cellular	   factor-­‐targeting	   shRNA	  
expression	   cassettes	   and	   cognate	   dual	   luciferase	   target	   constructs,	   the	   ratio	   of	   Renilla:firefly	  
luciferase	   activity	   was	   decreased	   by	   at	   least	   90%	   (p	   <0.001;	   Figure	   2.5).	   Cells	   treated	   with	   a	  
control	   shRNA,	   shHBVx,	   which	   targets	   a	   region	   within	   the	   HBV	   X	   protein,	   did	   not	   alter	   the	  
luciferase	  activity	   ratio.	  Similarly,	   the	   luciferase	  activity	   ratio	  was	  unaffected	   in	  cells	   transfected	  
with	  a	  pTZU6	  plasmid	  (with	  no	  shRNA	  expression)	  or	  dual	   luciferase	  target	  constructs	  only.	  This	  
demonstrates	  that	  the	  shRNA	  expression	  cassettes	  were	  able	  to	  specifically	  inhibit	  cognate	  target	  
sequences	  inserted	  downstream	  of	  the	  Renilla	  coding	  region.	  
	  
	  
Figure	  2.5:	  shRNAs	  significantly	  knock	  down	  their	  cognate	  targets	  in	  a	  dual	  luciferase	  reporter	  assay.	  Transfection	  of	  
HEK293	  cells	  with	  pTZU6+shRNA	  expression	  cassettes	  and	  cognate	  reporter	  constructs	  results	  in	  a	  significant	  inhibition	  
of	  Renilla	  luciferase	  activity	  relative	  to	  firefly	  luciferase	  activity	  48	  hours	  later.	  *,	  p	  <0.05,	  one-­‐way	  ANOVA	  with	  Dunnett	  
post-­‐tests	  relative	  to	  pTZU6.	  
	  
Such	   inhibition	   does	   not	   necessarily	   translate	   into	   suppression	   of	   endogenous	   target	  
mRNA	  and	  protein,	   however,	   as	   the	   context	   of	   the	   target	   sequence	  within	   a	  mRNA	  may	   affect	  
shRNA	  efficacy.	  For	  example,	  target	  sites	  within	  a	  mRNA	  may	  be	  protected	  from	  RNAi	  by	  bound	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protein	   or	   the	   formation	   of	   an	   obstructive	   structure	   (Overhoff	   et	   al.	   2005;	   Patzel	   et	   al.	   2005;	  
Schubert	  et	  al.	  2005).	  
Quantification	   of	   target	   mRNA	   by	   qRT-­‐PCR	   revealed	   that	   all	   three	   shRNAs	   targeting	  
htatsf1	  transcripts	  reduced	  levels	  relative	  to	  β-­‐actin	  mRNA	  (actb)	  by	  at	  least	  55%	  compared	  with	  a	  
pTZU6	  mock	   (p	  <0.01;	  Figure	  2.6).	  Both	  shP1	  and	  shP2	  significantly	   reduced	  psip1	   transcripts	   (p	  
<0.01),	   although	   shP1	   mediated	   greater	   knock	   down	   (81%)	   than	   shP2	   (52%).	   shS2	   showed	  
marginally	   greater	   efficacy	   than	   shS1	   (72%	   and	   87%	   knockdown,	   respectively;	   p	   <0.01).	   Thus,	  




Figure	   2.6:	   Not	   all	   shRNAs	   reduce	   levels	   of	   target	   mRNAs.	   Total	   RNA	   was	   analysed	   by	   qRT-­‐PCR	   48	   hours	   post-­‐
transfection	  of	  HEK293	  cells	  with	  shRNA	  expression	  plasmids	   in	  triplicate.	  Target	  mRNA	  levels	  are	  given	  relative	  to	  β-­‐
actin	  mRNA	  (actb).	  *,	  p	  <0.05,	  one-­‐way	  ANOVA	  with	  Dunnett	  post-­‐tests	  relative	  to	  pTZU6.	  
	  
In	   contrast,	   treatment	   of	   cells	   with	   shD1-­‐3,	   which	   target	   ddx3x	   mRNA,	   did	   not	   reduce	  
target	  transcript	  levels	  relative	  to	  actb	  mRNA	  (Figure	  2.6).	  This	  suggests	  that	  target	  sites	  for	  shD1-­‐
3	  may	   be	   inaccessible.	   Given	   that,	   concurrent	  with	   this	   work,	   DDX3X	  was	   validated	   as	   an	   HDF	  
through	  shRNA-­‐mediated	  suppression	   in	  a	   reporter	  cell	   line	   (Ishaq	  et	  al.	  2008),	   shD1-­‐3	  were	  no	  
longer	  pursued	  in	  this	  study.	  DDX3X	  was	  re-­‐examined	  as	  a	  potential	  TGS	  target	  in	  Chapter	  4.	  
	  
2.3.2	  shRNAs	  can	  reduce	  pNL4-­‐3.Luc.R-­‐.E-­‐	  luciferase	  activity	  
	  
The	  effect	  of	   cellular	   factor-­‐targeting	   shRNAs	  on	   the	  expression	  of	   the	  HIV-­‐1	   subtype	  B	  
molecular	   clone	   pNL4-­‐3.Luc.R-­‐.E-­‐,	   which	   contains	   a	   firefly	   luciferase	   reporter,	   was	   examined	   in	  
HEK293	   cells.	   This	   HIV	   molecular	   clone	   is	   readily	   transfectable	   into	   HEK	   cells	   but	   replication-­‐
defective	  as	  a	   result	  of	   two	   frame	  shifts	   rendering	   it	  Vpr-­‐	  and	  Env-­‐.	  Therefore,	  whilst	   this	  assay	  
may	  not	  identify	  HDFs	  with	  roles	  in	  the	  formation	  of	  infectious	  virions	  or	  viral	  entry,	  it	  is	  a	  quick	  
and	   convenient	   method	   for	   identification	   of	   proteins	   with	   a	   role	   in	   integration	   and	   viral	   gene	  
expression.	   Cells	   were	   cotransfected	   with	   shRNA	   expression	   cassettes,	   pNL4-­‐3.Luc.R-­‐.E-­‐	   and	   a	  
Renilla	   luciferase	   expression	   plasmid	   as	   a	   control	   for	   transfection	   efficiency.	   Two	   previously	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developed	  shRNAs	  that	  target	  the	  virus	  itself,	  shU5	  and	  shTAT	  (Barichievy	  et	  al.	  2007),	  were	  used	  
as	   positive	   controls	   for	   HIV-­‐1	   inhibition	   (Figure	   2.7A).	   shU5	   targets	   the	   leader	   RNA,	   just	  
downstream	  of	  the	  TAR	  element,	  which	  is	  found	  in	  all	  HIV	  transcripts,	  including	  pre-­‐genomic	  RNA.	  
shTAT	  targets	  a	  region	  common	  to	  both	  tat	  and	  rev	  mRNAs.	  
	  
	  
Figure	  2.7:	   shRNAs	  may	   inhibit	   pNL4-­‐3.Luc.R-­‐.E-­‐	   luciferase	  activity.	  A.	   Schematic	  of	   the	  HIV-­‐1	   genome	  depicting	   the	  
target	   sites	   of	   shU5	   and	   shTAT,	  which	  were	   used	   as	   positive	   controls.	  B.	   HEK293	   cells	  were	   transfected	  with	   shRNA	  
expression	   cassettes,	   pRSV-­‐RLuc	   and	   the	   HIV-­‐1	   subtype	   B	   molecular	   clone	   pNL4-­‐3.Luc.R-­‐.E-­‐	   and	   luciferase	   activities	  
determined	  48	  hours	  later.	  *,	  p	  <0.05,	  one-­‐way	  ANOVA	  with	  Dunnett	  post-­‐tests	  relative	  to	  pTZU6.	  
	  
Significant	   inhibition	   of	   pNL4-­‐3.Luc.R-­‐.E-­‐	   firefly	   luciferase	   activity	   was	   observed	   in	   cells	  
that	   received	   shH1,	   shP1	   and	   the	   two	   positive	   control	   shRNAs,	   but	   not	   either	   shRNA	   targeting	  
SMARCB1	  expression	   (p	  <0.05;	  Figure	  2.7B).	  This	   supports	  a	   role	   for	  HTATSF1	  and	  PSIP1	   in	  viral	  
gene	   expression	   and/or	   integration,	   and	   suggests	   that	   shH1	   and	   shP1	  may	  be	   the	  most	   potent	  
shRNAs	  against	  their	  respective	  targets	  in	  the	  context	  of	  HIV-­‐1	  infection.	  The	  latter	  is	  likely	  to	  be	  a	  
result	  of	  shP2	  targeting	  a	  region	  in	  psip1	  common	  to	  both	  p52	  and	  p75	  isoforms,	  whereas	  shP1	  is	  
p75-­‐specific,	   the	   isoform	  required	   for	  HIV	   integration.	   shH1-­‐3	   reduced	  mRNA	   levels	   to	  a	   similar	  
extent	   (Figure	   2.6),	   thus	   it	   is	   surprising	   that	   shH1	   is	   more	   effective	   than	   shH2	   and	   shH3	   in	  
inhibiting	   luciferase	  expression	  from	  pNL4-­‐3.Luc.R-­‐.E-­‐.	  This	  may	  reflect	  differences	   in	  the	  kinetics	  
of	  mRNA	  degradation:	  if	  shH1-­‐derived	  guide	  strands	  were	  expressed	  more	  efficiently,	  resulting	  in	  
a	  more	  rapid	  decline	   in	  HTATSF1,	   than	  those	   from	  shH2	  and	  shH3,	   it	  may	  give	  rise	   to	   increased	  
efficacy	   against	   pNL4-­‐3.Luc.R-­‐.E-­‐	   without	   reducing	  htatsf1	  mRNA	   concentrations	   48	   hours	   post-­‐
transfection	  to	  a	  greater	  extent.	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Overall,	  firefly	  luciferase	  inhibition	  did	  not	  exceed	  50%,	  which	  may	  be	  a	  result	  of	  the	  low	  
expression	  rate	  of	  pNL4-­‐3.Luc.R-­‐.E-­‐	  and	   it	  being	  competent	   for	  a	  single	  round	  of	  replication	  only	  
(Connor	  et	  al.	  1995;	  He	  et	  al.	  1995).	  This	  system	  suffers	  from	  additional	   limitations:	  transfection	  
of	  cells	  with	  a	  HIV-­‐1	  plasmid	  is	  not	  a	  good	  model	  for	  HIV-­‐1	  infection,	  particularly	  when	  validating	  
the	  roles	  of	  host	  proteins	   in	  the	   life	  cycle,	  as	  the	  mechanism	  of	  viral	  entry	  differs.	  Similarly,	   the	  
import	   of	   cellular	   factors	   that	   interact	  with	  Vpr	   and	   Env,	  which	   are	   deleted	   in	   pNL4-­‐3.Luc.R-­‐.E-­‐,	  
may	  be	  overlooked.	  To	  overcome	  the	  limitations	  associated	  with	  transfection	  of	  pNL4-­‐3.Luc.R-­‐.E-­‐,	  
experiments	  moved	  to	  a	  different	  cell	  line	  that	  permitted	  the	  use	  of	  a	  virus	  capable	  of	  productive	  
replication	   and	   HIV	   receptor-­‐mediated	   entry,	   whilst	   maintaining	   the	   ability	   to	   be	   easily	  
transfected	  with	  shRNA	  expression	  cassettes.	  
	  
2.3.3	  shRNAs	  suppress	  cognate	  targets	  in	  TZM-­‐bl	  cells	  by	  an	  RNAi	  mechanism	  
	  
TZM-­‐bl	  cells	  are	  derived	  from	  JC.53,	  a	  HeLa	  cell	  line	  that	  stably	  express	  large	  amounts	  of	  
the	   HIV	   receptors	   CD4	   and	   CCR5.	   The	   TZM-­‐bl	   cell	   line	   was	   generated	   from	   JC.53	   cells	   by	  
introducing	  separate	  integrated	  copies	  of	  the	  luciferase	  and	  β-­‐galactosidase	  genes	  under	  control	  
of	  the	  HIV-­‐1	  promoter	  (Platt	  et	  al.	  1998;	  Derdeyn	  et	  al.	  2000;	  Wei	  et	  al.	  2002).	  TZM-­‐bl	  cells	  are,	  
therefore,	   permissive	   to	   infection	   with	   diverse	   isolates	   of	   R5-­‐tropic	   HIV-­‐1	   and	   are	   a	   useful	  
indicator	  cell	   line	   for	  quantitative	  analysis	  of	  HIV,	  using	  either	   luciferase	  or	  β-­‐galactosidase	  as	  a	  
reporter.	  
Before	  assessing	  the	  ability	  of	  shRNAs	  to	  inhibit	  HIV-­‐1	  replication	  TZM-­‐bl	  cells,	  it	  was	  first	  
verified	   that	   the	   shRNAs	   suppressed	   their	   targets	   in	   these	   cells,	   as	   shRNA	   efficacy	   may	   vary	  
between	  cell	  lines.	  The	  ability	  of	  shRNAs	  to	  inhibit	  cognate	  targets	  in	  HeLa	  cells,	  from	  which	  TZM-­‐
bl	   are	   derived,	   was	   verified	   with	   a	   dual	   luciferase	   reporter	   assay.	   All	   shRNAs	   decreased	  
Renilla:firefly	  luciferase	  activity	  by	  greater	  than	  95%	  (p	  <0.001;	  Figure	  2.8A),	  which	  was	  similar	  to	  
that	   observed	   in	   HEK293	   cells	   (Figure	   2.5).	   Suppression	   of	   target	  mRNA	   levels	   relative	   to	   actb	  
mRNA	  when	  normalised	   to	  a	  pTZU6	  control	  was	  also	   similar	   in	  TZM-­‐bl	   cells	   to	  HEK293	  cells;	   all	  
cellular	  factor-­‐targeting	  shRNAs	  significantly	  suppressed	  levels	  of	  their	  cognate	  target	  transcripts	  
(p	   <0.01;	   Figure	   2.8B).	   shP1	   and	   shS2	   were	   more	   effective	   at	   reducing	   psip1	   and	   smarcb1	  
transcripts,	   respectively,	   than	   shP2	   (91%	   versus	   88%	   knock	   down)	   and	   shS1	   (71%	   versus	   61%	  
knock	   down).	   shH1	   reduced	  htatsf1	  mRNA	   levels	   to	   a	   lesser	   degree	   than	   shH2	   and	   shH3	   (38%	  
versus	  60%	  knock	  down).	  
Guide	  strand	  processing	  was	  confirmed	  for	  all	  shRNAs	  by	  small	  RNA	  Northern	  blot	  (Figure	  
2.8C).	  Conclusions	  cannot	  be	  drawn	  with	  respect	  to	  the	  relative	  levels	  of	  guide	  strands	  produced,	  
as	  different	  probes	  were	  required	  for	  their	  detection	  that	  differ	   in	  their	  hybridisation	  efficiency.	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Nonetheless,	   the	   detection	   of	   guide	   strands	   from	   all	   cellular	   factor	   shRNAs	   supports	   that	   the	  
htatsf1,	  psip1	  and	  smarcb1	  mRNA	  silencing	  was	  mediated	  by	  an	  RNAi	  mechanism.	  
	  
	  
Figure	  2.8:	  shRNAs	  knock	  down	  target	  mRNAs	  by	  an	  RNAi	  mechanism.	  A.	  shRNAs	  suppress	  cognate	  targets	  in	  a	  dual	  
luciferase	   reporter	  assay	   in	  HeLa	  cells	  48	  hours	  post-­‐transfection.	  B.	   Endogenous	   target	  mRNA	   levels	  are	   reduced	  by	  
shRNAs	  in	  HeLa-­‐derived	  TZM-­‐bl	  cells	  relative	  to	  β-­‐actin	  mRNA	  (actb).	  C.	  Guide	  strands,	  the	  product	  of	  RNAi	  processing	  
of	  shRNAs,	  were	  detected	  by	  small	  RNA	  PAGE	  Northern	  blot	  in	  TZM-­‐bl	  cells	  48	  hours	  post-­‐transfection.	  *,	  p	  <0.05,	  one-­‐
way	  ANOVA	  with	  Dunnett	  post-­‐tests	  relative	  to	  pTZU6.	  
	  
2.3.4	  shRNAs	  inhibit	  HIV-­‐1	  Tat-­‐induced	  luciferase	  activity	  in	  TZM-­‐bl	  reporter	  cells	  
	  
Infection	   of	   TZM-­‐bl	   cells	   with	   HIV-­‐1	   results	   in	   integration	   of	   the	   proviral	   DNA	   and,	  
subsequently,	  low-­‐level	  production	  of	  the	  viral	  transactivator	  Tat.	  Tat	  binding	  to	  the	  TAR	  element	  
in	   the	   viral	   promoter,	   or	   LTR,	   leads	   to	   a	   dramatic	   increase	   in	   transcription	   and	   thus,	   viral	   gene	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expression.	  The	  integrated	  luciferase	  genes	  in	  TZM-­‐bl	  are	  downstream	  of	  viral	  LTRs	  such	  that	  Tat	  
can	   also	   stimulate	   transcription	   of	   luciferase	   (Figure	   2.9).	   Consequently,	   assays	   for	   luciferase	  
activity	  in	  TZM-­‐bl	  cell	  lysates	  provide	  a	  simple,	  quantitative	  indicator	  of	  HIV-­‐1	  replication.	  
	  
	  
Figure	  2.9:	  Schematic	  of	  the	  HIV-­‐reporter	  ability	  of	  TZM-­‐bl	  cells.	  Following	  HIV	  infection	  and	  integration	  of	  the	  proviral	  
DNA,	  low	  levels	  of	  transcription	  produce	  the	  viral	  regulatory	  protein	  Tat.	  Tat	  can	  bind	  the	  TAR	  element	  in	  nascent	  RNA	  
transcripts	   at	   the	   viral	   promoter	   resulting	   in	   a	   dramatic	   increase	   in	   viral	   gene	   expression.	   TZM-­‐bl	   cells	   contain	   an	  
integrated	  firefly	  luciferase	  gene	  driven	  by	  the	  HIV	  promoter.	  As	  such,	  on	  HIV	  infection	  of	  these	  cells,	  Tat	  also	  induces	  
luciferase	  expression.	  
	  
TZM-­‐bl	  cells	  were	  transfected	  with	  various	  amounts	  of	  shRNA	  expression	  plasmids	  prior	  
to	   infection	   with	   the	   subtype	   C	   envelope-­‐pseudotyped	   subtype	   B	   molecular	   clone	  
pSG3Δenv.ZM53M	   at	   a	   TCID50	   of	   1000/ml.	   In	   contrast	   to	   pTZU6	   and	   shHBVx	   negative	   controls,	   a	  
shRNA	   dose-­‐dependent	   suppression	   of	   Tat-­‐induced	   luciferase	   activity	   was	   observed,	   with	  
maximum	   suppression	   typically	   when	   500	   ng	   of	   shRNA	   expression	   plasmid	   was	   transfected	  
(Figure	   2.10A).	   The	   only	   exception	   being	   shH3,	   which	   exhibited	   the	   greatest	   inhibition	   of	  
luciferase	   activity	   at	   1000	   ng,	   possibly	   reflecting	   differences	   in	   the	   kinetics	   of	   guide	   strand	  
processing.	   Since	   the	  majority	   of	   shRNAs	   exhibited	   greatest	   inhibition	   of	   Tat-­‐induced	   luciferase	  
activity	  at	  500	  ng,	  and	   the	   lowest	  effective	  dose	   is	  preferable	   to	  minimise	   toxicity,	   this	  amount	  
was	   used	   in	   subsequent	   experiments.	   At	   this	   dose,	   the	   greatest	   inhibition	   of	   luciferase	   activity	  
was	   with	   HTATSF1-­‐targeting	   shH1	   and	   shH2	   (~60%,	   p	   <0.01),	   with	   the	   exception	   of	   positive	  
controls	  shU5	  and	  shTAT	  (~80%,	  p	  <0.001;	  Figure	  2.10B).	  shP1	  and	  shS2	  also	  significantly	  inhibited	  
luciferase	  activity	  (p	  <0.01),	  although	  not	  to	  the	  same	  extent	  (43%	  and	  30%,	  respectively).	  
	  
	   65	  
	  
Figure	  2.10:	  shRNAs	  inhibit	  Tat-­‐induced	  luciferase	  activity	  in	  a	  dose-­‐dependent	  manner.	  A.	  TZM-­‐bl	  cells	  were	  infected	  
with	  pSG3Δenv.ZM53M	  at	  a	  TCID50	  of	  1000/ml	  24	  hours	  post-­‐transfection	  with	  various	  quantities	  of	   shRNA	  expression	  
plasmids.	  Firefly	  luciferase	  activity	  was	  determined	  48	  hours	  post-­‐infection	  in	  triplicate.	  B.	  As	  (A)	  but	  where	  500	  ng	  of	  
shRNA	  expression	  plasmid	  transfected	  only.	  *,	  p	  <0.05,	  one-­‐way	  ANOVA	  with	  Dunnett	  post-­‐tests	  relative	  to	  pTZU6.	  
	  
Similar	   results	   were	   obtained	   when	   cells	   were	   infected	   with	   a	   different	   subtype	   B	  
molecular	  clone,	  p81A-­‐4,	  and	  a	  virus	  passaged	  from	  a	  subtype	  C	  primary	  isolate,	  FV5	  (Figure	  2.11).	  
In	  general,	  the	  ability	  of	  shRNAs	  to	  inhibit	  Tat-­‐induced	  luciferase	  activity	  was	  reduced	  in	  the	  FV5-­‐
infected	   cells,	   including	  positive	   controls.	   This	  may	   indicate	   that	   the	  propagation	   rate	  of	   FV5	   is	  
greater	   than	   the	   subtype	   B	   molecular	   clone-­‐derived	   viruses	   used,	   which	   has	   been	   observed	  
previously	   (personal	   communication	   of	   M.	   Papathanasopoulos,	   S.	   Barichievy	   and	   S.	   Saayman).	  
Regardless,	   repeatedly	   the	   same	   shRNAs	   display	   the	   greatest	   efficacy,	   irrespective	   of	   whether	  
pNL4-­‐3.Luc.R-­‐.E-­‐,	  pSG3Δenv.ZM53M,	  p81A-­‐4	  or	  FV5	  was	  used,	  namely	  shH1,	  shP1	  and	  shS2	  for	  each	  
cellular	  factor	  targeted,	  which	  became	  the	  focus	  of	  subsequent	  experiments.	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Figure	   2.11:	   shRNAs	  mediate	   similar	   effects	   on	   different	   subtypes	   of	   HIV-­‐1.	   TZM-­‐bl	   cells	  were	   infected	  with	   either	  
subtype	  B	  molecular	  clone	  p81A-­‐4	  or	  virus	  passaged	  from	  subtype	  C	  isolate	  FV5,	  both	  at	  a	  TCID50	  of	  1000/ml,	  24	  hours	  
post-­‐transfection.	  Firefly	   luciferase	  activity	  was	  determined	  48	  hours	  post-­‐infection.	  *,	  p	  <0.05,	  one-­‐way	  ANOVA	  with	  
Dunnett	  post-­‐tests	  relative	  to	  pTZU6.	  
	  
2.3.5	  HTATSF1-­‐targeted	  shRNA	  inhibits	  HIV-­‐1	  infectious	  particle	  production	  
	  
The	  TZM-­‐bl	  luciferase	  reporter	  system	  is	  less	  sensitive	  for	  factors	  affecting	  the	  late	  stages	  
of	  viral	   replication,	   including	  assembly	  and	  budding,	  compared	  to	   those	   involved	   in	  early	  stages	  
(Brass	  et	  al.	  2008).	  Therefore,	  to	  indicate	  the	  import	  of	  targeted	  cellular	  factors	  in	  the	  entire	  viral	  
life	   cycle,	   whether	   shRNA-­‐targeting	   of	   HTATSF1,	   PSIP1	   and	   SMARCB1	   could	   inhibit	   infectious	  
particle	  production	  was	  examined.	  Culture	  supernatants	  from	  primary-­‐infected	  cells	  were	  assayed	  
for	   levels	  of	   the	  HIV-­‐1	  antigen	  p24	  and	   the	  ability	   to	   induce	   luciferase	  activity	   in	   fresh	   reporter	  
cells,	  thereby	  measuring	  infectious	  progeny	  (Figure	  2.12).	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Figure	   2.12:	   Schematic	   of	   the	   TZM-­‐bl	   reporter	   assay	   for	   HIV-­‐1	   infectious	   particle	   production.	   Following	   a	   primary	  
infection	  of	  shRNA-­‐transfected	  TZM-­‐bl	  cells,	   the	  HIV-­‐1	  antigen	  p24	  was	  quantified	   in	  culture	  supernatant	  by	  ELISA.	   In	  
addition,	  some	  of	   the	  culture	  supernatant	  was	  used	   in	  a	  secondary	   infection	  of	  untransfected	  TZM-­‐bl	  cells	   that	  were	  
analysed	  for	  Tat-­‐induced	  firefly	  luciferase	  activity	  48	  hours	  later.	  
	  
None	  of	  the	  shRNAs	  targeting	  host	  factors	  was	  able	  to	  suppress	  either	  p81A-­‐4	  or	  FV5	  p24	  
production,	   in	  contrast	  to	  positive	  controls	  shU5	  and	  shTAT	  (p	  <0.05;	  Figure	  2.13).	  Nonetheless,	  
shH1	  did	  mediate	  a	  significant	  drop	  in	  p81A-­‐4	  infectious	  particle	  production	  (62%,	  p	  <0.01;	  Figure	  
2.14),	  quantified	  by	   luciferase	  activity	   in	  cells	   receiving	  culture	  supernatant	   from	  shRNA-­‐treated	  
cells.	  This	  discord	  suggests	  that	  HTATSF1	  may	  have	  a	  role	  in	  HIV-­‐1	  replication	  that	  is	  required	  for	  
infectious	   particle,	   but	   not	   p24,	   production.	   shP1	   and	   shS2	   had	   no	   effect	   on	   the	   amount	   of	  
infectious	  progeny	  produced,	  whether	  quantified	  by	  p24	  levels	  or	  secondary	  luciferase	  assay.	  
	  
	  
Figure	  2.13:	  Host	  factor-­‐targeting	  shRNAs	  do	  not	  inhibit	  HIV-­‐1	  p24	  production.	  TZM-­‐bl	  cells	  were	  transfected	  with	  500	  
ng	  shRNA	  expression	  plasmids	  and	  infected	  with	  either	  p81A-­‐4	  or	  FV5	  at	  a	  TCID50	  of	  1000/ml	  24	  hours	  later.	  HIV-­‐1	  p24	  
was	  quantified	  in	  cell	  culture	  media	  48	  hours	  post-­‐infection	  by	  ELISA.	  *,	  p	  <0.05,	  two-­‐way	  ANOVA	  with	  Bonferroni	  post-­‐
tests.	  
	  
The	   contrast	   between	   the	   inhibition	   in	   primary	   luciferase	   activities	   but	   unaltered	   p24	  
levels	  with	   shH1,	   shP1	   and	   shS2	   suggests	   a	   bias	   in	   the	   primary	   luciferase	   activity	   assay	   toward	  
factors	   influencing	  early	  stages	  of	  the	   life	  cycle,	  which	  may	  be	  related,	   in	  part,	  to	  the	  numerous	  
copies	  of	  the	  integrated	  LTR-­‐luciferase	  reporter	  gene.	  Nevertheless,	  the	  lack	  of	  infectious	  particle	  
inhibition	   from	   shP1-­‐treated	   cells	   was	   surprising	   given	   the	   essential	   role	   of	   PSIP1	   in	   HIV-­‐1	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integration	  (Llano	  et	  al.	  2006a).	  Whether	  the	  lack	  of	  infectious	  particle	  inhibition	  in	  cells	  treated	  
with	  shP1	  and	  shS2	  was	  a	  result	  of	  insufficient	  protein	  suppression	  was	  investigated.	  
	  
	  
Figure	   2.14:	   HTATSF1-­‐targeting	   shRNA	   inhibits	   HIV-­‐1	   infectious	   particle	   production.	   Culture	   media	   were	   collected	  
from	  shRNA	  expression	  plasmid-­‐transfected	  TZM-­‐bl	   cells	  48	  hours	  post-­‐infection	  with	  p81A-­‐4	  at	   a	  TCID50	  of	  1000/ml	  
and	   used	   to	   infect	   untransfected	   TZM-­‐bl	   cells.	   Firefly	   luciferase	   activity	   was	   determined	   48	   hours	   post-­‐secondary	  
infection.	  *,	  p	  <0.05,	  one-­‐way	  ANOVA	  with	  Dunnett	  post-­‐tests	  relative	  to	  pTZU6.	  
	  
2.3.6	   shRNA-­‐mediated	  HTATSF1	   suppression	   is	   rapid	   but	   PSIP1	   and	   SMARCB1	  have	   long	   half-­‐
lives	  
	  
The	   TZM-­‐bl	   reporter	   system	   employed	   transient	   expression	   of	   shRNAs	   following	  
transfection	  of	  expression	  cassettes.	  Primary	  viral	  infections	  followed	  just	  24	  hours	  later,	  at	  which	  
time	   maximal	   target	   protein	   suppression	   may	   not	   have	   been	   attained.	   The	   kinetics	   of	   target	  
protein	  suppression	  was	  determined	  by	  Western	  blot.	  
Relative	   to	   β-­‐actin,	   HTATSF1	   levels,	   although	   unclear	   48	   hours	   post-­‐shH1	   transfection,	  
were	   significantly	   reduced	   to	   99.5%	   of	   the	   shHBVx	   control	   72	   hours	   post-­‐transfection	   (Figure	  
2.15).	  In	  contrast,	  p75	  levels	  were	  only	  marginally	  reduced	  at	  48	  hours	  post-­‐shP1	  transfection	  and	  
still	  at	  77%	  of	  shHBVx	  levels	  96	  hours	  post-­‐transfection.	  Together	  with	  the	  significant	  inhibition	  of	  
mRNA	  levels	  48	  hours	  post-­‐shP1	  transfection	  (>90%,	  p	  <0.001;	  Figure	  2.8B),	  this	  suggests	  that	  p75	  
has	  a	  slow	  turnover.	  This	  may	  account	  for	  the	  marginal	  inhibition	  of	  Tat-­‐induced	  luciferase	  activity	  
following	   primary	   infection	   and	   the	   lack	   of	   inhibition	   of	   HIV-­‐1	   infectious	   particle	   production.	  
Similarly	   to	   HTATSF1,	   SMARCB1	   suppression	   was	   maximal	   at	   72	   hours	   post-­‐shS2	   transfection,	  
though	  only	  dropping	  to	  47.5%	  of	  shHBVx	  (Figure	  2.15).	  Hence,	  suppression	  of	  SMARCB1	  may	  not	  
have	  been	  sufficient	  to	  have	  a	  detrimental	  impact	  on	  viral	  particle	  production,	  as	  with	  p75.	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Figure	  2.15:	  The	  half-­‐lives	  of	  targeted	  host	  proteins	  differ.	  TZM-­‐bl	  cell	  lysates	  were	  subject	  to	  PAGE	  and	  Western	  blot	  
at	   48,	   72	   and	   96	   hours	   post-­‐shRNA	   expression	   plasmid	   transfection.	   Expression	   is	   given	   relative	   to	   β-­‐actin	   and	  
normalised	  to	  cells	  treated	  with	  the	  negative	  control	  shHBVx	  at	  each	  time	  point.	  
	  
2.3.7	  shRNA-­‐mediated	  host	  factor	  suppression	  is	  not	  cytotoxic	  
	  
Having	   determined	   that	   maximal	   HTATSF1	   and	   SMARCB1	   suppression	   was	   attained	   72	  
hours	   post-­‐transfection	   (Figure	   2.15),	   the	   extent	   of	   apoptosis	   induction	   at	   this	   time	   point	   was	  
quantified	  by	   fluorescence	  microscopy	  of	   FITC-­‐conjugated	  Annexin	  V-­‐stained	   cells	   (Figure	  2.16).	  
Annexin	   V	   binds	   to	   phosphotidylserine,	   which	   becomes	   exposed	   on	   disruption	   of	   phospholipid	  
asymmetry	  during	  the	  early	  stages	  of	  apoptosis.	  
	  
	  
Figure	  2.16:	  shRNA-­‐mediated	  target	  suppression	  does	  not	  induce	  apoptosis.	  TZM-­‐bl	  cells	  were	  stained	  with	  Annexin	  V-­‐
FITC	  72	  hours	  following	  transfection	  with	  shRNA	  expression	  plasmids.	  As	  a	  positive	  control	  for	  apoptosis	  induction,	  cells	  
were	  treated	  with	  TSA	  16	  hours	  pre-­‐stain.	  Four	  images	  of	  FITC	  and	  transmitted	  light	  were	  acquired	  of	  stained	  cells	  per	  
sample	  and	  analysed	  by	  ImageJ.	  *,	  p	  <0.05,	  one-­‐way	  ANOVA	  with	  Dunnett	  post-­‐tests	  relative	  to	  pTZU6.	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No	   increase	   in	   early	   apoptotic	   cells	   was	   detected	   in	   cells	   transfected	   with	   any	   shRNA	  
expression	  plasmids	   (Figure	  2.16).	   In	   contrast,	   a	   significant	   increase	   in	  early	   apoptotic	   cells	  was	  
seen	   when	   cells	   were	   treated	   with	   500	   nM	   of	   TSA,	   which	   was	   used	   as	   a	   positive	   control	   for	  
apoptosis	  induction	  as	  it	  is	  toxic	  at	  high	  concentrations.	  
It	  is	  important	  to	  characterise	  as	  fully	  as	  possible	  whether	  suppression	  of	  cellular	  targets	  
has	   cytotoxic	   effects.	   Recently,	   it	   was	   suggested	   that	   HTATSF1,	   rather	   than	   being	   a	   general	  
elongation	  factor,	  plays	  a	  role	  in	  splicing	  of	  HIV-­‐1	  transcripts	  (Miller	  et	  al.	  2009).	  This	  report	  also	  
proposed	   that	   its	   role	   in	   splicing	   extended	   to	   endogenous	   cellular	   transcripts,	   although	  data	   in	  
support	   of	   the	   latter	   was	   not	   provided.	   To	   interrogate	   this	   possibility,	   the	   effects	   of	   HTATSF1	  
suppression	   on	   general	   cellular	   splicing	   were	   examined	   using	   pEGFP-­‐C1-­‐NAD,	   a	   GFP	   reporter	  
construct	   with	   an	   inserted	   intron	   from	   the	   NADH-­‐coenzyme	   Q	   reductase	   gene	   (NAD)	   (Figure	  
2.17A).	  A	  construct	  with	  mutated	  splice	  sites	  was	  used	  as	  a	  negative	  control	  for	  GFP	  production.	  
	  
	  
Figure	  2.17:	  HTATSF1	  suppression	  does	  not	  effect	  splicing	  of	  a	  GFP	  reporter.	  A.	  Schematic	  of	  GFP	  reporter	  constructs	  
used	  in	  splicing	  assay.	  An	  intron	  from	  the	  NAD	  gene	  was	  inserted	  within	  a	  GFP	  expression	  cassette	  such	  that	  GFP	  was	  
only	  expressed	  following	  normal	  transcription,	  splicing	  and	  translation.	  A	  construct	  with	  mutated	  splice	  sites,	  where	  no	  
GFP	  was	  produced,	  was	  used	  as	  a	   control.	  B.	   TZM-­‐bl	   cells	  were	   transfected	  with	  HTATSF1-­‐targeting	   shH1	  expression	  
plasmid	  or	   negative	   control	   shHBVx.	   Forty-­‐eight	   hours	   later,	   cells	  were	   transfected	  with	   either	   the	  NAD-­‐	   or	  mutant-­‐
intron	  GFP	  construct	   in	   triplicate.	   Fluorescence	  was	  determined	  by	   fluorometry	  another	  48	  hours	   later	  and	   reported	  
relative	   to	   total	   cellular	  protein.	  One-­‐way	  ANOVA	  with	  Dunnett	  post-­‐tests	   relative	   to	  pTZU6	  and	  an	  unpaired,	   two-­‐
tailed	  t-­‐test.	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Significant	  differences	  in	  the	  production	  of	  GFP,	  relative	  to	  total	  cellular	  protein,	  were	  not	  
observed	  between	  cells	  treated	  with	  either	  1.0	  or	  0.1	  µg	  of	  shHBVx	  or	  shH1	  expression	  plasmids	  
(p	   >0.25;	   Figure	   2.17B).	   This	   demonstrates	   that	   HTATSF1	   is	   not	   critical	   for	   splicing	   of	   such	   a	  
reporter	  construct	  and	  may	  not	  be	  involved	  in	  cellular	  splicing.	  
	  
2.3.8	   U6-­‐driven	   shRNA	   expression	   in	   TZM-­‐bl	   cells	   is	   not	   cytotoxic	   and	   does	   not	   activate	   an	  
immune	  response	  
	  
To	   verify	   that	   the	   high	   levels	   of	   U6-­‐driven	   shRNA	   expression	   were	   not	   cytotoxic,	   the	  
colourimetric	  MTT	   assay	  was	   performed	   to	   indicate	   the	   number	   of	   viable	   cells.	   TSA	  was	   again	  
used	   as	   a	   positive	   control	   for	   cytotoxicity.	   None	   of	   the	   shRNA	   expression	   plasmids	   altered	   the	  
number	  of	  viable	  cells	  48	  hours	  post-­‐transfection	  compared	  to	  the	  pTZU6	  control	  (Figure	  2.18A).	  
In	  addition,	  levels	  of	  eGFP	  expression	  in	  cells	  cotransfected	  with	  shRNA	  expression	  cassettes	  and	  
pCI-­‐eGFP	  were	  unchanged,	  determined	  by	  fluorescence	  microscopy	  (Figure	  2.18B).	  Together	  this	  
provides	  good	  evidence	  that	  the	  levels	  of	  shRNAs	  being	  produced	  in	  transfected	  TZM-­‐bl	  cells	  over	  
the	  short	  time-­‐scales	  involved	  in	  the	  HIV-­‐1	  reporter	  assays	  were	  not	  cytotoxic.	  
	  
	  
Figure	  2.18:	  shRNA	  expression	  does	  not	  alter	  cell	  viability.	  A.	  TZM-­‐bl	  cells	  were	  treated	  with	  MTT	  48	  hours	  post-­‐shRNA	  
expression	  plasmid	  transfection.	  TSA	  treatment	  was	  used	  as	  a	  positive	  control	  for	  reduced	  cell	  viability.	  B.	  Fluorescence	  
microscopy	   images	   of	   overlayed	  GFP	   and	   transmitted	   light.	   Bars	   100	  µm.	   *,	  p	   <0.05,	   one-­‐way	  ANOVA	  with	  Dunnett	  
post-­‐tests	  relative	  to	  pTZU6.	  
	  
Double-­‐stranded	  RNAs	  (dsRNAs)	  may	  induce	  a	  type	  I	   immune	  response,	  a	  component	  of	  
which	   is	   increased	   interferon-­‐β	   expression	   (Stark	   et	   al.	   1998).	   However,	   none	   of	   the	   cellular	  
factor-­‐targeting	   shRNAs	   significantly	   increased	   interferon-­‐β	  mRNA	   (ifnb1)	   levels	   relative	   to	  actb	  
mRNA	  compared	  to	  the	  pTZU6	  control,	  in	  contrast	  to	  the	  positive	  control	  poly(I:C)	  that	  caused	  a	  
>10-­‐fold	   increase	   (p	   <0.001;	   Figure	   2.19).	   This	   suggests	   that	   the	   shRNAs	   are	   not	   inducing	   an	  
immune	  response.	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Figure	  2.19:	  shRNAs	  do	  not	  induce	  an	  immune	  response.	  Levels	  of	  interferon-­‐β	  mRNA	  (ifnb1)	  relative	  to	  β-­‐actin	  mRNA	  
(actb)	   were	   determined	   by	   qRT-­‐PCR	   on	   total	   cellular	   RNA	   extracted	   48	   hours	   post-­‐transfection	   in	   triplicate.	   One	  
microgram	  of	  poly(I:C)	  RNA	  was	  used	  as	  a	  positive	  control	  for	  immune	  response	  induction.	  *,	  p	  <0.05,	  one-­‐way	  ANOVA	  
with	  Dunnett	  post-­‐tests	  relative	  to	  pTZU6.	  
	  
The	  MTT	   assay,	   fluorescence	  microscopy	   and	   interferon-­‐β	   expression	   data	   suggest	   that	  
any	   effects	   mediated	   by	   the	   shRNAs	   on	   viral	   replication	   are	   not	   a	   result	   of	   cytotoxicity	   and	  
immune	   response	   induction.	   Thus,	   the	   results	   in	   this	   chapter	   show	   that	   RNAi-­‐mediated	  
suppression	   of	   the	   cellular	   factor	   HTATSF1	   can	   inhibit	   Tat-­‐induced	   luciferase	   activity	   in	   HIV-­‐1-­‐
infected	   TZM-­‐bl	   cells	   without	   cytotoxic	   effects.	   However,	   long	   half-­‐lives	   of	   targets	   PSIP1	   and	  
SMARCB1	  hampers	  elucidation	  of	  their	  role	  in	  viral	  replication	  when	  using	  the	  TZM-­‐bl	  system	  and	  
transient	  shRNA	  expression.	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2.4	  Discussion	  
	  
The	   approach	   used	   in	   this	   study	   was	   to	   validate	   the	   role	   of	   cellular	   factors	   HTATSF1,	  
DDX3X	   and	   SMARCB1	   in	   HIV-­‐1	   replication	   through	   shRNA-­‐mediated	   PTGS.	   Whilst	   the	   results	  
confirm	  that	  HTATSF1	  is	  a	  HDF,	  they	  are	  inconclusive	  with	  respect	  to	  DDX3X	  and	  SMARCB1.	  
shRNAs	  were	   unable	   to	   suppress	   ddx3x	   mRNA	   levels	   (Figure	   2.6),	   despite	   considerable	  
suppression	  of	  cognate	  targets	  in	  a	  dual	  luciferase	  reporter	  assay	  (Figure	  2.5).	  This	  demonstrates	  
the	  drawback	  of	  using	  target	  reporters,	  as	  the	  isolated	  target	  sequence	  may	  be	  more	  accessible	  to	  
RNAi	   than	  when	   in	   the	   context	   of	   the	   endogenous	  mRNA,	   such	   that	   the	   reporter	   system	   lacks	  
physiological	   relevance.	   Several	   mechanisms	   can	   protect	   a	  mRNA	   from	   RNAi,	   including	  mRNA-­‐
bound	  proteins	   blocking	   the	   target	   site,	   the	   adoption	  of	   an	  obstructive	   structure	   and,	   possibly,	  
localisation	  to	  a	  subcellular	  compartment	  that	  is	  not	  surveyed	  by	  the	  RNAi	  machinery	  (Overhoff	  et	  
al.	  2005;	  Patzel	  et	  al.	  2005;	  Schubert	  et	  al.	  2005).	  Such	  factors	  may	  also	  account	  for	  the	  variation	  
in	  mRNA	  suppression	  observed	  with	  the	  shRNAs	  targeting	  HTATSF1,	  PSIP1	  and	  SMARCB1	  (Figures	  
2.6	  and	  2.8B).	  
The	   relationship	   between	  mRNA	   and	   protein	   levels	   is	   complex,	   however.	   Of	   the	   three	  
genes	   whose	   mRNA	   levels	   were	   suppressed	   by	   shRNAs,	   htatsf1	   mRNA	   displayed	   the	   least	  
inhibition	   (~60%;	   Figures	   2.6	   and	   2.8B),	   although	   the	   greatest	   suppression	   of	   HTATSF1	   protein	  
(>95%;	  Figure	  2.15).	  Conversely,	  suppression	  of	  psip1	  mRNA	  and	  p75	  protein	  was	  high	  and	   low,	  
respectively.	  This	  demonstrates	  that	  the	  kinetics	  of	  mRNA	  and	  protein	  turnover,	  transcription	  and	  
translation	  vary	  between	  genes.	  This	  means	  that	  use	  of	  RNAi	  in	  TZM-­‐bl	  cells	  to	  validate	  HDFs	  may	  
lead	  to	  notable	  omissions,	  such	  as	  p75.	  The	  long	  half-­‐life	  of	  p75	  identified	  here	  has	  been	  reported	  
previously	   (Llano	  et	  al.	  2006a)	  and	   it	   is	  not	  surprising,	   therefore,	   that	  PSIP1	  was	  notably	  absent	  
from	  the	  lists	  of	  HDFs	  identified	  in	  large-­‐scale	  RNAi	  screens	  (Brass	  et	  al.	  2008;	  Konig	  et	  al.	  2008;	  
Zhou	   et	   al.	   2008;	   Yeung	   et	   al.	   2009b).	   Thus,	   despite	   its	   inclusion	   as	   a	   positive	   control	   for	   HDF	  
suppression-­‐mediated	  inhibition	  of	  HIV-­‐1	  replication,	   in	  this	  reporter	  system,	   it	  did	  not	  fulfil	  this	  
role.	  
Of	  note	   is	  that	  only	  shP1	  caused	  a	  slight	   inhibition	  of	  Tat-­‐induced	   luciferase	  activity	  and	  
not	  shP2	  (Figures	  2.10	  and	  2.11).	  shP2	  targets	  a	   region	  common	  to	  both	  p52	  and	  p75	   isoforms,	  
although	  only	  p75	   is	   involved	   in	  HIV-­‐1	   integration.	  The	   relative	   levels	  of	  p52	  and	  p75	   in	  TZM-­‐bl	  
cells	   are	  unknown	  but	   it	   is	   possible	   that	  p52	  acts	   as	   a	   sponge	   for	   shP2	   such	   that	   less	   shRNA	   is	  
available	   for	   targeting	   of	   p75.	   Furthermore,	   it	   has	   been	   reported	   that	   p75	   levels	   need	   to	   be	  
reduced	   by	   >95%	   to	   have	   an	   effect	   on	  HIV-­‐1	   replication,	   on	   the	   basis	   that	   only	   at	   this	   level	   of	  
suppression	  are	  proteins	  depleted	  from	  chromatin	  (Llano	  et	  al.	  2006a).	  Thus,	   it	  seems	  the	  slight	  
difference	   in	  p75	  mRNA	  suppression	  mediated	  by	  shP1	  and	  shP2	  (~93%	  and	  ~86%,	  respectively;	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Figure	   2.8B)	   in	   TZM-­‐bl	   cells	   is	   sufficient	   to	   result	   in	   a	   significant	   difference	   in	   the	   ability	   of	   the	  
shRNAs	   to	   inhibit	   HIV-­‐1	   integration.	   Unfortunately,	  Western	   blot	   analysis	   of	   shP2-­‐treated	   cells	  
was	  not	  obtained	  to	  test	  this	  hypothesis.	  
From	   the	   results	   reported	   here	   it	   remains	   unclear	   whether	   SMARCB1	   is	   a	   HDF.	   The	  
moderate	   inhibition	  of	  Tat-­‐induced	   luciferase	  activity	   following	  primary	   infection	   (~20%;	  Figures	  
2.10	   and	   2.11)	   suggests	   that	   SMARCB1	   does	   play	   a	   viral	   cofactor	   role	   during	   an	   early	   stage	   of	  
infection.	  This	  fits	  with	  other	  studies	  that	  have	  reported	  a	  role	  for	  SMARCB1	  in	  the	  early	  life	  cycle,	  
including	  nuclear	  import	  of	  the	  PIC	  (Turelli	  et	  al.	  2001)	  and	  remodelling	  of	  the	  +1	  nucleosome	  to	  
facilitate	   Tat-­‐mediated	   activation	   of	   HIV-­‐1	   transcription	   (Ariumi	   et	   al.	   2006;	   Mahmoudi	   et	   al.	  
2006;	   Treand	   et	   al.	   2006).	   In	   addition,	   a	   more	   recent	   study	   has	   proposed	   that	   the	   Brm-­‐type	  
SWI/SNF	  complex	   is	   required	   for	   long	   transcript	   synthesis	   in	   the	  absence	  of	  Tat	  during	   the	  very	  
earliest	  stages	  of	  Tat-­‐independent	  viral	   transcription	   (Mizutani	  et	  al.	  2009).	  Conversely,	  another	  
study	   proposed	   an	   antiviral	   role	   for	   SMARCB1	   during	   early	   stages	   of	   infection	   (Maroun	   et	   al.	  
2006).	  Central	  to	  this	  observation,	  however,	  was	  the	  use	  of	  an	  HIV-­‐1	  molecular	  clone	  containing	  
an	  integrase	  (IN)	  mutant	  (K71R)	  that	  retained	  catalytic	  activity	  and	  the	  ability	  to	  bind	  p75,	  but	  a	  2-­‐
fold	   decreased	   association	   with	   SMARCB1.	   The	   possibility	   that	   such	   a	   mutant	   was	   capable	   of	  
enhanced	   association	   with	   other	   factors	   that	   resulted	   in	   increased	   viral	   replication	   was	   not	  
considered.	   Further,	   overexpression	   of	   SMARCB1	   suppressed	   replication	   (Maroun	   et	   al.	   2006),	  
which	  was	  seen	  as	   supporting	  an	  antiviral	   role.	  However,	  overexpression	  may	  have	  destabilised	  
the	   higher-­‐order	   structure	   of	   IN,	   as	   occurs	   with	   overexpression	   of	   the	   p75	   integrase-­‐binding	  
domain	  (Llano	  et	  al.	  2006b;	  Hombrouck	  et	  al.	  2007).	  Subsequently,	  it	  has	  been	  demonstrated	  that	  
multimerisation	  of	  SMARCB1	  is	  necessary	  for	  its	  ability	  to	  inhibit	  integration	  and	  influence	  particle	  
production	  (Das	  et	  al.	  2009).	  
Several	  studies	  have	  demonstrated	  SMARCB1	  inclusion	  in	  HIV-­‐1	  virions	  (Yung	  et	  al.	  2001;	  
Yung	  et	  al.	  2004;	  Sorin	  et	  al.	  2006).	  Furthermore,	  incorporation	  is	  restricted	  to	  HIV-­‐1	  and	  it	  is	  not	  
found	   in	   other	   closely	   related	  primate	   lentiviruses,	   such	   as	  HIV-­‐2	  or	   SIV-­‐1,	   or	   oncoretroviruses,	  
such	   as	   Mo-­‐MLV	   (Yung	   et	   al.	   2004).	   The	   incorporation	   of	   SMARCB1	   was	   correlated	   with	   the	  
infectivity	  of	  HIV-­‐1	  particles	  and	   reverse	   transcriptase	  activity	   (Sorin	   et	  al.	  2006).	  Mutants	  of	   IN	  
have	  been	  shown	  to	  affect	  reverse	  transcription	  and	  this	  function	  has	  been	  ascribed	  to	  the	  direct	  
binding	   of	   IN	   to	   RT	   (Wu	   et	   al.	   1999;	   Hehl	   et	   al.	   2004;	   Zhu	   et	   al.	   2004).	   Perhaps	   SMARCB1	  
association	  with	   IN	   stabilises	   the	  RT	   complex,	   although	   it	   cannot	   be	   excluded	   that	   SMARCB1	   is	  
necessary	  for	  a	  step	  prior	  to	  reverse	  transcription	  or	  that	  reduced	   infectivity	  of	  virions	  could	  be	  
due	  to	  a	  lack	  of	  other	  SMARCB1-­‐associated	  proteins,	  such	  as	  the	  SAP18-­‐HDAC1	  complex	  (Sorin	  et	  
al.	   2009).	   Admittedly,	   no	   evidence	   for	   a	   role	   of	   SMARCB1	   in	   infectious	   particle	   production	  was	  
obtained	  here	  (Figures	  2.13	  and	  2.14).	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It	   is	   unclear	   why	   moderate	   PSIP1	   and	   SMARCB1	   suppression	   inhibited	   Tat-­‐induced	  
luciferase	  activity	   in	  primary-­‐infected	  cells	  but	  not	  p24	   levels	  and	   infectious	  particle	  production.	  
One	  explanation	  predicts	  that	  these	  proteins	  have	  two	  independent	  roles	  in	  HIV-­‐1	  replication	  and	  
that	  the	  levels	  of	  the	  protein	  required	  to	  fulfil	  these	  roles	  differ.	  For	  example,	  that	  50%	  SMARCB1	  
suppression	   in	  TZM-­‐bl	  cells	   is	   insufficient	  to	  maintain	   its	  putative	  function	   in	  HIV-­‐1	  transcription	  
but	   sufficient	   for	   its	   putative	   incorporation	   into	   virions.	   Interestingly,	   several	   members	   of	   the	  
SWI/SNF	   complex	   are	   up-­‐regulated	   in	   actively-­‐infected	   versus	   latently-­‐infected	   cells	   and	  
activated-­‐	   versus	   resting-­‐infected	   cells	   (Krishnan	  and	  Zeichner	  2004;	  Mizutani	   et	  al.	   2009).	  Dual	  
roles	  in	  HIV-­‐1	  replication	  for	  PSIP1	  have	  not	  been	  described,	  however.	  
Alternatively,	   the	  discord	   in	   the	  effects	  of	  PSIP1	  and	  SMARCB1	  suppression	  had	  on	  Tat-­‐
induced	   luciferase	   activity	   and	   HIV-­‐1	   infectious	   particle	   production	   may	   be	   a	   result	   of	   biased	  
sensitivity	   of	   the	   system	   toward	   factors	   influencing	   early	   stages	   of	   the	   life	   cycle.	   This	   may	   be	  
understood	   with	   metabolic	   control	   analysis.	   In	   simple	   terms,	   the	   luciferase	   reporter	   output	   is	  
reached	  in	  fewer	  ‘steps’	  than	  p24	  and	  infectious	  particle	  outputs.	  Following	  integration	  and	  low-­‐
level	   Tat	   production,	   only	   transcription	   and	   translation	   are	   necessary	   for	   luciferase	   activity.	   In	  
contrast,	   full-­‐length	   viral	   transcripts,	   from	  which	   p24	   is	   derived,	   are	   only	   produced	   during	   the	  
later	  stages	  of	  viral	  transcription	  (Schwartz	  et	  al.	  1990).	  Furthermore,	  p24	  production	  requires	  not	  
just	  transcription	  and	  translation,	  but	  also	  assembly	  of	  Gag	  and	  Gag-­‐Pol	  precursor	  proteins	  with	  
viral	  RNA	  to	  form	  immature	  viral	  particles,	  release	  of	  PR	  and	  cleavage	  of	  the	  polypeptides	  to	  form	  
p24	  and	  mature	  viral	  particles	  with	  a	  condensed	  core	  (Yoshinaka	  and	  Luftig	  1977;	  Wiegers	  et	  al.	  
1998).	   Inhibition	   of	   pathway	   flux	   is	   dependent	   not	   just	   on	   the	   extent	   of	   suppression	   of	   an	  
intermediate,	  but	  also	  on	  the	  relative	  rates	  of	  transition	  from	  one	  intermediate	  to	  the	  next.	  Thus,	  
as	   particle	   assembly,	   maturation	   and	   budding	   are	   considerably	   slower	   than	   Tat-­‐activated	  
transcription,	   the	   same	   degree	   of	   PSIP1	   and	   SMARCB1	   suppression	   may	   inhibit	   the	   reporter	  
output	  but	  not	  the	  p24	  output.	  This	  is	  because	  although	  the	  production	  rates	  of	  the	  components	  
necessary	   for	   infectious	   particle	   production	   are	   reduced,	   the	   slow	   rate	   of	   the	   assembly,	  
maturation	   and	   budding	   processes	   ensures	   that	   there	   is	   sufficient	   accumulation	   of	   those	  
components	  for	  infectious	  particle	  production	  to	  be	  unaffected.	  
Although	  this	  hypothesis	  may	  account	  for	  the	  lack	  of	  inhibition	  of	  p24	  production	  in	  shH1-­‐
treated	   cells	   (Figure	   2.13),	   it	   does	   not	   account	   for	   the	   discord	   in	   the	   effects	   of	   HTATSF1	  
suppression	  on	  p24	  levels	  and	  infectious	  particle	  production	  (Figures	  2.13	  and	  2.14);	  particularly	  
as	  HTATSF1	  levels	  were	  dramatically	  reduced	  (>80%	  48	  hours	  post-­‐transfection;	  Figure	  2.15)	  and	  
inhibition	  of	  primary	  Tat-­‐induced	   luciferase	  activity	  was	  similar	  to	  that	  mediated	  by	  the	  positive	  
controls,	   shU5	   and	   shTAT	   (Figures	   2.10	   and	  2.11).	   The	  data	   rather	   suggests	   a	   role	   for	  HTATSF1	  
that	   impacts	   infectious	   particle	   production	   but	   not	   p24	   levels.	   Besides	   a	   role	   in	   transcription	  
	   76	  
elongation,	   two	  other	   roles	  have	  been	  suggested	   for	  HTATSF1	   in	  viral	   replication:	   (1)	   splicing	  of	  
HIV-­‐1	   transcripts	   (Miller	   et	   al.	   2009);	   and,	   (2)	   formation	   of	   influenza	   viral	   ribonucleoprotein	  
complexes	  (vRNP)	  (Naito	  et	  al.	  2007).	  
Splicing	   is	   known	   to	   occur	   cotranscriptionally	   (Moore	   and	   Proudfoot	   2009;	   Perales	   and	  
Bentley	   2009)	   and	   it	   has	   been	   shown	   that,	   primarily	   through	   the	   first	   RNA	   recognition	   motif,	  
HTATSF1	   interacts	   with	   spliceosomal	   U	   small	   nuclear	   ribonucleoproteins	   (snRNPs)	   (Yan	   et	   al.	  
1998;	  Fong	  and	  Zhou	  2001),	  which	  strongly	   stimulates	  HIV-­‐1	   transcription	  elongation	   (Fong	  and	  
Zhou	   2001).	   As	   the	  HTATSF1-­‐U	   snRNP	   complex	   also	   stimulates	   splicing	   in	   vitro	   (Fong	   and	   Zhou	  
2001),	   HTATSF1	   may	   serve	   as	   a	   dual-­‐function	   factor	   to	   facilitate	   reciprocal	   activation	   of	  
transcription	   and	   splicing.	   A	   more	   recent	   study	   suggests	   that	   HTATSF1	   plays	   no	   role	   in	   HIV-­‐1	  
transcription	  elongation	  at	  all,	  affecting	  HIV-­‐1	  splicing	  only	  (Miller	  et	  al.	  2009),	  which	  is	  in	  contrast	  
to	  all	  previous	  investigations	  into	  the	  role	  of	  HTATSF1	  in	  HIV-­‐1	  replication	  (Zhou	  and	  Sharp	  1996;	  
Li	   and	  Green	  1998;	  Kim	   et	  al.	   1999;	  Parada	  and	  Roeder	  1999;	  Fong	  and	  Zhou	  2001;	  Zhou	   et	  al.	  
2004a).	  Although	  a	  unique	  role	  of	  HTATSF1	  in	  splicing	  is	  consistent	  with	  the	  data,	  since	  p24	  is	  not	  
derived	  from	  spliced	  transcripts	  (Schwartz	  et	  al.	  1990),	  an	  elegant	  study	  has	  confirmed	  HTATSF1	  
as	  a	  facilitator	  of	  efficient	  RNA	  Pol	  II	  elongation	  (Chen	  et	  al.	  2009).	  
HTATSF1	  was	   found	   to	   stimulate	   influenza	  viral	  RNA	   synthesis	   through	  chaperoning	   the	  
viral	  nucleoprotein	  (NP)	  and	  enhancing	  its	  association	  with	  viral	  RNA	  to	  form	  vRNPs	  (Naito	  et	  al.	  
2007).	  These	  complexes	  are	  the	  basic	  unit	  for	  transcription	  and	  replication	  of	  the	  virus	  genome.	  
Several	  splicing	  proteins	  are	  candidate	  host	  cofactors	  for	  influenza	  virus	  replication,	  and	  influenza	  
gene	   transcription	   depends	   on	   functional	   RNA	   Pol	   II	   (Chan	   et	   al.	   2006).	   Thus,	   HTATSF1	   may	  
enhance	   viral	   RNA	   synthesis	   through	   promoting	   the	   association	   of	   transcriptionally	   functional	  
RNA	   Pol	   II,	   vRNPs	   and	   splicing	   factors.	   Interestingly,	   the	   yeast	   homolog	   of	   HTATSF1,	   CUS2,	  
chaperones	  U2	   snRNP	  prior	   to	   spliceosomal	  assembly	   in	  a	  manner	  dependent	  on	   the	   first	  RRM	  
domain	  (Yan	  et	  al.	  1998).	  Thus,	   together	  the	  data	  suggests	  a	  role	  of	  HTATSF1	   in	  enhancing	  RNA	  
synthesis	   through	   chaperoning	   snRNPs	   and	   coupling	   splicing	   to	   elongation,	   which	   may	   be	  
common	  to	  influenza	  virus,	  HIV-­‐1	  and	  normal	  cellular	  function.	  
	  There	   was	   no	   evidence	   of	   cytotoxicity	   associated	   with	   shRNA-­‐mediated	   HTATSF1	  
suppression	   (Figures	   2.16,	   2.17,	   2.18	   and	   2.19).	   Perhaps	   the	   levels	   of	   HTATSF1	   needed	   for	  
efficient	  HIV-­‐1	   replication	  are	  higher	   than	   those	   required	   for	   its	  normal	   cellular	   functions.	  Also,	  
there	   are	   several	   factors	   capable	   of	   enhancing	   splicing	   and	   elongation	   in	   cells,	   and	   this	  
redundancy	  may	  protect	   cells	   from	   toxic	   side	   effects	   associated	  with	  HTATSF1	   suppression	   and	  
explain	  why	  no	   significant	  decrease	   in	   splicing	  of	  a	  GFP	   reporter	  was	  observed	   (Figure	  2.17).	   In	  
contrast,	  productive	  elongation	  of	  HIV-­‐1	  transcripts	  involves	  a	  highly	  coordinated	  series	  of	  events,	  
including	  recruitment	  of	  Tat	  and	  cyclin	  T1	  to	  the	  TAR	  element,	  phosphorylation	  of	  the	  CTD	  of	  RNA	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Pol	   II	  and	  remodelling	  of	   the	  +1	  nucleosome.	  The	  role	  of	  HTATSF1	   in	   this	  process	  may	  be	  more	  
critical	  than	  in	  general	  elongation.	  
In	  summary,	  HTATSF1	  has	  been	  validated	  as	  an	  HDF,	  although	  how	  its	  suppression	  inhibits	  
infectious	  particle	  production	  without	  altering	  p24	   levels	   is	  unclear.	   In	  addition,	  expressed	  RNAi	  
mimics	  can	  suppress	  HTATSF1	  efficiently	  without	  cytotoxic	  effects.	  This	  implicates	  HTATSF1	  as	  an	  
anti-­‐HIV	  therapeutic	  target.	  However,	  the	  TZM-­‐bl	  reporter	  system	  for	  the	  identification	  of	  HDFs	  is	  
hampered	  by	   the	   inherent	  bias	   for	   factors	   involved	   in	  early	  stages	  of	   the	   life	  cycle.	  Further,	   the	  
kinetics	   of	   viral	   replication	  may	   significantly	   differ	   in	   this	   cell	   line	   compared	   to	   a	   physiological	  
substrate	   of	   HIV	   eg	   CD4+	   T	   cells,	  where	   host	   gene	   expression	   is	   different.	  Moreover,	   transient	  
expression	   of	   RNAi	  mimics	  may	   be	   insufficient	   to	   suppress	   target	   proteins	  with	   long	   half-­‐lives.	  
Consequently,	  PSIP1	  did	  not	  function	  as	  a	  positive	  control	  as	  hoped	  and	  whether	  SMARCB1	  is	  an	  
HDF	  or	  not	  remains	  unclear.	  Therefore,	  further	  validation	  of	  the	  anti-­‐HIV	  therapeutic	  potential	  of	  
targeting	  cellular	  factors	  HTATSF1	  and	  SMARCB1	  required	  a	  T	  cell-­‐derived	  line,	  stably	  expressing	  
RNAi	  mimics.	  This	  was	  the	  objective	  of	  the	  work	  described	  in	  Chapter	  3.	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CHAPTER	  3	  
Persistent	  suppression	  of	  HIV-­‐1	  replication	  in	  a	  CD4+	  SupT1	  cell	  line	  using	  




The	   work	   in	   Chapter	   2	   demonstrates	   that	   HTATSF1	   functions	   as	   an	   HDF	   and	   can	   be	  
suppressed	   to	   inhibit	   HIV-­‐1	   replication	   without	   cytotoxicity.	   However,	   there	   are	   a	   number	   of	  
limitations	   associated	   with	   validating	   the	   anti-­‐HIV	   therapeutic	   potential	   of	   targeting	   cellular	  
factors	  with	   RNAi	   in	   reporter	   cell	   lines	   such	   as	   TZM-­‐bl	   cells.	   These	   include	   a	   potential	   bias	   for	  
factors	  influencing	  early	  stages	  of	  the	  viral	  life	  cycle.	  In	  addition,	  TZM-­‐bl	  cells	  are	  not	  derived	  from	  
cells	   that	  are	  the	  natural	  hosts	  of	  HIV,	  which	  may	  alter	   the	  kinetics	  of	  HIV-­‐1	  replication	  and	  the	  
relative	  import	  of	  HDFs	  since	  the	  expression	  of	  genes	  varies	  between	  cell	  lines	  (see	  1.3.5).	  This	  is	  
especially	   important	   when	   the	   redundancy	   in	   cellular	   processes	   is	   considered,	   as	   it	   may	   be	  
possible	  for	  HIV-­‐1	  to	  adapt	  to	  another	  cofactor	  in	  one	  cell	  line	  but	  not	  another.	  The	  large	  number	  
of	   putative	   HDFs	   identified	   in	   HIV-­‐1	   host	   factor	   screens,	   which	   display	   little	   overlap	   with	   one	  
another	  but	  enrichment	  for	  proteins	  involved	  in	  certain	  biological	  processes	  (Goff	  2008;	  Bushman	  
et	  al.	  2009),	  may	  reflect	  host	  factor	  redundancy	  (see	  1.3.4).	  In	  addition,	  putative	  HDFs	  identified	  
in	  two	  genome-­‐wide	  screens	  are	  enriched	  in	   immune	  cells	  (Brass	  et	  al.	  2008;	  Konig	  et	  al.	  2008),	  
suggesting	   that	   these	   cells	   are	   especially	   proficient	   in	   the	   functions	   HIV	   needs	   for	   optimal	  
replication.	  It	   is	   important,	  therefore,	  to	  determine	  the	  ability	  of	  HTATSF1	  suppression	  to	  inhibit	  
HIV-­‐1	  replication	  under	  conditions	  that	  resemble	  those	  in	  the	  host	  as	  closely	  as	  possible.	  
Since	  T	  cell-­‐derived	  lines	  are	  difficult	  to	  transfect,	  a	  lentivirus	  may	  be	  employed	  to	  deliver	  
shRNA	   expression	   cassettes	   into	   these	   cells.	   Lentiviruses	   are	   a	   subclass	   of	   retroviruses	   and	   so	  
integrate	   their	   genomes	   into	   the	   host	   cell	   DNA	   allowing	   long-­‐term	   expression	   of	   inserted	  
therapeutic	   genes.	   This	   ensures	   maximal,	   sustained	   target	   suppression	   is	   obtained,	   even	   of	  
proteins	  with	  long	  half-­‐lives,	  such	  as	  SMARCB1	  and	  PSIP1.	  Lentiviruses	  are	  capable	  of	  transducing	  
both	   dividing	   and	  non-­‐dividing	   cells,	   but	   since	   native	   viruses	   can	   cause	   disease,	   non-­‐replicating	  
viruses	   are	   used	   in	   transgene	   expression.	   The	   safest	   forms	   are	   self-­‐inactivating	   (SIN)	   vectors	  
where	   the	   U3	   region	   of	   the	   LTR	   is	   deleted,	   and	   a	   heterologous	   promoter	   (eg	   CMV	   or	   EF1-­‐α)	  
ensures	  transcription	  of	  the	  entire	  vector	  mRNA,	  including	  the	  inserted	  expression	  cassette.	  This	  
stable	  shRNA	  expression	  permits	  examination	  of	  the	  impact	  of	  cellular	  factor	  suppression	  on	  HIV	  
replication	  kinetics	  over	  an	  extended	  time	  course.	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In	  this	  chapter,	  the	  ability	  of	  HTATSF1	  suppression	  to	  mediate	  prolonged	  suppression	  of	  
HIV-­‐1	  replication	   in	  a	  T	  cell-­‐derived	   line	  was	  determined.	  This	  was	  achieved	  by	  transducing	  cells	  
with	  lentiviruses	  carrying	  shRNA	  expression	  cassettes.	  To	  exclude	  changes	  in	  proliferation	  rate	  as	  
the	   source	   of	   variation	   in	   viral	   replication,	   shRNA-­‐expressing	   cell	   lines	  were	   examined	   for	   their	  
proliferative	  capacity.	  Whether	   the	   inhibition	  of	  viral	   replication	  on	  HTATSF1	  suppression	  was	  a	  
consequence	  of	  aberrant	  splicing	  of	  viral	  transcripts	  was	  also	  investigated.	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3.2	  Materials	  and	  methods	  
	  
3.2.1	  Mammalian	  cell	  culture	  
	  
Cells	   of	   the	   HEK293T	   cell	   line,	   HEK293	   cells	   transformed	   by	   the	   large	   T	   antigen	   from	  
Simian	  vacuolating	  virus	  40	  (SV40)	  that	  inactivates	  retinoblastoma	  protein	  (pRb),	  were	  maintained	  
in	   DMEM	   (BioWhittaker,	   MD,	   USA)	   supplemented	   with	   10%	   heat-­‐inactivated	   FCS	   (Delta	  
Bioproducts,	   Johannesburg,	   SA)	   at	   37	   °C	   and	   5%	   CO2	   in	   a	   Forma	   Series	   II	   3110	  water-­‐jacketed	  
incubator	  (Thermo	  Fisher	  Scientific,	  Inc.,	  MA,	  USA).	  
SupT1	   cells,	   a	   non-­‐Hodgkin’s	   T	   cell	   lymphoma	   cell	   line	   expressing	  high	   levels	   of	   surface	  
CD4,	  were	  maintained	  in	  the	  same	  media	  as	  HEK293T	  cells.	  SupT1	  cells	  grow	  in	  suspension	  and,	  
therefore,	  serial	  passage	  required	  centrifugation	  of	  cells	  at	  130	  x	  g.	  
To	   determine	   the	   correct	   number	   of	   cells	   for	   seeding,	   cells	   were	   counted	   on	   a	  
haemocytometer	  using	  a	  1:1	  mixture	  of	  Trypan	  Blue	  stain	  (Sigma-­‐Aldrich,	  MO,	  USA)	  and	  cells	  that	  
had	  been	  washed	  in	  phosphate	  buffered	  saline	  (PBS)	  (Gibco,	  BRL,	  UK).	  
	  
3.2.2	  Selection	  of	  lentivector	  for	  shRNA	  expression	  cassettes	  
	  
Lentiviruses	  derived	  from	  two,	  second	  generation	   lentivectors,	  pLVTH	  (Addgene	  plasmid	  
12262;	   deposited	   by	   D.	   Trono;	   Addgene,	   Inc.,	   MA,	   USA)	   (Wiznerowicz	   and	   Trono	   2003)	   and	  
pLVCTH	  (a	  gift	  from	  D.	  Trono),	  were	  analysed	  for	  their	  ability	  to	  transduce	  SupT1	  cells	  and	  express	  
their	   GFP	   reporter	   genes,	   driven	   by	   the	   EF1-­‐α	   and	   CMV	   promoters,	   respectively.	   Five	   hundred	  
microlitres	  of	  lentivirus	  generated	  by	  D.	  Ivacik	  were	  incubated	  for	  2	  hours	  with	  5	  x	  104	  SupT1	  cells	  
per	  well	   in	   a	   12-­‐well	   plate	   in	   triplicate.	   Cells	  were	   then	   collected	   by	   centrifugation	   at	   130	   x	  g,	  
resuspended	  in	  1	  ml	  media	  and	  returned	  to	  the	  culture	  plate	  for	  a	  further	  48	  hours.	  
Cells	   were	   harvested	   by	   centrifugation	   at	   130	   x	   g	   and	   resuspended	   in	   200	   µl	   PBS	  
containing	   4%	   FCS.	   Samples	   were	   run	   on	   a	   FACSCalibur™	   flow	   cytometer	   (BD	   Biosciences,	   NJ,	  
USA)	  and	  5	  x	  104	  events	  per	  sample	  acquired	  using	  CellQuest	  Pro™	  software	  (BD	  Biosciences,	  NJ,	  
USA).	  
Analysis	  was	  performed	  using	  FlowJo	  9.1	  (Tree	  Star,	  Inc.,	  OR,	  USA).	  SupT1	  cells	  were	  gated	  
based	   on	   forward	   and	   side	   scatter	   and	   GFP+	   cells	   determined	   from	   that	   subset	   by	   comparing	  
SupT1	  cells	  transduced	  with	  no	  virus	  (GFP-­‐)	  and	  those	  transudced	  with	  lentivirus	  (GFP+).	  All	  gates	  
were	  consistent	  throughout	  samples.	  
	  
	   81	  
3.2.3	  Cloning	  lentivector-­‐expressed	  shRNAs	  
	  
To	   generate	   shRNA-­‐expressing	   lentivectors,	   shRNA	   expression	   cassettes	   were	   removed	  
from	   pTZ	   plasmids	   and	   cloned	   into	   pLVTH.	   Five	   micrograms	   of	   pTZU6+shRNA	   plasmids	   were	  
digested	  with	  8.3	  U	  EcoRI	  and	  21.7	  U	  AccI	  (Fermentas,	  WI,	  USA)	  for	  3	  hours	  at	  37	  °C	  in	  a	  reaction	  
volume	  of	  30	  µl	  containing	  2x	  Tango	  Buffer	  (Fermentas,	  WI,	  USA).	  
The	   pLVTH	   backbone	   was	   prepared	   by	   removal	   of	   the	   H1	   promoter	   from	   within	   the	  
LTR/SIN.	  Firstly,	  3	  µg	  of	  pLVTH	  was	  digested	  with	  5	  U	  ClaI	  (Fermentas,	  WI,	  USA)	  for	  one	  and	  a	  half	  
hours	  at	  37	  °C	  in	  a	  reaction	  volume	  of	  15	  µl	  containing	  1x	  Tango	  Buffer.	  This	  was	  followed	  by	  a	  
second	  digestion	  with	  5	  U	  EcoRI	  in	  a	  volume	  of	  20	  µl	  containing	  2x	  Tango	  buffer	  for	  one	  and	  a	  half	  
hours	   at	   37	   °C.	   Finally,	   5	   U	   Antarctic	   phosphatase	   (New	   England	   Biolabs®,	   Inc.,	  MA,	   USA)	   and	  
Antarctic	  phosphatase	  buffer	  (New	  England	  Biolabs®,	  Inc.,	  MA,	  USA)	  were	  added	  to	  a	  final	  volume	  
of	   25	   µl.	   The	   dephosphorylation	   reactions	   were	   incubated	   for	   1	   hour	   at	   37	   °C,	   followed	   by	  
enzyme	  inactivation	  at	  65	  °C	  for	  5	  min.	  
Digestion	   products	   from	   both	   U6+shRNA	   and	   pLVTH	   reactions	   were	   resolved	   on	   a	   2%	  
agarose	  gel	  (see	  A1.2.3)	  and	  the	  desired	  fragment	  excised	  and	  purified	  using	  the	  MinElute™	  Gel	  
Extraction	   Kit	   (QIAGEN,	   CA,	   USA)	   (see	   A1.2.4).	   Forty	   femtomoles	   of	   the	   dephosphorylated	  
backbone	   was	   used	   in	   1	   hour,	   room	   temperature	   ligation	   reactions	   containing	   90	   fmol	   of	  
U6+shRNA	  insert	  and	  5	  U	  T4	  DNA	  ligase	  (Fermentas,	  WI,	  USA)	  in	  a	  volume	  of	  15	  µl.	  A	  mock	  pLVTH	  
construct,	   containing	   the	   U6	   promoter	   but	   no	   shRNA	   sequence,	   was	   also	   generated.	  
Transformation,	  colony	  screening	  and	  bulk	  vector	  preparation	  were	  as	  described	  in	  2.2.2,	  with	  the	  
exception	  that	  colonies	  were	  screened	  by	  BamH1	  (Fermentas,	  WI,	  USA)	  digestion.	  
	  
3.2.4	  Dual	  luciferase	  reporter	  assay	  
	  
To	  verify	  shRNA	  expression	  from	  pLVTH,	  a	  dual	  luciferase	  reporter	  assay	  was	  performed,	  
as	  described	  in	  2.2.6,	  using	  1.2	  x	  105	  HEK293T	  cells	  per	  well.	  psiCheck™-­‐2	  vectors	  with	  targets	  for	  
the	   control	   shRNAs,	   shHBVx,	   and	   shU5	   and	   shTAT,	   were	   provided	   by	   A.	   Ely	   and	   S.	   Barichievy,	  
respectively.	  
	  
3.2.5	  Generation	  of	  lentiviruses	  
	  
To	  generate	  lentiviruses	  from	  the	  shRNA-­‐expressing	  lentivectors,	  3.6	  x	  106	  HEK293T	  cells	  
were	  seeded	  in	  a	  60	  cm2	  Costar®	  dishes	  (Corning	  Inc,	  NY,	  USA)	  and	  each	  dish	  transfected	  24	  hours	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later	  with	  5	  µg	  pLVTH-­‐U6+shRNA,	  3.8	  µg	  psPAX2	  (Addgene	  plasmid	  12260;	  deposited	  by	  D.	  Trono;	  
Addgene,	   Inc.,	  MA,	  USA)	   and	   2.5	  µg	   pMD2.G	   (Addgene	   plasmid	   12259;	   deposited	   by	  D.	   Trono;	  
Addgene,	   Inc.,	  MA,	  USA)	  using	   the	  calcium	  chloride	  method	   (see	  A1.2.5).	  psPAX2	  provided	  Gag,	  
Pol,	   Tat	   and	   Rev,	   which	   are	   needed	   for	   replication,	   and	   pMD2.G	   determined	   tropism	   of	   the	  
resultant	   lentiviruses	  by	  providing	  Env,	   in	   this	  case	  VSV-­‐G,	  which	  permits	   transduction	  of	  SupT1	  
cells	  (Figure	  3.1).	  Both	  24	  and	  48	  hours	  post-­‐transfection,	  the	  culture	  media	  (10	  ml)	  was	  collected,	  
pooled,	  0.22	  µm-­‐filtered	  and	  stored	  at	  -­‐80	  °C	  in	  0.5	  ml	  aliquots.	  
	  
	  
Figure	   3.1:	   Schematic	   showing	   plasmids	   used	   to	   generate	   lentiviruses	   capable	   of	   delivering	   shRNA	   expression	  
cassettes	   to	   SupT1	   cells.	   HEK293T	   cells	   were	   transfected	   with	   pLVTH-­‐U6+shRNA	   plasmids	   along	   with	   packaging	  
plasmids	   psPAX2	   and	   pMD2.G.	   psPAX2	   provides	   proteins	   required	   for	   a	   single-­‐round	   of	   replication	   and	   pMD2.G	  
provides	  the	  envelope	  protein	  VSV-­‐G,	  which	  enables	  the	  resultant	  lentivirus	  to	  transduce	  SupT1	  cells.	  
	  
3.2.6	  Biological	  transduction	  titre	  of	  shRNA-­‐expressing	  lentiviruses	  
	  
Lentiviruses	  were	  titred	  based	  on	  the	  number	  of	  GFP+	  SupT1	  cells	  following	  transduction.	  
SupT1	  cells	  were	  seeded	  at	  1	  x	  104	  cells	  per	  well	   in	  a	  24-­‐well	  plate	   in	  a	  volume	  of	  100	  µl.	   Four	  
hundred	  microlitres	  of	  100,	  10-­‐1	  and	  10-­‐2	   lentivirus	  dilutions	  were	  added	  to	  the	  cells	   in	  duplicate	  
and	  incubated	  for	  24	  hours.	  Cells	  were	  then	  harvested	  by	  centrifugation	  at	  130	  x	  g,	  resuspended	  
in	  1	  ml	  media	  and	   returned	   to	   the	  culture	  plate	   for	  another	  48	  hours.	   Seventy-­‐two	  hours	  post-­‐
infection,	  cells	  were	  harvested	  by	  centrifugation,	  run	  on	  a	  FACSCalibur™	  (BD	  Biosciences,	  NJ,	  USA)	  
and	  the	  proportion	  of	  GFP+	  cells	  determined	  as	  described	  in	  3.2.2,	  with	  the	  exception	  that	  5	  x	  103	  
events	  were	  acquired	  per	  sample.	  Lentivirus	  titres	  were	  determined	  by	  applying	  sigmoidal	  dose-­‐
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response	  non-­‐linear	  regression	  analyses	  using	  GraphPad	  Prism	  4.0c	  (GraphPad	  Software,	  Inc.,	  CA,	  
USA).	  
	  
3.2.7	  Generation	  of	  shRNA-­‐expressing	  SupT1	  cell	  lines	  
	  
SupT1	  cells	  were	  seeded	  at	  3	  x	  105	  cells	  in	  a	  75	  cm2	  culture	  flasks	  (Nunc™,	  Thermo	  Fisher	  
Scientific,	  Inc.,	  MA,	  USA)	  and	  incubated	  with	  a	  volume	  of	  lentivirus	  calculated	  to	  transduce	  20%	  of	  
SupT1	   cells,	   based	   on	   the	   biological	   transduction	   titre.	   This	  was	   to	  minimise	   the	   probability	   of	  
there	  being	  more	  than	  one	  integrated	  shRNA	  expression	  cassette	  per	  cell.	  Cells	  were	  cultured	  for	  
5	   days	   to	   allow	   expansion	   prior	   to	   harvesting	   and	   resuspension	   in	   PBS	   with	   4%	   FCS	   to	   a	  
concentration	   of	   ~1	   x	   106	   cells/ml.	   Cells	  were	   sorted	   on	   a	   FACSCalibur™	  with	   sorting	   gates	   set	  
based	  on	  the	  GFP	  expression	  of	  both	  lentivirus-­‐transduced	  (GFP+)	  and	  untransduced	  (GFP-­‐)	  SupT1	  
cells.	  The	  sorted	  GFP+	  cells	  were	  concentrated	  by	  centrifugation	  at	  130	  x	  g	  and	  cultured	  in	  DMEM	  
with	   20%	   FCS,	   100	   U/ml	   penicillin,	   100	   µg/ml	   streptomycin,	   50	  µg/ml	   tetracycline,	   100	   µg/ml	  
ampicillin,	   170	  µg/ml	   chloramphenicol,	   50	  µg/ml	   kanamycin	   and	   100	  µg/ml	   ciprofloxacin	   for	   1	  
week.	  Sorted	  cell	   lines	  were	   then	  cultured	   for	  a	   further	  week	  without	  antibiotics	   to	  expand	  the	  
populations.	  Stocks	  were	  made	  and	  stored	   in	   liquid	  nitrogen	  so	   that	   low-­‐passage	  cells	   could	  be	  
used	  in	  all	  subsequent	  experiments.	  The	  proportion	  of	  GFP+	  SupT1	  cells	  was	  determined	  in	  each	  
cell	   line	   by	   flow	   cytometry	   as	   described	   in	   3.2.6,	   immediately	   prior	   to	   sorting	   (pre-­‐sort)	   and	  
freezing	  (post-­‐sort).	  
	  
3.2.8	  Detection	  of	  processed	  shRNA	  guide	  strands	  using	  PAGE	  and	  Northern	  blot	  analysis	  
	  
Total	  RNA	  was	  isolated	  from	  SupT1	  cell	  lines	  using	  TriReagent™	  (Sigma-­‐Aldrich,	  MO,	  USA)	  
(see	  A1.3.1).	  Thirty	  micrograms	  of	  RNA,	  as	  well	  as	  a	  ladder	  composed	  of	  5	  pmol	  of	  shHBVx	  (5’	  CCG	  
TGT	  GCA	  CTT	  CGC	  TTC	  3’)	  and	  U6	  (Table	  2.5)	  probes	  3’-­‐end	  labelled	  with	  digoxigenin	  (DIG)-­‐ddUTP,	  
were	  combined	  with	  an	  equal	  volume	  of	  RNA	  loading	  dye	  (Ambion,	  TX,	  USA)	  and	  denatured	  at	  80	  
°C	   for	   5	   min.	   Samples	   were	   resolved	   on	   a	   15%	   polyacrylamide	   gel,	   visualised	   on	   a	   UV	  
transilluminator	  and	  transferred	  and	  cross-­‐linked	  to	  a	  nylon	  membrane	  as	  described	  in	  2.2.9.	  
DNA	  oligonucleotide	  probes	  complementary	  to	  the	  processed	  shRNA	  guide	  strands	  (Table	  
2.5)	   were	   labelled	   using	   the	   DIG	   Oligonucleotide	   3’-­‐end	   Labelling	   Kit	   (Roche,	   Mannheim,	  
Germany).	  Briefly,	  100	  pmol	  of	  oligonucleotide	  probe	  was	  incubated	  with	  4	  µl	  reaction	  buffer	  (1	  
M	   potassium	   cacodylate,	   0.125	  M	   Tris.HCl,	   1.25	  mg/ml	   bovine	   serum	   albumin,	   pH	   6.6),	   5	  mM	  
CoCl2,	  0.05	  mM	  DIG-­‐ddUTP	  and	  20	  U	  terminal	  transferase	  in	  a	  volume	  of	  20	  µl	  for	  15	  min	  at	  37	  °C.	  
The	  labelling	  reaction	  was	  stopped	  with	  addition	  of	  2	  µl	  of	  0.2	  M	  EDTA,	  pH	  8.0.	  Immediately	  prior	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to	   hybridisation,	   5	   pmol	   of	  DIG-­‐labelled	   probe	  was	   denatured	   at	   95	   °C	   for	   5	  min.	   Probes	  were	  
then	  added	  to	  membranes	  pre-­‐hybridised	  with	  10	  ml	  DIG	  Easy	  Hyb	  solution	  (Roche,	  Mannheim,	  
Germany)	   in	   a	   rotating	   oven	   (Thermo	   Fisher	   Scientific,	   Inc.,	   MA,	   USA).	   Hybridisation	   was	  
permitted	  overnight	  at	  42	  °C.	  
Membranes	  were	  subject	  to	  a	  low	  stringency	  wash	  in	  50	  ml	  5x	  SSC	  (750	  mM	  NaCl,	  65	  mM	  
disodium	  citrate,	  pH	  7.0)	  and	  0.1%	  sodium	  dodecylsulphate	  (SDS)	  (Sigma-­‐Aldrich,	  MO,	  USA)	  for	  20	  
min	  at	  room	  temperature.	  Two	  high	  stringency	  washes	  were	  then	  performed	  at	  42	  °C,	  each	  with	  
50	   ml	   1x	   SSC	   (150	   mM	   NaCl,	   13	   mM	   disodium	   citrate,	   pH	   7.0)	   and	   0.1%	   SDS	   for	   15	   min.	  
Membranes	  were	   then	   rinsed	   in	   100	  ml	  wash	   buffer	   (0.1	  M	  maleic	   acid,	   0.15	  M	  NaCl,	   pH	   7.5,	  
0.03%	  Tween	  20)	   and	  blocked	   for	   30	  min	   at	   room	   temperature	   in	  100	  ml	   of	   5%	   skimmed	  milk	  
powder	  in	  PBS.	  DIG-­‐labelled	  oligonucletides	  were	  detected	  by	  incubation	  of	  the	  membranes	  with	  
1	   µl	   alkaline	   phosphatase-­‐conjugated	   anti-­‐DIG	   antibody	   in	   20	   ml	   PBS	   with	   1%	   skimmed	   milk	  
powder	  for	  30	  min	  at	  room	  temperature.	  Membranes	  were	  then	  washed	  4	  times	  for	  15	  min	  each	  
with	  wash	  buffer	  and	  incubated	  in	  detection	  buffer	  (0.1	  M	  Tris.HCl,	  0.1	  M	  NaCl,	  pH	  9.5)	  for	  5	  min,	  
all	   at	   room	   temperature.	   Chemiluminescence	   detection	   of	   labelled	   probes	   was	   enabled	   by	  
incubation	   of	   membranes	   with	   CDP-­‐Star™	   (Roche,	   Mannheim,	   Germany)	   for	   5	   min	   and	   image	  
acquisition	  with	  a	  G-­‐BOX	  (Syngene,	  MD,	  USA)	  using	  an	  exposure	  of	  up	  to	  1	  hour.	  
	  When	  necessary,	  membranes	  were	  stripped	  by	   rinsing	   in	  distilled	  water,	  washing	   twice	  
with	  stripping	  buffer	  (0.2	  M	  NaOH	  and	  0.1%	  SDS)	  for	  15	  min	  each	  at	  37	  °C	  and	  finally	  rinsing	  the	  
membrane	  in	  2x	  SSC	  for	  5	  min	  at	  room	  temperature.	  
	  
3.2.9	  SupT1	  cell	  proliferation	  rates	  by	  cell	  counting	  
	  
To	   ascertain	   whether	   the	   different	   shRNA-­‐expressing	   SupT1	   cell	   lines	   differed	   in	   their	  
proliferation	  rates,	  SupT1	  cells	  were	  seeded	  at	  5	  x	  104	  cells	  per	  well	  in	  a	  12-­‐well	  plate	  in	  duplicate.	  
Following	  seven	  days	  of	  culture,	  cells	  were	  harvested	  and	  counted	  as	  described	  in	  3.2.1.	  
	  
3.2.10	  SupT1	  cell	  proliferation	  rates	  by	  DNA	  quantification	  
	  
To	   further	  verify	   the	  proliferation	   rates	  of	   shRNA-­‐expressing	  SupT1	  cell	   lines,	   cells	  were	  
seeded	  and	  cultured	  as	  described	  in	  3.2.9,	  in	  duplicate.	  Following	  harvesting,	  cells	  were	  incubated	  
with	  1	  ml	  DNA	  extraction	  buffer	  (0.15	  M	  NaCl,	  20	  mM	  Tris.HCl,	  10	  mM	  EDTA	  and	  0.1%	  SDS)	  and	  
400	  µg/ml	  proteinase	  K	  (Roche,	  Mannheim,	  Germany)	  at	  37	  °C	  overnight.	  DNA	  was	  extracted	  by	  
addition	  of	  1	  ml	  phenol:chloroform:isoamyl	  alcohol	  (IAA)	  in	  a	  25:24:1	  ratio	  and	  centrifugation	  at	  4	  
°C,	  with	  the	  resulting	  aqueous	  layer	  stored	  in	  15µl	  3	  M	  NaOAc	  and	  300	  µl	  100%	  ethanol	  overnight	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at	  -­‐80	  °C.	  DNA	  precipitates	  were	  resuspended	  in	  100	  µl	  water	  and	  concentrations	  determined	  by	  
NanoDrop	  (Thermo	  Fisher	  Scientific,	  Inc.,	  MA,	  USA).	  
	  
3.2.11	  Assessment	  of	  p81A-­‐4	  replication	  in	  shRNA-­‐expressing	  SupT1	  cell	  lines	  
	  
To	  assess	  the	  ability	  of	  SupT1	  cell	  lines	  expressing	  shRNAs	  to	  inhibit	  HIV-­‐1	  replication,	  2	  x	  
104	  SupT1	  cells	  were	  seeded	  per	  well	   in	  a	  round-­‐bottomed	  96-­‐well	  plate	  and	  some	  immediately	  
infected	  with	   the	   subtype	   B	  molecular	   clone	   p81A-­‐4	   (NIH	   AIDS	   Research	  &	   Reference	   Reagent	  
Program,	  MD,	  USA)	  (Chesebro	  et	  al.	  1992;	  Walter	  et	  al.	  2005)	  at	  a	  TCID50	  (see	  A1.4.5)	  of	  50/ml	  in	  
duplicate.	   Twenty-­‐four	   hours	   post-­‐infection,	   plates	   were	   centrifuged	   at	   130	   x	   g	   and	   media	  
removed.	  Cells	  were	  washed	  three	  times	  with	  PBS	  to	  remove	  residual	  virus	  before	  resuspension	  in	  
350	  µl	  media.	  Following	  another	  centrifugation	  to	  pellet	  cells,	  150	  µl	  of	  media	  was	  removed	  and	  
stored	  as	  day	  0	  samples	  at	  -­‐80	  °C.	  48	  hours	  later	  (day	  2),	  cells	  were	  similarly	  collected	  and	  150	  µl	  
culture	   supernatant	   removed	   and	   stored.	   Cells	   were	   resuspended	   with	   the	   addition	   of	   150	   µl	  
media	  to	  replace	  that	  removed.	  Samples	  were	  taken	  in	  the	  same	  fashion	  on	  days	  4,	  7,	  10,	  14	  and	  
17	   (ie	   5,	   8,	   11,	   15	   and	   18	   days	   post-­‐infection,	   respectively).	   HIV-­‐1	   p24	   content	   in	   the	   frozen	  
samples	   was	   subsequently	   determined	   by	   ELISA	   (Murex	   Biotech	   Ltd,	   Kent,	   UK)	   (see	   A1.4.4).	  
Dilutions	   of	   the	   positive	   control	  within	   the	   kit	  were	   used	   to	   generate	   a	   standard	   curve	   of	   p24	  
levels	  from	  which	  absolute	  levels	  of	  p24	  in	  the	  experimental	  samples	  were	  determined.	  
	  
3.2.12	  qRT-­‐PCR	  measurement	  of	  mRNA	  concentrations	  
	  
To	   examine	   the	   duration	   of	   host	   factor	  mRNA	   suppression	  mediated	   by	   shRNAs	   in	   the	  
SupT1	  cells,	   total	  RNA	  was	  extracted	   from	  cells	  cultured	   for	  different	  periods.	  Day	  0,	  10	  and	  20	  
refer	  to	  time	  points	  in	  the	  p81A-­‐4	  infection	  assay	  (see	  3.2.11)	  and	  these	  samples	  were	  obtained	  
from	   RNA	   extractions	   performed	   on	   SupT1	   cells	   cultured	   for	   the	   equivalent	   periods.	   This	  
approximates	  to	  7,	  17	  and	  27	  days	  post-­‐thaw	  of	  the	  shRNA-­‐expressing	  SupT1	  cell	  line	  stocks.	  
Isolated	   RNA	   was	   treated	   with	   3	   U	   RQ1	   RNase-­‐free	   DNase	   (Promega,	   WI,	   USA)	   in	   a	  
reaction	  volume	  of	  40	  µl	  containing	  4	  mM	  Tris.Cl,	  pH	  8.0,	  10	  mM	  MgSO4	  and	  1	  mM	  CaCl2,	  at	  37	  °C	  
for	  30	  min.	  The	  reaction	  was	  stopped	  with	  addition	  of	  EGTA,	  pH	  8.0,	  to	  a	  final	  concentration	  of	  2	  
mM	  and	   incubation	  at	  65	  °C	   for	  10	  min.	  Approximately	  50	  ng	  of	  DNase-­‐treated	  RNA,	  1.5	  µg	  of	  
random	  primers	  (Invitrogen™,	  Life	  Technologies,	  CA,	  USA)	  and	  5	  nmol	  of	  dNTPs	  (Fermentas,	  WI,	  
USA)	  were	  incubated	  at	  65	  °C	  for	  5	  min	  and	  then	  placed	  on	  ice.	  Reverse	  transcription	  was	  carried	  
out	  using	  100	  U	  SuperScript®	  III	  RT,	  50	  mM	  Tris.HCl,	  pH	  8.3,	  75	  mM	  KCl,	  30	  mM	  MgCl2,	  5	  mM	  DTT	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and	  20	  U	  RNaseOUT™	  (Invitrogen™,	  Life	  Technologies,	  CA,	  USA)	   in	  a	  volume	  of	  10	  µl.	  Reactions	  
were	  incubated	  at	  25	  °C	  for	  5	  min,	  55	  °C	  for	  45	  min	  and	  finally	  70	  °C	  for	  15	  min.	  
qPCR	  and	  analysis	  was	  performed	  as	  described	  in	  2.2.7,	  with	  the	  exception	  that	  the	  qPCR	  
reactions	  utilised	  the	  SensiMix™	  Lite	  Kit	  (Quantace	  Ltd,	  London,	  UK)	  (see	  A1.3.4).	  
	  
3.2.13	  Detection	  of	  HTATSF1	  by	  SDS-­‐PAGE	  and	  Western	  blot	  analysis	  
	  
To	  examine	  the	  duration	  of	  shH1-­‐mediated	  HTATSF1	  suppression,	  protein	  extracted	  from	  
SupT1	  cells,	  cultured	  for	  periods	  equivalent	   to	  days	  0	  and	  20	  of	   the	  p81A-­‐4	   infection	  assay	   (see	  
3.2.11),	  were	  subject	   to	  SDS-­‐PAGE,	  Western	  blot	  and	  analysis,	  as	  described	   in	  2.2.11.	  A	  notable	  
difference	   is	   that	   100	  µg	  of	   cellular	   protein	  was	   resolved	  on	   a	   12%	  polyacrylamide	   gel.	  Day	   20	  
samples	  were	  prepared	  in	  duplicate.	  
	  
3.2.14	  Quantification	  of	  GFP+	  SupT1	  cells	  in	  shRNA-­‐expressing	  cell	  lines	  by	  flow	  cytometry	  
	  
To	  assess	  whether	  the	  proportion	  of	  GFP+	  cells	  within	  the	  shRNA-­‐expressing	  populations	  
was	  maintained	  over	  time,	  samples	  of	  the	  shRNA-­‐expressing	  SupT1	  cell	  lines	  were	  subject	  to	  flow	  
cytometry	  as	  described	  in	  3.2.6,	  at	  time	  points	  equivalent	  to	  days	  0	  and	  20	  of	  the	  p81A-­‐4	  infection	  
assay	  (see	  3.2.11).	  
	  
3.2.15	  Nuclear	  run-­‐on	  assay	  to	  determine	  htatsf1	  transcription	  rates	  in	  SupT1	  cell	  lines	  
	  
Transcription	   rates	   of	   the	  htatsf1	   gene	  were	   examined	   in	   SupT1	   cells	   expressing	   either	  
shH1	  or	  shU5	  following	  periods	  of	  cell	  culture	  equivalent	  to	  days	  0	  and	  20	  of	  the	  p81A-­‐4	  infection	  
assay	   (see	  3.2.11).	  SupT1	  cells	   (4	  x	  106)	  were	  harvested	  and	  washed	  with	  PBS.	  Cell	  pellets	  were	  
resuspended	  in	  1.5	  ml	  NP-­‐40	  lysis	  buffer	  (10mM	  Tris.Cl,	  pH	  7.4,	  10	  mM	  NaCl,	  3	  mM	  MgCl2,	  0.5%	  
NP-­‐40)	  and	  kept	  on	   ice	   for	  5	  min.	   Samples	  were	   then	  centrifuged	  at	  400	  x	  g	   for	  5	  min	  at	  4	  °C.	  
Following	  removal	  of	  the	  supernatant,	  the	  pellets	  were	  resuspended	  in	  0.75	  ml	  NP-­‐40	  lysis	  buffer	  
and	  immediately	  centrifuged	  at	  400	  x	  g	  for	  5	  min	  at	  4	  °C.	  Following	  removal	  of	  the	  supernatant,	  
the	  nuclei	  pellets	  were	  resuspended	  in	  100	  µl	  glycerol	  storage	  buffer	  (0.1mM	  EDTA,	  40%	  glycerol,	  
5	  mM	  MgCl2,	  50	  mM	  Tris.Cl,	  pH	  8.3)	  by	  gentle	  vortexing.	  Nuclei	  were	  flash-­‐frozen	  by	  transfer	  to	  
liquid	  nitrogen	  and	  stored	  for	  up	  to	  one	  month.	  
Thawed	  nuclei	  were	  subject	  to	  in	  vitro	  transcription	  reactions	  following	  addition	  of	  100	  µl	  
transcription	  reaction	  buffer	  (10	  mM	  Tris.HCl,	  pH	  8.0,	  5	  mM	  MgCl2,	  0.3	  M	  KCl,	  2.5	  mM	  of	  ATP,	  CTP	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and	   GTP	   (Roche,	  Mannheim,	   Germany),	   0.25	  mM	   biotin-­‐16-­‐UTP	   (Roche,	  Mannheim,	   Germany)	  
and	  100	  U	  RNaseOUT™	  (Invitrogen™,	  Life	  Technologies,	  CA,	  USA).	  Reactions	  were	  carried	  out	  at	  
30	   °C	   for	   45	   min.	   Reactions	   were	   stopped	   by	   the	   addition	   of	   50	   U	   RQ1	   RNase-­‐free	   DNase	  
(Promega,	  WI,	  USA)	  and	  incubation	  at	  37	  °C	  for	  10	  min.	  Three	  hundred	  microlitres	  of	  HSB	  buffer	  
(0.5	  M	  NaCl,	  50	  mM	  MgCl2,	  2	  mM	  CaCl2,	  10	  mM	  Tris.HCl,	  pH	  7.4)	  was	  used	  to	  resuspend	  nuclei	  
prior	  to	  incubation	  at	  30	  °C	  for	  5	  min.	  Nuclei	  were	  lysed	  with	  addition	  of	  100	  µl	  of	  SDS/Tris	  buffer	  
(5%	   SDS,	   0.5	   M	   Tris.HCl,	   pH7.4,	   0.125	   M	   EDTA).	   Five	   microlitres	   of	   proteinase	   K	   (Roche,	  
Mannheim,	   Germany)	   was	   also	   added	   and	   samples	   incubated	   for	   30	   min	   at	   42	   °C.	   RNA	   was	  
extracted	   by	   addition	   of	   650	  µl	   TriReagent™	   (Sigma-­‐Aldrich,	  MO,	   USA)	   and	   100	  µl	   chloroform.	  
Samples	   were	   centrifuged	   at	   16,000	   x	   g	   at	   4	   °C	   for	   10	   min	   and	   the	   resulting	   aqueous	   layers	  
transferred	  to	  300	  µl	   ice	  cold	  100	  %	  ethanol,	  100	  µl	  3	  M	  NaOAc	  and	  3	  µl	  glycogen	  (Ambion,	  TX,	  
USA),	  which	  were	  stored	  overnight	  at	  -­‐80	  °C.	  The	  following	  day,	  RNA	  isolation	  was	  completed	  by	  
centrifugation	  at	  16,000	  x	  g	  at	  4	  °C	  for	  10	  min.	  RNA	  pellets	  were	  washed	  with	  75%	  ethanol.	  Final	  
RNA	  preparations	  were	  resuspended	  in	  50	  µl	  DEPC-­‐treated	  water	  (Ambion,	  TX,	  USA).	  
RNA	   samples	   were	   treated	   with	   5	   U	   RQ1	   RNase-­‐free	   DNase	   (Promega,	   WI,	   USA)	   in	   a	  
reaction	  volume	  of	  60	  µl	  containing	  4	  mM	  Tric.Cl,	  pH	  8.0,	  10	  mM	  MgSO4	  and	  1	  mM	  CaCl2,	  at	  37	  °C	  
for	  30	  min.	  The	  reaction	  was	  stopped	  with	  addition	  of	  EGTA,	  pH	  8.0,	  to	  a	  final	  concentration	  of	  2	  
mM	   and	   incubation	   at	   65	   °C	   for	   10	   min.	   RNA	   concentration	   and	   purity	   was	   assessed	   on	   a	  
NanoDrop	  (Thermo	  Fisher	  Scientific,	  Inc.,	  MA,	  USA).	  
Dynabeads®	  MyOne™	   Streptavidin	   C1	   beads	   (Invitrogen™,	   Life	   Technologies,	   CA,	   USA),	  
which	   bind	   biotinylated	   RNA,	   were	   prepared	   for	   RNA	   binding	   by	   removal	   of	   RNase	   enzymes.	  
Firstly,	   a	   volume	  of	  beads	  equivalent	   to	  30	  µl	  per	   sample	  were	  washed	   twice	  with	  a	  volume	  of	  
solution	  A	   (DEPC-­‐treated	   0.1	  M	  NaOH)	   equal	   to	   the	   volume	  of	   beads.	   Throughout,	   beads	  were	  
separated	  from	  solution	  using	  a	  magnetic	  separator	  for	  1-­‐2	  min.	  Beads	  were	  then	  washed	  twice	  
with	  solution	  B	   (DEPC-­‐treated	  0.05	  M	  NaCl)	  and	  three	  times	  with	  2x	  bind	  &	  wash	   (B&W)	  buffer	  
(10	  mM	  Tris-­‐HCl,	  pH	  7.5,	  1	  mM	  EDTA	  and	  2	  M	  NaCl).	  Beads	  were	   finally	   resuspended	   to	  a	   final	  
concentration	  of	  5	  µg/ml	  (twice	  original	  volume)	  in	  2x	  B&W	  buffer.	  Twelve	  micrograms	  of	  RNA	  at	  
200	  ng/µl	  were	  added	  to	  an	  equal	  volume	  of	  beads	  (ie	  60	  µl	  sample	  +	  60	  µl	  beads)	  and	  incubated	  
at	  room	  temperature	  on	  a	  gently	  rotating	  RM-­‐2M	  Intelli-­‐mixer	  (ELMI	  Ltd.,	  Riga,	  Latvia)	  for	  15	  min.	  
RNA-­‐bound	  beads	  were	  washed	  three	  times	  with	  1x	  B&W	  buffer	  before	  resuspension	  in	  20	  µl	  1x	  
B&W	  buffer.	  
Reverse	  transcription	  reactions	  using	  1.5	  µl	  of	  RNA-­‐beads	  per	  reaction	  were	  carried	  out	  as	  
described	   in	  3.2.12.	  1	  U	  of	  RNase	  H	  (Invitrogen™,	  Life	  Technologies,	  CA,	  USA)	  was	  added	  to	  the	  
samples	   to	   degrade	   bead-­‐bound	   RNA	   and	   facilitate	   dissociation	   of	   cDNA.	   Reactions	   were	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incubated	  at	  37	  °C	  for	  20	  min,	   followed	  by	  95	  °C	  for	  5	  min	  to	   inactivate	  the	  enzyme.	  cDNA	  was	  
removed	   from	  the	  beads	  and	  used	   in	  qPCR,	  which	  was	  performed	  and	  analysed	  as	  described	   in	  
3.2.12.	  
	  
3.2.16	  Quantification	  of	  p81A-­‐4	  transcript	  classes	  by	  qRT-­‐PCR	  
	  
To	   examine	   whether	   HTATSF1	   suppression	   affects	   levels	   of	   different	   classes	   of	   HIV-­‐1	  
transcripts,	  SupT1	  cells	  were	  seeded	  at	  5	  x	  105	  per	  well	  in	  a	  6-­‐well	  plate	  and	  infected	  with	  p81A-­‐4	  
at	  a	  TCID50	  of	  50/ml.	  Cells	  were	  harvested	  and	  washed	  with	  PBS	  prior	  to	  extraction	  of	  total	  RNA	  48	  
hours	  later.	  RNA	  was	  DNase-­‐treated,	  reverse	  transcribed	  and	  the	  resulting	  cDNA	  used	  in	  qPCR	  as	  
described	  in	  3.2.12	  (see	  also	  A1.3.4).	  
	  
Table	  3.1:	  Primers	  used	  in	  qPCR	  to	  determine	  levels	  of	  HIV-­‐1	  transcript	  classes.	  	  
Primer	   Sequence	  (5’-­‐3’)	   Amplicon(s)	  
9	  kb	  forward	   TAGCAGTCCTCTATTGTGTGCA	  
9	  kb	  reverse	   GGAGGTTCTGCACTATAGGGTA	  
Unspliced	  
9	  +	  4	  kb	  forward	   GCTGTTAAATGGCAGTCTAGCA	  
9	  +	  4	  kb	  reverse	   TAAAATGCTCTGCCTGGTCCTA	  
Unspliced	  &	  singly	  spliced	  
2	  kb	  forward	   GAAGAGCTCATCAGAACAGTCA	  
2	  kb	  reverse	   AGATCGTCCCAGATAAGTGCTA	  
Multiply	  spliced	  
Total	  forward	   GGGTGGGAGCAGTATCTCGA	  
Total	  reverse	   TCTACAGCTGCCTTGTAAGTCA	  
Unspliced,	  singly	  spliced	  &	  
multiply	  spliced	  
	  
The	  qPCR	  primers	  were	  designed	   to	  amplify	  different	  classes	  of	  HIV-­‐1	   transcripts	   (Table	  
3.1).	  The	  9	  kb	  primers	  amplified	  a	  region	  only	  present	  in	  unspliced	  viral	  transcripts,	  the	  4	  +	  9	  kb	  
primers	  a	  region	  present	  in	  both	  unspliced	  and	  singly	  spliced	  viral	  transcripts	  and	  the	  2	  kb	  primers	  
span	   the	   Tat/Rev	   splice	   junction	   such	   that	   amplification	   only	   occurs	   from	  multiply	   spliced	   viral	  
transcripts.	   In	   addition,	   primers	   were	   used	   to	   amplify	   a	   region	   present	   in	   all	   classes	   of	   viral	  
transcripts.	  Levels	  of	  4	  kb,	  or	  singly	  spliced,	  transcripts	  were	  determined	  by	  subtracting	  the	  level	  
of	   9	   kb	   transcripts	   from	   the	   expression	   level	   obtained	   with	   the	   9	   +	   4	   kb	   primers.	   Total	   viral	  
transcripts	  were	  quantified	  by	  both	  summing	  the	  expression	  level	  of	  9,	  4	  and	  2	  kb	  transcripts	  (sum	  
total)	  and	  the	  value	  obtained	  by	  qPCR	  with	  the	  primers	  that	  amplify	  a	  region	  common	  to	  all	  HIV-­‐1	  
transcripts	   (common	   total).	   Expression	   of	   viral	   transcripts	   is	   reported	   relative	   to	  β-­‐actin	  mRNA	  
(see	  Table	  2.4	   for	  primers).	   In	  addition,	   levels	  of	  htatsf1	  mRNA	  were	  verified	   (see	  Table	  2.4	   for	  
primers).	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3.2.17	  Statistical	  analyses	  
	  
Data	   are	   expressed	   as	   the	   mean	   ±	   the	   standard	   error	   of	   the	   mean	   (SEM)	   and	   where	  
appropriate	  are	  normalised	  to	  a	  control	  sample	  within	  the	  experiment.	  Statistical	  difference	  was	  
considered	  to	  be	  significant	  (*)	  when	  p	  <0.05.	  Data	  was	  analysed	  using	  non-­‐linear	  regression,	  one-­‐
way	   ANOVAs,	   followed	   by	   a	   Dunnett‘s	   multiple	   comparison	   post-­‐test,	   and	   two-­‐way	   ANOVAs,	  
followed	   by	   Bonferroni	   post-­‐tests,	   where	   appropriate,	   calculated	   using	   GraphPad	   Prism	   4.0c	  
(GraphPad	  Software,	  Inc.,	  CA,	  USA).	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3.3	  Results	  
	  
3.3.1	  Selection	  of	  the	  lentivector	  pLVTH	  for	  shRNA	  expression	  
	  
To	  further	  examine	  the	  therapeutic	  potential	  of	  targeting	  HTATSF1	  and	  SMARCB1,	  CD4+	  
and	   CCR5+	   T	   cell-­‐derived	   lines	  were	   generated	   that	   stably	   expressed	  U6-­‐driven	   shRNAs.	   SupT1	  
cells,	  a	  non-­‐Hodgkin’s	  T	  cell	   lymphoma	  cell	   line	  expressing	  high	  levels	  of	  surface	  CD4,	  were	  used	  
as	  these	  are	  readily	   infectable	  with	  HIV-­‐1.	  Moreover,	  sustained	  inhibition	  of	  viral	  replication	  has	  
been	   reported	   in	   SupT1	   cells	   on	   stable	   expression	  of	   shRNAs	   targeting	   the	   integration	   cofactor	  
PSIP1	  (Llano	  et	  al.	  2006a),	  which	  was	   included	   in	  this	  study	  as	  a	  positive	  control.	  Before	  cloning	  
shRNA	   expression	   cassettes	   into	   a	   lentivector,	   lentiviruses	   LVTH	   and	   LVCTH,	   derived	   from	  
lentivectors	  pLVTH	  and	  pLVCTH,	  respectively,	  were	   first	   tested	   for	   their	  ability	   to	  transduce	  and	  
express	  their	  GFP	  reporter	  genes	  in	  SupT1	  cells.	  The	  heterologous	  promoter	  driving	  expression	  of	  
mRNA	  differed	  between	  the	  two	  vectors	  –	  EF1-­‐α	  in	  pLVTH	  and	  CMV	  in	  pLVCTH	  (Figure	  3.2A).	  
	  
Figure	  3.2:	  SupT1	  GFP	  reporter	  gene	  expression	  is	  greatest	  when	  transduced	  with	  pLVTH-­‐derived	  lentivirus.	  A.	  Two	  
different	   lentivectors,	  pLVTH	  and	  pLVCTH,	  were	  packaged	   in	  HEK293T	  cells.	  B.	   SupT1	  cells	  were	   transduced	  with	   the	  
resulting	   lentiviruses,	   LVTH	  and	   LVCTH,	   in	   triplicate	  and	   the	  proportion	  of	  GFP+	  SupT1	   cells	  was	  determined	  by	   flow	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cytometry	  48	  hours	   later.	  C.	   Representative	   flow	  cytometry	  plots	   showing	   the	  gating	   strategy.	   SupT1	   cells	  were	   first	  
selected	  (top-­‐left	  plots)	  and	  then	  GFP+	  cells	  determined	  from	  the	  SupT1	  subset.	  Gates	  were	  consistent	  for	  all	  samples.	  
	  
Following	  transduction	  of	  SupT1	  cells,	  cell	  populations	  were	  examined	  by	  flow	  cytometry	  
for	   GFP	   expression.	   A	   greater	   proportion	   of	   cells	   were	   GFP+	   when	   transduced	   with	   LVTH	  
compared	  with	   LVCTH	   (Figure	  3.2B	  and	  C).	  As	  both	   lentiviruses	  were	  prepared	  under	   the	   same	  
conditions,	   this	   suggests	   that	   either	   pLVTH-­‐derived	   viruses	   generate	   better	   titres	   than	   those	  
derived	   from	   pLVCTH,	   or	   expression	   of	   the	   GFP	   reporter	   is	   more	   efficient	   from	   pLVTH	   than	  
pLVCTH.	  Regardless,	  pLVTH	  was	  selected	  as	  the	  lentivector	  into	  which	  shRNA	  expression	  cassettes	  
were	  cloned.	  
	  
3.3.2	  shRNAs	  knock	  down	  cognate	  targets	  when	  expressed	  from	  a	  lentivector	  
	  
shRNA	  expression	   cassettes	  were	   cloned	   into	  ClaI	   and	  EcoRI	   sites	  within	   the	   LTR/SIN	  of	  
pLVTH,	   such	   that	   the	   H1	   promoter	   was	   replaced	   (Figure	   3.2A).	   Insertion	   within	   the	   LTR/SIN	  
ensured	   duplication	   of	   the	   U6-­‐shRNA	   expression	   cassette	   in	   the	   provirus	   following	   reverse	  
transcription.	   shRNA	   expression	   from	   the	   lentivector	   was	   verified	   by	   quantitation	   of	   cognate	  
target	   inhibition	  with	   a	   dual	   luciferase	   reporter	   assay	   in	  HEK293T	   cells.	   All	   shRNAs	   significantly	  
inhibited	  their	  target	  sequences,	  as	  determined	  by	  the	  ratio	  of	  Renilla	  to	  firefly	  luciferase	  activity,	  
compared	  with	  controls	   (>85%,	  p	   <0.001;	  Figure	  3.3).	  This	  demonstrates	   that	   transfer	  of	   shRNA	  
expression	  cassettes	  to	  a	  new	  plasmid	  backbone	  did	  not	  disrupt	  their	  expression	  and	  efficacy.	  
	  
	  
Figure	   3.3:	   shRNAs	   knock	   down	   their	   cognate	   targets	   when	   expressed	   from	   a	   lentivector.	   HEK293T	   cells	   were	  
transfected	   with	   pLVTH-­‐U6+shRNA	   expression	   cassettes	   and	   cognate	   psiCheck	   reporter	   constructs	   resulting	   in	   a	  
significant	  inhibition	  of	  Renilla	  luciferase	  activity	  relative	  to	  firefly	  luciferase	  activity	  48	  hours	  later.	  *,	  p	  <0.05,	  two-­‐way	  
ANOVA	  with	  Bonferroni	  post-­‐tests.	  
	  
3.3.3	  Generation	  of	  stable	  shRNA-­‐expressing	  SupT1	  cell	  populations	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Lentivectors	   were	   packaged	   in	   HEK293T	   cells	   by	   cotransfection	   with	   two	   separate	  
plasmids	  encoding	  the	  structural	  and	  regulatory	  genes	  in	  trans,	  and	  the	  env	  gene,	  which	  allowed	  
pseudotyping	   with	   VSV-­‐G	   and	   tropism	   for	   SupT1	   cells.	   This	   approach	   excludes	   the	   risk	   of	  
recreating	   replication	   competent	   wild	   type-­‐like	   viruses	   by	   chance.	   The	   resulting	   lentiviruses,	  
carrying	  the	  shRNA	  expression	  cassettes,	  were	  titred	  based	  on	  the	  proportion	  of	  GFP	  expression	  
in	  transduced	  SupT1	  cells	  (Figure	  3.4A).	  Very	  low	  viral	  titres	  for	  LVTH-­‐shTAT	  were	  obtained	  (data	  
not	   shown),	   which	   is	   probably	   due	   to	   the	   silencing	   of	   tat	  mRNA	   in	   packaging	   cells.	   Given	   that	  
another	   virus-­‐targeting	   positive	   control,	   LVTH-­‐shU5,	   was	   successfully	   packaged,	   shTAT	   was	   no	  
longer	  used	  in	  the	  study.	  
	  
	  
Figure	   3.4:	   Biological	   transduction	   titre	   of	   shRNA-­‐expressing	   lentiviruses.	   A.	   SupT1	   cells	   were	   transduced	   with	  
lentiviruses	   carrying	   shRNA	   expression	   cassettes	   and	   a	   GFP	   reporter	   gene.	   The	   proportion	   of	   GFP+	   SupT1	   cells	   was	  
determined	  by	  flow	  cytometry	  72	  hours	   later.	  B.	  The	  virus	  dilution	  required	  to	  give	  50%	  GFP+	  SupT1	  cells	  (EC50)	  was	  
determined	   by	   sigmoidal	   dose-­‐response	   non-­‐linear	   regression	   analysis,	   where	   Top	   =	   100	   and	   Bottom	   =	   0.	  
Rearrangement	  of	   the	  non-­‐linear	  equation	  permitted	   calculation	  of	   the	  dilution	  of	   virus	  needed	   to	  obtain	  20%	  GFP+	  
SupT1	  cells	  on	  transduction.	  
	  
Titration	  curve	  equations,	  derived	  from	  non-­‐linear	  regression,	  were	  used	  to	  calculate	  the	  
amount	  of	  virus	   to	  give	  GFP	  expression	   in	  50%	  (EC50)	  and	  20%	  of	  cells	   (Figure	  3.4B).	  This	   latter	  
virus	  dilution	  was	  used	  to	  transduce	  SupT1	  cells	   resulting	   in	  populations	  of	  SupT1	  cells	  with	  15-­‐
20%	  GFP	  expression	  (Figure	  3.5A).	  This	  degree	  of	  transduction	  was	  selected	  so	  as	  to	  reduce	  the	  
probability	   of	   more	   than	   one	   provirus	   being	   integrated	   per	   cell.	   Multiple	   shRNA	   expression	  
cassette	   integration	   events	  may	  be	   associated	  with	   toxicities	   related	   to	  detrimental	   integration	  
events	  or	  saturation	  of	  the	  RNAi	  pathway	  from	  high	  shRNA	  expression	  (Grimm	  et	  al.	  2006;	  Grimm	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et	  al.	  2010).	  The	  transduced	  cell	  populations	  were	  sorted	  for	  GFP	  expression	  by	  flow	  cytometry,	  
resulting	  in	  the	  generation	  of	  SupT1	  cell	  lines	  with	  >90%	  GFP	  expression	  (Figure	  3.5A	  and	  B).	  
	  
	  
Figure	  3.5:	  Sorting	  of	  lentivirus-­‐transduced	  SupT1	  cell	  lines.	  A.	  The	  proportion	  of	  GFP+	  SupT1	  cells	  was	  determined	  by	  
flow	  cytometry	  following	  transduction	  with	  lentiviruses	  both	  pre-­‐	  and	  post-­‐sort.	  B.	  Representative	  flow	  cytometry	  plots	  
demonstrating	  the	  cell	  sorting	  gating	  strategy.	  Gates	  were	  consistent	  across	  all	  samples.	  
	  
LVTH-­‐shS2	   SupT1	   cells	   proliferated	  at	   a	  noticeably	   reduced	   rate	   compared	   to	   the	  other	  
cell	   lines	  and,	  following	  expansion	  post-­‐sorting,	  the	  proportion	  of	  GFP+	  cells	  was	  only	  60%	  (data	  
not	  shown).	  This	  suggested	  that	  the	  shS2-­‐expressing	  cells	  were	  at	  a	  growth	  disadvantage	  to	  the	  
shRNA-­‐negative	  cells	  in	  the	  population.	  For	  this	  reason,	  this	  cell	  line	  was	  not	  used	  in	  the	  study	  and	  
so	  whether	  SMARCB1	  is	  an	  HDF	  in	  SupT1	  cells	  was	  not	  established.	  
shRNA	  expression	  and	  guide	  strand	  processing	  was	  confirmed	   in	  SupT1	  cells	   transduced	  
with	   LVTH-­‐shH1	  and	   LVTH-­‐shP1	  by	   small	   RNA	  Northern	  blot.	  As	   expected,	   the	   shH1-­‐	   and	   shP1-­‐
derived	   guide	   strands	   were	   detectable	   in	   SupT1	   cells	   transduced	   with	   LVTH-­‐shH1	   and	   -­‐shP1,	  
respectively	   (Figure	   3.6).	   This	   demonstrates	   that	   specific	   shRNAs	   are	   being	   expressed	   in	   the	  
transduced	  and	  sorted	  SupT1	  cell	  populations	  and	  that	  no	  cross-­‐contamination	  occurred.	  
	  
	  
Figure	   3.6:	   Processing	   of	   HDF-­‐targeting	   shRNAs	   in	   SupT1	   cells.	   Guide	   strands	   were	   detected	   by	   small	   RNA	   PAGE	  
Northern	  blot.	   Equal	   loading	  of	   RNA	  was	   verified	  by	   levels	   of	   5S	   rRNAs,	  which	  were	  detected	  by	   ethidium	  bromide-­‐
staining	  of	  the	  polyacrylamide	  gel.	  	  
	  
3.3.4	  Proliferative	  capacity	  is	  unaltered	  by	  shRNA	  expression	  in	  SupT1	  cells	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Different	  cell	  proliferation	  rates	  may	  affect	  HIV-­‐1	  replication	  kinetics	  because	  replication	  
is	  influenced	  by	  the	  extent	  of	  cell	  activation	  and	  the	  amount	  of	  cells	  present.	  Having	  observed	  a	  
reduction	  in	  proliferation	  rates	  on	  stable	  expression	  of	  the	  shRNA	  targeting	  SMARCB1,	  the	  other	  
shRNA-­‐expressing	  SupT1	  cell	   lines	  were	  examined.	  The	  number	  of	   cells	  present	   following	   seven	  
days	   culture	   did	   not	   significantly	   differ	   between	   the	   cell	   lines	   (p	   >0.05),	  whether	   quantified	   by	  
counting	   of	   viable	   cells	   within	   a	   Trypan	   blue-­‐stained	   population	   (Figure	   3.7A),	   or	  
spectrophotometry	   of	   isolated	   DNA	   (Figure	   3.7B).	   This	   confirms	   that	   any	   differences	   in	   HIV-­‐1	  
replication	  observed	  between	  the	  shRNA-­‐expressing	  SupT1	  cell	  populations	  will	  not	  be	  a	  result	  of	  
a	  difference	  in	  the	  cells	  available	  for	  HIV-­‐1	  to	  infect.	  
	  
	  
Figure	   3.7:	   SupT1	   cell	   line	   proliferation	   rates	   do	   not	   significantly	   differ.	   shRNA-­‐expressing	   SupT1	   cell	   lines	   were	  
cultured	  for	  seven	  days	  prior	  to	  (A)	  counting	  following	  a	  Trypan	  blue	  stain,	  and	  (B)	  quantification	  of	  isolated	  DNA.	  One-­‐
way	  ANOVAs.	  
	  
3.3.5	  A	  shRNA	  targeting	  HTATSF1	  mediates	  sustained	  inhibition	  of	  HIV-­‐1	  replication	  
	  
The	  kinetics	  of	  subtype	  B	  molecular	  clone	  p81A-­‐4	  replication	  was	  examined	  in	  the	  SupT1	  
cells	  expressing	   shRNAs.	   LVTH-­‐U6	  cells	  were	  also	   cultured	   in	   the	  absence	  of	   virus	  as	  a	  negative	  
control.	   24	   hours	   post-­‐infection,	   cells	   were	   washed	   to	   remove	   any	   residual	   virus	   used	   in	   the	  
infection	   (Day	   0).	   Levels	   of	   the	   HIV-­‐1	   antigen	   p24	   were	   quantified	   in	   culture	   supernatants	   at	  
various	  time	  points	  up	  to	  17	  days	  post-­‐infection.	  
Compared	   with	   SupT1	   cells	   with	   no	   shRNA	   expression,	   SupT1	   cells	   expressing	   shH1	  
significantly	   inhibited	  p24	  production	   for	  more	   than	  14	  days	  post-­‐infection	   (>95%	  on	  Day	  10,	  p	  
<0.001),	  and	  to	  a	  similar	  extent	  to	  that	  obtained	  with	  the	  positive	  control,	  shU5,	  which	  targets	  the	  
virus	   directly	   (75%	   on	   Day	   10,	   p	   <0.01;	   Figure	   3.8A	   and	   B).	   This	   demonstrates	   that	   shRNA-­‐
mediated	  suppression	  of	  HTATSF1	  expression	  in	  a	  T	  cell-­‐derived	  line	  can	  inhibit	  HIV-­‐1	  replication.	  
The	  extent	  of	  p24	   inhibition	  with	  shH1	  or	  shU5	  expression	  was	  not	  as	  great	  as	  that	  observed	   in	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the	   shP1-­‐expressing	   cell	   line,	   which	   was	   negligible	   throughout	   the	   time	   course.	   This	   is	   in	  
accordance	  with	  previous	  studies	  (Llano	  et	  al.	  2006a)	  and	  may	  relate	  to	  the	  pre-­‐integrative	  role	  of	  
p75.	   p24	   levels	   17	  days	  post-­‐infection	   in	   the	   cell	   lines	  with	  no	   shRNA	  expression	   (LVTH-­‐U6),	   or	  
expression	   of	   the	   negative	   control,	   shHBVx,	   are	   not	   shown	   as	   these	   populations	   exhibited	  
extensive	  cell	  death	  by	  this	  time	  point,	  which	  was	  observed	  by	  microscopy.	  
	  
	  
Figure	  3.8:	  HTATSF1-­‐targeting	  shRNA	  inhibits	  p81A-­‐4	  replication.	  A.	  Following	  infection	  of	  SupT1	  cells	  with	  subtype	  B	  
molecular	  clone	  p81A-­‐4	  at	  a	  TCID50	  of	  50/ml,	  p24	  levels	  were	  determined	  in	  culture	  supernatants	  by	  ELISA	  up	  to	  17	  days	  
post-­‐infection.	  Crosses	   indicate	  discontinued	  p24	  measurement,	  which	  was	  a	   result	  of	   cell	   death.	  B.	   As	   (A)	  with	  p24	  
levels	  10	  and	  14	  days	  post-­‐infection	  normalised	  to	  pLVTH-­‐U6.	  
	  
Interestingly,	  p24	  levels	  in	  shH1-­‐expressing	  SupT1	  cells,	  relative	  to	  the	  pLVTH-­‐U6	  control,	  
were	   increased	   14	   days	   post-­‐infection	   compared	   with	   10	   days	   post-­‐infection	   (Figure	   3.8B).	   In	  
contrast,	   the	   suppression	   of	   p24	   levels	   in	   shU5-­‐expressing	   cells	   was	   maintained.	   Several	  
mechanisms	  may	  account	  for	  the	  slight	  rebound	  in	  p24	  levels:	  adaptation	  of	  the	  virus	  to	  another	  
cofactor,	   increased	   HTATSF1	   as	   a	   result	   of	   increased	   HTATSF1	   transcription	   and	   increased	  
HTATSF1	  as	  a	  result	  of	  decreased	  shRNA	  expression.	  The	  first	  possibility	  is	  unlikely	  given	  the	  time	  
frame	  used	  in	  the	  assay.	  Also,	  escape	  from	  shU5	  would	  be	  expected	  to	  occur	  more	  rapidly	  than	  
cofactor	   adaptation,	   particularly	   as	   shH1	   and	   shU5	   mediate	   replication	   inhibition	   to	   a	   similar	  
degree.	  The	  other	  two	  possibilities	  were	  investigated.	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3.3.6	  HTATSF1	  levels	  increase	  through	  reduced	  shH1	  expression	  
	  
Firstly,	  whether	  HTATSF1	  levels	  were	  increasing	  over	  time	  was	  investigated.	  Fresh	  stocks	  
of	  SupT1	  cell	  lines	  were	  raised	  and	  cultured	  for	  the	  same	  duration	  as	  used	  in	  the	  p81A-­‐4	  challenge	  
assay.	  At	  time	  points	  equivalent	  to	  days	  0,	  10	  and	  20	  post-­‐infection,	  total	  RNA	  was	   isolated	  and	  
subject	   to	   qRT-­‐PCR.	   Levels	   of	   htatsf1	   mRNA	  were	   suppressed	   at	   each	   time	   point	   in	   the	   shH1-­‐
expressing	   cell	   line	   compared	   to	   the	   control	   LVTH-­‐U6	   (Figure	   3.9).	   However,	   there	   was	   a	  
significant	   increase	   in	  htatsf1	  mRNA	  levels	  at	  day	  20	  (~65%)	  from	  day	  10	  (~49%,	  p	  <0.01;	  Figure	  
3.9).	   In	   contrast,	   suppression	   of	   psip1	   mRNA	   was	   sustained	   in	   the	   shP1-­‐expressing	   cell	   line	  
throughout	  the	  time	  course,	  demonstrating	  that	  the	  reduction	  in	  RNAi	  over	  time	  was	  specific	  to	  
the	  shH1-­‐expressing	  cell	  line.	  
	  
	  
Figure	  3.9:	  HTATSF1	  mRNA	  levels	   increase	  in	  shH1-­‐expressing	  SupT1	  cells	  over	  time.	  HTATSF1	  or	  PSIP1	  mRNA	  levels	  
relative	  to	  β-­‐actin	  mRNA	  (actb)	  were	  determined	  by	  qRT-­‐PCR	  from	  total	  RNA	  extracted	  from	  shH1-­‐	  or	  shP1-­‐expressing	  
SupT1	  cells,	   respectively.	  RNA	  was	  extracted	  at	   time	  points	  equivalent	   to	  days	  0,	  10	  and	  20	  of	   the	  p81A-­‐4	  challenge	  
assay.	  *,	  p	  <0.05,	  two-­‐way	  ANOVA	  with	  Bonferroni	  post-­‐tests.	  
	  
The	   increase	   in	   htatsf1	   mRNA	   on	   day	   20	  was	   accompanied	   by	   an	   increase	   in	   HTATSF1	  
protein	  in	  the	  shH1-­‐expressing	  cell	  lines	  from	  ~31%	  of	  LVTH-­‐U6	  control	  on	  day	  0,	  to	  ~60%	  on	  day	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20	  (Figure	  3.10).	  This	  suggests	  that	  the	  slight	  attenuation	  of	  p24	  production	  inhibition	  over	  time	  in	  
cells	  expressing	  shH1	  may	  have	  been	  a	  result	  of	  increased	  HTATSF1	  expression.	  
	  
	  
Figure	   3.10:	   HTATSF1	   increases	   in	   shH1-­‐expressing	   SupT1	   cell	   lines	   over	   time.	   HTATSF1	   relative	   to	   β-­‐actin	   was	  
determined	  in	  SupT1	  cell	  lines	  after	  different	  periods	  of	  passage.	  One	  hundred	  micrograms	  of	  total	  cellular	  protein	  was	  
subject	  to	  PAGE	  and	  Western	  blot.	  Day	  20	  samples	  were	  prepared	  in	  duplicate	  and,	  as	  such,	  representative	  bands	  for	  
this	  time	  point	  are	  shown.	  
	  
Several	   experiments	   were	   performed	   to	   elucidate	   the	   mechanism	   of	   an	   increase	   in	  
HTATSF1	   expression	   over	   time.	   Flow	   cytometry	   of	   shRNA-­‐expressing	   SupT1	   cell	   populations	  
revealed	   that	   the	   increase	   in	  HTATSF1	  was	  accompanied	  by	  a	  drop	  of	  ~3%	   in	   the	  proportion	  of	  
GFP+	  cells	  in	  the	  shH1-­‐expressing	  population	  (Figure	  3.11),	  which	  was	  not	  observed	  in	  the	  shP1-­‐
expressing	   population.	   However,	   only	   a	   single	   population	   were	   cultured	   and	   analysed	   by	   flow	  
cytometry	  for	  each	  cell	  line,	  so	  the	  statistical	  relevance	  of	  these	  results	  is	  unclear.	  
	  
	  
Figure	  3.11:	  The	  proportion	  of	  GFP+	  SupT1	  cells	  in	  the	  shH1-­‐expressing	  cell	  line	  decreases	  over	  time.	  SupT1	  cell	  lines	  
were	  analysed	  by	  flow	  cytometry	  for	  the	  percentage	  of	  GFP+	  cells	  over	  time.	  
	  
Transcription	   rates	   of	   htatsf1	   were	   determined	   by	   nuclear	   run-­‐on	   assay	   performed	   on	  
nuclei	   isolated	   from	   SupT1	   cells	   expressing	   either	   shH1	   or	   shU5	   cultured	   for	   different	   time	  
periods.	   As	   expected,	   no	   change	   in	   htatsf1	   transcription	   rates	   were	   observed	   in	   the	   cells	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expressing	   shU5	  between	  day	  0	  and	  day	  20	   (Figure	  3.12A).	   Similarly,	  htatsf1	   transcription	   rates	  
were	  unaltered	  in	  shH1-­‐expressing	  cells	  over	  time,	  suggesting	  no	  regulatory	  mechanism	  in	  the	  cell	  
for	   the	   preservation	   of	   HTATSF1	   expression	   operating	   at	   the	   level	   of	   transcription.	   In	   contrast,	  
small	  RNA	  Northern	  blot	  revealed	  a	  drop	  of	  68%	  in	  shH1-­‐derived	  guide	  strand	  expression	  relative	  
to	   5S	   RNA	   from	   day	   0	   to	   day	   20	   (Figure	   3.12B).	   This	   was	   much	   greater	   than	   the	   observed	  
reduction	   in	   shP1-­‐derived	   guide	   strand	   expression	   (23%;	   Figure	   3.12B).	   Together	   the	   data	  
suggests	   that	   the	   attenuation	   of	   p24	   inhibition	   in	   shH1-­‐expressing	   SupT1	   cells	   is	   a	   result	   of	  
decreased	   shH1	   expression	   and,	   consequently,	   increased	   HTATSF1	   over	   time.	   The	   cause	   of	  
decreased	   shH1	  expression	  may	  be	  a	   result	  of	  epigenetic	   silencing	  of	   the	   integrated	  expression	  
cassette	  or	  a	  growth	  advantage	  of	  the	  cells	  within	  the	  population	  without	  shH1	  expression.	  
	  
	  
Figure	  3.12:	  Suppression	  of	  HTATSF1	  does	  not	  alter	  htatsf1	  transcription	  but	  shH1	  expression	  decreases	  over	  time.	  A.	  
SupT1	  cell	  lines	  were	  analysed	  for	  transcription	  of	  the	  htatsf1	  gene	  by	  nuclear	  run-­‐on	  assay.	  Two-­‐way	  ANOVA.	  B.	  Guide	  
strands	  were	  detected	  by	  small	  RNA	  PAGE	  Northern	  blot.	  Levels	  of	  guide	  strands	  are	  given	  relative	  to	  5S	  rRNAs,	  which	  
were	  detected	  by	  ethidium	  bromide-­‐staining	  of	  the	  polyacrylamide	  gel.	  
	  
3.3.7	  HTATSF1	  suppression	  does	  not	  alter	  the	  ratio	  of	  HIV-­‐1	  transcript	  classes	  in	  SupT1	  cells	  
	  
One	  group	  has	   solely	  attributed	   the	  HIV-­‐1	   cofactor	   role	  of	  HTATSF1	   to	  enhancement	  of	  
viral	   transcript	   splicing	   (Miller	   et	   al.	   2009).	   To	   investigate	   whether	   the	   inhibition	   of	   viral	  
replication	  observed	  in	  SupT1	  cells	  expressing	  shH1	  (Figure	  3.8)	  was	  a	  result	  of	  defects	  in	  splicing,	  
various	  primer	  sets	  were	  designed	  to	  amplify	  different	  classes	  of	  HIV-­‐1	  transcripts	  (Figure	  3.13).	  
One	  set	  uniquely	  amplified	  ~9	  kb,	  or	  unspliced,	  transcripts.	  A	  second	  set	  amplified	  both	  ~4	  kb,	  or	  
singly	   spliced,	   and	  ~9	  kb	   transcripts.	  A	   third	   set	  of	  primers	   spanned	   the	  Tat/Rev	   splice	   junction	  
and	  so	  only	  amplified	  ~2	  kb,	  or	  multiply	  spliced,	  transcripts.	  For	  the	  ~4	  kb	  class,	  expression	  was	  
calculated	   by	   subtracting	   the	   expression	   of	   unspliced	   transcripts	   from	   that	   obtained	   with	   the	  
second	   primer	   set	   that	   quantified	   both	   unspliced	   and	   singly	   spliced	   transcripts.	   Total	   p81A-­‐4	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transcript	   expression	  was	   quantified	   by	   summing	   expression	   for	   each	   of	   the	   three	   classes,	   and	  
also	  using	  a	  fourth	  primer	  set	  that	  amplified	  a	  region	  common	  to	  all	  three	  classes.	  
	  
	  
Figure	  3.13:	  Schematic	  of	  HIV-­‐1	  transcript	  classes	  and	  primers	  used	  to	  quantify	  them.	  HIV-­‐1	  transcripts	  fall	  into	  three	  
classes:	   ~9	   kb	   class,	  which	   are	   unspliced,	   ~4	   kb	   class,	   often	   referred	   to	   as	   singly	   spliced	   and	   ~2	   kb	   class,	  which	   are	  
multiply	   spliced.	   Primers	   were	   designed	   to	   amplify	   the	   9	   or	   2	   kb	   classes	   only,	   the	   4	   and	   9	   kb	   class	   and	   all	   HIV-­‐1	  
transcripts.	  
	  
Following	   infection	   of	   shRNA-­‐expressing	   SupT1	   cell	   lines	   with	   p81A-­‐4,	   total	   RNA	   was	  
extracted	   from	   washed	   cells	   48	   hours	   later	   and	   analysed	   by	   qRT-­‐PCR.	   Firstly,	   suppression	   of	  
htatsf1	  mRNA	  was	  confirmed	  in	  the	  shH1-­‐expressing	  cell	   line	  (~60%,	  p	  <0.01;	  Figure	  3.14A).	  The	  
same	   cDNA	   samples	   were	   then	   analysed	   for	   expression	   of	   the	   different	   classes	   of	   HIV-­‐1	  
transcripts,	   relative	   to	  actb	  mRNA.	  As	   expected,	   shP1-­‐expressing	   SupT1	   cells	   displayed	   reduced	  
expression	  of	  all	  three	  classes,	  consistent	  with	  its	  role	  in	  viral	  integration	  (Figure	  3.14B).	  Unspliced	  
transcripts	   were	   increased	   in	   the	   shU5-­‐expressing	   cell	   line,	   relative	   to	   the	   LVTH-­‐U6	   control,	  
suggesting	   that	   the	   target	   site	   may	   be	   less	   accessible	   in	   unspliced	   transcripts	   compared	   with	  
spliced.	  Surprisingly,	  an	  increase	  in	  all	  three	  classes	  of	  HIV-­‐1	  transcripts	  was	  observed	  in	  the	  shH1-­‐
expressing	  cell	  line	  compared	  to	  LVTH-­‐U6	  cells	  (Figure	  3.14B).	  
	  
	  
Figure	   3.14:	   All	   classes	   of	   p81A-­‐4	   transcripts	   are	   increased	   in	   shH1-­‐expressing	   SupT1	   cells.	   SupT1	   cell	   lines	   were	  
infected	  with	  p81A-­‐4	   at	   a	   TCID50	   of	   50/ml	   and	   total	   RNA	  extracted	  48	  hours	   later.	   *,	  p	   <0.05,	   one-­‐way	  ANOVA	  with	  
Dunnett	  post-­‐tests	  relative	  to	  uninfected	  SupT1	  cells.	  A.	  Levels	  of	  HTATSF1	  mRNA	  relative	  to	  β-­‐actin	  mRNA	  (actb)	  were	  
determined	  by	  qRT-­‐PCR.	  B.	  The	  same	  RNA	  was	  also	  used	  to	  quantify	  p81A-­‐4	  transcripts.	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The	  general	  increase	  in	  HIV-­‐1	  transcripts	  in	  shH1-­‐expressing	  cells	  was	  not	  accompanied	  by	  
a	  change	  in	  the	  relative	  ratios	  of	  the	  three	  transcript	  classes,	  however	  (p	  >0.05;	  Figure	  3.15A),	  and	  
this	  was	  the	  case	  for	  all	  SupT1	  cell	   lines.	  In	  addition,	  the	  total	  number	  of	  p81A-­‐4	  transcripts	  was	  
similar	  whether	  determined	  by	  summing	  the	  expression	  for	  the	  three	  classes	  or	  using	  the	  primers	  
common	  to	  all	  classes	  (Figure	  3.15B),	  which	  suggests	  that	  the	  observed	  results	  are	  unlikely	  to	  be	  a	  
result	  of	  significant	  differences	  in	  the	  amplification	  efficiency	  of	  the	  various	  primer	  sets.	  
	  
	  
Figure	  3.15:	  HTATSF1	  suppression	  does	  not	  alter	  the	  ratio	  of	  p81A-­‐4	  transcript	  classes.	  SupT1	  cell	  lines	  were	  infected	  
with	  p81A-­‐4	  at	   a	  TCID50	  of	  50/ml	  and	   total	  RNA	  extracted	  48	  hours	   later.	  A.	   The	   ratio	  of	  different	   classes	  of	  p81A-­‐4	  
transcripts	  to	  total	  viral	  transcripts	  relative	  to	  β-­‐actin	  mRNA	  (actb)	  were	  determined	  by	  qRT-­‐PCR.	  Total	  viral	  transcripts	  
are	  given	  by	  summing	  the	  different	  classes.	  B.	  Total	  viral	  transcripts	  relative	  to	  β-­‐actin	  mRNA	  (actb),	  determined	  both	  
by	   summing	   each	   class	   (sum	   total)	   and	   qRT-­‐PCR	   using	   primers	   which	   amplify	   a	   region	   common	   to	   all	   classes	   of	  
transcripts	  (common	  total).	  
	  
This	   data	   provides	   no	   evidence	   of	   a	   role	   for	   HTATSF1	   in	   splicing	   of	   viral	   transcripts	   in	  
SupT1	   cells.	   Rather,	   HTATSF1	   suppression	   leads	   to	   an	   accumulation	   of	   all	   classes	   of	   viral	  
transcripts	   two	  days	  post-­‐infection.	  Nevertheless,	   the	   inhibition	  of	  viral	   replication	  over	  14	  days	  
demonstrates	   that	   the	   increase	   in	  p81A-­‐4	   transcripts	   is	  not	   translated	   into	  enhanced	   infectious	  
particle	  production.	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3.4	  Discussion	  
	  
The	  approach	  used	  in	  this	  study	  was	  to	  validate	  the	  role	  of	  cellular	  factors	  HTATSF1	  and	  
SMARCB1	   in	   HIV-­‐1	   replication	   through	   shRNA-­‐mediated	   PTGS	   in	   a	   T	   cell	   line.	   The	   ability	   of	  
SMARCB1	   suppression	   to	   inhibit	   p81A-­‐4	   replication	   in	   SupT1	   cells	   was	   not	   determined	   as	   cells	  
expressing	   a	   shRNA	   targeting	   SMARCB1	   displayed	   diminished	   proliferative	   capacity.	   This	   is	  
seemingly	   in	   contrast	   to	   the	   role	   of	   SMARCB1	   as	   a	   tumour	   suppressor	   in	   rhabdoid	   cells,	  which	  
occurs	   by	   regulating	   the	   cell	   cycle	   through	   the	   pRb	   pathway	   [reviewed	   in	   (Stojanova	   and	   Penn	  
2009)].	   Mutations	   in	   smarcb1	   have	   been	   found	   in	   malignant	   rhabdoid	   tumours,	   a	   rare	   yet	  
aggressive	  paediatric	   cancer	   (Versteege	   et	  al.	   1998;	  Biegel	   et	  al.	   1999).	   Indeed,	  a	   survey	  of	  100	  
primary	   rhabdoid	  and	  central	  nervous	   system	   tumours	   found	   that	  75%	  of	   these	   carried	  genetic	  
alteration	   of	   the	   smarcb1	   locus	   (DeCristofaro	   et	   al.	   1999).	   However,	   SMARCB1	   regulates	  
approximately	   5-­‐10%	   of	   genes	   (Gresh	   et	   al.	   2005)	   and,	   recently,	   it	   was	   demonstrated	   that	  
deficiency	  in	  SWI/SNF	  chromatin	  remodelling	  complexes,	  of	  which	  SMARCB1	  is	  a	  core	  component,	  
results	   in	   aberrant	   chromatin	   organisation	   and	  mitotic	   failure	   (Bourgo	   et	   al.	   2009).	   In	   addition,	  
inactivation	  of	  SMARCB1	  in	  murine	  embryonic	  fibroblasts	  led	  to	  growth	  suppression	  triggered	  by	  
p53	   and	   p21	   (Isakoff	   et	   al.	   2005)	   and	   SMARCB1	   loss	   is	   associated	   with	   polyploidy	   and	  
chromosome	   instability	   (Vries	   et	   al.	   2005),	   but	   not	   disruptions	   in	   the	   DNA	   damage	   response	  
(McKenna	  et	  al.	  2008).	  Knudson’s	  2-­‐hit	  hypothesis	  for	  oncogenesis,	  which	  requires	  the	  occurrence	  
of	  at	   least	   two	  random	  somatic	  alterations	   (Knudson	  1971),	  may	  account	   for	   the	  discrepancy	   in	  
enhanced	   cell	   proliferation	   between	   malignant	   rhabdoid	   tumours	   and	   shS2-­‐expressing	   SupT1	  
cells.	  Of	  course,	  whether	  SupT1	  cells,	  which	  are	  derived	  from	  a	  leukaemia,	  have	  functioning	  p53,	  
p21	   or	   DNA	   damage	   response	   is	   unknown	   and	   so	   it	   is	   unclear	   by	   what	   mechanism	   SMARCB1	  
suppression	  inhibits	  proliferation	  or	  induces	  apoptosis	  in	  these	  cells.	  Admittedly,	  the	  decrease	  in	  
proliferation	   may	   have	   been	   a	   result	   of	   an	   off-­‐target	   effect	   of	   the	   shRNA,	   not	   mediated	   by	  
SMARCB1	  suppression.	  Nevertheless,	  the	  association	  of	  SMARCB1	  loss	  with	  cancer	  suggests	  that,	  
regardless	  of	  whether	  this	  protein	  is	  a	  HDF	  or	  not,	  it	  is	  not	  a	  good	  anti-­‐HIV	  therapeutic	  target.	  
Suppression	  of	  HTATSF1	  inhibited	  HIV-­‐1	  replication	  for	  over	  14	  days	  in	  SupT1	  cells	  (Figure	  
3.8).	   However,	   the	   major	   cofactor	   role	   HTATSF1	   plays	   in	   p81A-­‐4	   replication	   in	   SupT1	   cells	   is	  
unclear.	   Previously,	   HTATSF1	  was	   shown	   to	   enhance	   splicing	   of	   HIV-­‐1	   transcripts,	   with	   shRNA-­‐
mediated	   suppression	   of	   HTATSF1	   leading	   to	   an	   increase	   in	   unspliced,	   relative	   to	   total,	   HIV-­‐1	  
transcripts	  (Miller	  et	  al.	  2009).	  However,	  the	  work	  presented	  in	  this	  thesis	  suggests	  that	  HTATSF1	  
suppression	   has	   no	   effect	   on	   splicing	   of	   viral	   transcripts	   (Figure	   3.15A)	   and	   rather	   leads	   to	   an	  
accumulation	  of	  all	  classes	  of	  HIV-­‐1	  transcripts	  (Figure	  3.14B).	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Miller	   and	   colleagues	  used	   a	   very	   different	   approach	   to	   this	   study.	   Firstly,	   levels	   of	   the	  
three	  different	  HIV-­‐1	  transcript	  classes	  were	  assessed	  by	  Northern	  blot	  on	  RNA	  samples	  extracted	  
from	  anti-­‐HTATSF1	  shRNA-­‐expressing	  T-­‐Rex-­‐293	  cells	  48	  hours	  post-­‐transfection	  with	  the	  subtype	  
B	  HIV-­‐1	  plasmid	  pSG3ΔEnv.	  Similar	  to	  the	  findings	  here	  (Figure	  3.15A),	  HTATSF1	  depletion	  lead	  to	  
an	   increase	   in	   unspliced	   and	   singly	   spliced	   transcripts.	   However,	   this	   was	   accompanied	   by	   a	  
decrease	   in	   fully	   spliced	   transcripts,	   although	   this	  was	  not	  obvious	   from	   the	  blot	   as	   abundance	  
was	  quantified	  relative	  to	  fuzzy	  control	  bands,	  particularly	  for	  the	  fully	  spliced	  class.	   In	  addition,	  
transcript	   class	   abundance	   was	   not	   normalised	   to	   a	   housekeeping	   gene,	   despite	   GAPDH	  
expression	  clearly	  being	  greater	  in	  the	  samples	  expressing	  a	  HTATSF1-­‐targeting	  shRNA.	  They	  went	  
on	  to	  analyse	  the	  same	  RNA	  samples	  by	  qRT-­‐PCR,	  showing	  an	  increase	  in	  the	  ratio	  of	  unspliced	  to	  
total	  HIV-­‐1	  transcripts.	  However,	  again	  expression	  of	  neither	  were	  normalised	  to	  a	  housekeeping	  
gene.	  Also,	  it	  is	  unclear	  how	  the	  qPCR	  data	  was	  processed	  because	  the	  ratio	  of	  unspliced	  to	  total	  
HIV-­‐1	  transcripts	  was	  greater	  than	  one	  and	  the	  increase	  in	  unspliced	  transcripts	  was	  greater	  (>1.5-­‐
fold)	  than	  when	  quantified	  from	  Northern	  blot	  bands	  (~1.2-­‐fold),	  despite	  the	  two	  analyses	  being	  
performed	  on	  the	  same	  samples.	   In	  summary,	  critical	  analysis	  of	  the	  data	  presented	  in	  Miller	  et	  
al.	  raises	  doubt	  over	  their	  conclusion	  that	  HTATSF1	  regulates	  the	  relative	  levels	  of	  unspliced	  and	  
spliced	  HIV-­‐1	  transcripts.	  Most	  importantly,	  Miller	  and	  colleagues	  offer	  no	  explanation	  as	  to	  why	  
singly	  spliced	  transcripts	  are	  unaffected	  by	  HTATSF1	  suppression.	  
In	   contrast	   to	   Miller	   et	   al.,	   this	   study	   used	   SupT1	   cells	   and	   cells	   were	   infected,	   not	  
transfected,	  with	  HIV-­‐1.	  This	  alone	  may	  account	  for	  the	  differences	  between	  the	  two	  studies.	  For	  
example,	  HTATSF1	  may	  be	  a	  splicing	  cofactor	  but	   this	  may	  not	  be	   its	   rate-­‐limiting	  role	   in	  SupT1	  
cells.	  Alternatively,	  transfecting	  plasmid	  versus	  infecting	  with	  virus	  will	   lead	  to	  differences	  in	  the	  
kinetics	  of	  replication	  and	  it	  is	  possible	  that	  the	  time	  point	  at	  which	  the	  effect	  on	  splicing	  is	  most	  
discernible	   was	   not	   used	   in	   this	   study.	   Indeed,	   even	   Miller	   and	   colleagues	   comment	   that	   the	  
effect	   on	   splicing	   was	   only	   observed	   48	   hours	   post-­‐transfection.	   Moreover,	   a	   recent	   study	  
demonstrated	   a	   role	   for	   HTATSF1	   in	   promoting	   a	   transition	   from	   fully	   spliced	   to	   singly	   spliced	  
transcripts	   in	   the	  presence	  of	  Tat	   (Jablonski	   et	  al.	   2010),	   indicating	   that	  any	   role	  of	  HTATSF1	   in	  
splicing	  is	  complex	  and	  may	  change	  during	  the	  course	  of	  the	  viral	  life	  cycle.	  
Of	  interest	  is	  the	  accumulation	  of	  all	  classes	  of	  viral	  transcripts	  48	  hours	  post-­‐infection	  on	  
HTATSF1	   suppression	   (Figure	   3.14B).	   This	   was	   surprising	   given	   proposed	   roles	   for	   HTATSF1	   in	  
transcription	   elongation	   and	   splicing.	   Conversely,	   the	   increase	   in	   transcripts	   did	   not	   reflect	  
increased	   HIV-­‐1	   replication,	   as	   p24	   production	   was	   reduced	   for	   over	   14	   days	   compared	   with	  
LVTH-­‐U6	   and	   LVTH-­‐shHBVx	   controls	   (Figure	   3.8).	   This	   suggests	   a	   post-­‐transcription	   role	   for	  
HTATSF1,	  necessary	  for	  the	  formation	  of	  infectious	  particles,	  not	  yet	  described.	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HTATSF1	   has	   been	   implicated	   in	   the	   stabilisation	   of	   a	   number	   of	   nuclear	   RNA-­‐protein	  
complexes,	  including	  spliceosomal	  U	  snRNPs	  (Yan	  et	  al.	  1998;	  Fong	  and	  Zhou	  2001),	  the	  RNA	  Pol	  II	  
elongation	  complex	  (Zhou	  and	  Sharp	  1996;	  Li	  and	  Green	  1998;	  Parada	  and	  Roeder	  1999;	  Fong	  and	  
Zhou	   2001;	   Zhou	   et	   al.	   2004a)	   and	   influenza	   vRNPs	   (Naito	   et	   al.	   2007).	   Perhaps,	   therefore,	  
HTATSF1	   functions	   as	   a	   more	   general	   enhancer	   of	   the	   formation	   of	   nuclear	   RNA-­‐protein	  
complexes.	   This	   is	   certainly	   compatible	  with	   the	   structure	  of	  HTATSF1,	  which	   is	   composed	  of	   a	  
highly	   acidic	   carboxyl-­‐terminal	   half	   and	   an	   amino-­‐terminal	   half	   containing	   two	  RNA	   recognition	  
motifs	   (RRMs)	   (Zhou	   and	   Sharp	   1996).	   Nucleic	   acid-­‐binding	   proteins	   contain	   basic	   domains,	  
although	   these	   tend	   to	   aggregate	   in	   the	   absence	   of	   nucleic	   acid	   or	  molecular	   chaperones.	   The	  
acidic	  domain	  of	  HTATSF1	  may	  bind	  such	  basic	  regions,	  serving	  as	  a	  chaperone.	  HTATSF1	  may	  also	  
simultaneously	   bind	   RNA,	   through	   the	   amino-­‐terminal	   RRMs,	   and	   basic	   proteins,	   through	   the	  
carboxyl-­‐terminal	   acidic	   domain,	   stabilising	   RNA-­‐protein	   complexes.	   Thus,	   a	   hypothesis	   is	   that	  
HTATSF1	  is	  involved	  in	  export	  of	  viral	  transcripts	  in	  SupT1	  cells,	  either	  through	  chaperoning	  of	  the	  
RNA-­‐binding	  proteins	   required	   (eg	  Rev),	  or	   stabilisation	  of	   the	  exported	  RNA-­‐protein	  complexes	  
themselves.	   If	   this	  were	   the	  case,	   suppression	  of	  HTATSF1	  would	   result	   in	  accumulation	  of	  viral	  
transcripts	  without	   increasing	   replication,	   as	   observed	   here.	   Further	   experiments,	   such	   as	   RNA	  
fluorescence	  in	  situ	  hybridisation	  (FISH),	  are	  required	  to	  test	  this	  hypothesis.	  
The	  magnitude	  of	   the	   inhibition	  of	  p24	  production	   relative	   to	   LVTH-­‐U6	   control	  was	  not	  
maintained	   in	   the	   shH1-­‐expressing	   SupT1	   cell	   lines	   (Figure	   3.8),	   which	   is	   probably	   a	   result	   of	  
increased	   HTATSF1	   expression	   over	   time	   (Figures	   3.9	   and	   3.10).	   The	   increase	   in	   HTATSF1	  
suppression	  was	  not	  a	  result	  of	  increased	  htatsf1	  transcription	  (Figure	  3.12A)	  but	  likely	  a	  result	  of	  
decreased	  shH1	  guide	  strand	  expression	  (Figure	  3.12B).	  Although	  an	  effect	  on	  shRNA	  processing	  
cannot	  be	  excluded	  with	  the	  data	  reported	  here,	  the	  lack	  of	  a	  role	  for	  HTATSF1	  in	  RNAi	  renders	  it	  
more	   likely	   that	   the	   decrease	   in	   shH1-­‐derived	   guide	   strands	   is	   a	   result	   of	   a	   decrease	   in	   the	  
expression	  of	  the	  shRNA.	  This	  is	  unlikely	  to	  be	  through	  an	  HTATSF1	  suppression-­‐mediated	  effect	  
on	   transcription	  elongation,	   as	  HTATSF1	  has	  only	  been	   identified	   in	  RNA	  Pol	   II,	   not	  RNA	  Pol	   III,	  
elongation	  complexes	  (Kim	  et	  al.	  1999;	  Parada	  and	  Roeder	  1999;	  Chen	  et	  al.	  2009).	  
Two	   mechanisms	   may	   account	   for	   the	   decreased	   shRNA	   expression:	   (1)	   epigenetic	  
silencing	  of	  the	  shRNA	  expression	  cassette;	  and,	  (2)	  decreased	  growth	  of	  the	  shRNA-­‐positive	  cells	  
within	   the	   population	   relative	   to	   the	   shRNA-­‐negative	   cells.	   Although	   epigenetic	   silencing	   of	  
integrated	   viral	   sequences	   is	   acknowledged	   as	   a	   limitation	   of	   gene	   therapy,	   the	   former	   is	   less	  
likely	   to	   account	   for	   decreased	   shRNA	   expression	   because	   RNA	   Pol	   III	   U6	   promoters	   are	  more	  
resistant	  to	  epigenetic	  silencing	  than	  RNA	  Pol	  II	  promoters	  [reviewed	  in	  (Zhang	  and	  Rossi	  2010)],	  
although	  the	  possibility	  cannot	  be	  excluded	  with	  the	  data	  here.	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For	   normal	   cells	   to	   have	   a	   growth	   advantage	   over	   HTATSF1-­‐suppressed	   cells	   seems	  
plausible,	  particularly	  when	  the	  role	  of	  HTATSF1	  in	  transcription	  elongation	  is	  considered.	  Indeed,	  
stable	  HTATSF1	  knockdown	  has	  been	  suggested	  to	  cause	  growth	  arrest	  in	  HeLa	  cells	  (Chen	  et	  al.	  
2009).	   However,	   under	   these	   circumstances,	   decreased	   GFP+	   cells	   in	   the	   population	   should	  
accompany	  decreased	  shRNA	  expression.	  The	  discord	   in	  the	  extent	  of	  change	   in	  GFP	  expression	  
(Figure	  3.11)	  and	  shH1	  expression	  (Figure	  3.12B)	  over	  20	  days	  may	  relate	  to	  the	  methods	  used	  to	  
quantify	   the	   respective	   parameters	   –	   although	   flow	   cytometry	   is	   extremely	   sensitive,	   GFP	  
expression	  was	  assessed	   in	  only	  one	  replicate.	   In	  addition,	  shH1	  expression	  was	  quantified	  on	  a	  
Northern	  blot	   relative	   to	   5S	  RNA	  on	   an	  ethidium	  bromide-­‐stained	  polyacrylamide	   gel,	   although	  
transfer	   efficiency	   probably	   differed	   between	   the	   ~120	   nt	   5S	   RNA	   and	   ~21	   nt	   guide	   strands.	  
Furthermore,	  despite	  all	  experiments	  being	  performed	  on	  cell	   lines	  prepared	  at	   the	   same	   time,	  
the	   experiments	   were	   conducted	   up	   to	   several	   months	   apart.	   Thus,	   differences	   in	   culture	  
conditions	  between	  sampling	  for	  the	  qRT-­‐PCR,	  Western	  blot,	  Northern	  blot,	  nuclear	  run-­‐on,	  flow	  
cytometry,	  cell	  counting	  and	  DNA	  isolation,	  cannot	  be	  excluded.	  
Of	  course,	  growth	  arrest	   is	  not	  a	  desirable	  side	  effect,	  particularly	   in	   immune	  cells.	  This	  
brings	   into	   question	   the	   therapeutic	   potential	   of	   HTATSF1	   targeting	   as	   an	   anti-­‐HIV	   strategy.	  
However,	   significant	   differences	   in	   the	   proliferation	   rates	   between	   the	   various	   SupT1	   cell	   lines	  
were	  not	  observed	  (Figure	  3.7).	  Admittedly,	  the	  methods	  used	  (ie	  cell	  counting	  and	  quantification	  
of	   isolated	   DNA)	  may	   have	   been	   insufficiently	   sensitive	   over	   the	   seven	   days	   examined	   and	   an	  
assay	  based	  on	  the	  extent	  of	  BrdU	  incorporation	  would	  have	  been	  preferable.	  Nevertheless,	  the	  
effect	   HTATSF1	   suppression	   has	   on	   proliferation	   appears	   modest.	   Moreover,	   it	   has	   been	  
demonstrated	   that	   cells	   with	   greater	   resistance	   to	   HIV-­‐1	   replication	   undergo	   preferential	  
expansion	   in	  vivo	   (Swan	  et	  al.	  2006).	  Therefore,	  the	  selective	  disadvantage	  accrued	  on	  HTATSF1	  
suppression	  may	  be	  outweighed	  in	  vivo	  by	  a	  selective	  advantage	  in	  the	  context	  of	  a	  HIV	  infection.	  
Further	   experiments	   are	   needed	   to	   verify	   this	   is	   the	   case,	   but	   it	   suggests	   that	   targeting	   of	  
HTATSF1	  may	  be	  more	  suited	  to	  post-­‐infection	  treatment	  rather	  than	  prophylaxis.	  
Even	   if	   HTATSF1	   suppression	   does	   not	   confer	   a	   selective	   disadvantage	   in	   vivo,	   there	   is	  
another	  concern	  with	  respect	  to	  using	  HTATSF1	  as	  an	  anti-­‐HIV	  therapeutic	  target:	  the	  inhibition	  of	  
HIV-­‐1	  replication	  on	  HTATSF1	  suppression	  was	  moderate,	  in	  contrast	  to	  the	  pronounced	  inhibition	  
observed	   in	   LVTH-­‐shP1	   cells	   (Figure	   3.8).	   This	   suggests	   that	   whilst	   HTATSF1	   may	   increase	   the	  
efficiency	  of	  viral	  replication,	  it	  is	  not	  a	  critical	  HDF	  in	  SupT1	  cells.	  
In	   summary,	  HTATSF1	  may	  have	   complex	   roles	   in	  HIV-­‐1	   replication.	   Its	   suppression	   can	  
inhibit	  viral	  replication	  in	  T	  cell-­‐derived	  lines	  but	  the	  effect	  is	  moderate	  and	  may	  be	  accompanied	  
by	  a	  growth	  disadvantage.	  HTATSF1	  is,	  therefore,	  a	  HDF	  but	  not	  necessarily	  a	  promising	  anti-­‐HIV	  
therapeutic	   target.	   This	   study	   demonstrates	   that	   a	   thorough	   interrogation	   of	   HIV-­‐1	   replication	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kinetics	  and	  cytotoxicity	   in	  relevant	  cells	   is	  necessary	  to	  validate	  HDFs	  as	  therapeutic	  targets.	  As	  
such,	  a	  similar	  approach	  to	  that	  employed	  here	  should	  be	  applied	  to	  other	  novel	  HDFs	  identified	  
in	  genome-­‐wide	  screens.	  
Given	   that	   this	   thesis	   validates	   HTATSF1	   as	   an	   HDF,	   and	   a	   role	   for	   DDX3X	   in	   HIV-­‐1	  
replication	  was	  demonstrated	  elsewhere	  (Ishaq	  et	  al.	  2008),	  whether	  TGS	  of	   these	  genes	  would	  
inhibit	  HIV-­‐1	  replication	  was	  examined.	  This	  was	  the	  objective	  of	  the	  work	  described	  in	  Chapter	  4.	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CHAPTER	  4	  





TGS	  provides	  an	  alternative	  approach	  to	  PTGS	  for	  reducing	  gene	  expression	  (see	  1.4).	  Like	  
PTGS,	   Ago-­‐bound	   small	   RNAs	   elicit	   gene	   silencing	   although,	   rather	   than	   targeting	   a	  mRNA,	   the	  
guide	  strands	  are	  complementary	  to	  promoter-­‐associated	  transcripts	  (Han	  et	  al.	  2007)	  (see	  1.4.2).	  
A	  number	  of	  mechanisms	  have	  been	  proposed	  for	  the	  modulation	  of	  gene	  expression	  induced	  by	  
promoter-­‐targeting	  small	  RNAs	  (see	  1.4.1-­‐4).	  Classical	  TGS	  is	  accompanied	  by	  epigenetic	  changes	  
at	   the	   targeted	   region,	   including	   histone	  modifications	   and/or	   DNA	  methylation,	   resulting	   in	   a	  
more	  compact	  chromatin	  structure	  that	  is	  less	  conducive	  to	  transcription	  (see	  1.4.1).	  It	  has	  been	  
demonstrated	  that	  reduced	  gene	  expression	  may	  be	  sustained	  for	  over	  a	  month	  in	  the	  absence	  of	  
the	  promoter-­‐targeted	  small	  RNA,	  providing	  silent-­‐state	  chromatin	  was	  achieved	  during	  the	  TGS	  
induction	   (Hawkins	   et	   al.	   2009).	   This	   highlights	  one	  of	   the	  principal	   advantages	  of	   classical	   TGS	  
over	  PTGS	  –	  there	   is	   the	  potential	   for	   long-­‐term	  silencing,	  and	  so	  the	  frequency	  of	  guide	  strand	  
administration/expression	  may	   be	   reduced	   compared	  with	   PTGS,	   reducing	   toxicities	   associated	  
with	  saturation	  of	  the	  RNAi	  pathway.	  
Host	   proteins	   involved	   in	   HIV-­‐1	   replication	   are	   attractive	   therapeutic	   targets	   given	   the	  
high	  mutability	  of	  the	  virus	  (see	  1.2.5).	  Chapters	  2	  and	  3	  of	  this	  thesis	  have	  validated	  HTATSF1	  as	  a	  
HDF	  and	  shown	  that	  its	  suppression	  inhibits	  HIV-­‐1	  replication	  in	  both	  reporter	  TZM-­‐bl	  cells	  and	  T	  
cell-­‐derived	   lines.	   Although	   validation	   of	   the	   HDF	   DDX3X	   was	   not	   achieved	   in	   this	   study,	  
concurrent	  work	  has	  confirmed	  its	  potential	  as	  a	  therapeutic	  target	  since	  its	  suppression	  inhibits	  
HIV-­‐1	  replication	  without	  inducing	  apoptosis	  in	  HEK-­‐based	  reporter	  cells	  (Ishaq	  et	  al.	  2008).	  Given	  
the	   advantages	   of	   TGS	   over	   PTGS,	   a	   proof	   of	   principle	   study	  was	   conducted	   to	   investigate	   the	  
potential	  of	  TGS	  induction	  at	  HDFs	  to	  inhibit	  viral	  replication.	  
Obtaining	   TGS	   is	   sometimes	   hampered	   by	   the	   identification	   of	   target	   sites	   that	  
correspond	  to	  promoter-­‐associated	  transcripts	  but	  not	  mRNAs.	  Initial	  attempts	  to	   induce	  TGS	  at	  
htatsf1,	   ddx3x	   and	   psip1	   in	   HEK293T	   cells	   failed	   (see	   A2).	   In	   this	   pilot	   study,	   several	   siRNAs	  
reduced	  target	  expression	  but	  nuclear	  run-­‐on	  analysis	  showed	  that	  the	  observed	  suppression	  was	  
not	  at	  the	  transcriptional	   level.	  Subsequent	   interrogation	  of	  the	  siRNA	  target	  sites	  revealed	  that	  
the	  database	  used	  to	  retrieve	  TSSs	  was	  not	  always	  accurate	  and	  a	  number	  of	  the	  siRNAs	  were	  in	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fact	  targeting	  coding	  transcripts.	  Thus,	  difficulties	  identifying	  the	  most	  active	  TSS	  led	  to	  design	  of	  
siRNAs	  that	  were	  not	  targeting	  the	  appropriate	  region	  in	  gene	  promoters.	  
Unlike	  Saccharomyces	  cerevisiae	  (David	  et	  al.	  2006),	  human	  genes	  rarely	  have	  a	  defined	  
TSS,	  with	   transcription	   initiation	  more	   commonly	   occurring	   over	   a	   region	   (Juven-­‐Gershon	   et	   al.	  
2008).	   In	   addition,	   many	   genes	   have	   alternative	   promoters	   (Carninci	   et	   al.	   2006;	   Jacox	   et	   al.	  
2010).	   Identification	   of	   the	   active	   promoter	   is	   critical,	   however,	   to	   the	   design	   of	   TGS-­‐inducing	  
small	   RNAs.	   The	   preferred	  method	   for	   identification	   of	   the	  most	   active	   TSS	   in	   a	   cell	   line	   for	   a	  
specific	  gene	  is	  5’	  rapid	  amplification	  of	  cDNA	  ends	  (RACE).	  However,	  in	  the	  absence	  of	  such	  data,	  
promoters	  may	  be	  inferred	  from	  data	  obtained	  by	  the	  Functional	  Annotation	  of	  the	  Mammalian	  
Genome	  (FANTOM)	  project	  (Kawaji	  et	  al.	  2006b;	  Kawaji	  et	  al.	  2009;	  Kawaji	  et	  al.	  2010).	  
The	   FANTOM	   research	   project	   is	   an	   international	   collaboration	   to	   characterise	   the	  
mammalian	  transcriptome.	  The	  project	  led	  to	  the	  development	  of	  cap	  analysis	  of	  gene	  expression	  
(CAGE)	   technology	   (Maeda	   et	   al.	   2008):	   through	   a	   combination	   of	   cap	   trapping,	   cleavage	   by	  
restriction	  enzymes	  and	  deep	  sequencing,	  the	  5’	  27	  nt	  sequence	  of	  capped	  mRNAs	  are	  obtained	  
(Carninci	   et	   al.	   2005;	   Carninci	   et	   al.	   2006).	   These	   can	   be	   aligned	   to	   the	   genome	   providing	   a	  
genome-­‐wide	  map	  of	  TSSs.	  
During	   the	   latest	   (fourth)	   stage	   of	   the	   FANTOM	   project,	   the	   transcription	   regulatory	  
network	  was	  examined	  by	  mapping	  TSSs	  in	  a	  differentiating	  macrophage-­‐like	  cancer	  cell	  line,	  THP-­‐
1	   (Kawaji	   et	   al.	   2009).	   Interestingly,	   TSSs	   may	   be	   only	   a	   few	   base	   pairs	   apart	   with	   different	  
expression	   patterns	   (Balwierz	   et	   al.	   2009).	   To	   accommodate	   this	   when	   constructing	   a	  
“promoterome”,	   only	   nearby,	   coexpressed	   TSSs	   were	   grouped	   into	   transcription	   start	   clusters	  
(TSCs).	  TSCs	  with	  overlapping	  proximal	  promoters	  were	  further	  clustered	  into	  transcription	  start	  
regions	  (TSRs).	  TSCs	  and	  TSRs	  were	  annotated	  based	  on	  data	  from	  56	  human	  CAGE	  libraries,	  18	  of	  
which	  were	  obtained	  from	  THP-­‐1	  samples.	  TSR	  data,	   including	  the	  most	  active	  TSS	  within	  a	  TSR,	  
combined	  with	  enrichments	  of	  transcription	  factor	  binding	  sites,	  were	  compiled	  to	  provide	  a	  map	  
of	  promoter	  regions	  (Kawaji	  et	  al.	  2009).	  
This	  chapter	  examines	  the	  feasibility	  of	  transcriptional	  silencing	  of	  HDFs	  htatsf1	  and	  ddx3x	  
as	  an	  anti-­‐HIV	  strategy.	  The	  FANTOM	  project-­‐derived	  TSRs	  and	  promoter	  regions	  were	  used	  as	  a	  
proxy	   for	   target	   gene	   promoters	   in	   the	  HEK293T	   and	   TZM-­‐bl	   cell	   lines.	   Algorithms	   designed	   to	  
predict	  PTGS	   target	   sites	  were	  used	   in	  TGS	   target	   site	   selection,	  on	   the	  assumption	   that	   similar	  
thermodynamic	  principles	  apply,	  as	  Ago	  proteins	  are	  involved	  in	  both	  small	  RNA-­‐mediated	  gene-­‐
silencing	  pathways	  (Meister	  et	  al.	  2004;	  Janowski	  et	  al.	  2006;	  Kim	  et	  al.	  2006).	  The	  mechanism	  of	  
siRNA-­‐mediated	   silencing	  was	   interrogated	  by	   quantification	  of	   promoter-­‐associated	   transcripts	  
and	  nuclear	  run-­‐on	  analysis	  for	  the	  assessment	  of	  target	  gene	  transcription	  rates.	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4.2	  Materials	  and	  methods	  
	  
4.2.1	  Mapping	  the	  htatsf1	  promoter	  
	  
A	   rational	   approach	   to	   the	   design	   of	  htatsf1	   (Entrez	   gene	   ID	   27336)	   and	  ddx3x	   (Entrez	  
gene	  ID	  1654)	  promoter-­‐targeting	  siRNAs	  was	  employed,	  which	  first	  involved	  mapping	  features	  of	  
the	   promoters	   to	   the	   NCBI36/hg18	   (Mar	   2006)	   genome	   (Lander	   et	   al.	   2001).	   The	   RefSeq	  
transcription	   start	   sites	   of	   the	  htatsf1	   transcript	   NM_014500	   (chrX:135,407,337	   (+))	   and	  ddx3x	  
transcript	   NM_001356	   (chrX:41,077,595	   (+))	   were	   obtained	   from	   the	   UCSC	   Genome	   Browser	  
(http://genome.ucsc.edu/)	  (Kent	  et	  al.	  2002).	  
A	  region	  1000	  bp	  either	  side	  of	  the	  RefSeq	  TSS	  was	  examined	  for	  the	  presence	  of	  various	  
core	  promoter	  elements	  (Table	  4.1	  and	  Figure	  4.1)	  (Juven-­‐Gershon	  et	  al.	  2008;	  Anish	  et	  al.	  2009).	  
Their	   presence	   was	   considered	   evidence	   that	   these	   sequences	   function	   in	   transcriptional	  
regulation.	  
	  
Table	  4.1:	  Core	  promoter	  elements.	  
Motif	   Consensus	  sequence	   Position	  relative	  to	  TSS	   Associated	  factor	  
Initiator	  (Inr)	   YYANWYY	   -­‐2	  to	  +5	   TFIID	  
TATA	  box	   TATAWAWR	   -­‐30/31	  to	  -­‐24/23	   TBP	  (subunit	  of	  TFIID)	  
TFIIB	  recognition	  element,	  upstream	  
(BREu)	  
SSRCGCC	   Upstream	  of	  TATA	  box	   TFIIB	  




of	  TATA	  box	  
TFIIB	  
Downstream	  core	  element	  (DCE)	  SI	   CTTC	   ~+8	  
Downstream	  core	  element	  (DCE)	  SII	   CTGT	   ~+18	  
Downstream	  core	  element	  (DCE)	  SIII	   AGC	   ~+31	  
Proximal	  to	  TAF1	  
X	  core	  promoter	  element	  1	  (XCPE1)	   DSGYGGRASM	   -­‐8	  to	  +2	  
X	  core	  promoter	  element	  2	  (XCPE2)	   VCYCRTTRCMY	   -­‐9	  to	  +2	  
Unknown	  
The	   region	  1000	  bp	  either	   side	  of	   the	  RefSeq	  TSS	  was	  examined	   for	   the	  presence	  of	   these	   core	  promoter	  elements.	  
Degenerate	  nucleotides	  within	  consensus	  sequences	  are	  indicated	  according	  to	  the	  IUPAC	  nucleotide	  code.	  
	  
	  
Figure	  4.1:	  Schematic	  of	   the	  distribution	  of	  various	   core	  promoter	  elements.	   The	   region	  1000	  bp	  either	   side	  of	   the	  
RefSeq	  TSS	  was	  examined	  for	  the	  presence	  of	  these	  core	  promoter	  elements.	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Other	  promoter	  features	  were	  determined	  using	  data	  from	  the	  FANTOM	  project	  (Kawaji	  
et	   al.	   2006b;	   Kawaji	   et	   al.	   2009;	   Kawaji	   et	   al.	   2010).	   The	   locations	   of	   the	   htatsf1	   (TSR	   ID	  
TSR_hg18_v1_chrX_+_135407060,	   located	   chrX:135407036-­‐135407424	   (+))	   and	   ddx3x	   (TSR	   ID	  
TSR_hg18_v1_chrX_+_41078359,	  located	  chrX:41078354-­‐41078375	  (+))	  TSRs	  were	  obtained	  from	  
FANTOM	   data	   available	   on	   the	   SwissRegulon	   Portal	   (http://www.swissregulon.unibas.ch/cgi-­‐
bin/regulon)	   (Pachkov	   et	   al.	   2007).	   Also	   from	   this	   database	   were	   the	   htatsf1	   (cluster	   ID	  
L2_chrX_+_135407060,	   located	   chrX:135407036-­‐135407064	   (+))	   and	   ddx3x	   (cluster	   ID	  
L2_chrX_+_41078359,	   located	   chrX:41078357-­‐41078365	   (+))	   promoter	   regions	   and	   Motevo	  
algorithm-­‐predicted	  transcription	  factor	  binding	  sites	  (TFBS)	  (van	  Nimwegen	  2007)	  retrieved.	  The	  
htatsf1	  and	  ddx3x	  mapped	  FANTOM4	  TSSs	   (chrX:135407060	   (+)	  and	  chrX:41078359	   (+))	  may	  be	  
defined	  as	   the	  most	  active	  or	   representative	  TSS,	  governed	  by	   the	  highest	  number	  of	  sequence	  
tags	  within	  the	  TSR	  and	  promoter	  region.	  
	  
4.2.2	  Design	  of	  promoter-­‐targeting	  siRNAs	  
	  
A	  number	  of	  different	  tools	  were	  used	  in	  design	  of	  promoter-­‐targeting	  siRNAs,	  although	  
developed	   for	   the	   design	   of	   siRNAs	   targeting	   mRNAs.	   These	   online	   tools	   were	   Dharmacon’s	  
siDesign®	   Center	   (http://www.dharmacon.com/designcenter/designcenterpage.aspx),	   siRNA	  
target	   finder	   (http://www.ambion.com/techlib/misc/siRNA_finder.html)	   and	   siDirect	   v2.0	  
(http://sidirect2.rnai.jp/doc/)	   (Naito	   et	   al.	   2004;	   Naito	   et	   al.	   2009).	   The	   algorithms	   used	   by	   all	  
three	   tools	   include	   elements	   to	   favour	   functional	   siRNAs,	   based	   on	   efficacy	   predictions	  
incorporated	  in	  other	  algorithms	  (Amarzguioui	  and	  Prydz	  2004;	  Reynolds	  et	  al.	  2004;	  Ui-­‐Tei	  et	  al.	  
2004),	  and	  to	  reduce	  off-­‐target	  effects,	  through	  elimination	  of	  siRNAs	  with	  near-­‐perfect	  matches	  
to	  mRNAs	  or	  high	  thermodynamic	  stability	  in	  the	  seed	  region	  (Ui-­‐Tei	  et	  al.	  2008).	  
To	  further	  reduce	  off-­‐target	  effects,	  guide	  and	  passenger	  strand	  sequences	  were	  subject	  
to	   nucleotide	   BLAST	   (blastn)	   against	   all	   human	   genomic	   and	   transcript	   sequences.	   The	   current	  
standard	  reference	  assembly	  of	  the	  human	  genome,	  hg19/Genome	  Reference	  Consortium	  human	  
genome	   build	   37	   (GRCh37)	   (May	   2010),	   was	   used	   in	   alignments.	   Those	   siRNAs	   with	   ≥1	  
mismatches	   in	   the	   seed	   sequence	   or	   ≥3	   mismatches	   overall	   to	   non-­‐targeted	   regions	   were	  
eliminated.	   In	   addition,	   G	   nucleotides	   were	   avoided	   in	   the	   2-­‐nucleotide	   overhang	   to	   prevent	  
RNase	   activity	   on	   the	   siRNAs.	   Finally,	   siRNAs	  were	   selected	   that	   did	   not	   fully	   overlap	   TFBS	   and	  
that	  spanned	  the	  htatsf1	  TSR	  and	  promoter	  region	  (Table	  4.2).	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Table	  4.2:	  Oligonucleotide	  templates	  used	  to	  generate	  htatsf1	  and	  ddx3x	  promoter-­‐targeting	  siRNAs.	  
Target	  
siRNA	   Antisense/guide	  oligonucleotide	  template	   Sense/passenger	  oligonucleotide	  template	   Design	  tool	  
chrX:	  (+)	   GC	  content	  (%)	   Length	  (bp)	  
siH13	   ATGCCGGCGTCGGCGCTTTTTGACCTGTCTC	   ATTCAAAAAGCGCCGACGCCGGCCCTGTCTC	   siDirect	  
135407008-­‐
135407030	  
72	   23	  
siH14	   AATGGCGGCTGCGTCGGCCTGCCTGTCTC	   AACAGGCCGACGCAGCCGCCACCTGTCTC	   Ambion	  
135407080-­‐
135407100	  
71	   21	  
siH15	   CCTGAGCAGGGCTTAGTTTAGCCTGTCTC	   CCCTAAACTAAGCCCTGCTCACCTGTCTC	   Dharmacon*	  
135407097-­‐
135407117	  
52	   21	  
siH16	   CAGGGCTTAGTTTAGAAGTAACCTGTCTC	   CATTACTTCTAAACTAAGCCCCCTGTCTC	   Dharmacon*	  
135407103-­‐
135407123	  
38	   21	  
siH17	   AAGTAATTTCCTGACGTTGCCCCTGTCTC	   AAGGCAACGTCAGGAAATTACCCTGTCTC	   Ambion	  
135407118-­‐
135407138	  
43	   21	  
siH18	   CAGCGCCCTGGACCTAGCGGCCCTGTCTC	   CAGCCGCTAGGTCCAGGGCGCCCTGTCTC	   None	  
135407216-­‐
135407236	  
76	   21	  
siH19	   AAGCCAGGTGGGCGGCGGCGCCCTGTCTC	   AAGCGCCGCCGCCCACCTGGCCCTGTCTC	   Ambion	  
135407258-­‐
135407278	  
81	   21	  
siH20	   AAGAGCTCACAGCATCAGCGCGCCTGTCTC	   AACGCGCTGATGCTGTGAGCTCCCTGTCTC	   Ambion	  
135407281-­‐
135407302	  
59	   22	  
siH21	   AAGGGGCGGTGCAGCCGCCGAGCCTGTCTC	   AACTCGGCGGCTGCACCGCCCCCCTGTCTC	   Ambion	  
135407326-­‐
135407347	  
77	   22	  
siD13	   AACTCCGAGGCTGAGACTAGGCCTGTCTC	   AACCTAGTCTCAGCCTCGGAGCCTGTCTC	   Ambion	  
41078078-­‐
41078098	  
57	   21	  
siD14	   TAGCTCGAGAGAACTGGGACACCTGTCTC	   TATGTCCCAGTTCTCTCGAGCCCTGTCTC	   Dharmacon	  
41078124-­‐
41078144	  
52	   21	  
siD15	   CTGCTAGGGGCGACAGGACTACCTGTCTC	   CTTAGTCCTGTCGCCCCTAGCCCTGTCTC	   Dharmacon	  
41078175-­‐
41078195	  
62	   21	  
siD16	   CCGCGACAGGGAATTGCGGTGCCTGTCTC	   CCCACCGCAATTCCCTGTCGCCCTGTCTC	   Dharmacon	  
41078254-­‐
41078274	  
67	   21	  
siD17	   ACGTGCTGACGTAGCCGGCTTCCTGTCTC	   ACAAGCCGGCTACGTCAGCACCCTGTCTC	   Dharmacon	  
41078297-­‐
41078307	  
62	   21	  
All	  siRNA	  oligonucleotide	  templates	  had	  the	  CCTGTCTC	  sequence	  at	  their	  3’	  end	  to	  allow	  hybridisation	  with	  the	  T7	  promoter	  primer	  within	  the	  Silencer®	  siRNA	  Construction	  Kit	  (Ambion,	  TX,	  
USA).	  Target	  sequences	  are	  in	  italics.	  Two	  nt	  overhangs	  are	  underlined.	  *	  denotes	  target	  sequences	  slightly	  modified	  from	  that	  suggested	  by	  the	  design	  tool	  to	  allow	  for	  two	  nt	  overhangs	  in	  
the	  siRNAs	  without	  G	  nucleotides.	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4.2.3	  Generation	  of	  siRNAs	  by	  in	  vitro	  transcription	  
	  
siRNAs	  were	   constructed	   using	   the	  Silencer®	   siRNA	  Construction	   Kit	   (Ambion,	   TX,	  USA),	  
which	   involves	   in	   vitro	   transcription	   using	   T7	   RNA	   polymerase	   (Figure	   4.2).	   Oligonucleotide	  
templates	  were	  designed	  that	  carried	  an	  8-­‐nt	  leader	  sequence	  at	  the	  3’	  end	  to	  allow	  hybridisation	  
with	   the	   T7	   promoter	   primer	   (Table	   4.2).	   Two	  microlitres	   of	   100	  µM	   template	   oligonucleotide	  
were	  incubated	  with	  2	  µl	  T7	  promoter	  primer	  (concentration	  unknown)	  and	  6	  µl	  DNA	  hyb	  buffer	  
(proprietary	   information)	  at	  70	  °C	  for	  5	  min	  and	  then	  room	  temperature	  for	  a	  further	  5	  min.	  To	  
this	  reaction,	  2	  µl	  of	  10x	  Klenow	  reaction	  buffer	  (proprietary	  information),	  10x	  dNTP	  mix	  and	  exo-­‐
Klenow	  (concentrations	  unknown)	  were	  added	  and	  the	  reaction	  made	  up	  to	  20	  µl	  with	  nuclease-­‐
free	  water.	  These	  reactions	  were	  incubated	  at	  37	  °C	  for	  30	  min.	  
	  
	  
Figure	  4.2:	  Procedure	  for	  construction	  of	  siRNAs	  by	  an	   in	  vitro	  transcription	  method.	  siRNAs	  were	  constructed	  using	  
the	  Silencer®	   siRNA	  Construction	  Kit	   (Ambion,	   TX,	  USA),	  which	   employs	   T7	  RNA	  polymerase	   to	   synthesise	   sense	   and	  
antisense	   strands	   that	   are	   subsequently	   hybridised	   to	   form	   siRNAs	   with	   two	   nt	   overhangs.	   Figure	   adapted	   from	  
Silencer®	  siRNA	  Construction	  Kit	  (Ambion,	  TX,	  USA).	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Transcription	   reactions	  were	  assembled	  using	  2	  µl	  of	   siRNA	  template	   from	  the	  previous	  
Klenow	  DNA	  polymerase	  reaction,	  2	  µl	  10x	  T7	  reaction	  buffer	  (proprietary	  information),	  10	  µl	  2x	  
dNTP	   mix	   and	   2	   µl	   T7	   enzyme	   mix	   (concentrations	   unknown)	   in	   a	   final	   volume	   of	   20	   µl.	  
Transcription	  reactions	  were	  incubated	  at	  37	  °C	  for	  2	  hours	  before	  combining	  the	  cognate	  sense	  
and	   antisense	   reactions.	   Continued	   incubation	   at	   37	   °C	   overnight	   maximised	   RNA	   yield	   and	  
facilitated	  hybridisation	  of	  sense	  and	  antisense	  strands.	  
The	   single-­‐stranded	   RNA	   leader	   sequence	   of	   two	   G	   nt	   and	   DNA	   template	   were	  
simultaneously	   digested.	   To	   the	   transcription	   reactions,	   6	   µl	   of	   digestion	   buffer	   (proprietary	  
information),	   3	   µl	   RNase	   and	   2.5	   µl	   DNase	   (concentrations	   unknown)	   were	   added	   along	   with	  
nuclease-­‐free	   water	   to	   a	   volume	   of	   100	  µl.	   Digestion	   reactions	   were	   incubated	   at	   37	   °C	   for	   2	  
hours.	  
siRNAs	   were	   purified	   on	   supplied	   filter	   cartridges	   (Ambion,	   TX,	   USA).	   Firstly,	   400	   µl	  
binding	  buffer	   (proprietary	   information)	  was	  added	   to	   the	  digestion	   reactions	  and	   incubated	  at	  
room	  temperature	  for	  2-­‐5	  min.	  The	  siRNA-­‐binding	  buffer	  mix	  was	  applied	  to	  a	  filter	  cartridge	  pre-­‐
wet	  with	  100	  µl	  wash	  buffer	  (proprietary	  information).	  Cartridges	  were	  centrifuged	  at	  16,000	  x	  g	  
for	  1	  min	  and	  the	  flow-­‐through	  discarded.	  The	  filters	  were	  then	  washed	  twice	  by	  addition	  of	  500	  
µl	  wash	  buffer	  followed	  by	  centrifugation	  at	  16,000	  x	  g	  for	  1	  min	  and	  flow-­‐through	  discard.	  Filters	  
were	   transferred	   to	  a	  clean	   tube	  and	  wet	  with	  100	  µl	  nuclease-­‐free	  water,	  preheated	   to	  75	  °C.	  
Following	   a	   2	   min	   incubation	   at	   room	   temperature,	   siRNAs	   were	   eluted	   by	   centrifugation	   at	  
16,000	  x	  g	  for	  2	  min.	  
The	   concentration	   of	   siRNAs	   was	   determined	   by	   spectrophotometry	   on	   a	   NanoDrop	  
(Themo	  Fisher	  Scientific,	  Inc.,	  MA,	  USA)	  where	  1	  absorbance	  unit	  at	  a	  wavelength	  of	  260	  nm	  (A260)	  
equates	   to	   40	   µg/ml	   siRNA.	   Purity	   of	   samples	   was	   also	   determined	   by	   spectrophotometry	   ie	  
proximity	  of	  the	  A260/A280	  ratio	  to	  2.0.	  The	  molar	  concentration	  (µM)	  of	  siRNAs	  was	  determined	  by	  
dividing	  the	  concentration	  in	  µg/ml	  by	  14	  (as	  there	  are	  14	  µg	  of	  RNA	  in	  1	  nmol	  of	  an	  average	  21-­‐
mer	  dsRNA).	  Aliquots	  of	  siRNAs	  at	  33	  µM	  were	  prepared	  and	  stored	  at	  -­‐60	  °C.	  
In	   addition	   to	   synthesis	   of	   siRNAs	   designed	   to	   target	   the	  htatsf1	   and	  ddx3x	  promoters	  
(Table	   4.2),	   a	   control	   siRNA	   targeting	   the	   gapdh	   (Entrez	   gene	   ID	   2597)	   mRNA,	   siGAPDH,	   was	  
prepared	   using	   the	   control	   oligonucleotide	   templates	   (sequences	   not	   provided)	   supplied	   in	   the	  
Silencer®	  siRNA	  Construction	  Kit	  (Ambion,	  TX,	  USA).	  
	  
4.2.4	  Transfection	  of	  siRNAs	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Transfections	  were	  carried	  out	  in	  a	  similar	  manner	  as	  for	  DNA	  plasmid	  transfections	  (see	  
2.2.5).	   However,	   the	   transfection	   reagent	   used	   was	   Lipofectamine™	   RNAiMAX	   (Invitrogen,	   CA,	  
USA)	   at	   a	   volume	   of	   3	  µl	   for	   every	   100	   pmol	   siRNA	   (ie	   1:1	   volumetric	   ratio	  with	   33	  µM	  siRNA	  
stock).	   In	  all	  experiments,	   siRNAs	  were	   transfected	  at	  a	   concentration	  of	  100	  nM	   in	   the	  culture	  
media.	  
	  
4.2.5	  Mammalian	  cell	  culture	  
	  
HEK293T	  and	  TZM-­‐bl	  cells	  were	  cultured	  as	  described	  in	  3.2.1	  and	  2.2.4,	  respectively.	  
	  
4.2.6	  Screening	  siRNAs	  for	  inhibition	  of	  target	  expression	  
	  
HEK293T	  or	  TZM-­‐bl	  cells	  were	  seeded	  at	  1.5	  x	  105	  or	  3	  x	  104	  cells	  per	  well,	  respectively,	  in	  
a	  24-­‐well	  plate.	  Twenty-­‐four	  hours	  later,	  cells	  were	  transfected	  with	  either	  siRNAs	  at	  100	  nM	  (see	  
4.2.4)	  or	  500	  ng	  of	  DNA	  plasmids	  pTZU6+1	  and	  pTZU6+shH1	  (see	  2.2.5)	  per	  well	  in	  triplicate	  –	  the	  
latter	  to	  provide	  a	  positive	  control	  for	  htatsf1	  mRNA	  suppression.	  In	  some	  experiments,	  24	  hours	  
post-­‐transfection,	  cells	  were	  treated	  with	  the	  histone	  deacetylase	  inhibitor	  TSA	  (Sigma,	  MO,	  USA)	  
at	  either	  50	  or	  100	  nM,	  depending	  on	  whether	  HEK293T	  or	  TZM-­‐bl	  cells	  were	  used,	  respectively.	  
Seventy-­‐two	  hours	  post-­‐transfection,	  RNA	  was	  extracted	  (see	  A1.3.1),	  DNase-­‐treated	  and	  reverse	  
transcribed	  (see	  3.2.12).	  qPCR	  on	  the	  resulting	  cDNA	  was	  performed	  as	  described	   in	  2.2.7	  using	  
the	  SensiMix™	  Lite	  Kit	  (Quantace	  Ltd,	  London,	  UK)	  (see	  A1.3.4)	  and	  primers	  listed	  in	  Table	  2.4.	  
	  
4.2.7	  Detection	  of	  promoter-­‐associated	  transcripts	  
	  
To	   examine	   whether	   transcripts	   were	   detectable	   in	   various	   regions	   of	   the	   htatsf1	  
promoter,	  RNA	  was	  extracted	  from	  both	  HEK293T	  and	  TZM-­‐bl	  cells.	  One	  microgram	  of	  RNA	  was	  
DNase-­‐treated	  and	  reverse	  transcribed	  (see	  3.2.12)	  in	  quadruplicate.	  Another	  1	  µg	  of	  RNA	  per	  cell	  
line	  was	  DNase-­‐treated	  but	  not	  reverse	  transcribed	  to	  allow	  quantification	  of	  undigested	  genomic	  
DNA	  (gDNA).	  An	  additional	  control	  lacking	  RNA	  was	  included	  per	  cell	  line.	  
qPCR	  was	   performed	   as	   described	   in	   2.2.7	   using	   the	   SensiMix™	   Lite	   Kit	   (Quantace	   Ltd,	  
London,	  UK)	   (see	  A1.3.4).	  Primers	  were	  designed	   to	  amplify	  a	   region	  upstream	  of	   the	  FANTOM	  
promoter	   region	   (cluster	   ID	   L3_chrX_+_135407060)	   and	   a	   region	   within	   the	   TSR	  
(TSR_hg18_v1_chrX_+_135407060)	  (Table	  4.3).	  A	  coding	  region	  was	  also	  amplified	  using	  primers	  
described	   previously	   (Table	   2.4),	   to	   which	   promoter	   transcript	   abundance	   could	   be	   compared.	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Expression	  of	   transcripts	  was	   reported	  as	  a	   function	  of	   the	  Cp	  median,	  which	  was	  calculated	  by	  
the	  Lightcycler®	  V.2	  software	  (Roche,	  Mannheim,	  Germany):	  
	   	   	   	   	   (4.1)	  
Following	  qPCR,	  samples	  were	  extracted	   from	  capillaries	  by	  centrifugation	  at	  400	  x	  g	   for	  15	  sec	  
prior	  to	  resolution	  on	  a	  2%	  agarose	  gel	  (see	  A1.2.3).	  
	  
Table	  4.3:	  Primers	  used	  to	  determine	  levels	  of	  htatsf1	  promoter-­‐associated	  transcripts.	  	  
Primer	   Sequence	  (5’-­‐3’)	   Amplicon	  length	  (bp)	  
upstream	  forward	   AGCAGCGGGTCCCCCCAA	  
upstream	  reverse	   ACACGCCCACTATGGCGTCA	  
92	  
TSR	  forward	   TGCGTCGGCCTGAGCA	  
TSR	  reverse	   ACCGCCGCTAGGTCCA	  
151	  
	  
Orientation	  of	  promoter-­‐associated	  transcripts	  spanning	  the	  TSR	  and	  coding	  regions	  were	  
determined	   in	   a	   similar	   manner	   but	   the	   same	   DNase-­‐treated	   RNA	   extracted	   from	   HEK293T	   or	  
TZM-­‐bl	  cells	  was	  subject	  to	  strand-­‐specific	  reverse	  transcription.	  The	  procedure	  described	  in	  2.2.7	  
was	   followed	  with	   the	  exception	  that	   reverse	   transcription	  was	  primed	  with	  one	  of	   the	  primers	  
listed	   in	   Table	   4.3	   only,	   not	   random	   hexamers.	   It	   should	   be	   noted	   that	   the	   ‘forward’	   primers	  
(same	   sequence	   as	   the	   +	   strand	   of	   DNA	   and,	   therefore,	   the	   sense	   transcript)	   prime	   reverse	  
transcription	  of	  antisense	   transcripts	  and	   ‘reverse’	  primers	  prime	   reverse	   transcription	  of	   sense	  
transcripts.	  
	  
4.2.8	  Examination	  of	  the	  role	  of	  Ago	  proteins	  	  
	  
HEK293T	  or	  TZM-­‐bl	  cells	  were	  seeded	  at	  2	  x	  105	  or	  5	  x	  104	  cells	  per	  well,	  respectively,	  in	  a	  
24-­‐well	   plate.	   Immediately	   following	   administration	   of	   cells	   to	   culture	   plates,	   cells	   were	  
transfected	  with	   25	   nM	   of	   Dharmacon	   SMARTpool	   (Thermo	   Fisher	   Scientific,	   Inc.,	  MA,	   USA)	   in	  
triplicate.	  Each	  SMARTpool	  contains	  four	  siRNAs	  designed	  to	  induce	  a	  potent	  reduction	  in	  target	  
gene	   expression	   without	   off-­‐target	   effects.	   Three	   SMARTpools	   were	   used,	   two	   targeting	   Ago1	  
(EIF2C1;	  Entrez	  gene	  ID	  26523)	  or	  Ago2	  (EIF2C2;	  Entrez	  gene	  ID	  27161),	  and	  one	  containing	  non-­‐
specific	   siRNAs	  as	  a	   control.	   Transfections	  were	   carried	  out	  as	  described	   in	  2.2.5	  but	  using	  1	  µl	  
Dharmacon®	  DharmaFECT®	  per	  well.	  To	  examine	  the	  ability	  of	  the	  SMARTpools	  to	  suppress	  their	  
targets,	  RNA	  was	  extracted	  48	  hours	  post-­‐seeding	  and	  transfection	  (see	  A1.3.1).	  
To	  examine	  the	  role	  of	  Ago1	  and	  Ago2	  in	  siRNA-­‐mediated	  silencing	  of	  htatsf1,	  seeding	  and	  
SMARTpool	   transfection	   was	   repeated,	   as	   above.	   Twenty-­‐four	   hours	   later,	   cells	   were	   again	  
! 
Expression = 2
("C p (+RTsample )) " 2
("C p ("RTcontrol ))
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transfected,	  this	  time	  with	  siRNAs	  at	  100	  nM	  (see	  4.2.4)	  in	  triplicate	  and	  72	  hours	  later,	  RNA	  was	  
extracted	  (see	  A1.3.1).	  
All	  extracted	  RNA	  was	  DNase-­‐treated	  and	   reverse	   transcribed	   (see	  3.2.12).	  qPCR	  on	   the	  
resulting	  cDNA	  was	  performed	  as	  described	   in	  2.2.7	  using	  the	  SensiMix™	  Lite	  Kit	   (Quantace	  Ltd,	  
London,	  UK)	  (see	  A1.3.4)	  and	  primers	  listed	  in	  Table	  2.4.	  Additional	  primers	  specific	  to	  Ago1	  and	  
Ago2	  were	  also	  used:	  Ago1	  forward	  5’	  GCA	  CTG	  CCC	  ATT	  GGC	  AAC	  GAA	  3’;	  Ago1	  reverse	  5’	  CAT	  
TCG	  CCA	  GCT	  CAC	  AAT	  GGC	  T	  3’;	  Ago2	  forward	  5’	  GGC	  CCA	  GTA	  TTT	  CAA	  GGA	  CA	  3’;	  and,	  Ago2	  
reverse	   5’	   TTT	   CTG	   CTC	   CTG	   TCC	  GAC	   TT	   3’	   (Meister	   et	   al.	   2004;	   Turner	   et	   al.	   2009).	   Controls,	  
cycling	  parameters	  and	  reporting	  of	  data	  were	  as	  described	  in	  2.2.7.	  
	  
4.2.9	  Nuclear	  run-­‐on	  assay	  to	  determine	  htatsf1	  transcription	  rates	  
	  
The	   ability	   of	   promoter-­‐targeted	   siRNAs	   to	   alter	   the	   transcription	   rate	   of	   htatsf1	   was	  
assessed	  by	  nuclear	  run-­‐on	  assay.	  HEK293T	  cells	  were	  seeded	  at	  5	  x	  105	  cells	  per	  well	  in	  a	  6-­‐well	  
plate.	  Twenty-­‐four	  hours	  later,	  cells	  were	  transfected	  with	  siRNAs	  at	  100	  nM	  (see	  4.2.4)	  or	  2	  µg	  of	  
DNA	  plasmids	  pTZU6+1	  and	  pTZU6+shH1	  per	  well	  (see	  2.2.5)	  in	  triplicate	  –	  the	  latter	  to	  provide	  a	  
negative	   control	   for	   htatsf1	   transcription	   rate	   change.	   Seventy-­‐two	   hours	   post-­‐transfection,	  
media	  was	  removed	  and	  cells	  washed	  with	  PBS.	  Cells	  were	  harvested	  by	  treatment	  with	  trypsin	  
and	   centrifugation	   at	   400	   x	   g	   for	   5	   min	   at	   4	   °C.	   Cell	   pellets	   were	   then	   subject	   to	   the	   same	  
procedure	  described	  for	  SupT1	  cell	  pellets	  (see	  3.2.15).	  All	  remaining	  stages	  of	  the	  nuclear	  run-­‐on	  
assay	  were	  performed	  as	  described	  in	  3.2.15.	  
	  
4.2.10	  Quantification	  of	  p81A-­‐4	  infectious	  particle	  production	  
	  
TZM-­‐bl	  cells	  were	  seeded	  at	  3	  x	  104	  cells	  per	  well	  in	  a	  24-­‐well	  plate.	  Cells	  were	  transfected	  
24	  hours	  later	  with	  either	  siRNAs	  at	  100	  nM	  (see	  4.2.4)	  or	  500	  ng	  of	  DNA	  plasmids	  pTZU6+1	  and	  
pTZU6+shH1	  per	  well	   (see	   2.2.5)	   in	   triplicate.	   Twenty-­‐four	   hours	   later,	   cells	  were	   infected	  with	  
various	   R5-­‐tropic	   HIV-­‐1	   subtype	   B	   molecular	   clone	   p81A-­‐4	   (NIH	   AIDS	   Research	   &	   Reference	  
Reagent	  Program,	  MD,	  USA)	  (Chesebro	  et	  al.	  1992;	  Walter	  et	  al.	  2005)	  (see	  A1.4.2)	  at	  a	  TCID50	  (see	  
A1.4.3)	  of	  1000/ml	  in	  the	  presence	  of	  15	  µg/ml	  DEAE-­‐D	  (primary	  infection).	  
Cells	  were	  washed	  three	  times	  with	  PBS	  (Gibco,	  BRL,	  UK)	  24	  hours	  post-­‐infection.	  Forty-­‐
eight	  hours	  post-­‐infection,	  100	  µl	  of	  culture	  supernatant	  was	  used	  to	  infect	  additional	  TZM-­‐bl	  cells	  
seeded	  at	  3	  x	  104	  cells	  per	  well	  in	  a	  24-­‐well	  plate	  the	  preceding	  day,	  in	  the	  presence	  of	  15	  µg/ml	  
DEAE-­‐D	   (secondary	   infection).	   Tat-­‐induced	   luciferase	   activity	   was	   assessed	   48	   hours	   post-­‐
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secondary	   infection	   in	   cell	   lysates	   using	   the	   Bright-­‐Glo™	   Luciferase	   Assay	   System	   (Promega,WI,	  
USA)	  (see	  2.2.10).	  
	  
4.2.11	  Statistical	  analyses	  
	  
Data	   are	   expressed	   as	   the	   mean	   ±	   the	   standard	   error	   of	   the	   mean	   (SEM)	   and	   where	  
appropriate	  are	  normalised	  to	  a	  control	  sample	  within	  the	  experiment.	  Statistical	  difference	  was	  
considered	   to	   be	   significant	   (*)	   when	   p	   <0.05.	   Data	   was	   analysed	   using	   one-­‐way	   ANOVAs,	  
followed	   by	   a	   Dunnett‘s	   multiple	   comparison	   post-­‐test,	   and	   two-­‐way	   ANOVAs,	   followed	   by	  
Bonferroni	   post-­‐tests,	   where	   appropriate,	   calculated	   using	   GraphPad	   Prism	   4.0c	   (GraphPad	  
Software,	  Inc.,	  CA,	  USA).	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4.3	  Results	  
	  
4.3.1	  Promoter-­‐targeted	  siRNAs	  inhibit	  target	  HDF	  expression	  
	  
Initial	   attempts	   to	   induce	   TGS	   at	   HDFs	   failed	   (see	   A2),	   related	   in	   part	   to	   inaccurate	  
promoter	  annotation.	  Three	  siRNAs	  were	  already	  screened	  for	  TGS	  at	  htatsf1	  and	  ddx3x:	  neither	  
siH10,	  siH11	  nor	  siH12	  reduced	  htatsf1	  mRNA	  expression	  (Figure	  A2.3);	  siD10,	  siD11	  and	  siD12	  all	  
suppressed	   ddx3x	   mRNA	   levels,	   but	   transcription	   rates	   were	   unaltered	   in	   siD10-­‐treated	   cells	  
(Figure	  A2.9).	  To	  increase	  the	  likelihood	  of	  promoter	  targeting,	  5’	  RACE	  was	  performed	  to	  identify	  
the	  most	  active	  TSS	  for	  these	  genes	  in	  both	  HEK293T	  and	  TZM-­‐bl	  cells	  using	  the	  GeneRacer™	  Kit	  
(Invitrogen,	   CA,	   USA).	   However,	   despite	   no	   RNA	   degradation	   and	   the	   use	   of	   a	   nested	   PCR	  
approach,	   no	   amplification	   products	   from	   decapped,	   extended	  mRNA	  were	   detected	   (data	   not	  
shown).	   Thus,	   as	   a	   proxy	   for	   TSS	   and	   promoter	   identification,	   various	   features	   were	   mapped,	  
including	  TSRs,	  TFBS	  and	  core	  promoter	  elements	  (Figure	  4.3).	  
	  
	  
Figure	  4.3:	  Rational	  design	  of	  promoter-­‐targeting	  siRNAs.	  Features	  of	   the	   (A)	  htatsf1	  and	   (B)	  ddx3x	  promoters	  were	  
mapped	   to	   increase	   the	   likelihood	  of	  promoter	   targeting	  and,	   therefore,	  obtaining	   transcriptional	   silencing.	   Features	  
considered	   included	   the	  RefSeq	  TSS,	  TSR,	  promoter	   region,	  core	  promoter	  elements	  and	  TFBS.	  Most	  of	   the	  data	  was	  
retrieved	  from	  FANTOM	  project	  portals.	  siRNA	  target	  sites	  in	  blue	  were	  screened	  previously	  (see	  A2).	  
	  
For	  htatsf1,	   the	   upstream	   and	   downstream	   TFIIB	   recognition	   elements,	   BREu	   and	   BREd,	  
respectively,	   were	   present.	   For	  ddx3x,	   the	   region	  was	   found	   to	   contain	   the	   TATA	   box,	   two	   Inr	  
elements	  and	  DCE	  SI	  and	  SIII.	  The	  presence	  of	  such	  core	  promoter	  elements	  proximal	  to	  the	  TSRs	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of	  both	  genes	  supported	  that	  these	  regions	  are	  important	  in	  transcription	  initiation.	  siRNA	  target	  
sites	   were	   selected	   from	   regions	   within	   and	   proximal	   to	   the	   TSRs	   of	   HDFs	   htatsf1	   and	   ddx3x	  
(Figure	   4.3).	   TFBS	   were	   avoided	   where	   possible	   to	   minimise	   the	   possibility	   of	   decreasing	  
expression	  through	  blocking	  binding	  of	  a	  transcription	  factor,	  which	  may	  not	  be	  accompanied	  by	  
the	  epigenetic	  changes	  associated	  with	  long-­‐term	  silencing.	  
siRNAs	  were	  screened	  for	  their	  ability	  to	  suppress	  target	  gene	  expression	  by	  qRT-­‐PCR	  in	  
HEK239T	  cells.	  Levels	  of	  ddx3x	  mRNA	  were	  not	  significantly	  reduced	  in	  cells	  treated	  with	  siD13-­‐17	  
(Figure	   4.4B),	  with	   only	   the	   positive	   control	   siD10	   decreasing	   target	   gene	   expression	   (p	   <0.01),	  
which	   functions	   via	   PTGS	   (Figure	   A2.9).	   siD14-­‐treatment	   led	   to	   a	   moderate	   increase	   in	   ddx3x	  
mRNA	   compared	   to	   a	   GAPDH	   mRNA-­‐targeting	   control,	   siGAPDH	   (30%;	   p	   <0.05),	   suggesting	   a	  
degree	  of	  TGA	  (see	  1.4.4).	  This	  was	  not	  investigated	  further	  as	  the	  aim	  of	  this	  study	  was	  to	  silence	  
HDF	  expression	  with	  the	  ultimate	  goal	  of	  inhibiting	  HIV-­‐1	  replication.	  
	  
	  
Figure	  4.4:	  Promoter-­‐targeting	  siRNAs	  can	  suppress	  htatsf1	  mRNA	  levels.	  A.	  siRNAs	  targeting	  sequences	  in	  the	  htatsf1	  
promoter	  were	  screened	  in	  HEK293T	  cells	  for	  their	  ability	  to	  decrease	  levels	  of	  target	  mRNA	  in	  triplicate.	  Expression	  of	  
htatsf1	  mRNA	  is	  reported	  relative	  to	  actb	  mRNA	  and	  normalised	  to	  the	  negative	  control	  siGAPDH.	  shH1	  was	  included	  as	  
a	  positive	  control	   for	  htatsf1	  suppression	  and	  normalised	   to	   the	  mock	  plasmid	  pTZU6+1.	  qRT-­‐PCR	  was	  performed	  on	  
total	  RNA	  extracted	  72	  hours	  post-­‐transfection.	  B.	  As	   (A)	  but	   siRNAs	   targeted	   sequences	   in	   the	  ddx3x	   promoter	  and	  
ddx3x	   expression	   is	   reported.	   siD10	   was	   included	   as	   a	   positive	   control	   for	   ddx3x	   suppression	   	   *,	   p	   <0.05,	   one-­‐way	  
ANOVA	  with	  Dunnett	  post-­‐tests	  relative	  to	  siGAPDH/pTZU6.	  
	  
siH15,	   siH16	   and	   siH17	   significantly	   decreased	   htatsf1	   mRNA	   levels	   72	   hours	   post-­‐
transfection	   compared	   to	   the	   control	   siRNA	   by	   up	   to	   35%	   (p	   <0.05;	   Figure	   4.4A).	   However,	   as	  
demonstrated	  by	  the	  positive	  controls	  used	  for	  target	  gene	  silencing	  (ie	  shH1	  and	  siD10),	  qRT-­‐PCR	  
to	  discern	  mRNA	  levels	  in	  total	  RNA	  extracts	  is	  not	  discriminatory	  between	  PTGS	  and	  TGS.	  
	  
4.3.2	  siH15-­‐mediated	  htatsf1	  silencing	  is	  attenuated	  by	  TSA	  in	  HEK293T	  cells	  
	  
Classical	   TGS	   is	   accompanied	   by	   epigenetic	   changes	   at	   the	   target	   site	   associated	   with	  
silent-­‐state	  chromatin,	  including	  methylation	  of	  histone	  residues	  such	  as	  H3K27	  and	  H3K9	  (Ting	  et	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al.	  2005).	  During	  TGS	  induction,	  acetyl	  groups,	  which	  on	  histone	  residues	  such	  as	  H3K27	  and	  H3K9	  
are	   associated	   with	   active	   transcription,	   require	   removal	   by	   histone	   deacetylases	   to	   allow	   for	  
subsequent	  methylation.	   Consequently,	   classical	   TGS	   induction	  may	   be	   sensitive	   to	   the	   histone	  
deacetylase	  inhibitor	  TSA.	  
TSR-­‐targeting	   siRNA-­‐mediated	   suppression	   of	   htatsf1	   mRNA	   levels	   was	   attenuated	   by	  
treatment	  with	  50	  nM	  TSA	   in	  HEK293T	   cells	   (Figure	  4.5A).	   Silencing	  mediated	  by	   shH1	  was	  not	  
affected	  by	  TSA	  treatment	  in	  both	  HEK293T	  and	  TZM-­‐bl	  cells	  (Figure	  4.5A	  and	  B),	  consistent	  with	  a	  
mRNA-­‐targeted	  PTGS	  mechanism.	  Despite	  using	   twice	   the	   concentration	  of	   TSA,	   attenuation	   of	  
siH15-­‐mediated	   silencing	   was	   not	   observed	   in	   TZM-­‐bl	   cells	   (Figure	   4.5B).	   Similarly,	   the	   siH21-­‐
mediated	  increase	  in	  htatsf1	  levels	  was	  enhanced	  by	  TSA	  treatment	  in	  HEK293T	  (Figure	  4.5A),	  but	  
not	  in	  TZM-­‐bl	  (Figure	  4.5B),	  cells.	  Although	  it	  is	  possible	  that	  an	  even	  higher	  concentration	  of	  TSA	  
was	   needed	   to	   see	   an	   effect	   in	   TZM-­‐bl	   cells,	   this	   data	   suggests	   that	   both	   promoter-­‐targeted	  
siRNA-­‐induced	  suppression	  and	  activation	  of	  gene	  expression	   in	  HEK293T,	  and	  not	  TZM-­‐bl,	   cells	  
involves	  chromatin	  remodelling.	  
	  
	  
Figure	  4.5:	  Promoter-­‐targeting	  siRNA-­‐mediated	  silencing	  is	  sensitive	  to	  TSA	  in	  HEK293T	  cells.	  A.	  HEK293T	  cells	  were	  
transfected	  with	  siRNAs	  and	  24	  hours	  later	  media	  was	  replaced	  with	  either	  fresh	  media	  or	  media	  containing	  50	  nM	  TSA	  
in	  triplicate.	  qRT-­‐PCR	  was	  performed	  on	  total	  RNA	  extracted	  72	  hours	  post-­‐transfection.	  B.	  As	  (A)	  but	  using	  TZM-­‐bl	  cells	  
that	  were	  treated	  with	  100	  nM	  TSA.	  *,	  p	  <0.05,	  two-­‐way	  ANOVA	  with	  Bonferroni	  post-­‐tests.	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4.3.3	  Bidirectional	  promoter-­‐associated	  transcripts	  are	  present	  at	  the	  siH15	  target	  site	  
	  
Since	  promoter-­‐associated	  transcripts	  are	  required	  for	  TGS	  (Han	  et	  al.	  2007;	  Gonzalez	  et	  
al.	  2008;	  Schwartz	  et	  al.	  2008;	  Hawkins	  et	  al.	  2009;	  Tan	  et	  al.	  2009b;	  Yue	  et	  al.	  2010),	  whether	  
there	  was	  a	  difference	  in	  target	  region-­‐associated	  transcript	  levels	  between	  the	  two	  cell	  lines	  was	  
investigated.	  As	  the	  most	  active	  TSS	  was	  unknown,	  transcript	  levels	  associated	  with	  two	  different	  
regions,	  within	  and	  upstream	  of	  the	  htatsf1	  TSR,	  were	  examined	  (Figure	  4.6A).	  
	  
	  
Figure	   4.6:	   Transcription	   is	   detectable	   across	   the	   TSR	   but	   not	   upstream	   of	   the	   FANTOM	   TSS.	  A.	   Schematic	   of	   the	  
htatsf1	  promoter	  showing	  the	  regions	  analysed	  for	  transcription.	  Primers	  were	  designed	  to	  amplify	  transcripts	  present	  
upstream	  of,	  and	  within,	  the	  TSR.	  B.	  qRT-­‐PCR	  was	  performed	  on	  total	  RNA	  extracted	  from	  both	  HEK293T	  and	  TZM-­‐bl	  
cells	  in	  quadruplicate.	  Primers	  designed	  to	  amplify	  different	  regions	  of	  the	  htatsf1	  promoter	  were	  used.	  Primers	  specific	  
to	  a	  region	  in	  the	  htatsf1	  mRNA	  coding	  region	  were	  also	  included	  (amplicon	  171	  bp).	  C.	  Following	  qPCR,	  samples	  were	  
resolved	  on	  an	  agarose	  gel.	  Representative	  samples	  from	  HEK293T	  cells	  are	  shown.	  
	  
No	  transcripts	  were	  detectable	  by	  qPCR	  upstream	  of	  the	  TSR	  in	  either	  HEK239T	  or	  TZM-­‐bl	  
cells	  (Figure	  4.6B	  &	  C).	  Transcripts	  associated	  with	  a	  region	  within	  the	  TSR	  were	  detected	  in	  both	  
cell	  lines	  (Figure	  4.6	  B	  &	  C),	  albeit	  100-­‐fold	  less	  abundant	  than	  mRNAs	  (Figure	  4.6B).	  There	  was	  no	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significant	  difference	  in	  the	  levels	  of	  mRNA	  and	  TSR-­‐associated	  transcripts	  between	  the	  HEK293T	  
and	   TZM-­‐bl	   cell	   lines.	   The	   100-­‐fold	   difference	   between	   mRNA	   and	   TSR-­‐associated	   transcript	  
suggests	  that	  the	  latter	  may	  be	  a	  low-­‐copy,	  promoter-­‐associated,	  non-­‐coding	  transcript.	  
The	   orientation	   of	   the	   TSR-­‐associated	   transcripts	  was	   investigated;	   directional	   RT	   cDNA	  
products	   were	   subject	   to	   qPCR	   using	   both	  mRNA	   and	   TSR	   primers.	   Again,	   similar	   results	   were	  
obtained	  for	  both	  cell	  lines	  (Figure	  4.7A).	  
	  
	  
Figure	   4.7:	   Sense	   and	   antisense	   transcription	   is	   detectable	  within	   the	   TSR.	  A.	   Total	   RNA	  was	   extracted	   from	   both	  
HEK293T	  and	  TZM-­‐bl	  cells	  and	  subject	  to	  directional	  reverse	  transcription	  using	  a	  strand-­‐specific	  primer	  complementary	  
to	   sequences	   in	   either	   the	   TSR	   or	   coding	   region.	   The	   resulting	   cDNA	  was	   quantified	   by	   real-­‐time	   PCR.	  B.	   Schematic	  
illustrating	  the	  data	  in	  (A).	  
	  
Not	   surprisingly,	   transcripts	   associated	  with	  a	   coding	   region	  were	  predominantly	   sense,	  
with	  antisense	  transcripts	  barely	  detectable.	  Both	  sense	  and	  antisense	  TSR-­‐associated	  transcripts	  
were	   detectable	   and	   at	   similar	   levels	   (Figure	   4.7A),	   which	   may	   be	   a	   product	   of	   divergent	  
transcription	   initiation	   (Core	   et	   al.	   2008).	   This	   would	   also	   account	   for	   the	   observation	   that	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antisense	  transcripts	  at	  the	  TSR	  were	  higher	  than	  that	  observed	  at	  the	  mRNA-­‐associated	  region.	  
As	  expected,	  no	  TSR	  sense	  transcripts	  were	  detected	  with	  mRNA	  qPCR	  primers	  as	  the	  directional	  
RT	  employed	   the	  TSR	   reverse	  primer.	   Similarly,	  no	  mRNA	  antisense	   transcripts	  were	  detectable	  
with	  the	  TSR	  qPCR	  primers	  as	  the	  directional	  RT	  used	  the	  mRNA	  forward	  primer.	  Of	  note	  is	  that	  no	  
mRNA	  sense	  transcripts	  were	  detectable	  with	  the	  TSR	  qPCR	  primers,	  which	  suggests	  that	  the	  bulk	  
of	  htatsf1	  mRNAs	   are	   initiated	   downstream	   of	   the	   TSR	   amplicon	   in	   both	   cell	   lines.	   Conversely,	  
low-­‐level	   antisense	   TSR-­‐associated	   transcripts	  were	  detectable	  with	   the	  mRNA	  qPCR	  primers	   in	  
HEK293T	  cells,	  suggesting	  that	  ~1/10th	  of	  these	  antisense	  transcripts	  are	  initiated	  downstream	  of	  
the	  mRNA	  amplicon	  and,	   therefore,	   individual	   antisense	   transcripts	  may	   span	   the	  entire	   coding	  
and	  promoter	  regions	  of	  the	  htatsf1	  gene	  (Figure	  4.7B).	  
Together,	  this	  data	  suggests	  that	  both	  sense	  and	  antisense	  TSR-­‐associated	  transcripts	  are	  
present	  in	  HEK293T	  and	  TZM-­‐bl	  cells	  at	  similar	  levels.	  Based	  on	  a	  comparison	  with	  htatsf1	  mRNA	  
levels	   and	   directional	   RT-­‐PCR,	   it	   appears	   the	   sense	   TSR-­‐associated	   transcripts	   are	   not	   coding	  
transcripts.	  This	  supports	  that	  siH15	  is	  targeting	  a	  promoter-­‐associated	  transcript.	  
	  
4.3.4	  Ago1	  and	  Ago2	  suppression	  does	  not	  attenuate	  siH15-­‐mediated	  htatsf1	  silencing	  
	  
Whilst	  Ago2	  is	  unequivocally	  involved	  in	  siRNA-­‐mediated	  PTGS	  (Meister	  et	  al.	  2004),	  both	  
Ago1	  and	  Ago2	  have	  been	  implicated	  in	  TGS	  (Janowski	  et	  al.	  2006;	  Kim	  et	  al.	  2006;	  Gonzalez	  et	  al.	  
2008;	  Hawkins	  et	  al.	  2009;	  Tan	  et	  al.	  2009b;	  Turner	  et	  al.	  2009;	  Chu	  et	  al.	  2010).	  Therefore,	  the	  
relative	  roles	  of	  Ago1	  and	  Ago2	  in	  siRNA-­‐mediated	  modulation	  of	  htatsf1	  mRNA	  expression	  were	  
investigated.	  
Firstly,	   the	  ability	  of	   the	  SMARTpools	   to	  suppress	   target	  Ago	  expression	  was	  verified.	   In	  
both	  HEK293T	  and	  TZM-­‐bl	  cells,	  Ago1	  and	  Ago2	  mRNA	  levels	  were	  decreased	  by	  at	  least	  60%	  48	  
hours	   following	   transfection	   with	   the	   respective	   SMARTpool	   compared	   with	   a	   non-­‐specific	  
SMARTpool	  control	  (p	  <0.001;	  Figure	  4.8).	  Having	  confirmed	  that	  the	  SMARTpools	  were	  effective	  
in	  decreasing	  Ago	  mRNA	  expression,	  cells	  were	  first	  transfected	  with	  a	  SMARTpool	  and	  24	  hours	  
later,	  transfected	  again	  with	  either	  the	  control,	  siGAPDH,	  or	  siH15	  or	  siH21,	  which	  suppress	  and	  
increase	   htatsf1	   mRNA	   levels,	   respectively	   (Figure	   4.4A).	   Seventy-­‐two	   hours	   post-­‐siRNA	  
transfection	  (and	  96	  hours	  post-­‐SMARTpool	  transfection),	  total	  RNA	  was	  extracted	  and	  subject	  to	  
qRT-­‐PCR.	  No	   attenuation	  of	   siH15-­‐mediated	   effects	  was	   seen	  on	   suppression	  of	   either	  Ago1	  or	  
Ago2	   in	   both	   cell	   lines	   (Figure	   4.9A).	   There	  was	   attenuation	   of	   the	   siH21-­‐mediated	   increase	   in	  
htatsf1	  mRNA	  on	  suppression	  of	  Ago2,	  although	  this	  was	  not	  statistically	  significant.	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Figure	  4.8:	   SMARTpools	  effectively	   suppress	  Ago	  expression.	   Both	  HEK293T	  and	  TZM-­‐bl	   cells	  were	   transfected	  with	  
SMARTpools	  targeting	  either	  Ago1	  or	  Ago2,	  or	  a	  SMARTpool	  containing	  non-­‐specific	  siRNAs	  as	  a	  control,	   in	  triplicate.	  





Figure	  4.9:	  Ago	  suppression	  has	  no	  significant	  effect	  on	  siRNA-­‐mediated	  silencing.	  A.	  Both	  HEK293T	  and	  TZM-­‐bl	  cells	  
were	  transfected	  with	  SMARTpools	  targeting	  either	  Ago1	  or	  Ago2	  or	  a	  SMARTpool	  containing	  non-­‐specific	  siRNAs	  as	  a	  
control.	   24	   hours	   later,	   cells	   were	   again	   transfected	   with	   promoter-­‐targeting	   or	   control	   siRNAs	   in	   triplicate.	   htatf1	  
mRNA	  levels	  were	  assessed	  relative	  to	  actb	  by	  qRT-­‐PCR	  on	  RNA	  extracted	  96	  hours	  post-­‐SMARTpool	  transfection.	  B.	  As	  
(A),	  but	  showing	  levels	  of	  Argonaute	  mRNA	  levels	  in	  cells	  transfected	  with	  siGAPDH.	  *,	  p	  <0.05,	  two-­‐way	  ANOVA	  with	  
Bonferroni	  post-­‐tests.	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The	   lack	   of	   significant	   attenuation	   of	   siH15	   or	   siH21	   effects	  may	   be	   due	   to	   insufficient	  
suppression	   of	   Ago	   expression,	   which	   is	   difficult	   to	   determine	   without	   Western	   blot	   data.	  
Nonetheless,	  SMARTpool	  efficacy	  in	  the	  samples	  was	  confirmed	  and,	  although	  the	  suppression	  of	  
Ago1	  and	  Ago2	  mRNA	  was	  not	  as	  pronounced	  as	  that	  observed	  48	  hours	  post-­‐transfection	  (Figure	  
4.8),	   there	   was	   still	   considerable	   reduction	   in	   levels	   at	   96	   hours	   post-­‐transfection	   (p	   <0.001;	  
Figure	   4.9B).	   Moreover,	   the	   observed	   suppression	   of	   Ago	   mRNA	   levels	   is	   greater	   than	   that	  
attained	   in	   previous	   experiments	   using	   anti-­‐Ago	   siRNAs	   (A2.2.6;	   Figure	   A2.5B),	   which	   was	  
sufficient	   to	   significantly	   attenuate	   siRNA-­‐mediated	   PTGS	   of	   psip1	   (Figure	   A2.5A).	   Therefore,	  
together	  with	  this	  data,	  it	  seems	  Ago1	  and	  Ago2	  have	  redundant	  roles	  in	  siH15-­‐mediated	  silencing	  
or	   the	   silencing	   is	  Ago1-­‐	  and	  Ago2-­‐independent,	  perhaps	  with	  another	  Ago	  protein	   involved	   (ie	  
Ago3	  or	  Ago4).	  The	  lack	  of	  attenuation	  of	  siH15-­‐mediated	  silencing	  on	  Ago2	  suppression	  does	  not	  
support	  a	  PTGS	  mechanism.	  To	   clarify	  whether	   this	   is	   the	   case,	   transcription	   rates	  of	  htatsf1	   in	  
siRNA-­‐treated	  cells	  were	  quantified.	  	  
	  
4.3.5	  Promoter-­‐targeted	  siRNAs	  modulate	  the	  htatsf1	  transcription	  rate	  	  
	  
A	   nuclear	   run-­‐on	   experiment	   may	   discriminate	   between	   silencing	   by	   PTGS	   and	   TGS	  
mechanisms	  as	  it	  quantifies	  the	  transcription	  rate	  of	  a	  specific	  transcript.	  With	  PTGS,	  the	  levels	  of	  
target	   mRNA	   are	   decreased	   but	   the	   rate	   of	   transcription	   is	   unaffected.	  With	   TGS,	   both	   target	  
mRNA	  and	  transcription	  rate	  is	  suppressed.	  
Transcription	  rates	  were	  examined	  in	  HEK239T	  cells	  treated	  with	  shH1,	  known	  to	  reduce	  
htatsf1	  mRNA	  by	  PTGS,	  and	  a	  shRNA	  control,	  shHBVx,	  as	  well	  as	  the	  htatsf1	  promoter-­‐targeting	  
siRNAs	  and	  the	  siRNA	  control,	  siGAPDH.	  As	  expected,	  the	  htatsf1	  transcription	  rate	  in	  cells	  treated	  
with	   shH1	   was	   unaltered	   (Figure	   4.10).	   In	   contrast,	   a	   significant	   decrease	   (57%;	   p	   <0.01)	   and	  
increase	   (41%;	  p	   <	  0.01)	   in	   transcription	   rates	   from	  siH15-­‐	  and	  siH21-­‐treated	  cells,	   respectively,	  
were	   observed.	   This	   suggests	   that	   siH15	   and	   siH21	   are	   modulating	   htatsf1	   expression	   at	   the	  
transcriptional	  level	  in	  HEK293T	  cells.	  Unfortunately,	  inefficient	  in	  vitro	  transcription	  from	  TZM-­‐bl	  
nuclei	  did	  not	  enable	  a	  similar	  analysis	  in	  this	  cell	  line.	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Figure	  4.10:	  Promoter-­‐targeting	  siRNAs	  may	  alter	  htatsf1	  transcription	  rates.	  A	  nuclear	  run-­‐on	  assay	  was	  performed	  
on	  samples	  72	  hours	  post-­‐transfection	  with	  promoter-­‐targeting	  siRNAs.	  Transfection	  with	  shH1,	  which	  silences	  HTATSF1	  
expression	   via	   a	   PTGS	   mechanism,	   was	   included	   as	   a	   control.	   Transcription	   rates	   relative	   to	   that	   of	   actb	   were	  
normalised	  to	  the	  appropriate	  negative	  control.	  Results	  from	  two	  independent	  experiments	  are	  shown.	  *,	  p	  <0.05,	  one-­‐
way	  ANOVA	  with	  Dunnett	  post-­‐tests	  relative	  to	  shHBVx/siGAPDH.	  
	  
4.3.6	  siH15-­‐mediated	  HTATSF1	  suppression	  inhibits	  HIV-­‐1	  infectious	  particle	  production	  
	  
Having	   demonstrated	   that	   siRNA-­‐induced	   TGS	   of	   htatsf1	   is	   possible	   in	   HEK293T	   cells,	  
whether	  this	  mode	  of	  silencing	  is	  sufficiently	  potent	  to	  inhibit	  subtype	  B	  molecular	  clone	  p81A-­‐4	  
infectious	  particle	  production	  from	  TZM-­‐bl	  cells	  was	  assessed.	  Tat-­‐induced	  luciferase	  activity	  was	  
significantly	  reduced	  in	  TZM-­‐bl	  cells	  infected	  with	  culture	  media	  collected	  from	  cells	  treated	  with	  
siH15	   (84%,	   p	   <	   0.01;	   Figure	   4.10).	   As	   observed	   previously	   (Figure	   2.14),	   shH1	   also	   inhibits	  
infectious	   particle	   production	   (59%,	  p	   <	   0.01;	   Figure	   4.11).	   No	   significant	   increase	   in	   infectious	  
particle	  production	  was	  observed	  in	  cells	  treated	  with	  siH21,	  suggesting	  that	  physiological	   levels	  
of	  HTATSF1	   are	   not	   limiting	   for	   virus	   production.	   siRNAs	   targeted	   to	   the	  htatsf1	   promoter	   are,	  




Figure	   4.11:	   Promoter-­‐targeting	   siRNAs	   can	   decrease	   p81A-­‐4	   infectious	   particle	   production.	   TZM-­‐bl	   cells	   were	  
transfected	  with	  either	  promoter-­‐targeting	  siRNAs	  or	  a	  mRNA-­‐targeting	  shRNA	  and	  appropriate	  controls	  in	  triplicate.	  24	  
hours	  later,	  cells	  were	  infected	  with	  p81A-­‐4	  at	  a	  TCID50	  of	  1000/ml.	  48	  hours	  later,	  virus-­‐containing	  culture	  supernatant	  
was	  used	  to	   infect	  additional	  untransfected	  TZM-­‐bl	  cells	  and	  Tat-­‐induced	   luciferase	  activity	  quantified	  48	  hours	  post-­‐
infection.	  *,	  p	  <0.05,	  one-­‐way	  ANOVA	  with	  Dunnett	  post-­‐tests	  relative	  to	  shHBVx/siGAPDH.	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4.4	  Discussion	  
	  
The	  approach	  used	  here	  was	   to	   screen	   siRNAs	   targeting	   regions	  within	  and	  proximal	   to	  
the	  TSRs	  of	  htatsf1	  and	  ddx3x	  for	  TGS	  and	  examine	  whether	  silencing	  by	  this	  mechanism	  would	  be	  
sufficient	   to	   inhibit	   HIV-­‐1	   replication.	   This	   study	   shows	   that,	   whilst	   not	   all	   promoter-­‐targeting	  
siRNAs	  mediated	  silencing	  of	  their	  targets,	  there	  is	  some	  evidence,	  including	  promoter-­‐transcript	  
levels	  and	  orientation,	  sensitivity	  of	  silencing	  to	  TSA	  and	  decreased	  transcription	  rates,	  that	  siH15	  
induces	  TGS	  of	  htatsf1	  in	  HEK293T	  cells.	  
It	   is	  unclear	  why	  some	  of	   the	  promoter-­‐targeting	   siRNAs	   led	   to	  decreased	   target	  mRNA	  
levels	   whilst	   others	   did	   not.	   siD10	  mediated	   PTGS	   of	   ddx3x	   (Figures	   4.4	   &	   A2.9)	   whilst	   siRNAs	  
targeting	   nearby	   sites	   had	   no	   effect.	   For	   those	   targeting	   htatsf1,	   siH15-­‐17	   which	   suppressed	  
mRNA	  levels	  to	  the	  greatest	  extent	  were	  all	  clustered	  <100	  bp	  downstream	  of	  the	  FANTOM4	  TSS	  
and	  >200	  bp	  upstream	  of	   the	  RefSeq	   TSS.	  Whether	   this	   region	   is	   good	   to	   target	   because	  of	   its	  
location	  with	  respect	  to	  other	  promoter	  features	  and	  the	  TSS	  is	  unknown,	  in	  part	  because	  5’	  RACE	  
data	  to	  confirm	  the	  TSS	  was	  not	  obtained.	  The	  FANTOM4	  TSS	  may	  not	  be	  the	  most	  active	  TSS	  in	  
HEK293T	   or	   TZM-­‐bl	   cells,	   particularly	   as	   neither	   of	   these	   cell	   lines	   (or	   tissues	   from	  which	   they	  
were	  derived)	  were	  among	  the	  56	  human	  CAGE	  libraries	  used	  in	  TSR	  determination	  (Balwierz	  et	  
al.	  2009).	  
The	  reason	  siH15-­‐17	  mediated	  the	  greatest	  htatsf1	  inhibition	  may	  have	  been	  unrelated	  to	  
target	  location	  with	  respect	  to	  promoter	  features.	  The	  GC	  content	  of	  these	  three	  target	  sites	  were	  
the	  only	  ones	  within	  the	  htatsf1	  promoter	  <55%	  (Table	  4.2).	  This	  may	  be	  significant	  as	  it	  has	  been	  
suggested	  that	  siRNAs	  with	  low	  GC	  content	  (30-­‐50%)	  are	  more	  active	  in	  inducing	  PTGS	  than	  those	  
with	  high	  GC	  content	   (Ambion’s	   siRNA	   target	   finder,	  TX,	  USA).	   If	   this	  holds	   true	   for	  TGS,	   it	  may	  
prove	  difficult	  to	  design	  many	  promoter-­‐targeting	  siRNAs	  per	  gene	  because	  most	  promoters	  are	  
GC-­‐rich	  (Kim	  et	  al.	  2005;	  Balwierz	  et	  al.	  2009).	  
At	  present,	  only	  one	  study	  has	  examined	  where	  in	  the	  promoter	  to	  target	  in	  any	  depth.	  A	  
series	  of	  overlapping	  siRNAs	  were	  designed	  to	  target	  the	  open	  complex	  region	  revealing	  that	  the	  
resulting	  TI	  was	  extremely	  sensitive	  to	  single	  base	  shifts	  (Janowski	  et	  al.	  2005).	  The	  sensitivity	  was	  
attributed	   to	   the	   accessibility	   of	   the	   target	   to	   the	   guide	   strand.	   Less	   is	   known	   about	  where	   to	  
target	   in	   a	   promoter	   to	   obtain	   classical	   TGS.	   Some	   studies	   have	   used	   pools	   of	   siRNAs,	   and	   so	  
provide	   little	   information	   as	   to	   what	   constitutes	   a	   good	   target	   site	   (Pulukuri	   and	   Rao	   2007;	  
Gonzalez	  et	  al.	  2008).	  Most	  have	   focused	  on	  sequences	  up	   to	  200	  bp	  of	   the	  predicted	  TSS.	  The	  
rationale	  being	   that	   this	   is	  most	   likely	   to	   correspond	   to	   the	  nucleosome-­‐depleted	   region	   (NDR)	  
and,	  therefore,	  the	  best	  place	  to	  focus	  chromatin	  remodelling.	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In	   contrast,	   Gonzalez	  et	   al	  demonstrated	   TGS	   of	   four	   genes	   by	  miR-­‐17-­‐5p	   and	  miR-­‐20a	  
with	  the	  majority	  of	  target	  sites	  residing	  >1	  kb	  upstream	  of	  the	  RefSeq	  TSS	  (Gonzalez	  et	  al.	  2008).	  
The	  same	  article	  also	  reported	  that	  exogenous	  siRNAs	  could	  induce	  TGS	  of	  the	  INK4b-­‐ARF-­‐INK4a	  
locus	   by	   targeting	   the	   well-­‐known	   regulatory	   domain	   >1	   kb	   upstream.	   Thus,	   similarly	   to	   TGA	  
(Matilainen	   et	   al.	   2010),	   TGS	   may	   be	   induced	   by	   targeting	   distant	   regions.	   Furthermore,	  
regulatory	   elements	  may	   be	   important	   in	   choosing	   target	   sites	   and,	   thus,	   the	   optimal	   distance	  
from	  the	  TSS	  could	  vary	  substantially	  between	  genes.	  
In	  this	  study,	  the	  only	  regulatory	  elements	  mapped	  were	  TFBS.	  Different	  outcomes	  have	  
been	  reported	  following	  TFBS	  targeting:	  Janowski	  et	  al	  observed	  that	  siRNAs	  spanning	  Sp1	  binding	  
sites	  were	  better	  inducers	  of	  TI	  (Janowski	  et	  al.	  2006).	  In	  this	  case,	  blocking	  the	  TF	  binding	  site	  did	  
not	   result	   in	   chromatin	   remodelling,	  which	   is	   desirable	   to	   attain	   long-­‐term	   silencing.	   However,	  
other	  studies	  have	  designed	  guide	  strands	  to	  span	  transcription	  factor	  binding	  sites	  that	  did	  result	  
in	   heterochromatin	   formation	   (Murayama	   et	   al.	   2006;	   Suzuki	   et	   al.	   2008;	   Turner	   et	   al.	   2009;	  
Yamagishi	  et	  al.	  2009;	  Palanichamy	  et	  al.	  2010).	  In	  this	  study,	  TFBS	  were	  avoided	  where	  possible	  
to	  minimise	   the	  possibility	   of	   inducing	   a	   temporary	   TGS	  without	   epigenetic	   changes.	   siH13	   and	  
siH17	  did	  partially	  overlap	  TFBS,	  although	  these	  siRNAs	  did	  not	  significantly	  inhibit	  htatsf1	  mRNA	  
levels.	   This	   could	   be	   due	   to	   a	   number	   of	   reasons,	   including	   the	   generic,	   such	   as	   the	  
thermodynamics	   of	   the	   siRNAs	   and	   the	   accessibility	   of	   the	   target	   transcript.	   In	   addition,	   it	   is	  
unknown	   whether	   these	   regulatory	   elements	   are	   active	   in	   the	   cell	   lines	   used	   and	   whether	  
blocking	  of	  a	  single	  TFBS	  would	  have	  an	  effect	  given	  that	  such	  transcription	  factors	  may	  act	   in	  a	  
redundant	  or	  coordinate	  fashion.	  
To	   date,	   insufficient	   data	   on	  negative	   target	   sites	   is	   available	   to	   enable	   a	   bioinformatic	  
analysis	   on	  what	  makes	   a	   good	   TGS	   target	   site.	   Although	   algorithms	   designed	   to	   predict	   PTGS	  
target	  sites	  are	  often	  used,	  these	  algorithms	  do	  not	  take	  into	  account	  the	  context	  of	  the	  sequence	  
within	  the	  promoter	  architecture.	  
TGA	  of	  ddx3x	   and	  htatsf1	  was	  observed	  with	   siD10	  and	  siH21,	   respectively	   (Figure	  4.4).	  
Further	   investigation	  of	   the	  effects	  of	   siH21	   revealed	   increased	   transcription	   rates	   (Figure	  4.10)	  
and	   an	   attenuation	   of	   htatsf1	   activation	   on	   suppression	   of	   Ago2	   expression	   (Figure	   4.9).	   It	   is	  
possible	   that	   an	   Ago2-­‐containing	   RITS	   complex	   directly	   modulates	   chromatin	   architecture	   to	  
enhance	   transcription.	   Details	   of	   how	   this	   would	   occur	   are	   unclear,	   although	   it	   has	   been	  
suggested	   that	   such	   a	   mechanism	   involves	   targeting	   of	   antisense	   transcripts	   (Schwartz	   et	   al.	  
2008).	   In	  contrast,	   there	  have	  been	  reports	  where	  promoter-­‐targeted	  siRNAs	  have	   induced	  TGA	  
through	   unintended	   PTGS	   of	   an	   antisense	   transcript	  with	   regulatory	   function,	  mediated	   by	   the	  
passenger	   strand	   of	   the	   siRNA	   (Morris	   et	   al.	   2008).	   The	   feasibility	   of	   such	   a	   mechanism	   is	  
supported	  by	   reports	   that	   both	   strands	  of	   a	   siRNA	  duplex	   are	   equally	   eligible	   for	   incorporation	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into	   Ago2-­‐containing	   RISC	   in	   HEK293	   cells	   (Wei	   et	   al.	   2009).	   In	   addition,	   long,	   non-­‐coding	  
antisense	   transcripts	   have	   been	   described	   as	   endogenous	   TGS	   effectors	   (Hawkins	   and	   Morris	  
2010).	   Despite	   the	   bulk	   of	   reported	   evidence	   describing	   an	   indirect	   TGA	   mechanism,	   both	  
mechanisms	  are	   feasible	  with	   the	  data	  here,	  as	  antisense	   transcripts	  were	   identified	  above	  and	  
below	   the	   siH21	   target	   site	   and	   a	   proportion	   were	   likely	   spanning	   the	   coding	   and	   promoter	  
regions	   (Figure	   4.7).	   Alternatively,	   TGA	   may	   result	   if	   the	   siRNA	   simply	   blocked	   binding	   of	   a	  
transcriptional	   repressor	   or	   enhanced	   the	   association	   of	   RNA	  Pol	   II	   through	   stabilisation	   of	   the	  
open	   complex.	   Discrimination	   between	   potential	   TGA	   mechanisms	   would	   be	   facilitated	   by	  
examination	   of	   whether	   antisense	   cleavage	   products	   were	   generated	   and	   whether	   the	  
endogenous	  antisense	  transcripts	  subdued	  htatsf1	  transcription.	  
The	  presence	  of	  transcripts	  at	  the	  TSR	  and	  antisense	  transcripts	  at	  the	  coding	  region	  may	  
be	   a	   result	   of	   pervasive	   transcription	   (Kapranov	   et	   al.	   2002;	   Bertone	   et	   al.	   2004;	   Kampa	   et	   al.	  
2004;	  Schadt	  et	  al.	  2004;	  Carninci	  et	  al.	  2005;	  Cheng	  et	  al.	  2005;	  Carninci	  et	  al.	  2006;	  Birney	  et	  al.	  
2007;	  Kapranov	  et	  al.	  2007a;	  Kapranov	  et	  al.	  2007b;	  van	  Bakel	  et	  al.	  2010).	  However,	  the	  greater	  
abundance	  of	  antisense	  transcripts	  at	  the	  TSR	  over	  the	  coding	  region	  is	  not	  consistent	  with	  simply	  
‘background	   transcription’.	   What	   may	   account	   for	   this	   observation	   is	   that	   CpG	   islands	   are	  
associated	   with	   bidirectional	   promoter	   activity	   (Trinklein	   et	   al.	   2004;	   Core	   et	   al.	   2008),	   and	  
widespread	  divergent	  initiation,	  though	  not	  accompanied	  by	  productive	  elongation	  upstream,	  has	  
been	  described	  at	  human	  promoters	  (Core	  et	  al.	  2008).	  
Several	  lines	  of	  evidence	  support	  siH15-­‐induced	  TGS	  at	  the	  htatsf1	  promoter	  in	  HEK293T	  
cells:	   mRNA	   levels	   and	   transcription	   rates	   were	   decreased,	   target	   region-­‐associated	   sense	  
transcripts	  were	  less	  abundant	  than	  coding	  region	  transcripts	  and	  did	  not	  span	  the	  TSR	  and	  coding	  
regions	  and	  silencing	  was	  sensitive	  to	  TSA	  (Figure	  4.5A).	  No	  attenuation	  of	  siH15-­‐mediated	  htatsf1	  
silencing	  was	  observed	  on	  suppression	  of	  Ago1	  or	  Ago2.	  This	  may	  reflect	  redundancy	  in	  the	  role	  
of	  Ago	  proteins	  in	  TGS	  at	  the	  htatsf1	  promoter,	  which	  has	  been	  reported	  at	  other	  genes,	  including	  
pgr	   (Janowski	   et	   al.	   2006)	   and	   hoxd4	   (Tan	   et	   al.	   2009b).	   Admittedly,	   TSA	   sensitivity	   is	   not	  
definitive	  of	  TGS	  as	  the	  target	  gene	  may	  be	  more	  susceptible	  to	  a	  TSA-­‐induced	  increase	  in	  basal	  
transcription	  than	  the	  reference	  gene,	  in	  this	  case	  actb.	  Nonetheless,	  a	  mechanism	  of	  TGS	  for	  the	  
observed	  silencing	  of	  htatsf1	   is	  consistent	  with	  the	  data	  presented	  here.	   It	  cannot	  be	  ruled	  out,	  
however,	   that	   silencing	   is	   occurring	   by	   negative	   feedback	   of	   the	   siRNA	   on	   another	   gene	   that	  
affects	   transcription	   of	   htatsf1,	   or	   by	   interfering	   in	   cis	   with	   another	   RNA	   associated	   with	   the	  
transcription	   of	   htatsf1.	   Further	   experiments	   are	   required	   to	   clarify	   the	   mechanism,	   perhaps	  
looking	   at	   chromatin	   signatures	  using	  ChIP	  analysis,	   including	   those	  associated	  with	   silent-­‐state	  
chromatin	  eg	  H3K27me3,	  and	  ncRNAs	  eg	  H3K39me3.	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siH15-­‐mediated	  htatsf1	  silencing	  inhibited	  p81A-­‐4	  infectious	  particle	  production	  in	  TZM-­‐bl	  
cells	  (Figure	  4.11),	  although	  whether	  by	  a	  TGS	  mechanism	  is	  less	  clear.	  No	  sensitivity	  to	  TSA	  was	  
observed	  in	  this	  cell	   line	  (Figure	  4.5B).	  On	  the	  other	  hand,	   levels	  of	  transcripts	  at	  the	  target	  site	  
were	   similar	   to	   those	   seen	   in	  HEK293T	  cells	   (Figures	  4.6	  and	  4.7),	   supporting	   the	   targeting	  of	  a	  
non-­‐coding	  promoter-­‐associated	  transcript.	  Unfortunately,	  nuclear	  run-­‐on	  data	  was	  not	  obtained	  
to	   clarify	   how	   transcription	   rates	  were	   affected.	   Regardless,	   the	   aim	  of	   this	   study	  was	   to	   show	  
that	   a	   HDF	   could	   be	   silenced	   at	   the	   transcriptional	   level	   with	   siRNAs,	   and	   this	   objective	   was	  
achieved	   in	   HEK293T	   cells.	   	   As	   already	   discussed,	   TSS	   and	   promoter	   usage	  may	   vary	   between	  
tissues	  and	  so	  confirming	  TGS	  in	  TZM-­‐bl	  cells	  would	  not	  further	  the	  ultimate	  goal	  of	  inducing	  TGS	  
in	  a	  physiological	  substrate	  of	  HIV,	  such	  as	  T	  cells.	  To	  this	  end,	  it	  would	  be	  advantageous	  to	  screen	  
siRNAs	  in	  T	  cells.	  However,	  not	  only	  is	  this	  complicated	  by	  the	  technical	  difficulties	  associated	  with	  
electroporation	  of	  siRNAs	  or	  retroviral-­‐transduction	  of	  shRNAs	  into	  cells,	  but	  also	  by	  the	  potential	  
for	   TSS	   and	   promoter	   usage	   variation	   with	   T	   cell	   activation.	   At	   present,	   therefore,	   the	   best	  
approach	  for	  the	  induction	  of	  TGS	  at	  a	  HDF	  is	  still	  to	  identify	  candidate	  target	  sites	  by	  studies	  in	  
easy-­‐to-­‐transfect	  cells,	  such	  as	  HEK293Ts.	  Appropriate	   inducible	  shRNA	  expression	  cassettes	  can	  
then	  be	   stably	   introduced	   into	  HIV-­‐1-­‐infectable	   cell	   lines	   and	   studied	   for	   their	   ability	   to	   induce	  
TGS	  at	  a	  number	  of	  conditions.	  Time	  course	  ChIP	  experiments	  could	  then	  be	  used	  to	  quantify	  the	  
duration	  of	  the	  induced	  TGS	  and	  how	  this	  impacts	  HIV-­‐1	  replication	  kinetics.	  
In	   summary,	   induction	   of	   TGS	   at	   a	   HDF	   as	   an	   anti-­‐HIV	   strategy	   is	   complicated	   by	   the	  
difficulty	   in	   screening	   siRNAs	   in	   T	   cells	   and	   the	   variation	   in	   TSS	   and	   promoter	   usage	   between	  
tissues.	  Experiments	  can	  be	  performed,	  however,	  to	  confirm	  the	  susceptibility	  of	  a	  gene	  to	  TGS	  in	  
an	  easy-­‐to-­‐transfect	  cell	  line,	  such	  as	  HEK293T	  cells.	  Here,	  the	  HDF	  HTATSF1	  was	  transcriptionally	  
silenced	  by	  a	  siRNA	  targeted	  to	  the	  TSR,	  which	  was	  described	  by	  the	  FANOM4	  project.	  Treatment	  
with	  the	  TSR-­‐targeted	  siRNA	  mediated	  sufficient	  silencing	  of	  HTATSF1	  to	  inhibit	  HIV-­‐1	  replication.	  
Therefore,	  TGS	  at	  HDFs	  may	  provide	  a	  promising	  anti-­‐HIV-­‐1	  strategy.	  
The	   approach	   used	   here	   may	   be	   used	   to	   confirm	   that	   certain	   genes	   are	   capable	   of	  
undergoing	   TGS	   before	   proceeding	   to	   a	   more	   time-­‐consuming	   screen	   in	   T	   cells.	   TGS	   was	   not	  
induced	  at	  ddx3x	  and,	  whilst	  this	  may	  be	  a	  result	  of	  failing	  to	  identify	  the	  appropriate	  target	  site,	  
it	  is	  also	  conceivable	  that	  the	  promoters	  of	  some	  genes	  may	  not	  undergo	  RNA-­‐directed	  chromatin	  
remodelling.	   Since	   screening	   for	   target	   suppression	   with	   promoter-­‐targeted	   siRNAs	   is	   time	  
consuming,	   whether	   certain	   promoter	   features	   are	   associated	   with	   TGS	   susceptibility	   was	  
investigated	  in	  Chapter	  5.	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CHAPTER	  5	  
Promoter	  features	  associated	  with	  susceptibility	  to	  small	  RNA-­‐induced	  




TGS	   offers	   great	   therapeutic	   potential	   (see	   1.4),	   particularly	   as	   there	   are	   a	   number	   of	  
advantages	   to	   TGS	   over	   PTGS:	   TGS	   may	   be	   sustained	   in	   the	   absence	   of	   the	   small	   RNA	   that	  
initialises	  the	  TGS	  (Hawkins	  et	  al.	  2009);	  and,	  TGS	  targets	  promoters	  that	  are	  limited	  in	  number	  (ie	  
2	  copies	  per	  cell),	  whereas	  there	  may	  be	  many	  hundred	  mRNAs	  that	  are	  targeted	  by	  PTGS.	  Thus,	  
TGS	  may	  prove	   a	  more	   potent	   silencing	   strategy	   than	   PTGS,	   reducing	   toxicities	   associated	  with	  
RNAi	  saturation	  and	  off-­‐target	  effects.	  The	  work	  in	  Chapter	  4	  provided	  proof	  of	  concept	  that	  TGS	  
at	  HDFs	  may	   inhibit	  HIV-­‐1	   replication,	   through	   targeting	  htatsf1.	  However,	   TGS	  may	  be	   applied	  
not	  just	  to	  the	  silencing	  of	  HDFs	  to	  combat	  HIV-­‐1,	  but	  in	  other	  diseases	  such	  as	  cancer	  and	  those	  
characterised	  by	  dysregulated	  chromatin.	  Despite	  the	  enormous	  potential	  of	  TGS-­‐based	  therapy,	  
few	   genes	   have	   been	   reported	   as	   regulated	   by	   small	   RNAs	   at	   the	   transcriptional	   level.	   It	   is,	  
therefore,	  currently	  unknown	  whether	  all	  human	  gene	  promoters	  are	  susceptible	  to	  therapeutic	  
transcriptional	  regulation	  in	  a	  small	  RNA-­‐inducible	  manner.	  
Promoter	   architecture	   is	   important	   for	   selection	   of	   TGS	   target	   genes.	   Gonzalez	   et	   al	  
searched	  for	  genes	  significantly	  down-­‐regulated	  in	  two	  different	  colon	  cancer	  cell	  lines	  on	  miR-­‐17-­‐
5p	  and	  miR-­‐20a	  expression	  and	  with	  a	  canonical	  seed-­‐match	  hexamer	  in	  the	  forward	  strand	  of	  the	  
promoter	  regions	  (Gonzalez	  et	  al.	  2008).	  Of	  the	  104	  genes	  fulfilling	  this	  criteria,	  they	  focused	  on	  
five	   genes	   at	   random,	   only	   four	   of	   which	   were	   susceptible	   to	   TGS	   upon	   introduction	   of	   pre-­‐
miRNAs	  or	  miRNA	  mimics	   (Gonzalez	   et	  al.	  2008;	   Iida	   et	  al.	  2008).	  Furthermore,	   in	  yeast,	   siRNA-­‐
initiated	   silencing	  was	  observed	  at	  only	  a	   subset	  of	   target	   loci,	  which	   correlated	  with	  antisense	  
transcription	   and	   over-­‐expression	   of	   Swi6,	   the	   yeast	   homologue	   of	   HP1	   (Iida	   et	   al.	   2008).	  
Consequently,	   the	   target	   sequence	   alone	   is	   not	   sufficient	   for	   TGS	   and	   other	   promoter	  
characteristics	  are	  required	  for	  a	  TGS-­‐permissive	  state.	  	  
Studying	   genes	   with	   contrasting	   promoter	   architectures	   may	   inform	   which	   promoter	  
characteristics	   confer	   enhanced	   susceptibility	   to	   TGS.	   Cairns	   has	   suggested	   that	   some	   yeast	  
promoters	   show	  extreme	   contrasts	   in	   architecture,	   classed	   as	   ‘open’	   or	   ‘covered’	   (Cairns	   2009)	  
(Figure	  5.1).	  Open	  promoters	  are	  typically	  TATA-­‐less	  and	  associated	  with	  constitutively	  expressed	  
genes.	  They	  are	  characterised	  by	  large	  (~150	  bp)	  nucleosome-­‐depleted	  regions	  (NDRs)	  containing	  
poly(dA:T)	   tracts	   that	   deter	   nucleosome	   formation	   (Struhl	   1985),	   maintaining	   exposure	   of	   cis-­‐
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regulatory	  elements.	   In	  contrast,	  covered	  promoter	  cis-­‐regulatory	  elements	  are	   fully	  or	  partially	  
hidden	   by	   nucleosomes	   when	   the	   genes	   are	   in	   their	   repressed	   state	   (Cairns	   2009).	   Covered	  
promoters	  are,	  therefore,	  more	  reliant	  on	  chromatin	  remodelling	  for	  activity	  and	  are	  associated	  
with	  highly	   regulated	  genes	   (Kawaji	  et	  al.	  2006a;	  Cairns	  2009).	  Of	  course,	   the	  majority	  of	  genes	  
possess	  promoters	  which	  are	  somewhere	  between	  these	  two	  extremes.	  
	  
	  
Figure	  5.1:	  Extreme	  contrasts	  in	  promoter	  architecture.	  ‘Open’	  promoters	  are	  associated	  with	  constitutively	  expressed	  
genes	   and	   fixed	   position-­‐nucleosomes	   composed	   of	   the	   H2A	   variant	   H2A.Z,	   which	   is	   associated	   with	   transcription	  
initiation.	  Such	  promoters	  typically	  contain	  broad	  NDRs	  but	  no	  TATA	  boxes.	  In	  contrast,	  ‘covered’	  promoters	  are	  more	  
reliant	  on	  chromatin	  remodelling	  for	  exposure	  of	  cis-­‐regulatory	  elements	  and	  activity.	  
	  
Mammalian	   promoters	   can	   also	   be	   classified	   into	   two	   types	   and,	   in	   this	   case,	   the	   two	  
groups	   include	   the	  majority.	   Using	   data	   from	   the	   FANTOM	  project	   (Kawaji	   et	   al.	   2006a;	   Cairns	  
2009;	   Kawaji	   et	   al.	   2009),	   promoters	   were	   classed	   based	   on	   their	   C	   or	   G	   (CG)	   and	   CpG	  
dinucleotide	  content	   (Balwierz	   et	  al.	  2009).	  Significantly,	  promoters	  of	   low	  CG	  and	  CpG	  content	  
were	  associated	  with	  narrow	  TSRs	  (<10	  bp)	  and	  high	  CG	  and	  CpG	  content	  with	  wide	  TSRs	  (25-­‐250	  
bp)	  (Balwierz	  et	  al.	  2009).	  Most	  importantly,	  more	  than	  91%	  of	  promoters	  had	  a	  high	  probability	  
of	  belonging	  to	  either	  the	  high-­‐	  or	   low-­‐CpG	  class.	  Thus,	  the	  method	  is	  suitable	  for	  unambiguous	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classification	  of	  human	  promoters	  into	  two	  classes	  and	  different	  mechanisms	  may	  be	  involved	  in	  
their	  regulation.	  
The	  two	  promoter	  classes	  are	  enriched	   in	  different	  core	  promoter	  elements,	  which	  may	  
contribute	   to	   their	   differential	   regulation	   and	   focus	   the	   TSS.	   TATA	   boxes	   were	   strongly	   over-­‐
represented	   in	   narrow	   TSR	   promoters,	   whereas	   consensus	   Sp1	   sites	   were	   over-­‐represented	   in	  
broad	  promoters	  (Carninci	  et	  al.	  2006).	  This	   is	  consistent	  with	  the	  ability	  of	  Sp1	  to	  recruit	  TATA-­‐
binding	   protein	   (TBP)	   in	   the	   absence	   of	   TATA	   boxes	   (Butler	   and	   Kadonaga	   2002).	   Clearly,	  
promoters	  can	  be	  classed	  based	  on	  their	  architectures,	  which	  may	  reflect	  differences	  in	  regulation	  
and	  transcriptional	  plasticity.	  	  
Since,	   chromatin	   modifications	   and	   nucleosome	   remodelling	   are	   required	   for	   classical	  
TGS,	  one	  could	  speculate	  that	  the	  two	  classes	  of	  human	  promoters	  are	  differentially	  susceptible	  
to	   TGS.	   One	   hypothesis	   is	   that	   genes	   with	   broad	   TSRs	   are	   less	   conducive	   to	   TGS	   because	   of	  
features	  within	  the	  promoter	  that	  deter	  nucleosome	  formation.	  Broad	  TSRs	  and	  CpG	  islands	  are	  
associated	   with	   ubiquitous	   transcripts	   (Carninci	   et	   al.	   2006)	   and	   it	   has	   been	   suggested	   that	  
promoters	  have	  an	  intrinsic	  tendency	  to	  exclude	  nucleosomes	  (Sandelin	  et	  al.	  2007).	  
A	  contrary	  hypothesis	  is	  that	  broad	  TSRs	  are	  more	  susceptible	  to	  TGS	  as	  it	  implies	  a	  large	  
NDR,	   which	   could	   favour	   the	   production	   of	   promoter-­‐associated	   transcripts	   (see	   1.4.2).	   CpG	  
islands	   are	   associated	   with	   bidirectional	   promoter	   activity	   (Trinklein	   et	   al.	   2004).	   Further,	  
divergent	   transcription	   and	  gene	  activity	   correlate	  with	  each	  other	   and	  promoters	   containing	   a	  
CpG	   island	   (Core	   et	   al.	   2008).	   Promoter-­‐associated	   transcript	   levels	   have	   also	   been	   shown	   to	  
correlate	   generally,	   though	   not	   exclusively,	   with	   gene	   expression	   (Seila	   et	   al.	   2008;	   Taft	   et	   al.	  
2009).	   These	   include	   tiRNAs,	   which	   are	   ~18	   nt	   long	   and	   preferentially	   associate	   with	   GC-­‐rich	  
promoters	  (Taft	  et	  al.	  2009).	  Recently,	  it	  was	  suggested	  that	  these	  tiRNAs	  play	  a	  role	  in	  epigenetic	  
regulation	  of	  gene	  expression	  (Taft	  et	  al.	  2010).	  
However,	   the	   complexities	   of	   transcriptional	   regulation	   and	   promoter	   architecture	  may	  
disprove	  both	  these	  simple	  hypotheses,	  particularly	  as	  broad	  TSRs	  do	  not	  always	  indicate	  single,	  
dispersed	  promoters	  with	   large	  NDRs,	  but	  also	  overlapping	  proximal	  promoters	  with	  tissue-­‐	  and	  
temporal-­‐specific	   expression	   (ie	   multiple	   TSCs	   within	   a	   TSR).	   Indeed,	   distinct	   TSS	   usage	   is	  
observed	   in	   different	   tissues	   within	   TSRs	   (Kawaji	   et	   al.	   2006a).	   Broad	   TSRs	   can,	   therefore,	   be	  
regions	  with	  “fuzzy”	  nucleosome	  architecture,	  with	  nucleosome	  position	  defining	  TSS	  usage	  (Jiang	  
and	  Pugh	  2009).	  Whether	   a	   gene	   is	   susceptible	   to	   TGS	  may	  depend,	   therefore,	   not	   just	   on	   the	  
length	  of	  the	  TSR,	  but	  also	  on	  the	  number	  of	  TSCs	  present	  within	  that	  TSR.	  
In	   short,	   it	   is	   unknown	   whether	   small	   RNAs	   are	   capable	   of	   directing	   de	   novo	  
heterochromatin	   formation	   at	   every	   gene	   promoter.	   This	   chapter	   examines	  whether	   particular	  
promoter	   features	  are	  enriched	   in	  genes	  at	  which	  TGS	  has	  been	   reported	  with	   the	  objective	  of	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facilitating	  prediction	  of	  TGS-­‐susceptible	  genes.	  Following	  a	  literature	  review	  to	  identify	  genes	  at	  
which	   TGS	   was	   induced,	   14	   gene	   promoters	   were	   analysed	   based	   on	   features	   within	   and	  
surrounding	  the	  associated	  TSRs,	  comprising	  TSR	  length	  and	  CpG	  class,	  presence	  of	  TBP-­‐	  and	  Sp1-­‐
binding	   sites,	   RNA	   Pol	   II,	   nucleosome	   and	   histone	   variant	  H2A.Z	   occupancy,	   ratio	   of	   RNA	   Pol	   II	  
occupancy	  in	  resting	  versus	  activated	  cells,	  the	  number	  of	  TSCs	  per	  TSR,	  the	  combined	  epigenetic	  
score	  (CES)	  and	  tiRNA	  and	  ncRNA	  presence.	  In	  addition,	   levels	  of	  19	  histone	  methylation	  and	  18	  
histone	   acetylation	  modifications	  were	   examined.	   In	   total,	   data	   on	   49	   promoter	   features	  were	  
retrieved,	   all	   from	   previously	   published,	   peer-­‐reviewed	   studies.	   Initially,	   the	   TGS	   group	   was	  
compared	  to	  a	   random	  set	  of	  2,000	  TSRs	  and	  then	  all	  other	  TSRs	   in	   the	  genome.	  To	  control	   for	  
gene	  activation,	  two	  further	  analyses	  were	  performed	  comparing	  the	  TGS	  group	  features	  to	  those	  
active	  in	  the	  THP-­‐1	  cell	  line,	  in	  which	  the	  FANTOM4	  data	  was	  obtained,	  and	  housekeeping	  genes.	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5.2	  Materials	  and	  methods	  
	  
5.2.1	  Selection	  of	  small	  RNA-­‐induced	  transcriptionally-­‐silenced	  genes	  and	  TSR	  assignment	  
	  
An	   extensive	   literature	   review	   was	   conducted	   to	   identify	   genes	   reportedly	  
transcriptionally	   silenced	   by	   promoter-­‐targeted	   small	   RNAs.	   Inclusion	   in	   the	   study	   as	   a	  
transcriptionally-­‐silenced	  gene	  required	  compliance	  with	  a	  number	  of	  criteria:	  
(a)	  Induced	  silencing	  in	  human	  cells	  (determined	  by	  qRT-­‐PCR	  and/or	  Western	  blot);	  
(b)	  RNA	  guide	  strand	  <30	  nt;	  
(c)	  Specific	  silencing	  (ie	  use	  of	  controls	  to	  show	  no	  off-­‐target	  silencing);	  
(d)	  Accompanied	  by	  epigenetic	  changes	   (DNA	  methylation	  and/or	  enrichment	   for	  silent-­‐
state	  histone	  modifications);	  and,	  
(e)	  5’	  end	  of	   the	   target	  site	  within	  1,500	  bp	  upstream	  and	  1,000	  bp	  downstream	  of	   the	  
RefSeq	  TSS;	  
(f)	  5’	  end	  of	  the	  target	  site	  within	  1,500	  bp	  upstream	  and	  200	  bp	  downstream	  of	  the	  most	  
active	  TSS	  of	  the	  assigned	  TSR	  (see	  below).	  
Application	  of	   this	  selection	  criteria	   resulted	   in	  a	   list	  of	  14	  genes	   (Table	  5.2)	   that	  composed	  the	  
transcriptional	  gene-­‐silenced	  (TGS)	  group.	  
Each	  gene	  within	  the	  TGS	  group	  was	  assigned	  a	  TSR:	  the	  TSR	  nearest	  the	  RefSeq	  TSS	  in	  the	  
same	  orientation	  as	  the	  gene	  was	  designated	  the	  TSR	  for	  that	  transcriptionally-­‐silenced	  gene.	  
	  
5.2.2	  Promoter	  feature	  data	  sources	  and	  quantification	  
	  
To	  assess	  whether	  particular	  promoter	  architectures	  are	  associated	  with	  susceptibility	  to	  
small	  RNA-­‐induced	  transcriptional	  gene	  silencing,	  different	  features	  of	  promoters	  were	  examined.	  
All	  analysis	  used	  the	  NCBI36/hg18	  (Mar	  2006)	  human	  genome	  (Lander	  et	  al.	  2001).	  
TSR	  data,	  including	  TSR	  length,	  CpG	  class	  and	  the	  number	  of	  TSCs	  per	  TSR	  (Balwierz	  et	  al.	  
2009),	  were	  obtained	   from	  FANTOM	  data	   (Kawaji	   et	  al.	   2006b;	  Kawaji	   et	  al.	   2009;	  Kawaji	   et	  al.	  
2010)	   downloaded	   from	   the	   SwissRegulon	   Portal	   (http://www.swissregulon.unibas.ch/cgi-­‐
bin/regulon?page=downloads)	   (Pachkov	   et	  al.	   2007).	  A	  Bayesian	  procedure	  was	  used	   to	   classify	  
each	  TSR	  as	  either	  high-­‐	  or	   low-­‐CpG	  class,	  based	  on	  both	  G	  or	  C	  and	  CpG	  dinucleotide	   content	  
(Balwierz	  et	  al.	  2009).	   In	   this	  study,	   those	  TSRs	  of	  high-­‐CpG	  class	  were	  scored	  one	  and	  those	  of	  
low-­‐CpG	  class	  scored	  zero.	  The	  number	  of	  TSRs	  analysed	  following	  subtraction	  of	  those	  belonging	  
to	  the	  TGS	  group	  were	  43,159.	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The	  most	  active	  TSS	  within	  a	  TSR,	  or	  representative	  TSS,	  was	  identified	  from	  the	  genome	  
location	  given	   in	   the	  TSR	   ID.	  The	  number	  of	  Sp1	  binding	   sites	  and	  TATA	  boxes	   (Table	  4.1)	  were	  
determined	   in	   a	   2,000	   bp	   window	   centred	   on	   the	   representative	   TSS	   of	   each	   TSR.	   Consensus	  
sequences	   were	   determined	   from	   the	   regulatory	   motif	   weight	   matrices	   available	   on	   the	  
SwissRegulon	   Portal	   (http://www.swissregulon.unibas.ch/cgi-­‐bin/regulon?page=downloads)	  
(Pachkov	  et	  al.	  2007).	  
Nucleosome	   and	   RNA	   Pol	   II	   occupancy	   data	   was	   obtained	   from	   human	   CD4+	   T	   cells	  
(http://dir.nhlbi.nih.gov/papers/lmi/epigenomes/hgtcellnucleosomes.aspx)	  (Schones	  et	  al.	  2008).	  
The	  average	  nucleosome	  and	  Ser5P-­‐Pol	  II	  occupancy	  within	  the	  representative	  TSS-­‐centred	  2,000	  
bp	  window	  was	  calculated	  based	  on	   the	  data	  obtained	   from	  cells	  activated	  with	  anti-­‐CD3	  and	   -­‐
CD28	  antibodies.	  The	   log	  of	  the	  activated:resting	  CD4+	  T	  cells	  Ser5P-­‐Pol	   II	   ratio	  within	  the	  same	  
window	  is	  also	  reported.	  
	  
Table	  5.1:	  Histone	  modifications	  quantified	  in	  a	  2000	  bp	  window	  centred	  on	  the	  representative	  TSS.	  
Histone	  methylations	   Histone	  acetylations	  
H2BK5me1	   H2AK5ac	  
H3K27me1	   H2AK9ac	  
H3K27me2	   H2BK120ac	  
H3K27me3	   H2BK12ac	  
H3K36me1	   H2BK20ac	  
H3K36me3	   H2BK5ac	  
H3K4me1	   H3K14ac	  
H3K4me2	   H3K18ac	  
H3K4me3	   H3K23ac	  
H3K79me1	   H3K27ac	  
H3K79me2	   H3K36ac	  
H3K79me3	   H3K4ac	  
H3K9me1	   H3K9ac	  
H3K9me2	   H4K12ac	  
H3K9me3	   H4K16ac	  
H3R2me1	   H4K4ac	  
H3R2me2	   H4K8ac	  
H4K20me1	   H4K91ac	  
H4K20me3	   	  
Histone	   (H)	   number	   is	   followed	   by	   either	   a	   lysine	   (K)	   or	   arginine	   (R)	   residue	   and,	   finally,	   the	   histone	  modification:	  
methylation	  (me),	  dimethylation	  (me2),	  trimethylation	  (me3)	  or	  acetylation	  (ac).	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By	   the	   same	   ChIP-­‐Seq	  method,	   data	   on	   histone	   variant	   H2A.Z	   occupancy	   (Barski	   et	   al.	  
2007)	  and	  the	  frequency	  of	  a	  number	  of	  histone	  modifications	  were	  obtained	  for	  human	  CD4+	  T	  
cells.	   The	   genome-­‐wide	   distribution	   of	   19	   arginine	   and	   lysine	   histone	  methylations	   (Table	   5.1)	  
(http://dir.nhlbi.nih.gov/papers/lmi/epigenomes/hgtcell.aspx)	   (Barski	   et	   al.	   2007)	   as	   well	   as	   18	  
histone	   acetylations	   (Table	   5.1)	  
(http://dir.nhlbi.nih.gov/papers/lmi/epigenomes/hgtcellacetylation.aspx)	   (Wang	   et	   al.	   2008),	  
were	   retrieved.	   The	  average	  number	  of	   reads	   in	   a	   representative	   TSS-­‐centred	  2000	  bp	  window	  
was	  calculated	  for	  each	  TSR.	  
CpG	   islands,	   genomic	   regions	   characterised	   by	   exceptionally	   high	   CpG	   dinucleotide	  
frequency,	   are	   known	   to	   associate	   with	   active	   promoters	   (Kim	   et	   al.	   2005).	   According	   to	   the	  
Gardiner-­‐Garden	  sequence	  criteria	   (Gardiner-­‐Garden	  and	  Frommer	  1987),	  a	  genomic	  region	  has	  
to	  fulfil	  three	  conditions	  to	  classify	  as	  a	  CpG	  island:	  (1)	  GC	  content	  >50%;	  (2)	  ratio	  of	  observed-­‐to-­‐
expected	  number	  of	  CpG	  dinucleotides	  above	  0.6;	  and,	  (3)	  length	  greater	  than	  200	  bp.	  However,	  
this	   sequence	   only-­‐based	   definition	   does	   not	   distinguish	   between	   CpG	   islands	   that	   function	   as	  
transcriptional	   regulators	   from	   those	   lacking	   characteristics	  of	  promoter	   activity.	   The	   combined	  
epigenetic	  score	  (CES),	  which	  predicts	  the	  likelihood	  of	  a	  CpG	  island	  being	  bona	  fide,	  summarises	  
the	   inherent	   tendency	   of	   a	   CpG	   island,	   across	   different	   cell	   types	   and	   tissues,	   to	   exhibit	   an	  
unmethylated,	  open	  and	  transcriptionally	  competent	  chromatin	  structure	  (Bock	  et	  al.	  2007).	  Thus,	  
this	  score	  facilitates	  discrimination	  between	  regions	  that	  are	  just	  CpG-­‐rich	  and	  those	  that	  exhibit	  
promoter	  activity.	  The	  CESs,	  which	  may	  be	  visualised	  as	  a	  CGI	  scoring	  track	  on	  the	  UCSC	  Genome	  
Browser	   (http://genome.ucsc.edu/)	   (Kent	   et	   al.	   2002),	   were	   downloaded	   (http://epigraph.mpi-­‐
inf.mpg.de/download/CpG_islands_revisited/)	   and	   included	   in	   the	   analysis	   where	   a	   CpG	   island	  
overlapped	  the	  TSR.	  A	  CES	  value	  of	  zero	  corresponds	  to	  a	  completely	  silenced,	  inactive	  and	  buried	  
CpG	   island,	  while	   a	   value	  of	   one	   corresponds	   to	   an	  unmethylated,	   highly	   accessible	   CpG	   island	  
with	  strong	  promoter	  activity.	  
Promoter-­‐associated	   transcripts	  have	  been	   implicated	   in	   small-­‐RNA	   transcriptional	   gene	  
silencing.	   Therefore,	   the	  occurrence	  of	  ncRNAs	  was	  examined	  at	   TSRs.	  Human	  ncRNA	  data	  was	  
retrieved	   from	   the	   Functional	   RNA	  Database	   (http://www.ncrna.org/frnadb/download)	   and	   the	  
frequency	  of	  ncRNAs	  within	  a	  TSR	  recorded.	  A	  ncRNA	  was	  scored	  as	  present	  even	  if	  the	  ncRNA	  did	  
not	  fall	  entirely	  within	  the	  2,000	  bp	  window	  centred	  on	  the	  representative	  TSS	  of	  a	  TSR,	  and	  vice	  
versa.	  In	  addition,	  the	  location	  of	  a	  ncRNA	  was	  not	  strand-­‐specific,	  such	  that	  ncRNAs	  antisense	  to	  
the	  TSR	  were	  also	  included.	  
A	  subset	  of	  ncRNAs,	   tiRNAs,	  was	  recently	  shown	  to	  colocalise	  to	  TSSs	  and	  splice	  sites	   in	  
metazoans	  (Taft	  et	  al.	  2009;	  Taft	  et	  al.	  2010).	  These	  ~18	  nucleotide	  RNAs	  where	  identified	  using	  
data	  obtained	  by	  the	  FANTOM4	  project	  (Kawaji	  et	  al.	  2009;	  Kawaji	  et	  al.	  2010),	  focusing	  on	  small	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RNAs	  (~15	  to	  ~40	  nucleotides)	   from	  undifferentiated	  human	  THP-­‐1	  cells	  and	  at	   four	  time	  points	  
(<96	   hours)	   after	   stimulation	   with	   phorbol	   12-­‐myristate	   13-­‐acetate	   (PMA)	  
(http://fantom.gsc.riken.jp/4/download/Supplemental_Materials/Taft_et_al_2009/)	   (Taft	   et	   al.	  
2009).	   Given	   the	   association	   of	   tiRNAs	   to	   TSSs,	   their	   frequency	   at	   2,000	   bp	   windows	  
encompassing	  TSRs	  was	  examined.	  
	  
5.2.3	  Assignment	  of	  TSRs	  to	  the	  THP-­‐1	  dataset	  
	  
The	   FANTOM4	   project	   included	   measurement	   of	   the	   expression	   level	   of	   ~2,400	   genes	  
using	  a	  Illumina	  Human-­‐6	  v2	  chip	  in	  THP-­‐1	  cells	  at	  various	  time	  points	  following	  stimulation	  with	  
PMA	  (Taft	  et	  al.	  2009).	  This	  expression	  data	  was	  deposited	  in	  the	  Center	  for	  Information	  Biology	  
Gene	   Expression	   Database	   (CIBEX),	   Accession	   CBX46	  
(http://cibex.nig.ac.jp/cibex2/ExperimentMiame.do?queryExperimentalDesignAccession=CBX46).	  
All	  genes	  were	  sorted	  by	  their	  measured	  expression	  levels	  at	  12	  hours	  post-­‐PMA	  stimulation.	  The	  
top	  25%	  were	  considered	  ‘active’	  and	  thus	  included	  in	  the	  THP-­‐1	  dataset.	  
Gene	  expression	  data	  was	  listed	  by	  gene	  symbol	  as	  an	  identifier.	  To	  map	  the	  set	  of	  genes	  
to	  a	  TSR,	  the	  gene	  symbols	  were	  first	  translated	  into	  RefSeq	  mRNA	  IDs.	  Coordinates	  of	  the	  RefSeq	  
mRNAs	  were	  then	  obtained	  for	  the	  human	  genome	  build	  NCBI36/hg18	  (Mar	  2006)	  from	  the	  UCSC	  
genome	   browser	   (http://genome.ucsc.edu/)	   (Kent	   et	   al.	   2002).	   Genes	   whose	   RefSeq	   TSS	  
overlapped	  a	  TSR	  were	  assigned	  that	  TSR.	  The	  result	  was	  a	  list	  of	  TSRs	  (the	  THP-­‐1	  dataset)	  with	  an	  
associated	  expression	  level	  (n	  =	  351).	  
	  
5.2.4	  Assignment	  of	  TSRs	  to	  the	  housekeeping	  gene	  dataset	  
	  
Housekeeping	   (HK)	   genes	   are	  defined	   as	   genes	   constitutively	   expressed	   in	   all	   tissues	   to	  
maintain	   essential	   cellular	   functions.	   Experimental	   determination	   of	   HK	   genes	   suffers	   from	   a	  
number	   of	   limitations	   and	   so	   HK	   genes	   have	   recently	   been	   identified	   based	   on	   physical	  
characteristics	  of	  gene	  length	  and	  chromatin	  compactness.	  The	  HK	  genes	  used	  in	  this	  study	  were	  
mined	   based	   on	   combining	   such	   characteristics	   to	   create	   a	   powerful	   Naïve	   Bayes	   classifier	   (De	  
Ferrari	  and	  Aitken	  2006).	  Each	  Ensemble	  transcript	  ID	  was	  assigned	  with	  a	  probability	  of	  being	  a	  
HK	  gene.	  These	  transcript	  IDs	  could	  be	  readily	  mapped	  to	  a	  TSS	  and	  thus,	  to	  a	  TSR	  where	  overlap	  
occurred.	  Only	  where	  the	  Naïve	  Bayes	  classifier	  was	  >90%	  confident	  was	  a	  gene	   included	   in	  the	  
HK	  dataset	  (n	  =	  737).	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5.2.5	  Classification	  of	  htatsf1	  and	  ddx3x	  promoter	  features	  
	  
To	   examine	   which	   group	   the	   promoter	   features	   of	   htatsf1	   and	   ddx3x	   more	   closely	  
resemble,	   representative	   feature	   vectors	   (RFV)	   were	   created	   for	   each	   group,	   namely	   TGS,	   all	  
other	  TSRs,	  THP-­‐1	  and	  HK	  genes.	  Briefly,	  the	  values	  for	  each	  feature	  within	  a	  group	  were	  averaged	  
to	   give	   a	   single	   feature	   vector	   for	   each	   group.	   For	   example,	   if	   a	   group	  was	   composed	  of	   three	  
TSRs/vectors	  and	  defined	  by	  four	  features,	  a	  RFV	  would	  be	  calculated	  as	  follows:	  
Vector/TSR	   Feature1	   Feature2	   Feature3	   Feature4	  
A	   	   5.0	   	   22.3	   	   4.4	   	   5.3	  
B	   	   6.6	   	   18.7	   	   3.3	   	   4.3	  
C	   	   7.4	   	   14.1	   	   0.8	   	   7.3	  
D	   	   2.3	   	   25.5	   	   0.9	   	   3.4	  
	  
RFV	   	   5.3	   	   20.2	   	   2.4	   	   5.1	  
The	   Euclidean	   distance	   of	   a	   given	   vector	   can	   then	   be	   calculated	   from	   the	   RFV.	   This	   involves	  
summing	   the	   squared	   difference	   between	   the	   given	   vector	   and	   the	   RFV	   and	   taking	   the	   square	  
root:	  
	   	   	   	   	   	   (5.1)	  
where	  X	  is	  an	  unknown	  vector,	  d	  is	  the	  Euclidean	  distance,	  n	  is	  the	  number	  of	  features	  and	  f	  is	  the	  
series	  of	  average	  feature	  values	  within	  the	  vector.	  Thus,	  the	  smaller	  the	  Euclidean	  distance,	  the	  
closer	  the	  given	  feature	  set	  is	  to	  the	  average	  feature	  set	  of	  a	  group.	  
	  
5.2.6	  Statistical	  analyses	  
	  
For	  each	  promoter	  feature,	  a	  set	  of	  values	  was	  obtained	  for	  each	  group.	  The	  median	  for	  
each	   distribution	  was	   calculated	   and	   plotted,	   along	  with	   standard	   deviations.	   TSR	   lengths	   (and	  
standard	  deviations)	  were	  scaled	  by	  0.1	  to	  enable	  the	  inclusion	  of	  all	  features	  on	  a	  single	  plot.	  A	  
Mann-­‐Whitney	  U	  test	  was	  performed	  to	  give	  the	  probability	  that	  the	  medians	  for	  the	  distributions	  
are	   the	   same.	   When	   that	   probability	   was	   small	   (p	   <0.05),	   the	   difference	   in	   the	   medians	   was	  
considered	  to	  be	  significant	  (*).	  The	  Benjamini	  and	  Hochberg	  correction	  was	  used	  to	  correct	  for	  
multiple	  testing.	  This	  correction	  converts	  p-­‐values	  to	  false	  discovery	  rates	  (fdr).	  A	  conservative	  fdr	  
threshold	  of	   0.05	  was	  used,	   thus	   features	  with	   a	   calculated	   fdr	   <0.05	  were	   considered	   to	   have	  
! 
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significantly	   different	   medians	   (*).	   A	   chi-­‐square	   test	   was	   used	   to	   compare	   fractions	   between	  
groups.	  
	  
5.2.7	  Statement	  on	  contributions	  
	  
The	   work	   in	   this	   chapter	   is	   the	   result	   of	   collaboration	   between	   Loren	   Hansen,	   a	   PhD	  
student	   supervised	   by	  Dr	  David	   Landsman,	   Computational	   Biology	   Research	   Branch,	  NCBI,	   NIH,	  
Bethesda,	  USA,	  and	  myself.	  The	  concept	  behind	  the	  project	   is	  entirely	  my	  own	  and	  I	  sourced	  all	  
the	   data	   used	   in	   the	   analyses.	   I	   conducted	   the	   literature	   review,	   compiled	   the	   TGS	   group	   and	  
assigned	   them	   TSRs.	   Loren	   contributed	   by	   writing	   the	   programs	   (using	   Perl	   script)	   needed	   to	  
retrieve	  the	   information	   I	   requested	   from	  the	  data	  sources	   I	  had	   identified.	  Loren	  also	  assigned	  
TSRs	  to	  both	  the	  THP-­‐1	  and	  HK	  gene	  datasets,	  calculated	  medians,	  RFVs	  and	  Euclidean	  distances	  
and	   performed	   the	   statistical	   tests.	   Loren	   also	   engaged	   in	   helpful	   discussions	   regarding	   the	  
interpretation	  of	  the	  data.	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5.3	  Results	  
	  
5.3.1	  Identification	  of	  small-­‐RNA	  induced	  transcriptionally-­‐silenced	  TSRs	  
	  
To	  address	  whether	  TGS-­‐susceptible	  genes	  have	  particular	  promoter	  characteristics,	  small	  
RNA-­‐induced	   transcriptionally-­‐silenced	   genes	   had	   first	   to	   be	   identified.	   A	   literature	   review	  was	  
conducted	  to	  identify	  all	  reports	  of	  mammalian	  TGS.	  Criteria	  were	  applied	  resulting	  in	  a	  list	  of	  14	  
genes	   that	  were	  used	   in	   the	   study	   as	   the	   transcriptional	   gene-­‐silenced	   (TGS)	   group	   (Table	  5.2).	  
The	  criteria,	  detailed	  in	  5.2.1,	  ensured	  that	  only	  human	  genes	  targeted	  by	  a	  guide	  strand	  less	  than	  
30	   nt	   long	   (eg	   siRNA,	   shRNA,	   miRNA),	   at	   the	   5’	   end	   near	   a	   TSR,	   resulting	   in	   specific	   silencing	  
accompanied	  by	  epigenetic	  changes,	  were	  included	  in	  the	  study.	  
Epigenetic	  changes	  at	   the	  target	  site	  were	   included	   in	  the	  selection	  criteria	  as	  the	  focus	  
was	  to	  identify	  promoter	  characteristics	  associated	  with	  classical	  TGS.	  TGS	  by	  this	  mechanism	  has	  
the	  potential	   for	   long-­‐term	   silencing	  providing	   silent-­‐state	   chromatin	   is	   achieved;	   an	   advantage	  
over	   PTGS	   as	   continual	   administration	   of	   the	   silencing	   small	   RNA	   is,	   therefore,	   unlikely	   to	   be	  
necessary.	   The	   long-­‐term	   silencing	   potential	   of	   TI	   has	   not	   yet	   been	   examined,	   and	   so	   notable	  
exceptions	   from	   the	   TGS	   group	   include	   c-­‐Myc	   (Entrez	   gene	   ID	   4609)	   (Napoli	   et	   al.	   2009).	  
Progesterone	  receptor	   (PGR)	  was	   included	  despite	   initial	   reports	  of	  silencing	  by	  a	  TI	  mechanism	  
unaccompanied	  by	  epigenetic	  changes	  (Janowski	  et	  al.	  2005;	  Janowski	  et	  al.	  2006;	  Janowski	  et	  al.	  
2007;	   Schwartz	   et	   al.	   2008;	   Chu	   et	   al.	   2010).	   This	   is	   due	   to	   the	   most	   recent	   report	   of	   PGR	  
transcriptional-­‐modulation	  showing	  enrichment	   for	  H3K27	   trimethylation	  at	   the	   target	   site	   (Yue	  
et	  al.	  2010).	  
This	  study	  uses	  the	  TSR	  as	  the	  basic	  identifier,	  because	  of	  its	  importance	  in	  classification	  
of	  different	  promoter	  classes	  (Balwierz	  et	  al.	  2009)	  and	  the	  large	  amount	  of	  data	  already	  analysed	  
for	   this	   feature.	   Therefore,	   two	   genes,	   CCR5	   (Entrez	   gene	   ID	   1234)	   (Kim	   et	   al.	   2006;	  Han	   et	   al.	  
2007)	  and	   interleukin-­‐2	   (IL2;	  Entrez	  gene	   ID	  3558)	   (Murayama	  et	  al.	  2006),	  were	  excluded	   from	  
the	  TGS	  group	  because	  no	  TSRs	  were	  present	  at	  the	  5’	  end	  of	  these	  genes.	  
Only	   genes	   transcriptionally-­‐silenced	   by	   small	   RNAs	   in	   human	   cells	   were	   included.	  
Therefore,	   despite	   convincing	   evidence	   for	   TGS,	   vascular	   endothelial	   growth	   factor	   (VEGF-­‐A)	  
(Turunen	  et	  al.	  2009)	  and	  transforming	  growth	   factor-­‐beta	  receptor	   II	   (TGFβII)	   (Kim	  et	  al.	  2007)	  
were	  excluded	  as	  silencing	  was	  only	  reported	  in	  mouse	  and	  rat	  cell	  lines,	  respectively.	  
The	   final	   TGS	  group	   is	   composed	  of	   genes	  with	  a	   range	  of	   functions	   found	  on	  different	  
chromosomes	   and	   silenced	   by	   different	   types	   of	   small	   RNAs	   in	   different	   cell	   lines	   (Table	   5.2).	  
These	  genes	  were	  assigned	  TSRs	  based	  on	  proximity	  to	  the	  5’	  end	  of	  the	  RefSeq	  gene.	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Table	  5.2:	  Transcriptionally-­‐silenced	  genes	  included	  in	  the	  study	  and	  the	  assigned	  TSRs.	  
Identifiers	   Target	   TSR	  assignment	   Reported	  context	  
Name	   Gene	   Transcript	   Locus	   nt	   Start	   End	   TSR	  ID	  
Target-­‐
TSS	  
Effector	   Cell	  line	   Evidence	   References	  
Eukaryotic	  translation	  
elongation	  factor	  1	  
alpha	  
1915	   NM_001402	   6q14.1(-­‐)	   21	   74287582	   74287562	  
TSR_hg18_v1_chr
6_-­‐_74287478	  
-­‐104	   si	   HEK293T	  
DNA	  me;	  
Histone	  me	  
(Morris	  et	  al.	  2004;	  
Weinberg	  et	  al.	  2006;	  
Han	  et	  al.	  2007)	  














(Ting	  et	  al.	  2005)	  
Ras	  association	  




3p21.3(-­‐)	   22	   50353327	   50353306	  
TSR_hg18_v1_chr
3_-­‐_50353286	  
-­‐41	   sh	   HeLa	  
DNA	  me;	  
Histone	  me	  
(Castanotto	  et	  al.	  
2005;	  Kim	  et	  al.	  2006)	  
Plasminogen	  
activator,	  urokinase	  















Si1	   PC3	  
DNA	  me;	  
Run-­‐on	  
(Pulukuri	  and	  Rao	  
2007)	  
Cyclin-­‐dependen	  






9p21(-­‐)	   19	   21984852	   21984834	  
TSR_hg18_v1_chr
9_-­‐_21964857	  
+5	   si	   HEK293T	   Histone	  me	   (Wang	  et	  al.	  2007)	  
Polymerase	  (RNA)	  III	  
polypeptide	  D	  
661	   NM_001722	   8q21(+)	   23	   22158432	   22158454	  
TSR_hg18_v1_chr
8_+_22158588	  
-­‐156	   mi	   HEK293T	  
Histone	  
me;	  Run-­‐on	  



















Si2	   HEK293T	   Histone	  me	   (Gonzalez	  et	  al.	  2008)	  
Tubulin	  folding	  
cofactor	  E-­‐like	  
219899	   NM_152715	   11q23.3(+)	   23	   120399096	   120399118	  
TSR_hg18_v1_chr
11_+_120400020	  
-­‐924	   mi	   HCT116	   Histone	  me	   (Gonzalez	  et	  al.	  2008)	  
Ras	  p21	  protein	  
activator	  2	  
5922	   NM_006506	  
3q22-­‐	  
3q23(+)	  
23	   142687289	   142687311	  
TSR_hg18_v1_chr
3_+_142688572	  













mi3	   HCT116	   Histone	  me	   (Gonzalez	  et	  al.	  2008)	  
Wolf-­‐Hirschhorn	  
















mi3	   HCT116	   Histone	  me	   (Gonzalez	  et	  al.	  2008)	  








(Hawkins	  et	  al.	  2009)	  
Homeobox	  D4	   3233	   NM_014621	   2q31.1(+)	   23	   176723303	   176723325	  
TSR_hg18_v1_chr
2_+_176724543	  







(Tan	  et	  al.	  2009a)	  
Progesterone	  
receptor	  
5241	   NM_000926	  
11q22-­‐	  
11q23(-­‐)	  
19	   100505763	   100505745	  
TSR_hg18_v1_chr
11_-­‐_100505741	  
-­‐22	   si	   T47D	   Histone	  me	   (Yue	  et	  al.	  2010)	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Fourteen	  transcriptionally-­‐silenced	  genes	  met	  the	  criteria	  for	  inclusion	  in	  the	  study	  and	  were,	  therefore,	  assigned	  TSRs	  
which	   composed	   the	   transcriptional	   gene-­‐silenced	   (TGS)	  group.	  Target-­‐TSS	  gives	   the	  nt	  distance	  of	   the	  5’	  end	  of	   the	  
target	   site(s)	   from	   the	   representative	   TSS	   of	   the	   assigned	   TSR.	   1Four	   siRNAs	   were	   pooled	   in	   all	   experiments.	  
2Transcriptional	  silencing	  of	  this	  gene	  also	  reported	  with	  an	  endogenous	  asRNA	  (Yu	  et	  al.	  2008).	  3Multiple	  target	  sites	  
for	  a	  single	  guide	  strand	  within	  the	  target	  promoter	  ie	  multiple	  miRNA	  seed	  sequence	  matches.	  
	  	  
5.3.2	   The	   TGS	   group	   are	   enriched	   for	   promoter	   features	   associated	  with	   active	   transcription	  
compared	  with	  2000	  random	  TSRs	  
	  
To	   examine	   whether	   promoter	   features	   conferred	   susceptibility	   to	   TGS,	   the	   promoter	  
features	   of	   the	   TGS	   group	   required	   comparison	   to	   a	   control	   group.	   Unfortunately,	   reports	   of	  
failed	  TGS	  induction	  do	  not	  exist.	  There	  is	  no	  incentive	  to	  publish	  ‘negative’	  data	  and	  it	  is	  difficult	  
to	   exclude	   the	   possibility	   that	   the	   appropriate	   target	   site	   within	   the	   promoter	   was	   not	   found.	  
Without	  a	  TGS-­‐negative	  control	  group,	  the	  TGS	  group	  (n	  =	  14)	  promoter	  features	  were	  examined	  
for	  enrichment	  compared	  to	  2,000	  random	  TSRs	  (n	  =	  2000).	  
TSRs	   within	   the	   TGS	   group	   were	   significantly	   longer	   and	   of	   a	   higher	   CpG	   class	   than	   the	   2,000	  
random	  TSRs	  (Figure	  5.2).	  There	  was	  also	  a	  higher	  CES	  in	  the	  TGS	  group	  and	  enrichment	  for	  Sp1	  
binding	   sites.	   Together	   this	   provides	   confirmation	   that	   the	   data	   retrieval	   and	   analysis	   was	  
functioning	   because	   broad	   TSRs	   are	   associated	   with	   high	   GC	   and	   CpG	   content	   (Balwierz	   et	   al.	  
2009)	  and	  so	  would	  be	  expected	  to	  also	  be	  associated	  with	  high	  CpG	  class,	  high	  CES	  scores	  (which	  
predict	   the	   probability	   of	   a	   bona	   fide	   CpG	   island)	   and	   increased	   Sp1	   binding	   sites,	   which	   have	  
previously	  been	  shown	  to	  be	  over-­‐represented	   in	  broad	  promoters	   (Carninci	  et	  al.	  2006).	  There	  
were	   significant	   enrichments	   for	   H3K4me3	   and	   H4K20me1	   in	   the	   TGS	   group	   (Figure	   5.2).	   In	  
contrast,	   levels	  of	  H3K27me1	  were	  significantly	  diminished.	   Increased	  H3K4me3	  and	  H4K20me1	  
and	  decreased	  H3K27me1	  is	  associated	  with	  active	  gene	  expression	  at	  human	  promoters	  (Wang	  
et	   al.	   2008).	   Concordant	   with	   this	   observation	   is	   that	   nucleosome	   occupancy	   was	   significantly	  
decreased	  in	  the	  TGS	  group	  compared	  with	  the	  2,000	  random	  TSRs	  (Figure	  5.2).	  The	  enrichment	  
for	  promoter	  features	  associated	  with	  active	  transcription	  in	  the	  TGS	  group	  is	  unsurprising	  given	  
that	  only	  expressed	  genes	  are	  targeted	  for	  TGS.	  Whether	  the	  TGS	  genes	  are	  active	  in	  the	  cell	  lines	  
and	  conditions	  that	  the	  promoter	  feature	  data	  was	  extracted	  from	  (eg	  THP-­‐1	  and	  CD4+	  T	  cells)	  is	  
unknown.	   However,	   given	   that	   the	   TGS	   genes	   are	   active	   in	   at	   least	   one	   cell	   line	   and	   seen	   as	  
potential	  therapeutic	  targets,	  it	  is	  a	  reasonable	  assumption	  that	  a	  higher	  fraction	  of	  TGS	  genes	  are	  
likely	  to	  be	  active	  in	  the	  cell	  lines	  and	  conditions	  under	  which	  the	  data	  is	  extracted	  compared	  to	  
2,000	  random	  TSRs.	  Other	  features	  associated	  with	  active	  transcription	  were	  increased	  in	  the	  TGS	  
group,	  although	  not	   significantly.	   These	   included	  H2A.Z	  occupancy,	   a	  histone	  variant	  associated	  
with	   the	   +1	   nucleosome	   at	   actively	   transcribed	   genes	   (Verdel	   et	   al.	   2004;	   Sarma	   and	   Reinberg	  
2005;	  Wang	  et	  al.	  2008),	  and	  the	  elongating	  form	  of	  RNA	  Pol	  II,	  Ser5P-­‐Pol	  II.	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Figure	  5.2:	  The	  transcriptionally-­‐silenced	  group	  promoter	  features	  compared	  with	  those	  of	  2000	  random	  TSRs.	  TSR	  lengths	  were	  multiplied	  by	  0.1.	  Feature	  values	  were	  determined	  for	  each	  
TSR	  or,	  where	  appropriate,	  within	  a	  2,000	  bp	  window	  centred	  on	  the	  representative	  TSS	  of	  each	  TSR.	  Error	  bars	  indicate	  standard	  deviations.	  TGS	  group	  n	  =	  14.	  *,	  p	  <0.05,	  Mann-­‐Whitney	  U	  
test.	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Figure	   5.3:	   The	   transcriptionally-­‐silenced	   group	   promoter	   features	   compared	  with	   those	   of	   2000	   random	   TSRs	   and	   corrected	   for	  multiple	   testing.	  TSR	   lengths	  were	  multiplied	   by	   0.1.	  
Feature	  values	  were	  determined	  for	  each	  TSR	  or,	  where	  appropriate,	  within	  a	  2,000	  bp	  window	  centred	  on	  the	  representative	  TSS	  of	  each	  TSR.	  TGS	  group	  n	  =	  14.	  Error	  bars	  indicate	  standard	  
deviations.	  *,	  fdr	  <0.05,	  Benjamini	  and	  Hochberg	  correction.	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Statistical	   significance	  was	   initially	   determined	   using	   a	  Mann-­‐Whitney	   U	   test	   (p	   <0.05).	  
However,	   this	   does	   not	   correct	   for	   multiple	   testing.	   Therefore,	   the	   Benjamini	   and	   Hochberg	  
correction	   was	   applied	   and	   statistical	   significance	   instead	   determined	   on	   the	   basis	   of	   false	  
discovery	  rates	   (fdr	  <0.05).	  Following	  fdr-­‐correction,	  none	  of	   the	  promoter	   features	  significantly	  
differ	  between	  the	  TGS	  group	  and	  the	  2,000	  random	  TSRs	  (Figure	  5.3).	  This	  is	  likely	  to	  be	  false	  as	  
correcting	   for	  multiple	   testing	  tends	  to	  be	  excessively	  conservative.	  Nevertheless,	  correcting	   for	  
multiple	   testing	   is	   better	   than	   not,	   and	   the	   remainder	   of	   the	   analyses	   were	   corrected	   in	   this	  
fashion.	  
	  
5.3.3	   The	   TGS	   group	   are	   enriched	   for	   promoter	   features	   associated	  with	   active	   transcription	  
compared	  with	  all	  other	  human	  TSRs	  
	  
Having	   demonstrated	   that	   the	   data	   extraction	   and	   analysis	   was	   working	   well,	   the	   TGS	  
group	   of	   TSRs	   (n	   =	   14)	   was	   compared	   to	   all	   other	   TSRs	   annotated	   in	   the	   human	   genome	   (n	   =	  
43,159;	  Figure	  5.4).	  As	  expected,	  the	  results	  closely	  mimicked	  those	  obtained	  when	  the	  TGS	  group	  
were	   compared	   to	  2,000	   random	  TSRs.	   In	  other	  words,	   there	  were	  no	   significant	  differences	   in	  
promoter	   features	   between	   the	   two	   groups	   following	   fdr-­‐correction.	   There	   was	   increased	   TSR	  
length,	  CpG	  class,	  CES	  score	  and	  Sp1-­‐binding	  sites	  in	  the	  TGS	  group	  and	  an	  enrichment	  of	  features	  
associated	   with	   active	   transcription,	   including	   increased	   H3K4me3,	   H4K20me1	   and	   H2A.Z	  
occupancy	  and	  decreased	  H3K27me1	  and	  nucleosome	  occupancy.	  
Using	   the	   same	   rationale	   described	   in	   5.3.2,	   it	   is	   not	   surprising	   to	   see	   enrichment	   for	  
features	  associated	  with	  active	  transcription	  in	  the	  TGS	  group	  compared	  to	  all	  other	  TSRs	  in	  the	  
human	  genome.	  However,	  this	  is	  not	  helpful	  in	  identifying	  promoter	  features	  associated	  with	  TGS	  
susceptibility.	  Therefore,	  the	  TGS	  group	  TSRs	  were	  compared	  to	  those	  active	  in	  the	  THP-­‐1	  cell	  line,	  
from	  which	  FANTOM4	  data	  was	  obtained.	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Figure	  5.4:	  The	  transcriptionally-­‐silenced	  group	  promoter	  features	  compared	  with	  all	  other	  TSRs.	  TSR	  lengths	  were	  multiplied	  by	  0.1.	  Feature	  values	  were	  determined	  for	  each	  TSR	  or,	  where	  
appropriate,	  within	   a	   2,000	  bp	  window	  centred	  on	   the	   representative	   TSS	  of	   each	  TSR.	   Error	  bars	   indicate	   standard	  deviations.	   TGS	  group	  n	   =	   14;	   all	   other	   TSRs	  n	   =	   43159.	   *,	   fdr	   <0.05,	  
Benjamini	  and	  Hochberg	  correction.	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5.3.4	   The	   TGS	   group	   show	   reduced	   TSR	   length	   and	   number	   of	   TSCs	   per	   TSR	   compared	   with	  
active	  TSRs	  in	  the	  THP-­‐1	  cell	  line	  
	  
THP-­‐1	  cells	  are	  a	  macrophage-­‐like	  cancer	  cell	  line	  used	  in	  the	  fourth	  stage	  of	  the	  FANTOM	  
project.	  Thus,	  FANTOM4-­‐derived	  data,	  such	  as	  the	  number	  of	  tiRNAs,	  were	  determined	  in	  this	  cell	  
line.	  Other	  FANTOM	  data,	  including	  TSR	  length,	  CpG	  class	  and	  the	  number	  of	  TSCs	  per	  TSR,	  were	  
designated	   on	   the	   basis	   of	   56	   human	   CAGE-­‐tag	   libraries	   from	   different	   tissues	   (Balwierz	   et	   al.	  
2009).	   However,	   18	   of	   these	   were	   from	   FANTOM4	   THP-­‐1	   samples,	   introducing	   a	   heavy	   bias	  
toward	   this	   cell	   line.	   To	   see	   if	   the	   same	  promoter	   features	  were	  enriched	  when	   the	  TGS	  group	  
TSRs	  were	  compared	  to	  only	  active	  TSRs,	  TSRs	  associated	  with	  expressed	  genes	  in	  the	  THP-­‐1	  cell	  
line	  were	   identified	  –	   from	  THP-­‐1	  microarray	  expression	  data,	   the	  top	  25%	  of	  expressed	  RefSeq	  
genes,	  12	  hours	  post-­‐PMA	  stimulation,	  with	  TSRs	  overlapping	  the	  RefSeq	  TSS	  were	  included	  (n	  =	  
351).	  
In	   contrast	   to	   the	   previous	   analyses,	   the	   TSR	   length	   of	   the	   TGS	   group	  was	   significantly	  
lower	  than	  the	  THP-­‐1	  group	  and	  the	  CpG	  class	  of	  both	  groups	  was	  similar	  (Figure	  5.5).	  There	  was	  
also	   little	  difference	   in	  CES	  between	  the	  two	  groups,	  although	  there	  were	  significantly	   less	  TSCs	  
per	  TSR	  in	  the	  TGS	  group	  compared	  with	  the	  THP-­‐1	  group.	  This	  suggests	  that	  genes	  active	  in	  the	  
THP-­‐1	  cell	   line	  have	  proximal	  alternate	  promoters,	  which	  may	  be	  used	  during	  different	  stages	  of	  
cell	  activation,	  as	  well	  as	  different	  tissues.	  Several	  overlapping	  TSCs	  may	  account	  for	  the	  increased	  
length	  in	  TSR	  observed	  in	  the	  THP-­‐1	  group.	  
Several	   histone	  modifications	   associated	  with	   active	   transcription	  were	   enriched	   in	   the	  
THP-­‐1	   group,	   namely	   H3K36me1,	   H3K4me2,	   H3K4me3,	   H3K79me1,	   H3K79me2,	   H3K79me3,	  
H2BK5ac,	  H3K27ac,	  H3K9ac,	  H4K8ac	  and	  H4K91ac	  (Figure	  5.5).	  In	  addition,	  the	  silent-­‐state	  histone	  
modification	  H3K27me3	  was	  enriched	  in	  the	  TGS	  group	  compared	  to	  the	  THP-­‐1	  group.	  In	  contrast,	  
the	  silent-­‐state	  histone	  modification	  H3K27me1	  was	  also	  enriched	  in	  the	  THP-­‐1	  group.	  However,	  
the	  proportion	  of	  TSRs	  in	  the	  THP-­‐1	  group	  are	  more	  likely	  to	  be	  associated	  with	  H3K27me1	  than	  
H3K27me2	   and	   H3K27me3,	   which	   are	   more	   strongly	   associated	   with	   gene	   silencing.	   Indeed,	  
H3K27me3	  is	  at	  a	  significantly	  lower	  level	  in	  the	  THP-­‐1	  group	  than	  the	  TGS	  group,	  and	  H3K27ac,	  
which	  is	  associated	  with	  active	  transcription,	  is	  at	  a	  higher	  level.	  On	  the	  whole,	  therefore,	  histone	  
modifications	  associated	  with	  active	  transcription	  are	  enriched	   in	   the	  THP-­‐1	  group	  compared	  to	  
the	   TGS	   group.	   Indeed,	   most	   of	   the	   acetylation	   modifications	   associated	   with	   active	   TSSs	  
(H2AK9ac,	  H2BK5ac,	  H3K18ac,	  H3K27ac,	  H3K36ac,	  H3K9ac	  and	  K4K91ac)	  (Wang	  et	  al.	  2008)	  were	  
significantly	   enriched	   in	   the	   THP-­‐1	   group,	   whilst	   those	   associated	   with	   promoters	   and	   actively	  
transcribed	   regions	   (H2BK120ac,	   H2BK20ac,	   H2BK12ac,	   H3K4ac,	   H4K12ac,	   H4K16ac,	   H4K5ac,	  
H4K8ac)	  (Wang	  et	  al.	  2008),	  though	  increased,	  were	  not	  enriched	  significantly,	  with	  the	  exception	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Figure	  5.5:	  The	  transcriptionally-­‐silenced	  group	  promoter	  features	  compared	  with	  TSRs	  assigned	  to	  genes	  expressed	  in	  THP-­‐1	  cells.	  TSR	  lengths	  were	  multiplied	  by	  0.1.	  Feature	  values	  were	  
determined	  for	  each	  TSR	  or,	  where	  appropriate,	  within	  a	  2,000	  bp	  window	  centred	  on	  the	  representative	  TSS	  of	  each	  TSR.	  Error	  bars	  indicate	  standard	  deviations.	  TGS	  group	  n	  =	  14;	  THP-­‐1	  
dataset	  n	  =	  351.	  *,	  fdr	  <0.05,	  Benjamini	  and	  Hochberg	  correction.	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of	  H4K8ac.	   In	  addition,	  methylation	  modifications	  associated	  with	  active	  promoters	  (H3K27me1,	  
H3K4me2,	  H3K4me3,	  H3K79me1,	  H3K79me2,	  H3K79me3,	  H3K9me1)	  (Wang	  et	  al.	  2008)	  were	  all	  
significantly	  enriched	  in	  the	  THP-­‐1	  group,	  with	  the	  exception	  of	  H3K9me1.	  This	  demonstrates	  that	  
assignment	   of	   the	   TSRs	   to	   the	   THP-­‐1	   dataset	   was	   successful,	   as	   active	   TSS-­‐associated	   features	  
would	  be	  expected	  to	  be	  over-­‐represented	  in	  the	  representative	  TSS-­‐focused	  windows	  used	  in	  the	  
analyses.	  Enrichment	  for	  histone	  modifications	  associated	  with	  active	  TSSs	  in	  the	  THP-­‐I	  group	  also	  
suggests	  that	  the	  majority	  of	  the	  top	  25%	  of	  expressed	  genes	  in	  THP-­‐1	  cells	  are	  also	  expressed	  in	  
CD4+	  T	  cells,	  the	  cell	  line	  from	  which	  the	  histone	  modification	  data	  was	  obtained.	  Using	  the	  THP-­‐1	  
dataset	   as	   a	   control	   for	   active	   genes,	   therefore,	   is	   reasonable,	   despite	   not	   all	   the	   promoter	  
feature	  data	  being	  acquired	  from	  these	  cells.	  
In	  contrast	  to	  the	  previous	  plots,	  the	  THP-­‐1	  promoter	  feature	  values	  are	  generally	  higher	  
than	  the	  TGS	  group,	  which	  again	  probably	  reflects	  the	  difference	  in	  the	  proportion	  of	  active	  genes	  
between	  these	  two	  groups.	  This	  makes	  it	  difficult	  to	  claim	  the	  differences	  seen	  are	  due	  to	  some	  
genes	  having	  the	  ability	  to	  be	  transcriptionally	  silenced	  while	  other	  genes	  are	  not.	  Some	  features	  
are	  less	  dependent	  on	  gene	  activity,	  ie	  TSR	  length,	  CpG	  class,	  TBP-­‐	  and	  Sp1-­‐binding	  sites,	  TSCs	  per	  
TSR,	  CES	  and	  tiRNA	  and	  ncRNA	  levels,	  although	  there	  presence/levels	  are	  still	  dependent	  on	  the	  
tissue/cell	   line(s)	   used	   in	   data	   acquisition.	   To	   examine	   whether	   differences	   exist	   in	   these	  
characteristics	  between	  the	  TGS	  group	  and	  active	  genes	  in	  all	  tissues,	  comparisons	  were	  made	  to	  
housekeeping	  gene-­‐associated	  TSRs.	  
	  
5.3.5	   The	   TGS	   group	   are	   enriched	   for	   promoter	   features	   associated	   with	   reduced	   activity	  
compared	  with	  housekeeping	  gene	  TSRs	  
	  
Housekeeping	   (HK)	   genes	   were	   used	   as	   a	   control	   group	   not	   just	   because	   by	   definition	  
they	   are	   expressed	   in	   all	   tissues,	   but	   also	   because	   they	   are	   a	   set	   of	   genes	  most	   unlikely	   to	   be	  
susceptible	  to	  TGS.	  This	  is	  because	  silencing	  them	  would	  likely	  result	  in	  cell	  death.	  HK	  genes	  were	  
identified	   based	   on	   a	   number	   of	   physical	   properties	   (De	   Ferrari	   and	   Aitken	   2006).	   Those	   that	  
could	  be	  assigned	  TSRs	  (where	  a	  TSR	  overlapped	  the	  5’	  end	  of	  the	  RefSeq	  gene)	  were	  included	  in	  
the	  HK	  gene	  group	  (n	  =	  737).	  
There	  was	  significant	  enrichment	  for	  the	  same	  histone	  modifications	  in	  the	  HK	  gene	  group	  
as	   the	   THP-­‐1	   group,	   plus	   additional	   histone	   modifications	   associated	   with	   active	   promoters	  
(Figure	   5.6).	   Again	   this	   may	   be	   attributable	   to	   differences	   in	   the	   proportion	   of	   active	   TSRs	  
between	  the	  groups.	  Although	  the	  proportion	  of	  active	  TSRs	  in	  the	  HK	  gene	  and	  THP-­‐1	  groups	  in	  
CD4+	  T	  cells	  are	  both	  expected	  to	  be	  close	  to	  100%,	  TGS	  group	  TSRs	  are	  more	  likely	  to	  be	  active	  in	  
the	  CD4+	  T	  cell	  line	  than	  constitutively	  active	  ie	  a	  HK	  gene.	  It	  is	  therefore	  unsurprising	  that	  there	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Figure	   5.6:	   The	   transcriptionally-­‐silenced	   group	   promoter	   features	   compared	   with	   TSRs	   assigned	   to	   housekeeping	   genes.	   TSR	   lengths	   were	   multiplied	   by	   0.1.	   Feature	   values	   were	  
determined	   for	   each	   TSR	   or,	   where	   appropriate,	   within	   a	   2,000	   bp	   window	   centred	   on	   the	   representative	   TSS	   of	   each	   TSR.	   Error	   bars	   indicate	   standard	   deviations.	   TGS	   group	   n	   =	   14;	  
housekeeing	  (HK)	  genes	  n	  =	  737.	  *,	  fdr	  <0.05,	  Benjamini	  and	  Hochberg	  correction.	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is	  a	  greater	  difference	  in	  active	  transcription-­‐associated	  promoter	  feature	  values	  between	  the	  HK	  
gene	  group	  and	  the	  TGS	  group	  than	  the	  THP-­‐1	  group	  and	  the	  TGS	  group.	  
With	  respect	  to	  promoter	  features	  less	  dependent	  of	  gene	  activity,	  the	  median	  TSR	  length	  
and	   TSC	   number	   per	   TSR	   were	   lower	   in	   the	   TGS	   group	   than	   the	   HK	   gene	   group	   (Figure	   5.6),	  
although	  not	  statistically	  significant	  as	  was	  the	  case	  with	  the	  THP-­‐1	  group	  (Figure	  5.5).	  
To	   summarise,	   the	   proportion	   of	   active	   genes	   within	   the	   respective	   groups	   dominates	  
differences	   in	   histone	   modifications	   and	   H2A.Z,	   nucleosome	   and	   RNA	   Pol	   II	   occupancy.	   Thus,	  
inspection	  of	  features	  independent	  of	  gene	  activation	  may	  prove	  more	  informative	  with	  respect	  
to	   identification	  of	  TGS-­‐associated	  promoter	   features.	  TGS	  group	  TSR	   length	   is	  greater	   than	   the	  
average	  in	  the	  genome	  but	  smaller	  than	  TSRs	  associated	  with	  HK	  genes	  or	  those	  active	  in	  the	  THP-­‐
1	  cell	  line.	  In	  addition,	  the	  bulk	  of	  TGS	  group	  TSRs	  contain	  only	  one	  TSC,	  which	  is	  the	  case	  for	  the	  
majority	  of	  TSRs	  in	  the	  genome,	  but	  not	  those	  in	  the	  THP-­‐1	  and	  HK	  gene	  groups.	  The	  number	  of	  
Sp1-­‐binding	  sites,	  TSR	  CpG	  class	  and	  CES	  for	  TGS	  group	  TSRs	  are	  greater	  than	  the	  average	  TSR	  but	  
similar	  to	  the	  THP-­‐1	  and	  HK	  gene	  groups.	  Together,	  this	  demonstrates	  that	  TGS	  susceptible	  genes	  
have	  broad,	  high	  CpG	  class	  TSRs	  containing	  bona	  fide	  CpG	  islands	  and	  Sp1-­‐binding	  sites.	  However,	  
the	  TSRs	  are	  not	  as	  broad	  as	  those	  comprised	  of	  multiple	  TSCs.	  This	  suggests	  that	  TGS-­‐susceptible	  
genes	   are	   characterised	   by	   broad	   TSRs	   with	   a	   single	   TSC,	   which	  may	   be	   indicative	   of	   a	   single,	  
broad	  NDR.	  
	  
5.3.6	  The	  fraction	  of	  TSRs	  with	  ncRNA	  overlap	  is	  greatest	  in	  the	  TGS	  group	  
	  
A	  hypothesis	  stated	  in	  5.1	  was	  that	  broad	  TSRs	  are	  more	  susceptible	  to	  TGS	  by	  favouring	  
production	  of	  promoter-­‐associated	   transcripts.	  Despite	  enrichment	   for	  broad	  TSRs	  with	  a	   single	  
TSC	   in	   the	   TGS	   group,	   none	   of	   the	   analyses	   revealed	   a	   significant	   enrichment	   in	   tiRNAs	   and	  
ncRNAs	   compared	   to	   control	   groups.	  Nevertheless,	   the	  median	  TGS	  group	   tiRNA	   level	   is	   higher	  
than	  controls	  throughout,	  despite	  the	  proportion	  of	  active	  genes	   in	  each	  control	  group	  differing	  
substantially.	  This	  suggests	  that	  factors	  besides	  gene	  activation	  determine	  tiRNA	  level.	  
The	  ncRNA	  median	  for	  all	  groups	  was	  close	  to	  zero.	  This	  was	  because	  the	  majority	  of	  TSR	  
do	   not	   overlap	   any	   ncRNAs,	  which	   is	   probably	   a	   consequence	   of	   the	   paucity	   of	   ncRNA	  data.	   A	  
better	   analysis	   was,	   therefore,	   to	   compare	   the	   fraction	   of	   TSRs	   overlapping	   a	   ncRNA	   in	   each	  
group.	   TGS	   group	   TSRs	   do	  overlap	   ncRNAs	   to	   a	   greater	   degree	   than	   any	   of	   the	   other	   datasets,	  
although	  the	  p	  values	  are	  not	  significant	  (Table	  5.3).	  The	  small	  number	  of	  TGS	  group	  TSRs	  and	  the	  
scarcity	  of	  ncRNA	  datasets	  preclude	  conclusions	  as	  to	  the	  whether	  ncRNAs	  are	  enriched	  at	  TGS-­‐
susceptible	  promoters.	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Table	  5.3:	  Fraction	  of	  ncRNA	  overlap	  with	  TSRs	  in	  the	  various	  groups.	  
TSR	  Group	  







TGS	  group	  (p-­‐value)	  
TGS	   5	   9	   35.71	   	  
All	  other	   7927	   35232	   18.37	   0.094	  
THP-­‐1	   162	   737	   21.98	   0.221	  
HK	   110	   241	   31.13	   0.729	  
The	  given	  p-­‐value	  indicates	  whether	  the	  fraction	  of	  2,000	  bp	  windows	  centred	  on	  the	  representative	  TSS	  of	  TGS	  TSRs	  
that	  overlap	  a	  ncRNA	  is	  significantly	  different	  from	  the	  fraction	  for	  the	  various	  controls.	  Chi-­‐square	  test.	  	  
5.3.7	  Classification	  of	  htatsf1	  and	  ddx3x	  promoter	  features	  
	  
To	   determine	   which	   group	   the	   htatsf1	   and	   ddx3x	   promoters	   most	   closely	   resemble,	   a	  
representative	   feature	   vector	   (RFV)	  was	   generated	   for	   each	   group	  and	   their	   Euclidean	  distance	  
from	  htatsf1	  and	  ddx3x	  promoter	  features	  calculated.	  The	  htatsf1	  promoter	  feature	  vector	  most	  
closely	   resembles	   the	   THP-­‐1	   group	   RFV	   and	   the	   ddx3x	   promoter	   feature	   vector	   most	   closely	  
resembles	  the	  RFV	  for	  non-­‐TGS	  TSRs	  in	  the	  genome	  (Table	  5.4).	  	  
	  
Table	  5.4:	  The	  Euclidean	  distance	  between	  htatsf1	  and	  ddx3x	  promoter	  features	  and	  various	  TSR	  groups.	  
Euclidean	  distance	  
TSR	  Group	  
HTATSF1	   DDX3X	  
TGS	   280.65	   92.03	  
All	  other	   301.95	   76.45	  
THP-­‐1	   25.55	   344.82	  
HK	   174.66	   194.27	  
The	  Euclidean	  distance	  of	  promoter	   feature	   vectors	   for	  htatsf1	   (TSR	   ID	  TSR_hg18_v1_chrX_+_135407060)	   and	  ddx3x	  
(TSR	  ID	  TSR	  ID	  TSR_hg18_v1_chrX_+_41078358)	  from	  the	  RFV	  of	  each	  group	  is	  shown.	  
	  
A	  drawback	  of	  clustering	  by	  this	  method	  is	  that	  features	  that	  by	  their	  nature	  have	  a	  large	  
scale	  will	  be	  inordinately	  important	  in	  determining	  distance	  to	  the	  cluster	  centre.	  In	  this	  case,	  this	  
means	   TSR	   length	  will	   be	   far	  more	   important	   in	   assigning	  membership	   than,	   for	   example,	   CES,	  
since	   TSR	   length	   can	   be	   hundreds	   of	   base	   pairs	   whilst	   the	   CES	   ranges	   from	   zero	   to	   one.	   The	  
lengths	   of	   the	   TSR	   assigned	   to	  htatsf1	   and	  ddx3x	   are	   389	   bp	   and	   22	   bp,	   respectively.	   It	   is	   not	  
surprising,	   therefore,	   that	  htatsf1	   and	  ddx3x	   promoters	   clustered	  with	   the	   THP-­‐1	   and	   all	   other	  
TSRs	  groups,	  respectively.	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5.4	  Discussion	  
	  
The	   approach	   used	   here	   was	   to	   identify	   promoter	   features	   associated	   with	   TGS	  
susceptibility	  by	  looking	  for	  enrichment	  of	  features	  in	  promoters	  at	  which	  TGS	  had	  been	  reported	  
compared	  to	  various	  control	  groups.	  This	  approach	  relies	  on	  the	  assumption	  that	  some	  genes	  are	  
not	  susceptible	  to	  TGS	  and	  that	  there	  are	  a	  sufficient	  number	  of	  these	  TGS-­‐resistant	  genes	  in	  each	  
control	  group	  for	  relevant	  differences	  to	  become	  apparent.	  One	  could	   imagine	  that	  some	  genes	  
would	  have	  evolved	  TGS-­‐resistance	  if	  transcriptional	  silencing	  of	  the	  gene	  by	  an	  endogenous	  TGS	  
mechanism	   were	   detrimental	   to	   the	   cell.	   HK	   genes	   are	   expressed	   in	   all	   tissues	   because	   they	  
perform	  essential	  cellular	  functions	  and	  so	  this	  is	  the	  most	  probable	  group	  of	  TGS-­‐resistant	  genes.	  
However,	  one	  of	   the	  TGS	  group	  TSRs,	  associated	  with	  eukaryotic	   translation	  elongation	  factor	  1	  
alpha	  (EEF1A1),	  is	  also	  in	  the	  HK	  gene	  group.	  This	  may	  be	  construed	  as	  good	  evidence	  that	  this	  is	  
not	  a	  HK	  gene	  after	  all.	  In	  other	  words,	  that	  the	  Naïve	  Bayes	  method	  incorrectly	  predicted	  it	  to	  be	  
a	  HK	  gene	  (De	  Ferrari	  and	  Aitken	  2006).	  However,	  EEF1A1	  has	  also	  been	  identified	  as	  expressed	  in	  
all	  conditions	  tested	  in	  a	  publicly	  available	  database	  of	  microarray	  results	  (Eisenberg	  and	  Levanon	  
2003).	  Thus,	  it	  seems	  that	  at	  least	  some	  HK	  genes	  are	  susceptible	  to	  TGS.	  
The	   analysis	  was	   hampered	  by	   the	   extraction	  of	   genome-­‐wide	  promoter	   data	   from	   cell	  
lines	  different	  to	  those	  in	  which	  TGS	  was	  reported.	  For	  example,	  tiRNA	  levels	  were	  determined	  in	  
THP-­‐1	  cells,	  an	  acute	  myeloid	   leukaemia	  cell	   line,	  histone	  modifications	   in	  CD4+	  T	  cells	  and	  TSR	  
data	  from	  a	  number	  of	  different	  cell	  lines	  and	  tissues	  with	  a	  bias	  towards	  THP-­‐1.	  Nonetheless,	  the	  
cosignificance	  of	   features	   retrieved	   from	  different	   sources	   that	  are	  known	   to	  associate,	   such	  as	  
TSR	  length,	  CES	  and	  Sp1	  binding	  sites,	  shows	  the	  retrieval	  and	  analysis	  methodology	  was	  effective	  
and	  that	  different	  data	  sources	  did	  not	  interfere	  with	  detection	  of	  promoter	  feature	  associations.	  
Other	  observations	  supported	  the	  validity	  and	  effectiveness	  of	  the	  approach.	  Enrichment	  
for	   active	   histone	   modifications	   in	   the	   THP-­‐1	   group	   demonstrates	   that	   the	   majority	   of	   highly	  
expressed	  genes	  in	  THP-­‐1	  cells	  are	  also	  expressed	  in	  CD4+	  T	  cells	  (Figure	  5.5).	  Perhaps	  this	  relates	  
to	   both	   the	   THP-­‐1	   group	   and	   histone	   modification	   data	   being	   derived	   from	   stimulated	  
haematopoietic	  cells.	  This	  validates	  the	  use	  of	  the	  THP-­‐1	  group	  to	  control	  for	  features	  associated	  
with	   active	   gene	   expression,	   in	   particular	   histone	   modifications.	   In	   addition,	   the	   histone	  
acetylation	  modifications	  significantly	  different	  between	  the	  TGS	  group	  and	  the	  THP-­‐1	  group	  were	  
mainly	   those	   associated	   with	   the	   TSS,	   rather	   than	   those	   associated	   with	   both	   promoters	   and	  
actively	  transcribed	  regions.	  Compartmentalisation	  of	  acetylation	  patterns	  relates	  to	  the	  histone	  
acetyltransferase	   (HAT)	  associated	  with	  RNA	  Pol	   II:	  PCAF	   is	  known	  to	  associate	  with	  elongation-­‐
competent	   RNA	   Pol	   II	   and	   p300	   with	   initiation-­‐competent	   RNA	   Pol	   II	   (Cho	   et	   al.	   1998).	   The	  
enrichment	  for	  TSS-­‐associated	  histone	  acetylations	  in	  the	  THP-­‐1	  group	  (Figure	  5.5)	  confirms	  that	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assignment	  of	  THP-­‐1	  TSRs	  was	  effective	  and	  that	  the	  probability	  of	  the	  representative	  TSS	  being	  
the	  most	  active	  TSS	  in	  stimulated	  CD4+	  T	  cells	  is	  high.	  Likewise,	  the	  number	  of	  TSCs	  per	  TSR	  was	  
greater	   for	   the	   HK	   gene	   group	   than	   the	   TGS	   group	   (Figure	   5.6),	   which	   agrees	   with	   previous	  
findings	  that	  even	  HK	  genes	  display	  alternate	  promoter	  usage	  with	  tissue-­‐preference	  (Jacox	  et	  al.	  
2010),	  and	  suggests	  that	  assignment	  of	  HK	  gene	  TSRs	  was	  also	  effective.	  
One	   of	   the	   major	   difficulties	   of	   this	   study	   is	   discriminating	   between	   enrichment	   for	  
promoter	   features	   that	   arise	   as	   a	   result	   of	   enhanced	   TGS	   susceptibility	   or	   a	   difference	   in	   the	  
proportion	   of	   active	   genes.	   Thus,	   features	   less	   dependent	   on	   gene	   activity	   are	   probably	   most	  
informative	  in	  discerning	  features	  associated	  with	  enhanced	  TGS	  susceptibility.	  Such	  features	  had	  
the	  added	  advantage	  of	  being	  retrieved	  from	  sources	  that	  used	  several	  tissues	  and	  cell	  lines,	  with	  
the	  exception	  of	  tiRNAs.	  Interrogation	  of	  these	  features	  suggests	  that	  TGS	  susceptible	  genes	  have	  
broad	  TSRs	  comprising	  a	  single	  TSC.	  One	  could	  argue	  that	  a	  high	  number	  of	  TSCs	  within	  a	  TSR	  may	  
be	  associated	  with	   increased	  gene	  susceptibility	  to	  TGS,	  as	   it	   implies	   increased	  regulation	  of	  the	  
region	  and	  a	  propensity	  for	  nucleosome	  remodelling.	  However,	  one	  can	  speculate	  that,	  within	  a	  
promoter	  architecture	  composed	  of	  a	  broad	  TSR	  and	  a	  single	  TSC,	  a	  stochastic	  process	  within	  the	  
transcription	  machinery-­‐accessible	  region	  determines	  the	  TSS	  usage	  (Balwierz	  et	  al.	  2009).	  Hence,	  
a	  broad	  TSR	  with	  one	  TSC	  implies	  a	  large	  accessible	  region,	  or	  NDR.	  This	  may	  favour	  production	  of	  
promoter-­‐associated	   transcripts	   and	   thus,	   increase	   TGS	   susceptibility.	   The	   TGS	   group	  were	   also	  
characterised	   by	   high	   CpG	   class	   and	   CES.	   Together,	   it	   is	   unclear	   how	   informative	   this	   is	   as	   the	  
majority	  of	  genes	  have	  high	  CpG	  class	  promoters,	  which	   is	   correlated	  with	  broad	  TSRs,	  and	   the	  
majority	  of	  TSRs	  comprise	  only	  one	  TSC	  (Balwierz	  et	  al.	  2009).	  Perhaps,	  therefore,	  the	  majority	  of	  
human	   genes	   are	   indeed	   susceptible	   to	   TGS,	   or	   perhaps	   these	   features	   do	   not	   define	   a	   TGS	  
susceptible	   gene	   at	   all.	  Without	   a	   larger	   TGS	   group	   it	   is	   difficult	   to	  make	   definite	   conclusions.	  
Regardless,	  whilst	  the	  majority	  of	  promoters	  are	  high	  CpG	  class	  (Carninci	  et	  al.	  2006;	  Balwierz	  et	  
al.	  2009),	  the	  majority	  of	  genes	  is	  not	  expressed	  in	  any	  given	  cell	  line	  at	  one	  time,	  indicating	  that	  
broad	  TSR,	  high	  CpG	  class	  promoters	  are	  not	  all	  constitutively	  expressed	  and	  undergo	  silencing.	  
The	  hypothesis	  that	  TGS	  susceptible	  genes	  are	  characterised	  by	  broad	  TSRs	  with	  a	  single	  
TSC	  through	  enhanced	  promoter-­‐associated	  transcript	  production	  predicts	  that	  ncRNAs	  would	  be	  
enriched	   in	   the	   TGS	   group.	   There	  was	   a	   trend	   toward	   increased	   tiRNAs,	   a	   ncRNA	   implicated	   in	  
epigenetic	  silencing,	  at	  TGS	  group	  TSRs	  compared	  with	  all	  control	  groups,	  irrespective	  of	  whether	  
the	  proportion	  of	  active	  TSRs	  was	  greater	  in	  the	  TGS	  or	  control	  groups.	  It	  has	  been	  reported	  that	  
although	  promoters	  with	  tiRNAs	  are	  more	  highly	  expressed	  than	  promoters	  without	  tiRNAs,	  there	  
is	  not	  a	  direct	  correlation	  (Taft	  et	  al.	  2009).	  However,	   there	   is	  a	  correlation	  between	  promoters	  
with	   tiRNAs	   and	   promoters	   with	   either	   a	   broad,	   general	   distribution	   of	   TSSs	   or	   a	   broad	  
distribution	  with	  a	  dominant	  TSS	  peak	  (Taft	  et	  al.	  2009);	   in	  other	  words,	  those	  with	  a	  broad	  TSR	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and	  a	   single	  TSC.	   In	   contrast,	   tiRNAs	  are	  not	   correlated	  with	  promoters	  of	   a	  bi-­‐	   or	  multi-­‐modal	  
distribution	   (Taft	   et	   al.	   2009),	   or	   those	  with	  multiple	   TSCs.	   These	   findings	   are	  mirrored	   in	   this	  
study,	  where	   increased	  tiRNAs	   in	  the	  TGS	  group	  are	  observed	  compared	  with	  the	  HK	  genes	  and	  
THP-­‐1	  groups,	  which	  have	  a	  higher	  number	  of	  TSCs	  per	  TSR.	  
How	   tiRNAs	   could	   influence	   susceptibility	   to	   TGS	   is	   unclear.	   It	   has	   been	   suggested	   that	  
tiRNAs	  are	  TFIIS	  cleavage	  products,	  which	  arise	  when	  RNA	  Pol	  II	  ‘backtracks’	  at	  certain	  promoters	  
(Taft	  et	  al.	  2009).	  It	   is	  unlikely	  that	  they	  are	  simply	  signatures	  of	  transcription,	  however,	  as	  their	  
size	  and	  non-­‐random	  distribution	  is	  evolutionarily	  conserved	  and	  the	  relationship	  between	  tiRNA	  
and	  gene	  expression	  level	   is	  complex.	  Small	  RNA	  inducers	  of	  TGS	  are	  effective	  when	  targeted	  to	  
specific	  regions	  and	  can	  be	  extremely	  sensitive	  to	  single	  base-­‐pair	  shifts	  (Janowski	  et	  al.	  2005).	  A	  
role	   for	   tiRNAs	   in	   chromatin	   regulation	   would	   be	   consistent	   with	   promoter-­‐targeted	   siRNAs	  
interfering	   with	   their	   production.	   Alternatively,	   tiRNAs	   could	   be	   the	   target	   with	   which	   guide	  
strands	   hybridise	   or	   endogenous	   TGS-­‐inducers	   themselves,	   fine-­‐tuning	   gene	   expression.	  
Consequently,	   their	   presence	   may	   indicate	   TGS	   susceptibility,	   although	   a	   larger	   TGS	   group	   is	  
needed	   to	   test	   this	   hypothesis.	   Experimental	   evidence	   for	   a	   role	   of	   tiRNAs	   in	   TGS	   is	   lacking.	  
However,	   ncRNAs	   displaying	   the	   characteristics	   of	   tiRNAs	   have	   also	   been	   found	   at	   splice	   sites,	  
termed	  spliRNAs	  (Taft	  et	  al.	  2010),	  and	  small	  RNA	  TGS-­‐inducers	  have	  also	  been	  shown	  to	  regulate	  
splicing	   through	  chromatin	   remodelling	  when	   targeted	   to	   splice	   sites.	  This	  may	  be	  coincidental,	  
but	  the	  small	  size	  of	  these	  RNAs	  and	  their	  similarity	  to	  the	  RNAs	  used	  in	  TGS	  induction	  may	  have	  
prohibited	  detection	  of	  a	  role	  in	  TGS	  to	  date.	  
The	   fraction	   of	   TSRs	  with	   overlapping	   ncRNAs	  was	   greatest	   in	   the	   TGS	   group,	   although	  
there	  was	  not	  a	  statistically	  significant	  enrichment	  when	  compared	  to	  the	  various	  control	  groups	  
(Table	  5.3).	  ncRNAs	  have	  already	  been	  shown	  to	  be	  endogenous	   inducers	  of	  TGS.	  These	   include	  
small	  RNAs,	  such	  as	  miRNAs	   (Gonzalez	  et	  al.	  2008;	  Kim	  et	  al.	  2008;	  Tan	  et	  al.	  2009b),	  and	   long,	  
antisense	  ncRNAs	  (Morris	  et	  al.	  2008;	  Yu	  et	  al.	  2008;	  Hawkins	  and	  Morris	  2010;	  Su	  et	  al.	  2010).	  
Often,	  these	  ncRNAs	  are	  encoded	  across	  or	  proximal	  to	  the	  targeted	  gene	  (Kim	  et	  al.	  2008;	  Morris	  
et	   al.	   2008;	   Yu	   et	   al.	   2008;	   Tan	   et	   al.	   2009b;	   Hawkins	   and	   Morris	   2010).	   Unfortunately,	   only	  
recently	   has	   the	   extent	   of	   non-­‐coding	   transcription	   been	   appreciated	   and,	   consequently,	   the	  
functional	   import	   of	   ncRNAs	   in	   regulating	   gene	   expression.	   Although	   functional	   genomics	  
strategies	   are	   being	   used	   to	   improve	   ncRNA	   annotation	   (Forrest	   et	   al.	   2009;	   Mattick	   2009),	  
current	  databases	  likely	  grossly	  underestimate	  their	  number.	  Therefore,	  no	  significant	  enrichment	  
for	   ncRNAs	   in	   the	   TGS	   group	  may	   be	   due	   to	   the	   group’s	   small	   size	   and	   the	   current	   paucity	   of	  
ncRNA	   data.	   Of	   course,	   the	   number	   of	   TGS	   susceptible	   genes	   in	   the	   control	   groups	   may	   also	  
influence	  whether	  significant	  results	  are	  obtained.	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TGS	  was	   induced	   in	   HEK293T	   cells	   at	   htatsf1	   but	   not	   ddx3x	   (see	   Chapter	   4).	   Promoter	  
features	  of	  these	  genes	  were	  closest,	  determined	  by	  Euclidean	  distance,	  to	  the	  RFVs	  of	  the	  THP-­‐1	  
group	   and	   all	   other	   TSRs,	   respectively	   (Table	   5.4).	   Unfortunately,	   the	   TSR	   length	   inordinately	  
influenced	  the	  clustering	  analysis.	  There	  are	  more	  sophisticated	  methods	   for	  clustering,	   such	  as	  
the	  Naïve	   Bayes	   algorithm,	   but	   for	   the	  most	   part	   they	   are	   not	   useful	  when	   dealing	  with	   small	  
sample	  sizes,	  which	  is	  the	  case	  here.	  Another	  drawback	  of	  this	  analysis	   is	  that	  the	  probability	  of	  
correctly	   classifying	   two	   genes	   as	   TGS	   permissive	   or	   not	   by	   chance	   is	   high	   at	   0.25.	   In	   addition,	  
knowing	  whether	  a	  clustering	  method	  is	  effective	  depends	  on	  being	  certain	  of	  htatsf1	  and	  ddx3x	  
TGS	   susceptibility.	   It	   is	   possible	   that	   an	   appropriate	   target	   site	  was	  not	   found	   in	  ddx3x,	   or	   that	  
ddx3x	   is	  not	   susceptible	   to	  TGS	   in	  HEK293T	  cells	   in	  particular.	   Thus,	   a	  more	   rigorous	  prediction	  
tool	  first	  requires	  a	  larger	  TGS	  group	  and	  this	  needs	  to	  be	  tested	  on	  more	  genes,	  which	  requires	  a	  
great	  deal	  more	  experimental	  data.	  
Manual	   inspection	   of	   the	   htatsf1	   and	   ddx3x	   genes	   reveals	   TSRs	   of	   389	   and	   22	   bp,	  
respectively.	  Both	  are	  high	  CpG	  class	  and	  comprise	  a	  single	  TSC.	  Based	  on	  these	  features	  alone,	  
one	  would	  predict	  htatsf1	  to	  be	  more	  susceptible	  to	  TGS,	  if	  indeed	  broad	  TSRs	  favour	  production	  
of	  promoter-­‐associated	  transcripts.	  However,	  no	  experimental	  data	  on	  the	  relative	  abundance	  of	  
promoter-­‐associated	  transcripts	  for	  these	  genes	  was	  obtained.	  
To	  conclude,	  it	  would	  be	  helpful	  to	  be	  able	  to	  predict	  which	  genes	  are	  susceptible	  to	  TGS.	  
To	  this	  end,	  there	  is	  a	  need	  to	  understand	  the	  context-­‐dependent	  ability	  of	  small	  RNAs	  to	  induce	  
TGS,	  which	  may	  depend,	  in	  part,	  on	  promoter	  architecture.	  The	  small	  number	  of	  genes	  at	  which	  
TGS	   has	   been	   reported	   currently	   precludes	   definitive	   identification	   of	   promoter	   characteristics	  
associated	   with	   TGS	   susceptibility	   and	   the	   classification	   of	   genes	   as	   TGS-­‐permissive	   or	   not.	  
However,	   this	  analysis	   is	   the	   first	   to	  demonstrate	   that	   there	   is	  enrichment	   for	  certain	  promoter	  
features	   at	   genes	   where	   TGS	   has	   been	   reported.	   These	   include	   a	   high	   CpG	   class,	   broad	   TSR	  
comprising	  a	   single	  TSC,	  which	  may	   facilitate	   the	  production	  of	  promoter-­‐associated	   transcripts	  
that	   are	   the	   targets	   of	   TGS-­‐inducing	   small	   RNAs.	   In	   support	   of	   this	   hypothesis,	   there	   is	   some	  
evidence	  of	  an	   increase	   in	  ncRNAs	  overlapping	  TGS	  TSRs,	  but	  a	   larger	  sample	  size	   is	  required	  to	  
confirm	   this	   association.	   Nonetheless,	   this	   study	   provides	   initial	   guidelines	   for	   selection	   of	   TGS	  
targets	  based	  on	  the	  architecture	  of	  promoters.	  




5.1	  Summary	  of	  findings	  
	  
There	   is	   still	   a	   need	   for	   novel	   anti-­‐HIV	   therapies,	   particularly	   those	   that	   reduce	   viral	  
escape,	   toxicity	   and	   administration	   frequency.	   This	   thesis	   examined	   whether	   putative	   HDFs	  
HTATSF1,	   DDX3X	   and	   SMARCB1,	   are	   potential	   therapeutic	   targets	   that	   warrant	   further	  
investigation	  and	  whether	  they	  are	  susceptible	  to	  TGS.	  Through	  exploitation	  of	  the	  RNAi	  pathway,	  
it	  was	   confirmed	   for	   the	   first	   time	   that	  HTATSF1	   is	   a	  HDF	   in	   T	   cell-­‐derived	   SupT1	   cells	   and,	   on	  
shRNA-­‐mediated	  suppression,	  inhibits	  HIV-­‐1	  replication	  without	  overt	  cytotoxicity	  (Chapters	  2	  and	  
3).	   The	   approach	   used	   here	   did	   not	   reveal	   a	   role	   for	   HTATSF1	   in	   splicing	   of	   HIV-­‐1	   transcripts	  
(Chapter	  3),	  contributing	  toward	  the	  controversy	  surrounding	  the	  exact	  role(s)	  of	  HTATSF1	  in	  the	  
viral	  life	  cycle	  (Naito	  et	  al.	  2007;	  Chen	  et	  al.	  2009;	  Miller	  et	  al.	  2009).	  This	  work	  also	  showed	  that	  
expression	   of	   HTATSF1	   could	   be	   reduced	   by	   induction	   of	   TGS	   with	   small,	   promoter-­‐targeted	  
siRNAs	   and	   that	   this	   was	   sufficient	   to	   inhibit	   viral	   replication,	   which	   ultimately	   may	   provide	   a	  
durable	   silencing	   strategy	   (Chapter	   4).	   The	   inability	   to	   confirm	   whether	   DDX3X	   and	   SMARCB1	  
were	  HDFs	  highlighted	  the	  limitations	  associated	  with	  RNAi-­‐mediated	  suppression	  and	  the	  use	  of	  
reporter	  cell	  systems	  for	  monitoring	  effects	  on	  HIV-­‐1	  replication	  (Chapters	  2	  and	  3).	  TGS	  induction	  
was	   not	   successful	   at	   the	   ddx3x	   promoter	   (Chapter	   4	   and	   A2),	   leading	   to	   the	   examination	   of	  
promoter	   architectures	   genome-­‐wide	   to	   assess	   whether	   certain	   features	   are	   associated	   with	  
small	  RNA-­‐induced	  TGS	  susceptibility.	  This	  novel	  analysis	   revealed	   that	  promoters	  at	  which	  TGS	  
has	  been	   reported	  displayed	  broad	  TSRs	  comprising	  a	   single	  TSC,	  a	  high	  CES	  and	  CpG	  class	  and	  
were	  enriched	  for	  overlapping	  ncRNAs	  (Chapter	  5),	  which,	  hopefully,	  will	  assist	  researchers	  with	  
TGS	  target	  selection	  in	  the	  future.	  
Inhibition	   of	   HIV-­‐1	   replication	   in	   SupT1	   cells	   was	   not	   very	   pronounced	   on	   HTATSF1	  
suppression	  and	  may	  be	  accompanied	  by	  growth	  arrest	   (Chapter	  3).	   Thus,	   the	   rigorous	  analysis	  
employed	   here,	   whilst	   validating	   HTATSF1	   as	   a	   HDF	   in	   T	   cell-­‐derived	   lines,	   does	   not	   implicate	  
HTATSF1	  as	  a	  drug	   target.	  However,	   it	   should	  be	  noted	   that,	  although	   the	  SupT1	  cell	   line	  more	  
closely	  resembles	  the	  natural	  hosts	  of	  HIV-­‐1	  than	  the	  HeLa-­‐derived	  TZM-­‐bl	  reporter	  cells,	   this	   is	  
still	  a	  model	  system.	  Levels	  of	  HDFs	  differ	  between	  cell	  types,	  which	  can	  alter	  the	  kinetics	  of	  HIV-­‐1	  
replication	   (Li	   et	   al.	   2010).	   To	   completely	   exclude	   the	   possibility	   of	   HTATSF1-­‐targeting	   as	   a	  
therapeutic	  strategy,	  an	   improved	  system	  is	  required,	  such	  as	  primary	  cells	  and/or	  a	  humanised	  
mouse	  model	  of	  HIV-­‐1	  infection.	  The	  latter	  will	  hopefully	  reveal	  whether	  a	  selective	  advantage	  of	  
	   158	  
cells	   with	   HTATSF1	   suppression	   is	   sufficient	   to	   overcome	   the	   observed	   slight	   decrease	   in	   cell	  
growth	  (Chapter	  3)	  in	  the	  context	  of	  HIV-­‐1	  infection	  in	  vivo.	  A	  biochemical	  approach	  to	  clarify	  the	  
role(s)	   of	  HTATSF1	   in	  HIV-­‐1	   infection	  would	   also	   be	   useful.	   Regardless	   of	  whether	   such	   studies	  
implicate	  HTATSF1	  as	  a	  drug	  target	  or	  not,	  the	  validation	  of	  HTATSF1	  as	  a	  HDF	  described	  here	  may	  
have	   implications	   for	   gene-­‐association	   studies,	   as	   heterogeneity	   in	   HTATSF1	   expression	   may	  
affect	  patient	  susceptibility	  to	  HIV-­‐1	  infection	  and	  the	  rate	  of	  disease	  progression.	  
	  
5.2	  Viral	  escape	  
	  
The	  high	  mutability	  of	  HIV-­‐1	  is	  problematic	  to	  the	  generation	  of	  therapies	  with	  sustained	  
efficacy	  (see	  1.2.5).	  HTATSF1	  suppression	  inhibited	  p81A-­‐4	  replication	  in	  SupT1	  cells	  for	  up	  to	  14	  
days	   (Figure	   3.8),	   although	   there	   is	   still	   the	   possibility	   that,	   over	   time,	   the	   virus	   will	   adapt	   to	  
another	  cofactor.	  The	  lack	  of	  overlap	  between	  HDFs	  identified	  in	  genome-­‐wide	  screens	  (Brass	  et	  
al.	  2008;	  Konig	  et	  al.	  2008;	  Zhou	  et	  al.	  2008;	  Yeung	  et	  al.	  2009b)	  suggests	  a	  redundancy	  within	  the	  
processes	   hijacked	   by	   the	   virus	   (see	   1.3.4),	   which	   may	   facilitate	   viral	   escape	   from	   HDF	  
suppression.	  Altered	  cofactor	  usage	  is	  likely	  to	  reduce	  replication	  efficiency,	  although	  it	  may	  also	  
create	  a	  selective	  pressure	  on	  the	  tropism	  of	  the	  virus.	  For	  example,	  HTATSF1	  suppression	  could	  
drive	  a	  shift	   in	  the	  cell	   type	   in	  which	  the	  virus	  preferentially	  replicates	  to	  those	  where	  HTATSF1	  
suppression	   is	   incomplete,	   or	   to	   those	   where	   a	   redundant,	   albeit	   less	   efficient,	   cofactor	   is	  
expressed	   at	   high	   levels.	   In	   turn,	   shifts	   in	   tropism	   could	   alter	   the	  pathogenesis	   associated	  with	  
HIV-­‐1	  infection.	  
To	  date,	  viral	  escape	  in	  the	  context	  of	  HDF	  suppression	  has	  not	  been	  observed,	  although	  
few	  studies	  have	  examined	  this	  phenomenon.	  Nevertheless,	  the	  apparent	  cure	  of	  a	  HIV-­‐infected	  
patient	  treated	  with	  a	  special	  bone	  marrow	  transplant	  containing	  haematopoietic	  stem	  cells	  with	  
the	  Δ32	  CCR5	  allele	  (Hutter	  et	  al.	  2009;	  Allers	  et	  al.	  2010),	  despite	  the	  reported	  ability	  of	  HIV-­‐1	  to	  
use	   other	   coreceptors	   (Alkhatib	   and	  Berger	   2007),	   raises	   the	   intriguing	   possibility	   that	   cofactor	  
adaptation	  in	  certain	  circumstances	  may	  be	  impossible.	  One	  report	  has	  specifically	  examined	  the	  
ability	  of	  RNAi	  against	  cellular	  factors	  to	  mediate	  durable	  inhibition	  of	  HIV-­‐1:	  the	  authors	  showed	  
that	   cell	   lines	  with	   suppressed	   ALIX,	   TRBP	   or	   ATG16	   expression	  were	   less	   susceptible	   to	   HIV-­‐1	  
replication	  for	  up	  to	  two	  months	  (Eekels	  et	  al.	  2011),	  albeit	  using	  a	  virus	  derived	  from	  a	  molecular	  
clone,	  not	  a	  primary	  isolate	  containing	  multiple	  variants.	  Admittedly,	  the	  potential	  for	  viral	  escape	  
may	   vary	   considerably	   with	   the	   HDF	   targeted,	   the	   cell	   type	   infected	   and	   the	   strain	   of	   virus	  
involved,	  necessitating	  long-­‐term	  studies	  in	  development	  of	  HDF-­‐targeting	  therapies.	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Besides	  increasing	  the	  genetic	  barrier	  to	  viral	  escape,	  another	  advantage	  to	  HDF	  targeting	  
is	   that	   the	   accessibility	   of	   the	   target	   is	   consistent	   between	   cell	   types	   infected	   by	   HIV-­‐1.	   In	  
contrast,	  viral	  targets	  may	  be	  less	  accessible	  in	  macrophages	  than	  T	  cells	  because	  new	  virions	  are	  
released	  into	  endocytic	  organelles	  where	  they	  accumulate	  prior	  to	  release	  as	  an	  exosome.	  Virions	  
with	   these	   exosomes	   evade	   the	   immune	   system	   and,	   importantly,	   are	   sheltered	   from	   antiviral	  
therapies	   and	   the	   RNAi	   machinery	   (Verani	   et	   al.	   2005).	   Incoming	   viral	   genomic	   RNA	   is	   also	  
protected	   from	   RNAi,	   as	   it	   remains	   partially	   encapsidated	   during	   reverse	   transcription	  
(Westerhout	  et	  al.	  2006;	  Arhel	  et	  al.	  2007;	  Gao	  et	  al.	  2008).	  
Of	  course	  the	  disadvantage	  of	  targeting	  a	  HDF	  such	  as	  HTATSF1	  is	  that	  the	  target	  must	  be	  
expressed	   in	   all	   cell	   types	   infected	   by	   HIV	   and	   the	   dosage	   needed	   to	   effectively	   inhibit	   HDF	  
function	  without	  cytotoxic	  effects	  must	  be	  similar	  in	  all	  of	  them.	  Tissue-­‐specific	  delivery	  or	  ex	  vivo	  
treatments	   accompanied	   by	   engraftments	   become	   crucial	   where	   systemic	   inhibition	   is	  
accompanied	   by	   toxic	   side	   effects.	   It	   is	   hoped	   that	   selection	   of	   cellular	   targets	   that	   are	  
dispensable	   for	   cellular	   function	  or	   up-­‐regulated	   specifically	   in	   cells	   infected	  by	  HIV	  will	   reduce	  
these	   difficulties,	   but	   complete	   abolition	   of	   HDF	   function	  may	   not	   be	   desirable.	   Consequently,	  
HDF-­‐targeted	  therapies	  may	  prove	  most	  effective	  when	  used	  in	  combination	  with	  those	  targeting	  
the	  virus	  directly	  (see	  1.3.6).	  
It	   has	   been	   appreciated	   for	   some	   time	   that	   combinatorial	   strategies	   are	   required	   to	  
minimise	  viral	  escape	  (Vandamme	  et	  al.	  1998;	  Chang	  et	  al.	  2005;	  Leonard	  and	  Schaffer	  2005;	  ter	  
Brake	  et	  al.	  2006;	  Aviran	  et	  al.	  2010).	  The	  addition	  of	  a	  compound	  capable	  of	  inhibiting	  HTATSF1	  
function,	  even	  if	  only	  able	  to	  mediate	  a	  partial	  inhibition	  of	  HIV-­‐1	  replication	  by	  itself,	  may	  have	  a	  
synergistic	   effect	   on	   the	   long-­‐term	   efficacy	   of	   combinatorial	   therapy	   by	   reducing	   viral	   escape.	  
Indeed,	   several	   groups	   are	   developing	   a	   HIV-­‐HDF	   combinatorial	   approach.	   For	   example,	  
bifunctional	  siRNAs	  have	  been	  designed	  that	  simultaneously	  direct	  cleavage	  of	  HIV	  transcripts	  and	  
CCR5	  mRNA	  (Ehsani	  et	  al.	  2010).	  In	  addition,	  a	  triple	  RNA-­‐based	  combination	  therapy	  composed	  
of	   a	   siRNA	   targeting	   Tat/Rev,	   a	   TAR	   decoy	   and	   a	   CCR5-­‐targeting	   ribozyme	   has	   been	   shown	   to	  
inhibit	   HIV-­‐1	   replication	   in	   primary	   haematopoietic	   cells	   (Li	   et	   al.	   2005)	   and	   SCID-­‐hu	   mouse-­‐
derived	   T	   cells	   (Anderson	   et	   al.	   2007)	   to	   such	   an	   extent	   that	   this	   treatment	   has	   progressed	   to	  
clinical	   trials	   (DiGiusto	   et	   al.	   2010).	   The	   addition	   of	   small-­‐molecule	   HDF	   inhibitors	   to	   existing	  
HAART	  is	  also	  under	  investigation,	  such	  as	  those	  that	  abolish	  p75-­‐IN	  and	  CCR5-­‐gp120	  interactions	  
[reviewed	   in	   (Arhel	   and	   Kirchhoff	   2010)].	   Successful	   utilisation	   of	   HDF	   inhibitors	  may	   open	   the	  
door	   to	  modulation	   of	   other	   cellular	   factors	   in	   HIV-­‐1	   treatment,	   such	   as	   over-­‐expressing	   those	  
functioning	   as	   viral	   restriction	   factors	   (eg	   APOBEC3G	   and	   TRIM5α	   [reviewed	   in	   (Strebel	   et	   al.	  
2009;	  Arhel	  and	  Kirchhoff	  2010)]	  and	  inhibiting	  those	  involved	  in	  maintaining	  latency.	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5.3	  Application	  of	  HDF-­‐targeted	  TGS	  
	  
Small	  RNA-­‐induced	  TGS	  presents	  a	  novel	  therapeutic	  approach	  for	  silencing	  expression	  of	  
HDFs,	   including	  HTATSF1	   (Chapter	   4).	   This	   gene	   silencing	   strategy	   has	   the	   potential	   to	  mediate	  
long-­‐term	   target	   suppression	   (Hawkins	   et	   al.	   2009)	   (see	   1.4.1),	   which	   may	   reduce	   toxicities	  
associated	  with	  exploitation	  of	  the	  PTGS	  arm	  of	  the	  RNAi	  pathway	  (Grimm	  et	  al.	  2006;	  Grimm	  et	  
al.	   2010)	   where	   continuous	   guide	   strand	   expression	   is	   required.	   The	   durability	   of	   TGS	   in	   the	  
absence	   of	   promoter-­‐targeted	   guide	   strand	   is	   likely	   to	   vary	   substantially	   between	   genes,	  
however.	   Although	   controversial,	   a	   number	   of	   studies	   suggest	   transcription	   is	   pervasive	  
(Kapranov	  et	  al.	  2002;	  Bertone	  et	  al.	  2004;	  Kampa	  et	  al.	  2004;	  Schadt	  et	  al.	  2004;	  Carninci	  et	  al.	  
2005;	  Cheng	  et	  al.	  2005;	  Carninci	  et	  al.	  2006;	  Birney	  et	  al.	  2007;	  Kapranov	  et	  al.	  2007a;	  Kapranov	  
et	   al.	   2007b;	   van	   Bakel	   et	   al.	   2010),	   which	   may	   lead	   to	   reactivation	   of	   the	   targeted	   gene	   or	  
prevent	  complete	  silencing.	  In	  addition,	  given	  the	  target	  gene	  is	  actively	  transcribed	  prior	  to	  TGS,	  
other	   pathways	   in	   the	   cell	   may	   favour	   reactivation	   of	   the	   gene.	   Duration	   of	   TGS	   may	   be	  
influenced	   by	   long-­‐range	   chromosomal	   interactions:	   coregulated	   genes	   are	   preferentially	  
associated	  within	  transcription	  factories	  (Schoenfelder	  et	  al.	  2010),	  but	  little	  is	  known	  about	  the	  
regulation	  of	  transcription	  factory	  association	  and	  so	  it	  is	  unclear	  whether	  long-­‐term	  TGS	  requires	  
a	   loss	   of	   target	   association	   with	   these	   specialised	   transcriptional	   hotspots.	   Hopefully,	   future	  
studies	  will	   examine	  how	  3D	   chromosomal	   interactions	   are	   affected	  by	   small	   RNA-­‐induced	  TGS	  
and	  the	  role	  of	  these	  interactions	  in	  TGS	  duration.	  
The	   widespread	   application	   of	   TGS	   is	   compounded	   by	   sparse	   knowledge	   of	   the	  
mechanism(s)	  involved	  (see	  1.4)	  and	  what	  governs	  efficacy	  in	  selection	  of	  both	  a	  target	  gene	  and	  
a	   target	   site	   within	   a	   promoter.	   Several	   promoter	   features	   were	   enriched	   in	   TGS	   susceptible	  
genes	   (Chapter	   5),	   the	   application	   of	   which	   may	   facilitate	   selection	   of	   additional	   HDF	   targets	  
besides	  HTATSF1.	  The	  significance	  of	   these	   findings	   is	  unclear,	  however,	  as	  TGS	  reports	  are	   few	  
and	   a	   number	   describe	   TGS	   at	   sites	   other	   than	   the	   promoter,	   including	   regulatory	   domains	  
(Gonzalez	   et	  al.	   2008),	  downstream	  of	  3’	  UTRs	   (Yue	   et	  al.	   2010)	  and	  alternatively	   spliced	  exons	  
(Allo	   et	   al.	   2009;	   Luco	   et	   al.	   2011).	   These	   regions	   do	   not	   display	   all	   the	   promoter	   features	  
identified	   as	   enriched	   in	   TGS	   susceptible	   genes,	   suggesting	   that	   more	   experimental	   data	   is	  
required	  before	  conclusions	  can	  be	  drawn	  on	  what	  discriminates	  a	  good	  TGS	  target.	  
Although	  guidelines	   for	   selection	  of	   TGS	   target	   genes	  and	   sites	  within	   a	  promoter	  have	  
not	  been	  defined,	  it	  may	  be	  possible	  to	  increase	  the	  potency	  of	  TGS	  by	  creating	  a	  TGS-­‐permissive	  
state	   within	   the	   cell.	   Nascent	   RNA	   Pol	   II	   transcripts	   are	   required	   for	   small	   RNA-­‐induced	  
transcriptional	   regulation	   (Han	   et	   al.	   2007).	   Therefore,	   enhanced	   TGS	   susceptibility	   may	   be	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achieved	  by	  inhibiting	  the	  exosome,	  which	  has	  been	  shown	  to	  increase	  the	  life-­‐span	  of	  promoter-­‐
associated	  RNAs	  (Preker	  et	  al.	  2008).	  
Selective	  periods	  of	  the	  cell	  cycle	  may	  be	  preferentially	  TGS-­‐permissive.	  In	  S.	  pombe,	  brief	  
centromeric	   repeat	   transcription	  during	  S	  phase	   is	   required	  to	  maintain	  heterochromatin	  at	   the	  
region	   through	   successive	   cell	   divisions	   by	   producing	   the	   RNAi	   effectors	   (Chen	   et	   al.	   2008).	  
Similarly,	   convergent	   genes	   in	  S.	   pombe	  employ	  a	   cell	   cycle-­‐regulated	   transcription	   termination	  
mechanism	   that	   involves	   dsRNA	   production	   and	   heterochromatin	   formation	   (Gullerova	   and	  
Proudfoot	   2008).	   In	   human	   cells,	   TGS-­‐inducing	   rRNAs	   are	   increased	   in	   a	   cell	   cycle-­‐regulated	  
manner	  (Santoro	  et	  al.	  2010).	  Further,	  intrachromosomal	  interactions	  between	  enhancer	  regions	  
and	  the	  TSS	  can	  be	  periodic,	  varying	  in	  a	  ligand-­‐	  and	  cell	  cycle-­‐dependent	  fashion	  (Matilainen	  et	  
al.	  2010).	  Such	  periodicity	  may	  affect	  target	  gene	  susceptibility	   if	  using	  enhancer-­‐targeted	  guide	  
strands.	   These	   studies	   suggest	   that	   RNA-­‐induced	   heterochromatin	   formation	  may	   be	   favoured	  
during	   specific	   periods	   of	   the	   cell	   cycle,	   through	   up-­‐regulation	   of	   pathway	   components	   and/or	  
enhanced	  association	  of	  the	  targeted	  region	  with	  the	  proximal	  promoter.	  
Decreasing	   the	   elongation	   rate	   of	   RNA	   Pol	   II	   may	   enhance	   siRNA-­‐mediated	  
heterochromatin	   formation.	   Recently,	   siRNAs	   have	   been	   shown	   to	   inhibit	   RNA	   Pol	   II	   during	  
elongation	  in	  C.	  elegans	  (Guang	  et	  al.	  2010).	  In	  S.	  pombe,	  6-­‐azauracil	  inhibits	  RNA	  Pol	  II	  elongation	  
and	   enhances	   RNA-­‐induced	   gene	   silencing	   (S.	   I.	   Grewal,	   personal	   communication).	   Similarly,	   in	  
human	  cells,	  decreased	  RNA	  Pol	  II	  processivity	  has	  been	  associated	  with	  heterochromatin	  marks	  
and	  recruitment	  of	  HP1	  isoforms	  (Allo	  et	  al.	  2009).	  Thus,	  introducing	  a	  drug	  to	  inhibit	  RNA	  Pol	  II	  
processivity	  at	  the	  same	  time	  as	  introducing/expressing	  the	  TGS-­‐inducing	  small	  RNA	  may	  enhance	  
TGS	  establishment.	  
A	  major	  concern	  of	  a	  TGS-­‐based	  gene	  therapy	  is	  the	  potential	  for	  off-­‐target	  effects.	  Small	  
RNA	  TGS	   effectors	   resemble	  miRNAs	   and	   so	   have	   the	  potential	   to	   induce	  PTGS	  of	  mRNAs	  with	  
cognate	  seed-­‐match	  hexamers	  (Jackson	  et	  al.	  2003;	  Jackson	  and	  Linsley	  2004;	  Jackson	  et	  al.	  2006).	  
They	  could	  also	  give	  rise	  to	  unwanted	  changes	  in	  alternative	  splicing	  (Allo	  et	  al.	  2009;	  Luco	  et	  al.	  
2011)	   through	  TGS-­‐mediated	  affects.	  Even	   if	   care	   is	   taken	   to	  avoid	  such	   target	   redundancy,	   the	  
demonstration	   that	   similar	   small	   RNAs	   can	   induce	   both	   TGS	   and	   TGA	   (Janowski	   et	   al.	   2007;	  
Turunen	   et	  al.	   2009)	   (see	  1.4.4)	   in	  a	   currently	  unpredictable	  manner	   raises	   the	   issue	  of	  how	   to	  
avoid	  unwanted	  TGA	  on	  systemic	  administration	  of	  TGS	  effectors.	  Currently,	  there	  is	  no	  data	  on	  
the	  consequences	  of	  HTATSF1	  over-­‐expression.	  No	  doubt	  the	  progress	  of	  TGS	  to	  the	  clinic	  will	  be	  
assisted	   by	   developments	   in	   tissue-­‐specific	   delivery	   of	   RNAi	  mimics	   [reviewed	   in	   (Tiemann	   and	  
Rossi	  2009;	  Lares	  et	  al.	  2010)].	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5.4	  Delivery	  of	  HDF-­‐targeted	  TGS-­‐based	  gene	  therapy	  
	  
Although	   non-­‐encapsulated	   siRNAs	   have	   been	   delivered	   directly	   to	   cells	   by	   gymnosis	  
(Stein	   et	   al.	   2010),	   this	   is	   not	   generally	   feasible	   for	   most	   therapeutic	   applications,	   including	  
antiviral	   therapy.	   siRNAs	  are	   inherently	  unstable,	   vulnerable	   to	  degradation	  and	  may	   trigger	   an	  
immune	  response,	  thus	  a	  method	  of	  delivery	  is	  required	  to	  ensure	  siRNAs	  remain	  functional	  long	  
enough	  to	  reach	  their	  target	  cells.	  Chemical	  modifications,	  such	  as	  locked	  nucleic	  acids	  and	  2’-­‐O-­‐
methyl-­‐modified	   uridine	   or	   guanine	   nucleosides,	   have	   been	   used	   to	   increase	   resistance	   to	  
nuclease	   activity	   and	   target	   specificity,	   and	   decrease	   inflammation	   [reviewed	   in	   (Shukla	   et	   al.	  
2010)].	   Importantly,	   introduction	   of	   such	   modifications	   did	   not	   alter	   the	   ability	   of	   promoter-­‐
targeted	  agRNAs	  to	  induce	  TGS	  (Watts	  et	  al.	  2010),	  although	  care	  must	  be	  taken	  as	  incorporation	  
of	  too	  many	  modifications	  can	  cause	  toxicity	  and/or	  reduce	  efficacy.	  
Lipid-­‐based	  delivery	   vehicles,	   including	   liposomes,	   lipoplexes	   and	  nanostructured	  gyroid	  
cubic	   lipid	  matrices	   (Leal	   et	  al.	   2010),	  protect	   from	  nuclease	  degradation	  and	  mediate	  high	   cell	  
transfection	  efficiency	  but	  do	  not	  permit	  tissue-­‐specific	  delivery	  of	  siRNAs	  [reviewed	  in	  (Lares	  et	  
al.	  2010)].	  Liposomes	  may	  be	  replaces	  by	  peptides,	  such	  as	  histidine-­‐lysine	  polymers,	  which	  may	  
be	   conjugated	   to	   ligands	   for	   cell	   type-­‐specific	   delivery,	   but	   the	   transfection	   efficiency	   of	   such	  
vehicles	   is	   generally	   low	   (Leng	   et	   al.	   2007).	   The	   first	   Phase	   I	   clinical	   trial	   involving	   systemic	  
administration	  of	  siRNAs	  successfully	  achieved	  solid	  tumour-­‐targeting	  using	  nanoparticle	  vehicles	  
composed	  of	  a	   linear,	  cyclodextrin-­‐based	  polymer,	  a	  human	  transferring	  protein	  ligand	  to	  target	  
the	  transferring	  receptor	  and	  a	  hydrophilic	  polymer	  (polyethylene	  glycol)	  to	  promote	  nanoparticle	  
stability,	  as	  well	  as	  the	  anti-­‐ribonucleotide	  reductase	  siRNA.	  
Other	  ligand-­‐based	  targeting	  methods	  have	  been	  developed	  specifically	  for	  the	  delivery	  of	  
siRNAs	   to	   HIV-­‐infected	   cells	   that	   avoid	   the	   requirement	   for	   polymer-­‐based	   nanoparticles.	  
Aptamers	  are	  structured	  nucleic	  acids	  with	  high	  affinity	  to	  a	  chosen	  target.	  They	  have	  the	  distinct	  
advantage	   of	   being	   relatively	   easy	   to	   produce	   in	   vitro	   as	   siRNA-­‐aptamer	   chimaeras	   may	   be	  
synthesised	   as	   a	   single	   polymer.	   Two	   RNA	   aptamers	   that	   bind	   the	   HIV-­‐1	   gp120	   have	   been	  
developed:	  one	  is	  an	  aptamer-­‐siRNA	  chimaera,	  the	  other	  contains	  a	  GC-­‐bridge	  between	  the	  two	  
to	   facilitate	   interchange	   of	   siRNAs	   (Zhou	   et	   al.	   2009).	   Whilst	   the	   aptamer	   alone	   inhibits	   HIV	  
replication,	   the	   chimaeras	   provide	  more	   potent	   inhibition	   through	   delivery	   of	   siRNAs	   targeting	  
HIV	   transcripts.	   An	   alternative	   method	   for	   delivery	   of	   siRNAs	   to	   HIV-­‐infected	   cells	   is	   the	  
conjugation	   of	   siRNAs	   to	   antibody	   fragments.	   One	   approach	   used	   a	   fusion	   protein,	   protamine,	  
which	  binds	   siRNA,	   conjugated	   to	   the	   Fab	   fragment	  of	   an	  HIV-­‐1	  envelope	  antibody	   (Song	   et	   al.	  
2005).	  However,	   it	   is	   unknown	  whether	   delivery	   strategies	   employing	   aptamers	   and	   antibodies	  
targeting	  highly	   variable	  HIV	  envelope	  proteins	  will	   select	   for	   resistant	   virus.	  Another	   approach	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used	  a	  modified	  scFv	  antibody,	  which	  targets	  T	  cell	  surface	  protein	  CD7,	  to	  allow	  conjugation	  to	  a	  
nona-­‐D-­‐arginine	   peptide	   that	   engaged	   with	   siRNA	   (Kumar	   et	   al.	   2008).	   Clearly,	   great	  
improvements	  in	  the	  tissue-­‐specific	  delivery	  of	  siRNAs	  are	  being	  made,	  although	  it	  has	  not	  been	  
examined	  whether	  these	  methods	  mediate	  efficient	  nuclear	  delivery	  of	  siRNAs,	  which	  is	  required	  
for	  TGS.	  
Other	   methods	   are	   being	   developed	   for	   the	   delivery	   of	   RNAi	   expression	   cassettes,	  
including	   hijacking	   the	   Sleeping	   Beauty	   DNA	   transposon	   (Fletcher	   2010)	   and	   viral	   vectors,	   in	  
particular	   lentiviruses.	   Lentiviruses	   may	   infect	   a	   number	   of	   different	   cell	   types,	   including	  
haematopoietic	   stem	   cells	   and	   non-­‐dividing	   resting	   memory	   T	   cells	   (Yam	   et	   al.	   2002).	  
Improvements	   have	   been	   made	   to	   prevent	   low	   titres	   through	   siRNA	   production	   targeting	  
components	  of	  the	  packaging	  system	  (Poluri	  and	  Sutton	  2008;	  Liu	  et	  al.	  2010),	  although	  this	  is	  less	  
likely	  to	  be	  an	  issue	  with	  HDF-­‐targeting	  effectors.	   In	  addition,	  safer	  vectors	  are	  being	  developed	  
that	   minimise	   the	   risk	   of	   recombination	   with	   infectious	   HIV	   to	   produce	   new	   hybrid	   viruses	  
(Miyoshi	   et	   al.	   1998;	   VandenDriessche	   et	   al.	   2002).	   Insertional	   mutagenesis	   is	   a	   concern	   and,	  
although	   it	   has	   not	   yet	   been	   observed	   with	   lentiviruses,	   it	   may	   be	   prevented	   by	   targeting	  
integration	   away	   from	   functional	   genes	   using	   an	   artificial	   tethering	   factor	   (Gijsbers	   et	   al.	   2010;	  
Silvers	   et	   al.	   2010).	   Strategies	   to	   insulate	   lentiviral	   vector-­‐expressed	   transgenes	   from	   the	  
influence	  of	  neighbouring	  chromatin	  have	  also	  been	  described	  (Ramezani	  and	  Hawley	  2010).	  
Tissue-­‐specific	   expression	   of	   guide	   strand	   precursors	   may	   be	   obtained	   by	   the	   use	   of	  
appropriate	  RNA	  Pol	  II	  promoters.	  Although	  products	  of	  pri-­‐miRNA	  mimics	  have	  not	  been	  shown	  
to	  mediate	  TGS,	  products	  of	  shRNAs	  have	  (Castanotto	  et	  al.	  2005;	  Kim	  et	  al.	  2006;	  Murayama	  et	  
al.	   2006;	   Hawkins	   et	   al.	   2009;	   Turunen	   et	   al.	   2009;	   Yamagishi	   et	   al.	   2009),	   suggesting	   that	  
incorporation	  of	  TGS-­‐inducing	  guide	   strands	   into	  mimics	   that	   require	  Dicer	  processing	  does	  not	  
ablate	  efficacy	  and	  may	  be	  extended	  to	  those	  which	  also	  require	  Drosha	  processing.	  This	  may	  be	  
facilitated	  by	  use	  of	  pri-­‐miRNA	  scaffolds	  derived	  from	  endogenous	  miRNAs	  shown	  to	  mediate	  TGS	  
(Gonzalez	   et	   al.	   2008;	   Kim	   et	   al.	   2008;	   Tan	   et	   al.	   2009b).	   Expression	   specifically	   in	  HIV-­‐infected	  
cells	  may	  be	  permitted	  through	  the	  use	  of	  mobilisation	  competent	  vectors	  and	  inducible	  systems	  
whose	   activation	   is	   stimulated	   by	   the	   presence	   of	   Tat	   (Unwalla	   and	   Rossi	   2008;	   Turner	   et	   al.	  
2009),	  although	  these	  would	  be	  refractory	  in	  the	  context	  of	  latent	  infection.	  
In	  summary,	  many	  promising	  methods	  for	  delivery	  of	  RNAi	  mimics	  have	  been	  developed	  
that	  may	  be	  applied	  to	  the	  delivery	  of	  TGS	  effectors	  to	  the	  nucleus	  of	  their	  intended	  targets.	  The	  
most	   effective	   delivery	   strategy	   may	   depend	   on	   the	   nature	   of	   the	   other	   components	   of	   the	  
combinatorial	  therapy.	  Providing	  efficient	  delivery	  to	  HIV-­‐infected	  cells	  is	  achieved,	  it	  is	  unknown	  
the	  extent	  to	  which	  the	  efficacy	  of	  TGS	  effectors	  will	  be	  affected	  by	  HIV-­‐mediated	  modulation	  of	  
the	  RNAi	  pathway.	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5.5	  Modulation	  of	  RNAi	  by	  HIV	  
	  
The	   role	   of	   RNAi	   as	   an	   antiviral	   defence	   mechanism	   in	   mammalian	   cells	   remains	  
controversial	   (Saumet	   and	   Lecellier	   2006).	   Several	   pathogenic	   human	   viruses	   were	   shown	   to	  
encode	  proteins	  that	  function	  as	  suppressors	  of	  RNAi	  [reviewed	  in	  (de	  Vries	  and	  Berkhout	  2008)],	  
supporting	  that	  RNAi	  serves	  as	  an	  innate	  defence	  response	  in	  mammals.	  In	  addition,	  components	  
of	   the	   RNAi	  machinery,	   including	   TRBP	   and	   PACT,	   have	   also	   been	   described	   as	   inducers	   of	   an	  
interferon	  response	  [reviewed	  in	  (Lares	  et	  al.	  2010)].	  
An	   interesting	   interplay	   exists	   between	   HIV	   and	   the	   RNAi	   machinery	   [reviewed	   in	  
(Corbeau	  2008)].	  RNAi	  is	  capable	  of	  restricting	  HIV-­‐1	  replication	  by	  targeting	  viral	  transcripts	  with	  
either	  miRNAs	  or	  siRNAs	  (Klase	  et	  al.	  2007;	  Liu	  et	  al.	  2009;	  Nathans	  et	  al.	  2009;	  Wang	  et	  al.	  2009b;	  
Yeung	   et	  al.	  2009a).	  Ablation	  of	  Dicer	   (Triboulet	   et	  al.	  2007),	  or	  disruption	  of	  P	  body	  structures	  
(Nathans	  et	  al.	  2009),	  increases	  HIV-­‐1	  replication	  in	  T	  cells,	  suggesting	  an	  anti-­‐HIV	  role	  for	  RNAi.	  It	  
is	   perhaps	   not	   surprising,	   therefore,	   that	   HIV	   counteracts	   RNAi	   in	   T	   cells:	   Tat	   interacts	   directly	  
with	   Dicer	   reducing	   its	   ability	   to	   produce	   miRNAs	   and	   the	   viral	   TAR	   element	   sequesters	   TRBP	  
(Bennasser	  et	  al.	  2005;	  Bennasser	  and	  Jeang	  2006).	  This	  suppression	  of	  RNAi	  may	  serve	  to	  reduce	  
the	  production	  of	  HIV-­‐targeted	  host	  miRNAs	  (Hariharan	  et	  al.	  2005;	  Huang	  et	  al.	  2007),	  as	  well	  as	  
reduce	  the	  production	  of	  miRNAs	  that	  regulate	  HDFs,	  such	  as	  miR-­‐17-­‐5p	  and	  miR-­‐20	  that	  silence	  
PCAF	  (Triboulet	  et	  al.	  2007).	  Other	  host	  miRNAs	  are	  up-­‐regulated	  on	  HIV	   infection	  (Yeung	  et	  al.	  
2005;	   Triboulet	   et	   al.	   2007)	   but	   the	   molecular	   basis	   of	   the	   up-­‐regulation	   of	   some	   and	   down-­‐
regulation	  of	  others	  is	  not	  understood.	  
A	  global	  suppression	  of	  RNAi	  may	  not	  be	  beneficial	  to	  the	  virus	  as	  HIV	  appears	  to	  encode	  
a	   number	   of	   its	   own	   miRNAs.	   The	   earliest	   direct	   evidence	   for	   a	   viral	   miRNA	   was	   found	   by	  
Northern	  blot	  analysis	  (Klase	  et	  al.	  2007;	  Ouellet	  et	  al.	  2008).	  More	  powerful	  techniques,	  such	  as	  
primer-­‐directed	   sequencing	   (Klase	   et	   al.	   2009)	   and	   pyrosequencing	   (Yeung	   et	   al.	   2009a),	   have	  
verified	  that	  viral	  miRNAs	  are	  produced.	  Of	  note	  is	  a	  viral	  miRNA	  derived	  from	  the	  TAR	  element,	  
produced	   during	   productive	   and	   latent	   infections,	   which	   serves	   two	   known	   functions	   in	   the	  
maintenance	  of	   latency:	   to	   induce	  TGS	  at	   the	   LTR	   (Klase	   et	   al.	   2007;	   Suzuki	   et	   al.	   2008)	   and	   to	  
down-­‐regulate	   host	   genes	   by	   PTGS	  with	   roles	   in	   DNA	   repair,	   cytokine	   signalling	   and	   apoptosis,	  
thus	   promoting	   the	   survival	   of	   latently-­‐infected	   cells	   (Klase	   et	   al.	   2009).	   Another	   viral	   miRNA,	  
hiv1-­‐mir-­‐H1,	   down-­‐regulates	   an	   immune	   response	   and	   inhibits	   expression	   of	   Vpr-­‐targeting	  
cellular	  miR-­‐149	  (Kaul	  et	  al.	  2009).	  
The	  reciprocal	  interactions	  between	  HIV	  and	  RNAi	  are	  further	  complicated	  by	  differences	  
between	  the	  cell	  types	  HIV	  infects.	  It	  has	  been	  suggested	  that	  miR-­‐198	  restricts	  HIV-­‐1	  replication	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in	   monocytes	   through	   targeting	   of	   the	   HDF	   cyclin	   T1	   (Sung	   and	   Rice	   2009).	   However,	   Dicer	   is	  
absent	   from	   monocytes	   (Klase	   et	   al.	   2007)	   with	   low-­‐level	   miRNA	   generation	   in	   these	   cells	  
dependent	  on	  PIWIL4	  (Coley	  et	  al.	  2010),	  a	  member	  of	  the	  Ago	  family	  of	  proteins	  whose	  function	  
was	  previously	  believed	  restricted	  to	  the	  formation	  of	  heterochromatin	  guided	  by	  piwi-­‐interacting	  
RNAs	   (piRNAs)	   at	   transposable	   elements	   [reviewed	   in	   (Kim	   et	   al.	   2009)].	   Dicer	   expression	   was	  
detected	  on	  differentiation	  of	  monocytes	  into	  monocyte-­‐derived	  macrophages,	  although	  this	  was	  
inhibited	   in	  the	  presence	  of	  HIV	   in	  a	  manner	  dependent	  on	  Vpr	   (Coley	  et	  al.	  2010).	   Intriguingly,	  
this	   suggests	   that	   RNAi	   is	   suppressed	   in	   both	   monocytes	   and	   T	   cells	   by	   two	   independent	  
mechanisms.	  
Thus,	  the	  global	  impact	  of	  the	  reciprocal	  interactions	  between	  HIV	  and	  RNAi,	  and	  how	  this	  
impacts	   the	  efficacy	  of	  TGS-­‐based	  gene	  therapy,	  on	   in	  vivo	   infection	  remains	   to	  be	  determined.	  
Other	  strategies	  for	  TGS	   induction	  may	  need	  to	  be	  considered,	   including	  the	  expression	  of	   long,	  
antisense	  ncRNAs.	  Endogenous	  asRNAs	  have	  been	  shown	  to	   regulate	  gene	  expression	  and	   their	  
over-­‐expression	  may	   lead	   to	   heterochromatin	   formation	   and	   TGS	   (Morris	   et	   al.	   2008;	   Yu	   et	   al.	  
2008;	  Hawkins	  and	  Morris	  2010).	  
	  
5.6	  Concluding	  remarks	  
	  
Despite	   being	   the	   most	   studied	   infectious	   agent	   of	   this	   century,	   HIV	   remains	   a	   major	  
global	   health	   concern.	   The	   high	   mutability	   of	   the	   virus	   has	   countered	   attempts	   to	   develop	   a	  
prophylactic	   vaccine	   and	   a	   cure.	   The	   reliance	   of	   viruses,	   including	   HIV,	   on	   their	   hosts	   for	  
replication	  raises	  the	  intriguing	  possibility	  of	  targeting	  a	  host	  factor	  as	  opposed	  to	  the	  virus	  itself.	  
Whilst	   this	  may	  engender	   toxicity,	   it	   is	  hoped	   that	   this	  will	   reduce	   the	  ability	  of	  HIV	   to	  develop	  
treatment	  resistance	  and	  will	  also	  provide	  a	  therapy	  that	  is	  broadly	  inhibitory	  of	  HIV	  subtypes.	  
The	   observation	   that	   homozygosity	   for	   the	   naturally	   occurring	   CCR5	  Δ32	   allele	   confers	  
resistance	  to	  R5-­‐tropic	  viruses	  without	  any	  observed	  detrimental	  effects	  to	  the	  host,	  suggests	  that	  
it	  may	  be	  possible	   to	   treat	  HIV	  by	   targeting	  host	   proteins	   required	   for	   viral	   replication	  without	  
toxic	   side	   effects.	   A	   number	   of	   genome-­‐wide	   screens	   has	   been	   performed	   to	   identify	   host	  
proteins	  involved	  in	  HIV-­‐1	  replication,	  although	  all	  were	  subject	  to	  a	  number	  of	  limitations.	  Given	  
that	  levels	  of	  HDFs	  influence	  HIV	  replication	  kinetics	  and	  gene	  expression	  varies	  between	  tissues,	  
it	   is	   important	   that	   putative	   HDFs	   identified	   by	   these	   screens	   are	   validated	   with	   additional	  
experiments,	  preferably	  in	  cells	  that	  are	  natural	  substrates	  of	  HIV	  infection.	  
This	  thesis	  presents	  an	  effective	  protocol	  for	  the	  validation	  of	  HDFs	  and	  elucidation	  of	  the	  
therapeutic	  potential	  of	  their	  targeting.	  Application	  of	  this	  protocol	  has	  contributed	  to	  the	  list	  of	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validated	   HDFs	   by	   confirming	   that	   HTATSF1	   functions	   as	   an	   HDF	   in	   T	   cell-­‐derived	   SupT1	   cells.	  
Reduced	  HTATSF1	   expression	  moderately	   decreased	   the	   efficiency	   of	   HIV-­‐1	   replication	  without	  
overt	  cytotoxicity,	  although	  this	  may	  be	  accompanied	  by	  decreased	  proliferative	  capacity	  of	  cells.	  
Further	  studies	  are	  required	  to	  clarify	  the	  significance	  of	  HTATSF1	  suppression	  on	  viral	  replication	  
in	   vivo,	   and	   whether	   HTATSF1	   inhibitors	   would	   improve	   existing	   combinatorial	   strategies	   by	  
increasing	  the	  genetic	  barrier	  to	  viral	  escape.	  However,	  the	  work	  presented	  in	  this	  thesis	  suggests	  
that	  HTATSF1	  may	  not	  constitute	  a	  therapeutic	  target,	  as	  its	  suppression	  did	  not	  have	  a	  dramatic	  
effect	   on	   viral	   replication.	   Whether	   a	   drug	   target	   or	   not,	   validation	   of	   HTATSF1	   as	   a	   HDF	   is	  
valuable	   since	   its	   expression	   level	   may	   influence	   disease	   progression.	   Thus,	   the	   degree	   of	  
HTATSF1	  heterogeneity	  within	  the	  population	  should	  be	  examined	  and	  htatsf1	  should	  be	  included	  
in	   gene-­‐association	   studies	   for	   the	   detection	   of	   HIV	   risk	   factors.	   Most	   importantly,	   the	  
methodology	  employed	  here	  was	  successful	  at	  discriminating	  a	  validated	  HDF	   from	  a	  promising	  
drug	  target.	  This	  thesis	  demonstrates	  that	  a	  thorough	  analysis	  of	  each	  putative	  HDF	  is	  necessary	  
to	  confirm	  its	  therapeutic	  potential	  and,	  as	  such,	  a	  protocol	  similar	  to	  that	  executed	  in	  this	  thesis	  
should	  be	  applied	  when	  validating	  results	  from	  genome-­‐wide	  screens.	  
Current	   HIV	   treatment	   regimens	   suffer	   from	   limitations	   associated	   with	   their	   chronic,	  
daily	   administration,	   including	   toxic	   side	   effects	   and	   patient	   compliance.	   Alternative	   therapies	  
that	  reduce	  intervention	  frequency	  and	  are	  practical	  to	  resource-­‐poor	  settings,	  would,	  therefore,	  
be	   of	   benefit.	   Small	   RNA-­‐induced	   TGS	   is	   an	   arm	   of	   the	   RNAi	   pathway	   recently	   identified	   in	  
mammalian	  cells	  that	  has	  the	  potential	  to	  provide	  durable	  silencing,	  providing	  heterochromatin	  is	  
achieved	   at	   the	   targeted	   promoter.	   This	   thesis	   demonstrated	   that	   it	   is	   possible	   to	   suppress	  
HTATSF1	  expression	  through	  induction	  of	  TGS	  at	  the	  htatsf1	  promoter,	  expanding	  the	  options	  for	  
targeting	  of	  this	  HDF.	  This	  thesis	  also	  provides	  proof	  of	  principle	  that	  TGS	  at	  a	  HDF	  promoter	  may	  
inhibit	   HIV-­‐1	   replication.	   Before	   implementation	   as	   a	   therapeutic	   strategy,	   future	   work	   must	  
examine	  the	  potential	  for	  TGS	  at	  HDF	  promoters	  in	  T	  cells	  and	  whether	  this	  is	  sufficiently	  potent	  
to	  inhibit	  viral	  replication	  over	  time.	  
The	  huge	  progress	  made	  in	  delivery	  of	  RNAi	  effectors	  ensures	  that	  this	  should	  not	  prove	  a	  
barrier	  to	  the	  implementation	  of	  TGS-­‐based	  gene	  therapies.	  Of	  greater	  concern	  is	  the	  potential	  of	  
HIV	  to	  modulate	  the	  RNAi	  pathway	  and	  how	  this	  may	   impact	  TGS	  efficacy	   in	  vivo.	  Furthermore,	  
difficulties	   in	  TGS	   target	   identification	  currently	  precludes	  widespread	  exploitation	  of	   this	  gene-­‐
silencing	   phenomenon,	   although	   the	   novel	   analysis	   employed	   here	   for	   the	   identification	   of	  
promoter	   features	   enriched	   in	   TGS	   susceptible	   genes	   will	   provide	   the	   groundwork	   for	  
improvements	   in	   this	   regard.	   In	   conclusion,	   this	   thesis	   provides	   an	   experimental	   strategy	   for	  
elucidation	   of	   the	   therapeutic	   potential	   of	   targeting	  HDFs	   and,	   ultimately,	   paves	   the	  way	   for	   a	  
HDF-­‐targeted	  TGS-­‐based	  treatment	  that	  provides	  durable,	  sustained	  inhibition	  of	  the	  virus.	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APPENDICES	  
	  
A1	  Standard	  laboratory	  practices	  
	  
A1.1	  Bacterial	  procedures	  
	  
A1.1.1	  Bacterial	  growth	  
	  
All	  of	  the	  work	  used	  the	  bacterial	  strain	  Escherichia	  coli	  DH5α	   (Hanahan	  1983).	  Cultures	  
were	   grown	   in	   LB	   broth	   (10%	   tryptone,	   5%	   yeast	   extract	   and	   10%	   NaCl	   (Merck,	   Darmstadt,	  
Germany))	  at	  37	  °C	  with	  shaking	  at	  350	  rpm	  in	  an	  orbital	  shaker	  (New	  Scientific	  Co,	  Inc.,	  NJ,	  USA).	  
Colonies	   were	   grown	   on	   LB	   agar	   plates	   (LB	   with	   10%	   agar	   (Merck,	   Darmstadt,	   Germany))	  
supplemented	  with	  200	  µg/ml	  ampicillin	  (Sigma-­‐Aldrich,	  MO,	  USA).	  
TA	  cloning	  required	  blue/white	  screening	  of	  colonies.	  In	  this	  case,	  ampicillin	  LB	  agar	  plates	  
were	   coated	   with	   800	   µg	   of	   both	   5-­‐bromo-­‐4-­‐chloro-­‐3-­‐indoyl-­‐β-­‐D-­‐galactopyranoside	   (X-­‐gal)	  
(Sigma,	   MO,	   USA)	   and	   isopropyl-­‐β-­‐D-­‐1-­‐thiogalactopyranoside	   (IPTG)	   (Roche,	   Mannheim,	  
Germany)	  and	  dried	  prior	  to	  plating	  of	  transformed	  bacteria.	  
	  
A.1.1.2	  Preparation	  of	  transformation-­‐competent	  DH5α 	  
	  
Chemically	  competent	  cells	  for	  use	  in	  transformations	  were	  prepared	  by	  growing	  DH5α	  in	  
100	  ml	  LB	  until	  log	  phase,	  or	  OD600	  0.4-­‐0.6.	  Cells	  were	  centrifuged	  for	  12	  min	  at	  59.5	  x	  g	  and	  the	  
cell	  pellets	  resuspended	  in	  transformation	  buffer	  (60	  mM	  CaCl2,	  15%	  glycerol	  and	  10	  mM	  PIPES,	  
pH	  7.0)	  and	  incubated	  on	  ice	  for	  30	  min.	  Cells	  were	  centrifuged	  at	  4	  °C	  for	  10	  min	  at	  59.5	  x	  g	  and	  
resuspended	  in	  2	  ml	  transformation	  buffer.	  Aliquots	  of	  100	  µl	  of	  competent	  cells	  were	  stored	  at	  -­‐
80	  °C.	  
	  
A1.1.3	  Transformation	  of	  DH5α 	  
	  
DNA	  was	  added	  to	  100	  µl	  of	  competent	  cells	  in	  a	  volume	  that	  did	  not	  exceed	  10	  µl.	  Cell-­‐
DNA	   mixtures	   were	   incubated	   on	   ice	   for	   30	   min,	   heat-­‐shocked	   at	   42	   °C	   for	   90	   sec	   and	   then	  
returned	  to	  ice	  for	  5	  min.	  Pre-­‐warmed	  LB	  (1	  ml)	  was	  added	  to	  the	  transformed	  cells	  which	  were	  
then	  incubated	  at	  37	  °C	  for	  1	  hour	  to	  allow	  expression	  of	  antibiotic	  resistance	  genes.	  Cells	  were	  
then	  plated	  onto	  LB	  agar	  plates	  supplemented	  with	  ampicillin,	  as	  described	  in	  A1.1.1.	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A1.1.4	  Storage	  of	  transformed	  DH5α 	  
	  
Samples	  of	  transformed	  DH5α	  were	  stored	  at	  -­‐80	  °C	  by	  adding	  1	  ml	  of	  log	  phase	  cultures	  
to	  0.3	  ml	  of	  100%	  glycerol.	  New	  cultures	  were	  inoculated	  by	  adding	  scrapings	  of	  the	  frozen	  stock	  
to	  LB	  supplemented	  with	  ampicillin,	  as	  described	  in	  A1.1.1.	  
	  
A1.2	  DNA	  procedures	  
	  
A1.2.1	  Small-­‐scale	  plasmid	  DNA	  preparation	  
	  
Plasmid	   DNA	   was	   isolated	   from	   4	   ml	   bacterial	   cultures	   using	   the	   High	   Pure	   Plasmid	  
Isolation	  Kit	  (Roche,	  Mannheim,	  Germany).	  Cultures	  were	  centrifuged	  at	  3,000	  x	  g	  for	  10	  min	  and	  
cell	  pellets	  resuspended	  in	  250	  µl	  suspension	  buffer	  (50	  mM	  Tris.HCl,	  10	  mM	  EDTA,	  pH	  8.5	  and	  2.5	  
mg	   RNase	   A).	   To	   suspensions,	   250	   µl	   lysis	   buffer	   (0.2	   M	   NaOH	   and	   1%	   SDS)	   was	   added	   and	  
samples	  were	   inverted	  several	   times	  to	  mix	  prior	   to	   incubation	  at	   room	  temperature	   for	  5	  min.	  
Three	  hundred	  and	  fifty	  microliters	  binding	  buffer	  (4	  M	  guanidine	  hydrochloride,	  0.5	  M	  potassium	  
acetate,	   pH	   4.2)	   was	   added	   and	   samples	   incubated	   on	   ice	   for	   5	  min	   prior	   to	   centrifugation	   at	  
16,000	  x	  g	  for	  1	  min.	  Supernatant	  was	  transferred	  to	  a	  High	  Pure	  filter	  tube	  that	  was	  centrifuged	  
for	  1	  min	  at	  16,000	  x	  g.	  Flow-­‐through	  was	  discarded	  and	  700	  µl	  wash	  buffer	  (20	  mM	  NaCl,	  2	  mM	  
Tris.HCl,	   pH	   7.5)	   added	   and	   samples	   were	   again	   centrifuged	   at	   16,000	   x	   g	   for	   1	   min.	   After	  
discarding	   the	   flow-­‐through	   once	  more,	   another	   centrifugation	   step	  was	   performed	   to	   remove	  
residual	  wash	  buffer	   from	  the	   filter.	  Filters	  were	  then	  transferred	  to	  a	  clean	  tube	  and	  100	  µl	  of	  
elution	   buffer	   (10	   mM	   Tris.HCl,	   pH	   8.5)	   applied.	   Samples	   were	   allowed	   to	   stand	   at	   room	  
temperature	   for	   2	   min	   prior	   to	   a	   final	   centrifugation	   at	   16,000	   x	   g	   to	   elute	   the	   filter-­‐bound	  
plasmid	  DNA.	  
The	   concentration	  of	   all	  DNA	  preparations	  was	  determined	  by	   spectrophotometry	  on	   a	  
NanoDrop	   (Themo	  Fisher	  Scientific,	   Inc.,	  MA,	  USA)	  where	  1	  absorbance	  unit	  at	  a	  wavelength	  of	  
260	   nm	   (A260)	   equates	   to	   50	   µg/ml	   dsDNA.	   Purity	   of	   samples	   was	   also	   determined	   by	  
spectrophotometry	  ie	  proximity	  of	  the	  A260/A280	  ratio	  to	  1.8.	  
	  
A1.2.2	  Bulk	  preparation	  of	  plasmid	  DNA	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Bulk	  plasmid	  DNA	  preparation	  from	  300	  ml	  LB	  bacterial	  cultures	  used	  the	  QIAGEN	  Plasmid	  
Maxi	  Kit	  (QIAGEN,	  CA,	  USA).	  Cells	  were	  centrifuged	  at	  3,000	  x	  g	   for	  20	  min	  and	  bacterial	  pellets	  
resuspended	  in	  10	  ml	  buffer	  P1	  (50	  mM	  Tris.HCl,	  pH	  8.0,	  10	  mM	  EDTA	  and	  100	  µg/ml	  RNase	  A).	  
Ten	  millilitres	  buffer	  P2	  (200	  mM	  NAOH	  and	  1%	  SDS)	  was	  then	  added,	  samples	  thoroughly	  mixed	  
by	  inversion	  and	  incubated	  at	  42	  °C	  for	  15	  min.	  Finally,	  10	  ml	  of	  buffer	  P3	  (3	  M	  potassium	  acetate,	  
pH	   5.5)	   was	   added	   to	   the	   lysate	   and	   samples	   were	   centrifuged	   at	   3,000	   x	   g	   for	   30	   min.	  
Supernatant	  was	  transferred	  to	  a	  QIAGEN-­‐tip	  500	  column,	  previously	  equilibrated	  with	  10	  ml	  QBT	  
buffer	   (750	  mM	  NaCl,	  50	  mM	  MOPS,	  pH	  7.0,	  15%	   isopropanol	   (v/v),	  0.15%	  Triton®	  X-­‐100	  (v/v)).	  
After	   the	   lysate	  had	  passed	   through	   the	   column,	   the	   column	  was	  washed	   twice	  with	  30	  ml	  QC	  
buffer	  (1	  M	  NaCl,	  50	  mM	  MOPS,	  pH	  7.0,	  15%	  isopropanol	  (v/v)).	  Bound	  DNA	  was	  eluted	  into	  10	  ml	  
isopropanol	   with	   addition	   of	   15	   ml	   QF	   buffer	   (1.25	   M	   NaCl,	   50	   mM	   Tris.HCl,	   pH	   8.5,	   15%	  
isopropanol	   (v/v))	   and	   then	   stored	  at	   -­‐20	   °C	  overnight.	   The	   following	  day,	  DNA	  precipitate	  was	  
collected	  by	  centrifugation	  at	  8,000	  x	  g	  at	  4	  °C	  for	  60	  min.	  DNA	  pellets	  were	  air-­‐dried	  for	  5	  min	  
before	  resuspension	  in	  250	  µl	  nuclease-­‐free	  water.	  
	  
A1.2.3	  DNA	  gel	  electrophoresis	  
	  
Agarose	   gels	   were	   prepared	   by	   heating	   the	   appropriate	   amounts	   of	   agarose	   (Sigma-­‐
Aldrich,	  MO,	  USA)	   and	  TAE	  buffer	   (40	  mM	  Tris	   acetate	   and	  1	  mM	  EDTA)	  until	   the	   agarose	  was	  
dissolved.	   Prior	   to	   pouring,	   1	   µl	   of	   ethidium	   bromide	   was	   added	   per	   50	   ml	   of	   agarose-­‐TAE	  
solution.	   DNA	   samples	   were	   mixed	   with	   6x	   orange	   loading	   dye	   (Fermentas,	   WI,	   USA)	   before	  
loading	   on	   the	   gel.	   Five	   microlitres	   of	   O’GeneRuler™	   DNA	   ladder	   (Fermentas,	   WI,	   USA)	   was	  
included	  in	  each	  gel.	  Electrophoresis	  was	  carried	  out	  at	  ~100	  volts.	  
	  
A1.2.4	  DNA	  extraction	  from	  agarose	  gels	  
	  
The	  MiniElute™	  Gel	  Extraction	  Kit	  (QIAGEN,	  CA,	  USA)	  was	  used	  to	  extract	  DNA	  fragments	  
from	  agarose	  gels.	  Desired	  fragments	  were	  excised	  using	  a	  scalpel,	  weighed	  and	  a	  volume	  of	  QG	  
buffer	  (proprietary	  information)	  equal	  to	  3x	  the	  weight	  of	  the	  gel	  fragment	  added	  to	  the	  sample.	  
Gel	  slices	  were	  dissolved	  by	   incubation	  at	  50	  °C	  for	  10	  min.	  One	  gel	  volume	  of	   isopropanol	  was	  
added	  and	  the	  mixture	  then	  transferred	  to	  a	  QIAquick	  spin	  column	  that	  was	  centrifuged	  for	  90	  sec	  
at	  16,000	  x	  g.	  Flow-­‐through	  was	  discarded	  and	  500	  µl	  QG	  buffer	  added	  to	  the	  column.	  Columns	  
were	  again	  centrifuged	  and	  flow-­‐through	  discarded	  as	  before.	  Filters	  were	  washed	  with	  750	  µl	  PE	  
buffer	  (proprietary	  information)	  and	  then	  an	  additional	  centrifugation	  step	  was	  performed	  to	  dry	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the	  column.	  DNA	  was	  eluted	  into	  a	  clean	  tube	  on	  application	  of	  50	  µl	  EB	  buffer	  (10	  mM	  Tris.HCl,	  
pH	  8.5)	  to	  the	  filter	  and	  centrifugation	  at	  16,000	  x	  g	  for	  2	  min.	  
	  
A1.2.5	  Calcium	  chloride	  method	  for	  DNA	  transfection	  
	  
DNA	  (<20	  µg)	  was	  mixed	  with	  62.5	  µl	  of	  buffer	  1	  (2	  M	  CaCl2)	  and	  then	  made	  up	  to	  500	  µl	  
with	  distilled	  water.	  Gradually,	  the	  DNA-­‐CaCl2	  mix	  was	  added	  to	  500	  µl	  buffer	  2	  (280	  nM	  NaCl,	  50	  
mM	  HEPES	  and	  1.5	  mM	  Na2HPO4,	  pH	  7.05)	  and	  incubated	  at	  room	  temperature	  for	  20	  min.	  The	  
DNA	  mix	  was	  added	  drop-­‐wise	  to	  cells	  and	  left	  overnight	  at	  37	  °C,	  5%	  CO2,	  pH	  5.	  
	  
A1.3	  RNA	  procedures	  
	  
A1.3.1	  RNA	  extraction	  from	  mammalian	  cells	  
	  
TriReagent™	  (Sigma-­‐Aldrich,	  MO,	  USA)	  was	  added	  to	  PBS-­‐washed	  cells	  that	  were	  then	  left	  
to	   stand	   at	   room	   temperature	   for	   5	  min.	   A	   volume	   of	   TriReagent™	  was	   used	   sufficient	   to	   just	  
cover	  adherent	  cells	  ie	  ~1	  ml	  per	  15	  cm2,	  or	  to	  lyse	  suspension	  cells	  ie	  ~1	  ml	  per	  1	  x	  107	  cells.	  200	  
µl	   chloroform	   per	  ml	   TriReagent™	  was	   added	   to	   samples	   that	   were	   then	   vortexed	   for	   10	   sec.	  
Samples	  stood	  at	  room	  temperature	  for	  5	  min	  prior	  to	  centrifugation	  at	  16,000	  x	  g	  for	  10	  min	  at	  4	  
°C.	  The	  RNA-­‐containing	  aqueous	  layer	  was	  transferred	  to	  700	  µl	  isopropanol	  per	  ml	  TriReagent™	  
and	   samples	   stored	   overnight	   at	   -­‐80	   °C	   to	   precipitate	   RNA.	   The	   following	   day,	   samples	   were	  
centrifuged	  at	  16,000	  x	  g	  for	  12	  min	  at	  4	  °C.	  The	  RNA	  pellets	  were	  washed	  with	  75%	  ethanol	  and	  
centrifuged	  again	  at	  16,000	  x	  g	  for	  8	  min	  at	  4	  °C.	  RNA	  was	  air-­‐dried	  for	  5	  min	  before	  resuspension	  
in	  DEPC-­‐treated	  nuclease-­‐free	  water	  (Ambion,	  TX,	  USA).	  Typically,	  RNA	  isolated	  from	  24-­‐well	  plate	  
cultures	  were	  resuspended	  in	  30	  µl.	  
	  
A1.3.2	  DNase	  treatment	  and	  reverse	  transcription	  
	  
RNA	   isolated	   from	  HEK293	   or	   TZM-­‐bl	   cells	  was	   prepared	   for	   qPCR	   by	  DNase	   treatment	  
and	   reverse	   transcription	   using	   the	   QuantiTect	   Reverse	   Transcription	   Kit	   (QIAGEN,	   CA,	   USA).	  
Genomic	   DNA	   elimination	   reactions	   contained	   ~100	   ng	   total	   RNA,	   1	   µl	   gDNA	   wipeout	   buffer	  
(proprietary	  information)	  and	  nuclease-­‐free	  water	  to	  a	  total	  volume	  of	  7	  µl,	  which	  were	  incubated	  
at	  42	  °C	  for	  2	  min	  before	  transfer	  to	  ice.	  To	  each	  sample,	  0.5	  µl	  Quantiscript	  reverse	  transcriptase,	  
2	  µl	  of	  Quantiscript	  RT	  buffer	   (proprietary	   information)	  and	  0.5	  µl	  of	  RT	  primer	  mix	  was	  added,	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followed	   by	   incubation	   at	   42	   °C	   for	   15	   min.	   Subsequent	   incubation	   at	   95	   °C	   for	   3	   min	   was	  
performed	   to	   inactivate	   the	   RT	   enzyme.	   The	   resultant	   cDNA	   was	   stored	   at	   -­‐20	   °C	   if	   not	   used	  
immediately	  in	  qPCR.	  
	  
A1.3.3	  Preparation	  of	  radiolabelled	  Decade™	  Marker	  
	  
Radiolabelled	   Decade™	   Marker	   (Ambion,	   TX,	   USA)	   was	   prepared	   by	   mixing	   100	   ng	  
Decade™	  Marker	  RNA,	  20	  pmol	  γ-­‐32P-­‐ATP	   (~6,000	  Ci/mmol),	   10	  U	  T4	  polynucleotide	  kinase	  and	  
kinase	  reaction	  buffer	  (proprietary	  information)	  in	  a	  volume	  of	  10	  µl	  and	  incubation	  at	  37	  °C	  for	  1	  
hour.	  Subsequently,	  cleavage	  reagent	  (proprietary	  information)	  was	  added	  to	  reactions	  made	  up	  
to	  20	  µl	  and	  incubated	  for	  5	  min	  at	  room	  temperature.	  
	  
A1.3.4	  Quantitative	  polymerase	  chain	  reaction	  (qPCR)	  
	  
cDNA	   generated	   from	  HEK293	   or	   TZM-­‐bl	   cells	   was	   subject	   to	   qPCR	   reactions	   using	   the	  
Lightcycler®	   FastStart	   DNA	  MasterPLUS	   SYBR	   Green	   I	   Kit	   (Roche,	   Mannheim,	   Germany).	   Twenty	  
microlitre	  reactions	  contained	  1	  µl	  cDNA	  (see	  A1.3.2),	  20	  µmol	  of	  each	  primer	  and	  4	  µl	  of	  Master	  
Mix	   (proprietary	   information).	   Reactions	   were	   set	   up	   in	   chilled	   capillaries	   (Roche,	   Mannheim,	  
Germany)	   that	  were	   centrifuged	   at	   700	   x	  g	   for	   15	   sec	   prior	   to	   loading	   into	   the	  Carousel-­‐Based	  
Lightcycler®	  V.2	  System	  (Roche,	  Mannheim,	  Germany).	  
cDNA	  generated	  from	  SupT1	  cells	  was	  subject	  to	  qPCR	  reactions	  using	  the	  SensiMix™	  Lite	  
Kit	   (Quantace	  Ltd,	  London,	  UK).	  As	  above,	  the	  reactions	  were	  20	  µl	   in	  volume	  and	  assembled	   in	  
capillaries.	   Reactions	   contained	   1	   µl	   cDNA,	   4	   µl	   SensiMix™	   (proprietary	   information),	   1.5	   µl	  
enzyme	   (proprietary	   information),	  0.4	  µl	   SYBR	  solution	   (proprietary	   information)	  and	  4	  µmol	  of	  
each	  primer.	  
	  
A1.4	  Viral	  procedures	  
	  
A1.4.1	  Propagation	  of	  HIV-­‐1	  subtype	  C	  isolate	  FV5	  
	  
A	  thawed	  aliquot	  of	  FV5	  was	  added	  to	  a	  70%	  confluent	  75	  cm2	  flask	  of	  TZM-­‐bl	  cells	  in	  the	  
presence	   of	   15	  µg/ml	   DEAE-­‐D.	   Twenty-­‐four	   hours	   later,	   the	  media	  was	   removed	   and	   10	  ml	   of	  
fresh	  media	  added	   to	  cells.	  Another	  24	  hours	   later,	   the	  media	  was	  collected,	   filtered,	  aliquoted	  
and	  stored	  at	  -­‐80	  °C.	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A.1.4.2	  Generation	  of	  HIV-­‐1	  subtype	  B	  molecular	  clone	  p81A-­‐4	  
	  
A	  25	  cm2	   flask	  was	  seeded	  with	  1.2	  x	  106	  HEK293T	  cells.	  24	  hours	   later,	  4	  µg	  of	  p81A-­‐4	  
was	  mixed	  with	  150	  µl	  serum-­‐free	  DMEM	  containing	  40	  µl	  PolyFect	  transfection	  reagent	  (QIAGEN,	  
CA,	  USA).	  The	  DNA	  mix	  was	  allowed	  to	  stand	  at	  room	  temperature	  for	  5	  min	  prior	  to	  addition	  to	  
cells.	  Twenty-­‐four	  hours	  later,	  the	  culture	  media	  was	  replaced	  with	  fresh	  media.	  Another	  24	  hours	  
later,	  media	  was	  collected,	  filtered,	  made	  up	  to	  20%	  FCS,	  aliquoted	  and	  stored	  at	  -­‐80	  °C.	  
	  
A.1.4.3	  Median	  tissue	  culture	  infectious	  dose	  (TCID50)	  from	  luciferase	  output	  
	  
TZM-­‐bl	  cells	  were	  seeded	  at	  1	  x	  104	  cells	  per	  well	  in	  a	  96-­‐well.	  The	  remaining	  wells	  were	  
filled	  with	  PBS	   to	  minimise	  plate	  dehydration.	  Twenty-­‐four	  hours	   later,	  all	  media	  was	   removed.	  
For	   subtype	   B	   molecular	   clones	   pSG3Δenv.ZM53M	   and	   p81A-­‐4,	   an	   8-­‐fold	   dilution	   of	   virus	   was	  
prepared	  and	  added	  to	  the	  cells	  in	  triplicate,	  along	  with	  100	  µl	  media	  containing	  30	  µg/ml	  DEAE-­‐
D,	  resulting	  in	  a	  final	  concentration	  of	  DEAE-­‐D	  of	  15	  µg/ml	  and	  a	  final	  dilution	  of	  virus	  of	  4-­‐2.	  To	  
the	  other	  wells,	  150	  µl	  media	  was	  added,	  containing	  15	  µg/ml	  DEAE-­‐D.	  50	  µl	  of	  virus-­‐containing	  
media	   from	   the	   three	   4-­‐2	  wells	  was	   transferred	   to	   another	   3	  wells	   ie	   a	   4-­‐fold	   dilution,	   4-­‐3.	   This	  
transfer	  of	  50	  µl	  was	  repeated	  across	  the	  plate	  until	  a	  virus	  dilution	  of	  4-­‐8	  was	  obtained.	  Another	  
set	   of	   wells	   received	   150	   µl	   of	   media	   only	   ie	   no	   virus.	   A	   similar	   dilution	   series	   was	   used	   in	  
determining	   the	   TCID50	   for	   subtype	   C	   isolate	   FV5,	   but	   in	   this	   case	   an	   8-­‐fold	   dilution	   series	  was	  
used,	  spanning	  2-­‐4	  to	  2-­‐22.	  
Twenty-­‐four	   hours	   post-­‐infection,	   cells	   were	   washed	   three	   times	   with	   300	   µl	   PBS	   and	  
then	  received	  150	  µl	  media.	  Another	  24	  hours	  later,	  Tat-­‐induced	  luciferase	  activity	  was	  quantified	  
using	   the	   Bright-­‐Glo™	   Luciferase	   Assay	   System	   (Promega,WI,	   USA),	   as	   described	   in	   2.2.10.	  
Samples	  were	  considered	   luciferase	  positive	   if	   the	   luminescence	  signal	  was	  greater	   than	  that	  of	  
the	  mean	  of	  the	  no	  virus	  samples	  plus	  two	  standard	  deviations.	  
TCID50	  was	  calculated	  using	  the	  Spearman-­‐Karber	  method	  (Chou	  and	  Talalay	  1984;	  Kahan	  
et	  al.	  1991):	  
	  	   	   	   	   	   	   	   (A1.1)
	  
where	  M	  is	  the	  viral	  dilution	  at	  which	  50%	  of	  cells	  are	  luciferase	  positive,	  k	  is	  the	  dose	  of	  
the	  highest	  dilution	  (k	  =	  -­‐8	  for	  p81A-­‐4	  and	  k	  =	  -­‐22	  for	  FV5),	  d	  is	  the	  spacing	  between	  dilutions	  (d	  =	  
! 
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1	  for	  p81A-­‐4	  and	  d	  =	  3	  for	  FV5),	  s	  is	  the	  number	  of	  negative	  samples	  and	  n	  is	  the	  wells	  per	  dilution	  
(n	  =	  3).	  The	  50%	  endpoint	  was	  converted	  to	  a	  viral	  titre	  as	  follows:	  
	   	   	   	   	   	   (A1.2)	  
where	  v	  is	  the	  culture	  volume	  (ml)	  and	  r	  is	  the	  radix	  for	  the	  dilution	  series	  (r	  =	  4	  for	  p81A-­‐
4	  and	  r	  =	  2	  for	  FV5).	  
	  
A1.4.4	  HIV-­‐1	  p24	  ELISA	  
	  
Culture	  supernatant	  isolated	  from	  HIV-­‐1-­‐infected	  samples	  were	  analysed	  for	  levels	  of	  the	  
HIV-­‐1	  antigen	  p24	  by	  ELISA	  using	  the	  Murex	  HIV	  antigen	  mAb	  (Murex	  Biotech	  Ltd,	  Kent,	  UK).	  One	  
hundred	  microlitres	  of	  sample	  was	  incubated	  with	  100	  µl	  of	  conjugate	  1	  (biotinylated	  murine	  anti-­‐
p24	  monoclonal	  antibodies,	  bovine	  albumin,	  Proclin®	  preservative,	  aggregated	  human	  IgG	  in	  PBS,	  
heat	   inactivated	   mouse	   serum,	   and	   NP40,	   bovine	   casein	   and	   bovine	   aprotinin;	   concentrations	  
unreported)	  in	  wells	  pre-­‐coated	  with	  human	  anti-­‐HIV	  polyclonal	  antibodies	  at	  37	  °C	  for	  1	  hour.	  In	  
each	  assay,	  a	  negative	  control	  (human	  serum	  negative	  for	  HIV	  antigens)	  was	  included,	  as	  well	  as	  a	  
positive	  control	  (recombinant	  p24)	  at	  various	  dilutions	  in	  matrix	  (PBS	  containing	  bovine	  proteins)	  
to	   enable	   generation	   of	   a	   p24	   standard	   curve	   and	   absolute	   determination	   of	   p24	   levels	   in	  
samples.	  
Following	  the	  incubation	  with	  conjugate	  1,	  wells	  were	  washed	  five	  times	  with	  300	  µl	  wash	  
fluid	   (PBS	   with	   Proclin®	   preservative).	   Two	   hundred	   microlitres	   conjugate	   2	   (peroxidase	  
conjugated	  streptavidin,	  PBS,	  Proclin®	  preservative,	  bovine	  casein	  and	  bovine	  aprotinin)	  was	  then	  
added	   to	   each	   well	   followed	   by	   an	   incubation	   at	   37	   °C	   for	   30	   min.	   Wells	   were	   washed	   as	  
previously	   prior	   to	   addition	   of	   200	   µl	   substrate	   solution	   (tetramethylbenzidine,	   DMSO,	  
thiomersal,	  phosphate	  citrate	  and	  hydrogen	  peroxide)	  and	  incubation	  at	  room	  temperature	  for	  30	  
min.	   Finally,	   50	  µl	   of	   2	  M	   sulphuric	   acid	  was	   added	   to	  each	  well	  which	  were	   then	   left	   at	   room	  
temperature	  for	  5	  to	  15	  min.	  Absorbance	  at	  a	  wavelength	  of	  450	  nm	  with	  655	  nm	  as	  reference	  
was	  determined	  in	  a	  Model	  680	  microplate	  reader	  (BioRad,	  CA,	  USA).	  
Some	   samples	   were	   first	   analysed	   at	   various	   dilutions	   to	   determine	   the	   appropriate	  
dilution	  to	  achieve	  an	  output	  within	  the	  range	  of	  the	  standard	  curve	  (A450	  <1.2).	  
	  
A.1.4.5	  Median	  tissue	  culture	  infectious	  dose	  (TCID50)	  from	  p24	  output	  
	  
SupT1	  cells	  were	  seeded	  at	  1	  x	  104	  cells	  per	  well	   in	  a	  96-­‐well	  plate.	  The	  remaining	  wells	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x	  g	  to	  pellet	  cells	  and	  all	  media	  was	  removed.	  For	  subtype	  B	  molecular	  clone	  p81A-­‐4,	  cells	  were	  
resuspended	  in	  200	  µl	  of	  4-­‐fold	  serial	  virus	  dilutions,	  ranging	  from	  4-­‐2	  to	  4-­‐8.	  	  For	  subtype	  C	  isolate	  
FV5,	  cells	  were	  resuspended	  in	  200	  µl	  of	  8-­‐fold	  serial	  virus	  dilutions,	  ranging	  from	  2-­‐4	  to	  2-­‐22.	  
Twenty-­‐four	   hours	   post-­‐infection,	   plates	   were	   centrifuged	   at	   130	   x	   g	   and	   all	   media	  
removed.	  Cells	  were	  then	  washed	  three	  times	  with	  PBS	  by	  addition	  of	  300	  µl	  per	  well	  followed	  by	  
centrifugation	  at	  130	  x	  g	  and	  PBS	  removal.	  SupT1	  cells	  were	  then	  resuspended	  in	  350	  µl	  media,	  
centrifuged	  at	  130	  x	  g	  and	  150	  µl	   stored	  at	   -­‐80	  °C	  as	  day	  0	  samples.	  Cells	  were	   incubated	  for	  7	  
days	  prior	  to	  centrifugation	  to	  pellet	  cells	  and	  removal	  of	  150	  µl	  media.	  Both	  day	  0	  and	  7	  samples	  
were	  analysed	  by	  p24	  ELISA	  (see	  A1.4.4),	  the	  former	  to	  verify	  that	  there	  was	  no	  residual	  infecting-­‐
virus	  following	  washing.	  Day	  7	  samples	  were	  run	  neat	  and	  classed	  as	  negative	  if	  the	  A450	  was	  less	  
than	  the	  absorbance	  of	  the	  negative	  control	  +	  0.50.	  The	  viral	  titre	  was	  calculated	  as	  described	  in	  
equations	  A1.1	  and	  A1.2	  (see	  A1.4.3).	  
	  
A1.5	  Other	  standard	  laboratory	  procedures	  
	  
A1.5.1	  Bicinchoninic	  acid	  (BCA)	  method	  for	  protein	  quantification	  
	  
Protein	   in	   cell	   lysates	  was	   quantified	   using	   the	   Pierce®	   bicinchoninic	   acid	   (BCA)	   Protein	  
Assay	  Kit	  (Thermo	  Fisher	  Scientific	  Inc,	  IL,	  USA).	  This	  method	  combines	  reduction	  of	  Cu+2	  to	  Cu+1	  by	  
protein	   in	  an	  alkaline	  medium	  (the	  biuret	   reaction)	  with	  colourimetric	  detection	  of	   the	  cuprous	  
cation	  (Cu+1)	  using	  a	  reagent	  containing	  bicinchoninic	  acid.	  Briefly,	  10	  µl	  of	  cell	   lysate	  was	  mixed	  
with	  186	  µl	  of	  Reagent	  A	  and	  4	  µl	  of	  Reagent	  B	  and	  incubated	  at	  37	  °C	  for	  30	  min.	  Absorbance	  at	  a	  
wavelength	  of	  562	  nm	  was	  determined	   in	  a	  BioSpec-­‐mini	   spectrophotometer	   (Shimadzu,	  Kyoto,	  
Japan),	  blanked	  with	  a	  sample	  that	  contained	  10	  µl	  RIPA	  buffer	  instead	  of	  cell	  lysate.	  A	  standard	  
curve,	   generated	   by	   L.	   Thompson	   using	   bovine	   serum	   albumin	   at	   various	   concentrations,	   was	  
used	  to	  determine	  the	  concentration	  of	  protein	  in	  samples.	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A2	  Transcriptional	  gene	  silencing	  of	  HIV-­‐dependency	  factors	  	  
A2.1	  Introduction	  
	  
This	  appendix	  describes	  initial	  attempts	  to	  induce	  classical	  TGS	  at	  HDFs	  and	  preceded	  the	  
work	  reported	  in	  Chapter	  4.	  This	  work	  was	  performed	  at	  The	  Scripps	  Research	  Institute,	  La	  Jolla,	  
CA,	  USA,	  in	  collaboration	  with	  K.	  Morris.	  	  
TGS	   effectors	  may	   be	   processed	   from	   longer	   dsRNA	   precursors	   or	   from	   siRNAs	   by	   the	  
RNAi	   pathway.	   In	   addition,	   promoter-­‐targeted	   expressed	   antisense	   RNAs	   (asRNAs)	   alone	   have	  
been	   shown	   to	   mediate	   TGS	   (Weinberg	   et	   al.	   2006).	   PTGS	   of	   PSIP1/LEDGF/p75	   (Llano	   et	   al.	  
2006a),	  HTATSF1	  (Miller	  et	  al.	  2009)	  and	  DDX3X	  (Ishaq	  et	  al.	  2008)	  have	  all	  been	  shown	  to	  inhibit	  
HIV-­‐1	  replication.	  Given	  the	  advantages	  of	  TGS	  over	  PTGS,	  this	  study	  investigated	  the	  possibility	  of	  
inducing	  TGS	  at	  these	  genes	  with	  promoter-­‐targeting	  asRNAs	  and/or	  siRNAs	  in	  HEK293T	  cells.	  
Both	   asRNA	   and	   siRNA	   target	   sites	   were	   initially	   selected	   by	   K.	   Morris	   using	   the	   Cold	  
Spring	  Harbor	  (CSH)	  transcriptional	  regulatory	  element	  database	  (TRED)	  (Zhao	  et	  al.	  2005;	  Jiang	  et	  
al.	  2007).	  Although	  some	  siRNAs	  did	  result	   in	  suppressed	  PSIP1	  expression,	  further	   investigation	  
into	  the	  mode	  of	  knock	  down,	  including	  examination	  of	  the	  levels	  of	  target	  region	  transcripts,	  the	  
role	  of	  Ago	  proteins,	  histone	  modifications	  at	  the	  target	  region	  and	  transcription	  rate,	  supported	  
a	  PTGS,	  not	  TGS,	  mechanism.	  Alignment	  of	  the	  target	  site	  with	  the	  genome	  revealed	  targeting	  of	  
the	  psip1	   3’	   UTR,	   not	   the	   promoter,	   demonstrating	   that	   regulatory	   element	   databases	  may	   be	  
flawed	  in	  their	  prediction	  of	  TSSs.	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A2.2	  Materials	  and	  methods	  
	  
A2.2.1	  Design	  of	  target	  sites	  within	  HDF	  promoters	  
	  
Target	  sequences	  were	  selected	  by	  K.Morris,	  The	  Scripps	  Research	  institute,	  CA,	  USA,	  as	  
follows:	  promoters	  for	  htatsf1	  (Entrez	  gene	  ID	  27336;	  promoter	  ID	  43694),	  psip1	  (Entrez	  gene	  ID	  
11168;	  promoter	  ID	  123760)	  and	  ddx3x	  (Entrez	  gene	  ID	  1654;	  promoter	  ID	  43224)	  were	  retrieved	  
from	  the	  CSH	  TRED	  (http://rulai.cshl.edu/cgi-­‐bin/TRED/tred.cgi?process=home)	  (Zhao	  et	  al.	  2005;	  
Jiang	  et	  al.	  2007).	  Sequences	  700	  bp	  upstream	  of	   the	  designated	  TSS	   for	   these	  promoters	  were	  
analysed	   by	   siRNA	   target	   finder	   (http://www.ambion.com/techlib/misc/siRNA_finder.html)	  
(Ambion,	  TX,	  USA)	  (Table	  A2.1).	  
	  
A2.2.2	  Cloning	  of	  expressed	  asRNAs	  
	  
Generation	   of	   asRNA	   expression	   cassettes	   was	   by	   a	   PCR	   approach.	   Amplification	   was	  
carried	   out	   with	   a	   U6	   forward	   primer	   (Table	   2.2),	   containing	   a	   BamHI	   restriction	   site,	   and	   a	  
reverse	  primer	  that	  contained	  sequences	  complementary	  to	  the	  3’	  end	  of	  the	  U6	  promoter,	  the	  
asRNA	   and	   a	   Pol	   III	   termination	   signal	   (Table	  A2.1).	   The	  DNA	  plasmid	   pTZU6+1	   (Bertrand	   et	   al.	  
1997),	  which	  contains	  the	  human	  U6	  small	  nuclear	  RNA	  promoter	  (GenBank®	  accession	  number	  
X59362),	  was	  used	  as	  a	  template.	  PCR	  was	  performed	  on	  a	  Mastercycler®	  (BioRad,	  CA,	  USA)	  using	  
Expand	   High	   FidelityPLUS	   PCR	   System	   reagents	   (Roche,	  Mannheim,	   Germany).	   The	   PCR	   reaction	  
included	  10	  ng	  template,	  Expand	  HiFiPLUS	  reaction	  buffer	  (proprietary	  information),	  1.5	  mM	  MgCl2,	  
200	  µM	   dNTP	  mix,	   2.5	   U	   of	   Expand	   HiFiPLUS	   Taq	   polymerase	   and	   10	   pmol	   of	   each	   primer	   in	   a	  
volume	  of	  50	  µl.	  	  Thermocycling	  conditions	  were	  95	  °C	  for	  10	  min,	  30	  cycles	  of	  denaturation	  at	  95	  
°C,	  annealing	  at	  62	  °C	  and	  extension	  at	  72	  °C,	  each	  for	  30	  sec,	  followed	  by	  a	  final	  extension	  at	  72	  
°C	   for	   10	   min.	   Amplification	   specificity	   was	   confirmed	   by	   resolution	   of	   PCR	   products	   on	   a	   2%	  
agarose	  gel	  (see	  A1.2.3).	  
PCR	   products	   were	   ligated	   directly	   into	   pTZ57R/T	   (Fermentas,	   WI,	   USA),	   a	   TA	   cloning	  
vector.	  The	  ligation	  reaction	  contained	  a	  3:1	  molar	  ratio	  of	  insert	  to	  vector	  (180	  fmol	  insert	  to	  60	  
fmol	  vector)	  and	  20	  U	  T4	  DNA	  ligase	  (New	  England	  Biolabs®,	  Inc.,	  MA,	  USA)	  in	  a	  volume	  of	  20	  µl,	  
which	   was	   incubated	   at	   room	   temperature	   overnight.	   Ten	   microlitres	   of	   the	   ligation	   reaction	  
mixture	  was	  used	  to	  transform	  100	  µl	  of	  chemically	  competent	  Escherichia	  coli	  DH5α	  (Invitrogen,	  
CA,	   USA)	   (see	   A1.1.1,	   A1.1.2	   and	   A1.1.3).	   Transformed	   cells	   were	   plated	   on	   LB	   agar	   plates	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containing	   ampicillin	   (Gibco,	   BRL,	   UK),	   X-­‐gal	   (Sigma,	   MO,	   USA)	   and	   IPTG	   (Roche,	   Mannheim,	  
Germany)	  and	  incubated	  at	  37	  °C	  overnight	  (see	  A1.1.1).	  
	  
Table	  A2.1:	  Oligonucleotide	  primers	  used	  to	  generate	  asRNAs	  targeting	  HDF	  promoters.	  
Primer	   Sequence	  (5’-­‐3’)	  
Target	  location	  
(relative	  to	  TSS)	  
asH1	  reverse	   AAAAAAGAAGCGGAGTTTCCCGGCGGTGTTTCGTCCTTTCCACAA	   -­‐542	  to	  -­‐522	  
asH2	  reverse	   AAAAAAGTTCGAAGCTCGAGCGCCAGGTGTTTCGTCCTTTCCACAA	   -­‐471	  to	  -­‐451	  
asH3	  reverse	   AAAAAAGCTCGAGCGCCACTGAAATGGTGTTTCGTCCTTTCCACAA	   -­‐464	  to	  -­‐444	  
asH4	  reverse	   AAAAAAGACGCGGTTCCTGAGCGGGTGTTTCGTCCTTTCCACAA	   -­‐194	  to	  -­‐174	  
asP1	  reverse	   AAAAAATCATGATGCTTATACGGTGTTTCGTCCTTTCCACAA	   -­‐571	  to	  -­‐551	  
asP2	  reverse	   AAAAAATCATGGCTATATTGTTTTGGTGTTTCGTCCTTTCCACAA	   -­‐506	  to	  -­‐486	  
asP3	  reverse	   AAAAAATGGCTTAAGACCAGCGTCGGTGTTTCGTCCTTTCCACAA	   -­‐256	  to	  -­‐236	  
asP4	  reverse	   AAAAAAGACCAGCGTCTCTGTATGAGGTGTTTCGTCCTTTCCACAA	   -­‐247	  to	  -­‐227	  
asP5	  reverse	   AAAAAACCTGCATATATACCAGTCAGGTGTTTCGTCCTTTCCACAA	   -­‐122	  to	  -­‐102	  
Sequences	   complementary	   to	   the	   3’	   end	   of	   the	   U6	   promoter	   are	   underlined	   and	   to	   a	   Pol	   III	   termination	   signal	   are	  
shaded	  grey.	  Those	  complementary	  to	  the	  asRNA	  (and,	  therefore,	  the	  same	  sequence	  as	  the	  target	  site)	  are	  in	  bold.	  
	  
White	   colonies	   were	   screened	   for	   the	   presence	   of	   asRNA	   expression	   cassettes	   by	  
culturing	   in	   4	   ml	   LB	   broth	   supplemented	   with	   ampicillin	   overnight	   at	   37	   °C	   with	   shaking	   (see	  
A1.1.1).	   Plasmids	   were	   prepared	   using	   the	   High	   Pure	   Plasmid	   Isolation	   Kit	   (Roche,	  Mannheim,	  
Germany)	  (see	  A1.2.1)	  and	  screened	  for	  insert	  presence	  and	  orientation	  by	  digesting	  5	  µg	  with	  5	  
U	  EcoRI	   and	  5	  U	  of	  either	  HindIII	   or	  BamHI	   (Fermentas,	  WI,	  USA)	   for	   I	   hour	  at	  37	   °C	   in	  a	  20	  µl	  
reaction	   containing	  Tango	  Buffer	   (Fermentas,	  WI,	  USA).	  Digestion	   reactions	  were	   resolved	  on	  a	  
2%	  agarose	  gel	  (see	  A1.2.3).	  Clones	  that	  exhibited	  the	  desired	  digestion	  products	  were	  sequenced	  
using	  M13	  forward	  (5’	  GTA	  AAA	  CGA	  CGG	  CCA	  G	  3’)	  and	  reverse	  (5’	  CAG	  GAA	  ACA	  GCT	  ATG	  AC	  3’)	  
primers	  by	  automated	  cycle	  sequencing	  (Inqaba	  Biotec,	  Pretoria,	  South	  Africa).	  Those	  containing	  
correct	  asRNA	  expression	  cassettes	  were	  cultured	  in	  300	  ml	  ampicillin-­‐supplemented	  LB	  overnight	  
at	   37	   °C	   (see	   A1.1.1)	   with	   shaking	   prior	   to	   bulk	   plasmid	   DNA	   preparation	   using	   the	   QIAGEN	  
Plasmid	  Maxi	  Kit	  (QIAGEN,	  CA,	  USA)	  (see	  A1.2.2).	  
	  
A2.2.3	  Design	  and	  generation	  of	  siRNAs	  	  
	  
Target	   sequences	  were	   again	   selected	  by	  K.	  Morris,	   as	   described	   in	  A2.2.1,	   focusing	  on	  
sequences	  within	  200	  bp	  upstream	  of	   the	  TSS,	  as	  empirically	  he	  had	   the	  most	   success	   inducing	  
TGS	  when	   targeting	   this	   region.	   siRNAs	  were	   generated	   from	   oligonucleotide	   templates	   (Table	  
A2.2)	  using	  the	  Silencer®	  siRNA	  Construction	  Kit	  (Ambion,	  TX,	  USA)	  (see	  4.2.3).	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Table	  A2.2:	  Oligonucleotide	  templates	  used	  to	  generate	  HDF	  promoter-­‐targeting	  siRNAs.	  
siRNA	   Strand	   Oligonucleotide	  template	   Target	  location	  (relative	  to	  TSS)	  
Sense/passenger	   AACAGGACAAATTTCTCTGGCCCTGTCTC	  
siH10	  
Antisense/guide	   AAGCCAGAGAAATTTGTCCTGCCTGTCTC	  
-­‐132	  to	  -­‐112	  
Sense/passenger	   AATGGGGCGGACAGGACAAATCCTGTCTC	  
siH11	  
Antisense/guide	   AAATTTGTCCTGTCCGCCCCACCTGTCTC	  
-­‐123	  to	  -­‐103	  
Sense/passenger	   AAGAAGGAAGGCGTGGGAATACCTGTCTC	  
siH12	  
Antisense/guide	   AATATTCCCACGCCTTCCTTCCCTGTCTC	  
-­‐47	  to	  -­‐27	  
Sense/passenger	   AAACAAGTTTACACGTTGAACCCTGTCTC	  
siP10	  
Antisense/guide	   AAGTTCAACGTGTAAACTTGTCCTGTCTC	  
-­‐44	  to	  -­‐24	  
Sense/passenger	   AAATGAAAACAAGTTTACACGCCTGTCTC	  
siP11	  
Antisense/guide	   AACGTGTAAACTTGTTTTCATCCTGTCTC	  
-­‐38	  to	  -­‐18	  
Sense/passenger	   AATTCTTTAATGAAAACAAGTCCTGTCTC	  
siP12	  
Antisense/guide	   AAACTTGTTTTCATTAAAGAACCTGTCTC	  
-­‐31	  to	  -­‐11	  
Sense/passenger	   AAAGGTCTAAGCTCAAGGGATCCTGTCTC	  
siD10	  
Antisense/guide	   AAATCCCTTGAGCTTAGACCTCCTGTCTC	  
-­‐157	  to	  -­‐137	  
Sense/passenger	   AAAATTCCCTGTCGCGGCGACCCTGTCTC	  
siD11	  
Antisense/guide	   AAGTCGCCGCGACAGGGAATTCCTGTCTC	  
-­‐111	  to	  -­‐91	  
Sense/passenger	   AACCTCCCTCTCACACCGCAACCTGTCTC	  
siD12	  
Antisense/guide	   AATTGCGGTGTGAGAGGGAGGCCTGTCTC	  
-­‐94	  to	  -­‐74	  
All	   siRNA	   oligonucleotide	   templates	   had	   the	   CCTGTCTC	   sequence	   at	   their	   3’	   end	   to	   allow	   hybridisation	  with	   the	   T7	  
promoter	  primer	  within	   the	  Silencer®	   siRNA	  Construction	  Kit	   (Ambion,	  TX,	  USA).	  Target	   sequences	  are	   in	   italics.	   Two	  
nucleotide	  overhangs	  are	  underlined.	  
	  
A2.2.4	  Screening	  for	  suppression	  of	  target	  gene	  expression	  
	  
To	  assess	  whether	  asRNAs	  or	  siRNAs	  targeting	  HDF	  promoters	  were	  capable	  of	  reducing	  
target	  mRNA	  levels,	  HEK293T	  cells	  were	  seeded	  at	  2	  x	  105	  cells	  per	  well	  in	  a	  24-­‐well	  plate.	  Twenty-­‐
four	   hours	   later,	   cells	  were	   transfected	  with	   1	  µg	   plasmid	  DNA	  per	  well	   (see	   2.2.5)	   or	   100	   nM	  
HDF-­‐targeting	   siRNA	   (see	  4.2.4)	   in	   triplicate.	  A	  negative	   control	   siRNA,	  R149,	   targeting	   the	   ccr5	  
promoter	  (Entrez	  gene	  ID	  1234)	  with	  guide	  sequence	  5’	  CCG	  CCA	  AGA	  GAG	  CUU	  GAU	  AAA	  3’	  was	  
also	   used	   (gift	   from	   K.	  Morris)	   (Kim	   et	   al.	   2006).	   Another	   negative	   control	   siRNA	   targeting	   the	  
gapdh	   (Entrez	   gene	   ID	   2597)	  mRNA,	   siGAPDH,	   was	   prepared	   using	   the	   control	   oligonucleotide	  
templates	  (sequences	  not	  provided)	  supplied	  in	  the	  Silencer®	  siRNA	  Construction	  Kit	  (Ambion,	  TX,	  
USA)	   (see	   4.2.3).	   Seventy-­‐two	   hours	   post-­‐transfection,	   RNA	  was	   extracted	   (see	   A1.3.1),	   DNase-­‐
treated	   and	   reverse	   transcribed	   (see	   3.2.12).	   qPCR	   on	   the	   resulting	   cDNA	   was	   performed	   as	  
described	   in	   2.2.7	   using	   the	   SensiMix™	   Lite	   Kit	   (Quantace	   Ltd,	   London,	   UK)	   (see	   A1.3.4)	   and	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primers	   listed	   in	   Table	   2.4.	   Where	   indicated,	   target	   gene	   expression	   was	   reported	   relative	   to	  
gapdh	  mRNA	  (for	  primers	  see	  Table	  A2.3),	  rather	  than	  actb.	  
	  
A2.2.5	  Detection	  of	  promoter-­‐associated	  transcripts	  
	  
To	   examine	   whether	   transcripts	   were	   detectable	   in	   various	   regions	   of	   the	   htatsf1	   and	  
psip1	   promoter,	   RNA	   was	   extracted	   from	   HEK293T	   cells.	   One	   microgram	   of	   RNA	   was	   DNase-­‐
treated	  and	  reverse	  transcribed	  (see	  3.2.12)	   in	  duplicate.	  Another	  1	  µg	  of	  RNA	  per	  cell	   line	  was	  
DNase-­‐treated	   but	   not	   reverse	   transcribed	   to	   allow	   quantification	   of	   undigested	   genomic	   DNA	  
(gDNA).	  An	  additional	  control	  lacking	  RNA	  was	  included	  per	  cell	  line.	  
qPCR	  was	   performed	   as	   described	   in	   2.2.7	   using	   the	   SensiMix™	   Lite	   Kit	   (Quantace	   Ltd,	  
London,	   UK)	   (see	   A1.3.4).	   Primers	   were	   designed	   to	   amplify	   regions	   encompassing	   the	   siRNA	  
target	  sites	  and	  a	  region	  upstream	  of	  the	  siRNA	  target	  sites	  in	  the	  psip1	  promoter	  (Table	  A2.3).	  A	  
coding	   region	   within	   gapdh	   was	   also	   amplified	   (Table	   A2.3),	   to	   which	   promoter	   transcript	  
abundance	  could	  be	  compared.	  Expression	  of	  transcripts	  was	  calculated	  as	  described	  in	  4.2.5	  and	  
qPCR	  products	  resolved	  on	  a	  2%	  agarose	  gel	  (A1.2.3).	  
	  
Table	  A2.3:	  Primers	  used	  to	  determine	  levels	  of	  promoter-­‐associated	  transcripts.	  	  
Primer	   Sequence	  (5’-­‐3’)	   Amplicon	  length	  (bp)	  
psip1	  upstream	  forward	   AGCAACTGACATGGAACTGAGA	  
psip1	  upstream	  reverse	   TATACCCAGTCAGTTGTCTGCA	  
125	  
psip1	  siRNA	  target	  forward	   AGAGGTCTTATAATGGAACTAGGA	  
psip1	  siRNA	  target	  reverse	   GCAAGAAAGTAATTTACTAGCAGA	  
191	  
htatsf1	  siRNA	  target	  forward	   AAAAGACGCGGTTCCTGA	  
htatsf1	  siRNA	  target	  reverse	   GGAGGGAAACGGAAGGAA	  
179	  
gapdh	  forward	   CCACCCATGGCAAATTCC	  
gapdh	  reverse	   TGGGATTTCCATTGATGACAAG	  
69	  
	  
A2.2.6	  Examination	  of	  the	  role	  of	  Ago	  proteins	  
	  
HEK293T	   cells	   were	   seeded	   at	   2	   x	   105	   cells	   per	   well	   in	   a	   24-­‐well	   plate.	   Immediately	  
following	   administration	  of	   cells	   to	   culture	  plates,	   cells	  were	   transfected	  with	  50	  nM	  of	   siRNAs	  
targeting	   either	   Ago1,	   Ago2	   (Hawkins	   et	   al.	   2009)	   or	   the	   HIV-­‐1	   LTR	   (Weinberg	   et	   al.	   2006)	   (all	  
siRNAs	  gifts	  from	  K.	  Morris)	  (Table	  A2.4),	  as	  described	  in	  4.2.4.	  Twenty-­‐four	  hours	  later,	  cells	  were	  
again	   transfected,	   this	   time	  with	   siP10	  or	  R149	  at	  100	  nM	   (see	  4.2.4)	   in	   triplicate.	   Seventy-­‐two	  
hours	  later,	  RNA	  was	  extracted	  (see	  A1.3.1),	  DNase-­‐treated	  and	  reverse	  transcribed	  (see	  3.2.12).	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qPCR	   on	   the	   resulting	   cDNA	  was	   performed	   as	   described	   in	   2.2.7	   using	   the	   SensiMix™	   Lite	   Kit	  
(Quantace	   Ltd,	   London,	   UK)	   (see	   A1.3.4)	   and	   primers	   given	   in	   Table	   2.4,	   4.2.7	   and	   Table	   A2.3.	  
Controls	   and	   cycling	   parameters	   were	   as	   described	   in	   2.2.7.	   Gene	   expression	   was	   reported	  
relative	  to	  gapdh	  mRNA.	  
	  
Table	  A2.4:	  siRNAs	  used	  to	  examine	  the	  role	  of	  Ago	  proteins	  in	  siP10-­‐mediated	  psip1	  silencing.	  
siRNA	   Strand	   Sequence	  (5’-­‐3’)	  
Guide	   GUGUUAGAGUGGAGGUUUGUU	  
Anti-­‐HIV	  LTR	  
Passenger	   CCAACCUCCACUCUAACACC	  
Guide	   CGUUGCCAAUGGGCAGUGCUU	  
Anti-­‐Ago1	  
Passenger	   GCACUGCCCAUUGGCAACG	  
Guide	   UUCAGAUGGACUUCCGUGCUU	  
Anti-­‐Ago2	  
Passenger	   GCACGGAAGUCCAUCUGAA	  
	  
A2.2.7	   Chromatin	   immunoprecipitation	   (ChIP)	   assay	   to	   examine	   epigenetic	   changes	   at	   siRNA-­‐
targeted	  regions	  
	  
Costar®	  60	  cm2	  dishes	   (Corning,	   Inc.,	  NY,	  USA)	  were	  seeded	  with	  4	  x	  106	  HEK293T	  cells.	  
Cells	   were	   transfected	   immediately	   post-­‐seeding	   with	   100	   nM	   siP10	   or	   R149	   in	   duplicate,	   as	  
described	  in	  4.2.4.	  Seventy-­‐two	  hours	   later,	  formaldehyde	  was	  carefully	  added	  to	  cells	  to	  a	  final	  
concentration	   of	   1%	   and	   cells	   then	   incubated	   on	   a	   shaking	   platform	   for	   10	   min	   at	   room	  
temperature.	  Crosslinking	  was	  stopped	  by	  the	  addition	  of	  glycine	  to	  a	  final	  concentration	  of	  0.125	  
M	  and	   continued	   shaking	   for	   5	  min.	  Culture	  media	  was	   removed	  and	  3	  ml	  PBS	  with	  0.1%	   (v/v)	  
phenylmethanesulfonylfluoride	   (PMSF)	   (Sigma-­‐Aldrich,	   MO,	   USA),	   a	   serine	   protease	   inhibitor,	  
added	  to	  cells.	  Cells	  were	  harvested	  by	  scraping	  from	  dishes	  and	  centrifugation	  at	  130	  x	  g	   for	  4	  
min.	  Cell	  pellets	  were	  lysed	  in	  600	  µl	  ChIP	  lysis	  buffer	  (50	  mM	  HEPES,	  140	  mM	  NaCl,	  1%	  Triton	  X-­‐
100,	  0.1%	  sodium	  deoxycholate)	  with	  0.1%	  (v/v)	  PMSF	  and	  incubated	  on	  ice	  for	  10	  min.	  Samples	  
were	  centrifuged	  at	  2,000	  x	  g	  for	  5	  min	  at	  4	  °C	  to	  pellet	  nuclei.	  The	  pellet	  was	  again	  resuspended	  
in	  600	  µl	  ChIP	   lysis	  buffer	  with	  0.1%	  (v/v)	  PMSF	  and	   incubated	  on	   ice	  for	  10	  min.	  Samples	  were	  
sonicated	  on	  ice	  to	  produce	  chromatin	  of	  an	  average	  length	  of	  200	  bp:	  6	  intervals	  of	  25	  sec	  pulses	  
and	  2	  min	   rests	  on	  power	   setting	  3	  using	  a	  S-­‐50	   sonicator	   (Branson	  Ultrasonics	  Corp,	  CT,	  USA).	  
Sonicated	  samples	  were	  centrifuged	  at	  8,000	  x	  g	   for	  5	  min	  at	  4	  °C	  and	  the	  supernatant	  of	  each	  
sample	  transferred	  to	  a	  clean	  tube.	  Background	  was	  reduced	  by	  pre-­‐clearing	  chromatin	  with	  25	  µl	  
protein	  A	  sepharose	  beads	  blocked	  with	  salmon	  sperm	  (Invitrogen,	  CA,	  USA)	  and	  incubation	  on	  a	  
gently	   rotating	   RM-­‐2M	   Intelli-­‐mixer	   (ELMI	   Ltd.,	   Riga,	   Latvia)	   at	   room	   temperature	   for	   15	   min.	  
Beads	  were	  removed	  by	  centrifugation	  at	  16,000	  x	  g	  and	  the	  chromatin-­‐containing	  supernatant	  
	   211	  
was	  distributed	  between	   three	   tubes.	  The	  volume	   in	  each	   tube	  was	  adjusted	   to	  1	  ml	  with	  ChIP	  
lysis	  buffer	  with	  0.1%	  (v/v)	  PMSF.	  A	  tube	  of	  each	  sample	  received	  1	  µg	  of	  either	  anti-­‐dimethylated	  
histone	  3	  lysine	  9	  (H3K9me2)	  (Upstate	  #07-­‐441;	  Millipore,	  MA,	  USA)	  or	  anti-­‐trimethylated	  histone	  
3	  lysine	  27	  (H3K27me3)	  (Upstate	  #07-­‐449)	  antibody	  or	  no	  antibody	  and	  gently	  rotated	  on	  a	  RM-­‐
2M	  Intelli-­‐mixer	  (ELMI	  Ltd.,	  Riga,	  Latvia)	  at	  4	  °C	  overnight.	  
To	   samples	   20	   µl	   of	   magnetic	   protein	   G	   Dynabeads®	   blocked	   with	   salmon	   sperm	  
(Invitrogen,	   CA,	   USA)	   was	   added	   prior	   to	   incubation	   on	   a	   gently	   rotating	   RM-­‐2M	   Intelli-­‐mixer	  
(ELMI	  Ltd.,	  Riga,	  Latvia)	  at	  room	  temperature	  for	  15	  min.	  Beads	  were	  separated	  using	  a	  magnet	  
and	   supernatant	   from	   no	   antibody	   controls	   transferred	   to	   a	   clean	   tube	   and	   stored	   as	   ‘input’	  
samples.	  Supernatant	  from	  samples	  subject	  to	  immunoprecipitation	  was	  discarded.	  
Beads	  were	  washed	  with	  600	  µl	  ChIP	  lysis	  buffer,	  600	  µl	  ChIP	  lysis	  high	  salt	  buffer	  (50	  mM	  
HEPES,	   500	  mM	  NaCl,	   1%	   Triton	   X-­‐100	   and	   0.1%	   sodium	   deoxycholate)	   and	   600	  µl	   ChIP	   wash	  
buffer	   (10	  mM	  Tris.HCl,	  250	  mM	  LiCl,	  1	  mM	  EDTA,	  0.5%	  sodium	  deoxycholate	  and	  0.5%	  NP-­‐40).	  
For	  each	  wash,	  beads	  were	  resuspended	  and	  samples	  rotated	  for	  3	  min	  prior	  to	  bead	  separation	  
with	  a	  magnet.	  Beads	  were	  finally	  resuspended	  in	  100	  µl	  elution	  buffer	  (50	  mM	  Tris.HCl,	  1%	  SDS	  
and	  10	  mM	  EDTA)	  and	  incubated	  at	  65	  °C	  for	  10	  min	  to	  elute	  antibody-­‐protein-­‐DNA	  complexes.	  
Beads	  were	  separated	  and	  the	  supernatant	  transferred	  to	  clean	  tubes.	  Elution	  was	  repeated	  and	  
supernatant	  combined	  with	  that	  recovered	  from	  the	  first	  elution.	  
Samples,	   including	   input	  samples,	  were	  mixed	  with	  10	  µg	  RNase	  A	  (Invitrogen,	  CA,	  USA)	  
and	  20	  µl	  of	  5	  M	  NaCl	  and	  incubated	  at	  65	  °C	  for	  4	  hours.	  To	  the	  combined	  eluates,	  10	  µl	  0.5	  M	  
EDTA,	  20	  µl	  of	  1	  M	  Tris.HCl,	  pH	  6.9,	  and	  20	  µg	  proteinase	  K	   (Roche,	  Mannheim,	  Germany)	  was	  
added	   and	   incubated	   at	   45	   °C	   for	   1	   hour.	   DNA	   was	   recovered	   by	   addition	   of	   250	   µl	  
phenol:chloroform:IAA	   in	  a	  25:24:1	   ratio	   (Ambion,	  TX,	  USA),	   centrifugation	  at	  16,000	  x	  g	   for	  10	  
min	  at	  4	  °C,	  transfer	  of	  the	  aqueous	  layer	  to	  300	  µl	  ethanol,	  100	  µl	  3	  M	  sodium	  acetate	  and	  3	  µl	  
glycogen	  (Ambion,	  TX,	  USA)	  and	  storage	  at	  -­‐20	  °C	  overnight.	  
DNA	  precipitate	  was	  recovered	  by	  centrifugation	  of	  samples	  at	  16,000	  x	  g	  for	  10	  min	  at	  4	  
°C.	  Pellets	  were	  washed	  with	  0.5	  ml	  75%	  ethanol,	  allowed	  to	  air-­‐dry	  for	  5	  min	  and	  resuspended	  in	  
30	  µl	   nuclease-­‐free	  water.	  DNA	  was	  analysed	  by	  qPCR	  using	  primers	   spanning	   the	   siRNA	   target	  
site	  and	  an	  upstream	  region	  (Table	  A2.3)	  using	  the	  SensiMix™	  Lite	  Kit	  (Quantace	  Ltd,	  London,	  UK)	  
(see	   A1.3.4).	   Total	   DNA	   isolated	   from	   HEK293T	   cells	   (1	   ng,	   100	   pg,	   10	   pg	   and	   1	   pg)	   was	   also	  
analysed	  by	  qPCR	  and	  used	  to	  construct	  a	  standard	  curve	  for	  each	  primer	  set	  using	  Cp	  medians,	  
which	  were	  calculated	  by	  the	  Lightcycler®	  V.2	  software	  (Roche,	  Mannheim,	  Germany).	  From	  the	  
standard	   curve,	   the	   amount	   of	   DNA	   in	   each	   sample	   was	   calculated	   and	   then	   expressed	   as	   a	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function	  of	  a	  radix	  of	  10	  (arbitrary	  units).	  No	  antibody	  values	  were	  subtracted	  as	  background	  and	  
the	  remaining	  values	  expressed	  as	  a	  fraction	  of	  the	  input	  samples.	  
	  
A2.2.8	  Nuclear	  run-­‐on	  assay	  to	  determine	  targeted	  HDF	  transcription	  rates	  
	  
Transcription	   rates	   in	   siRNA-­‐treated	  HEK293T	  cells	  were	  assessed	  as	  described	   in	  3.2.15	  
and	  4.2.8.	  
In	   the	  qPCR	  analysis	  of	  psip1	   transcription	  rates,	  previously	  used	  primers	  specific	   to	   the	  
p75	  isoform	  were	  used	  (Table	  2.4),	  as	  well	  as	  primers	  that	  amplify	  a	  region	  common	  to	  both	  the	  
p52	  and	  p75	   isoforms:	  p52	  &	  p75	  forward	  5’	  GTG	  ACA	  ACA	  GCA	  ACA	  GCA	  TCT	  G	  3’;	  and,	  p52	  &	  
p75	  reverse	  5’	  TGA	  TGT	  CAC	  TCT	  CTG	  AAG	  GAC	  AG	  3’.	  Transcription	  rates	  are	  reported	  relative	  to	  
that	  of	  gapdh	  using	  primers	  given	  in	  Table	  A2.3.	  
	  
A2.2.9	  Alignment	  of	  siRNA	  target	  sites	  to	  the	  genome	  
	  
siRNA	   target	   sites	   were	   aligned	   to	   all	   human	   genomic	   and	   transcript	   sequences	   using	  
nucleotide	   BLAST	   (blastn).	   The	   current	   standard	   reference	   assembly	   of	   the	   human	   genome,	  
hg19/Genome	  Reference	  Consortium	  human	  genome	  build	  37	  (GRCh37)	  (May	  2010),	  was	  used	  in	  
alignments.	  No	  mismatches	  between	  genome	  sequence	  and	  siRNA	  target	  sites	  were	  permitted.	  
	  
A2.2.10	  Statistical	  analyses	  
	  
Data	   are	   expressed	   as	   the	   mean	   ±	   the	   standard	   error	   of	   the	   mean	   (SEM)	   and	   where	  
appropriate	  are	  normalised	  to	  a	  control	  sample	  within	  the	  experiment.	  Statistical	  difference	  was	  
considered	   to	   be	   significant	   (*)	  when	  p	   <0.05.	   Data	  was	   analysed	   using	   unpaired,	   two-­‐tailed	   t-­‐
tests,	   one-­‐way	   ANOVAs,	   followed	   by	   a	   Dunnett‘s	   multiple	   comparison	   post-­‐test,	   and	   two-­‐way	  
ANOVAs,	  followed	  by	  Bonferroni	  post-­‐tests,	  where	  appropriate,	  calculated	  using	  GraphPad	  Prism	  
4.0c	  (GraphPad	  Software,	  Inc.,	  CA,	  USA).	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A2.3	  Results	  
	  
A2.3.1	  asRNAs	  do	  not	  inhibit	  target	  gene	  expression	  
	  
Host	  proteins	  known	  to	  be	  involved	  in	  HIV-­‐1	  replication	  were	  targeted	  for	  TGS.	  As	  asRNAs	  
alone	   are	   sufficient	   to	   induce	   TGS	   (Weinberg	   et	   al.	   2006;	   Turner	   et	   al.	   2009),	  U6-­‐driven	   asRNA	  
expression	   cassettes	   targeting	   the	   psip1	   and	   htatsf1	   promoters	   were	   constructed.	   These	   were	  
designed	   to	   express	   asRNAs	   with	   perfect	   sequence	   complementarity	   to	   regions	   up	   to	   700	   bp	  
upstream	  of	  the	  TSS	  (Figure	  A2.1),	  which	  was	  retrieved	  from	  the	  CSH	  TRED	  by	  K.	  Morris.	  
	  
	  
Figure	  A2.1:	   Promoter-­‐targeting	  with	   expressed	   asRNAs.	   A.	   Schematic	   of	   the	   asRNA	   expression	   cassettes	   and	   their	  
mode	  of	  targeting.	  B.	  The	  psip1	  and	  htatsf1	  promoters	  relative	  to	  the	  TSSs	  retrieved	  from	  the	  CSH	  TRED.	  Target	  sites	  
selected	  from	  suggestions	  by	  the	  siRNA	  target	  finder	  (Ambion,	  TX,	  USA)	  are	  shown.	  	  
	  
The	   asRNA	   expression	   plasmids	  were	   screened	   for	   their	   ability	   to	   suppress	   target	   gene	  
expression	   in	   HEK293T	   cells.	   The	   asRNAs	   had	   no	   effect	   with	   a	   significant	   decrease	   in	   target	  
expression	  only	  observed	  in	  cells	  receiving	  shRNA	  expression	  plasmids	  known	  to	  mediate	  effective	  
PTGS	  (Figure	  A2.2).	  
A	   number	   of	   reasons	   may	   account	   for	   the	   lack	   of	   gene	   silencing	   with	   the	   asRNAs,	  
including	  poor	   expression,	   a	   failure	   to	  be	   recruited	   into	   the	  RITS	   complex	   and/or	   inappropriate	  
targeting	  within	  the	  gene	  promoter.	  To	  exclude	  the	   latter	  possibility,	  more	  target	  sites	  required	  
examination.	   However,	   the	   time-­‐consuming	   generation	   of	   asRNA	   expression	   plasmids	   is	   not	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conducive	  to	  large-­‐scale	  screening.	  Therefore,	  further	  screening	  for	  TGS	  was	  carried	  out	  using	   in	  
vitro	  transcribed	  siRNAs.	  
	  
	  
Figure	   A2.2:	   asRNAs	   do	   not	   suppress	   expression	   of	   target	   HDFs.	   asRNAs	   were	   screened	   for	   suppression	   of	   target	  
expression.	  HEK293T	  cells	  were	  transfected	  with	  asRNA	  expression	  constructs,	  or	  a	  shRNA	  expression	  construct	  known	  
to	  mediate	  target	  silencing	  as	  a	  positive	  control,	  in	  triplicate.	  qRT-­‐PCR	  was	  performed	  on	  total	  RNA	  extracted	  72	  hours	  
post-­‐transfection.	  *,	  p	  <0.05,	  one-­‐way	  ANOVA	  with	  Dunnett	  post-­‐tests	  relative	  to	  pTZU6.	  
	  
A2.3.2	  siRNAs	  inhibit	  psip1	  expression	  
	  
Additional	   target	   sites	   were	   selected	   by	   K.	  Morris	   within	   200	   bp	   upstream	   of	   the	   CSH	  
TRED	  TSS	  following	  an	  observation	  that	  this	  region	  is	  most	  conducive	  to	  TGS	  induction	  (personal	  
communication).	   Six	   siRNAs	  were	   constructed	   and	   screened	   for	   their	   ability	   to	   suppress	   either	  
psip1	  or	  htatsf1	  expression.	  
htatsf1	   mRNA	   levels	   were	   unaltered	   in	   cells	   treated	   with	   promoter-­‐targeting	   siRNAs	  
compared	  with	   those	   receiving	   a	   control	   siRNA,	   R149,	  which	   targets	   the	   ccr5	   promoter	   (Figure	  
A2.3).	   In	  contrast,	  all	  psip1	  promoter-­‐targeting	  siRNAs	  resulted	   in	  a	  significant	  decrease	   in	  psip1	  
expression,	   with	   siP10	   having	   the	   greatest	   effect	   (0.39%	   of	   R149	   control).	   Given	   that	   TGS	  
induction	   requires	   promoter-­‐associated	   transcripts	   (Han	   et	   al.	   2007;	   Gonzalez	   et	   al.	   2008;	  
Schwartz	  et	  al.	  2008;	  Hawkins	  et	  al.	  2009;	  Tan	  et	  al.	  2009b;	  Yue	  et	  al.	  2010),	  whether	  the	  discord	  
in	   psip1	   and	   htatsf1	   suppression	   related	   to	   levels	   of	   promoter-­‐associated	   transcripts	   was	  
investigated.	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Figure	   A2.3:	   psip1	   promoter-­‐targeted	   siRNAs	   can	   suppress	   target	   expression.	   A.	   The	   psip1	   and	   htatsf1	   promoters	  
relative	  to	  the	  TSSs	  retrieved	  from	  the	  CSH	  TRED.	  siRNA	  target	  sites	  within	  200	  bp	  of	  the	  TSS	  were	  selected	  by	  the	  siRNA	  
target	   factor	   (Ambion,	   TX,	   USA).	   B.	   Screen	   of	   siRNAs	   for	   suppression	   of	   target	   expression.	   HEK293T	   cells	   were	  
transfected	  with	   siRNAs,	  or	  a	   shRNA	  expression	  construct	  known	   to	  mediate	   target	   silencing	  as	  a	  positive	  control,	   in	  
triplicate.	  qRT-­‐PCR	  was	  performed	  on	  total	  RNA	  extracted	  72	  hours	  post-­‐transfection.	  *,	  p	  <0.05,	  one-­‐way	  ANOVA	  with	  
Dunnett	  post-­‐tests	  relative	  to	  R149/pTZU6.	  
	  
A2.3.3	  Transcripts	  overlap	  siRNA	  target	  sites	  
	  
To	   quantify	   the	   levels	   of	   promoter-­‐associated	   transcripts,	   primers	   were	   designed	   to	  
amplify	  regions	  spanning	  the	  siRNA	  target	  sites	  (Figure	  A2.4A).	  	  Levels	  of	  transcripts	  from	  a	  region	  
>700	  bp	  upstream	  of	  the	  psip1	  TSS	  were	  also	  examined.	  
Transcripts	  were	  detectable	  by	  qRT-­‐PCR	   from	  all	   regions	   (Figure	  A2.4B),	   although	   those	  
transcribed	   from	   the	   htatsf1	   siRNA	   target	   site	   were	   >100-­‐fold	   less	   abundant	   than	   those	   from	  
either	   the	   psip1	   siRNA	   target	   site	   or	   psip1	   upstream	   region.	   Indeed,	   htatsf1	   siRNA	   target	   site	  
amplicons	  were	  not	  sufficiently	  abundant	   to	  visualise	  on	  an	  agarose	  gel	   (Figure	  A2.4C).	  The	   low	  
abundance	   of	   transcripts	   at	   the	   htatsf1	   siRNA	   target	   site	   may	   account	   for	   the	   lack	   of	   gene	  
silencing.	  
Surprisingly,	  the	  levels	  of	  transcripts	  originating	  from	  both	  the	  psip1	  siRNA	  target	  site	  and	  
upstream	   regions	   were	   similar	   to	   gapdh	   mRNA	   (Figure	   A2.4B),	   suggesting	   a	   high	   level	   of	  
	   216	  
transcription	  across	  the	  psip1	  promoter.	  The	  lack	  of	  5’	  or	  3’	  RACE	  data	  means,	  however,	  that	  it	  is	  
unknown	   whether	   these	   transcripts	   are	   coding	   (with	   an	   extended	   5’	   UTR)	   or	   non-­‐coding.	   If	  
coding,	   the	   gene	   silencing	   induced	   with	   siP10	   may	   not	   be	   TGS,	   particularly	   as	   TGS	   and	   PTGS	  
cannot	   be	   distinguished	   by	   qRT-­‐PCR	   on	   total	   RNA.	   Thus,	   additional	   evidence	   for	   TGS	   as	   the	  
mechanism	  of	  siP10-­‐mediated	  psip1	  silencing	  was	  sought.	  
	  
	  
Figure	  A2.4:	  Transcription	  is	  detectable	  at	  siRNA	  target	  regions.	  A.	  psip1	  and	  htatsf1	  promoters	  showing	  the	  regions	  
analysed	   for	   transcription.	  Primers	  were	  designed	   to	  amplify	   transcripts	  present	  at	   siRNA	   target	   regions	  and,	   for	   the	  
psip1	   promoter,	   upstream.	   B.	   qRT-­‐PCR	   was	   performed	   on	   total	   RNA	   extracted	   from	   HEK293T	   in	   duplicate.	   Primers	  
specific	  to	  a	  region	  in	  the	  gapdh	  mRNA	  coding	  region	  were	  also	  included.	  C.	  Following	  qPCR,	  samples	  were	  resolved	  on	  
an	  agarose	  gel.	  
	  
A2.3.4	  Ago2	  suppression	  attenuates	  psip1	  silencing	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The	  relative	  roles	  of	  Ago1	  and	  Ago2	  in	  siP10-­‐mediated	  psip1	  silencing	  were	  investigated.	  
HEK293T	   cells	   were	   first	   treated	  with	   siRNAs	   targeting	   either	   Ago1	   or	   2	   or	   the	   HIV-­‐1	   LTR	   as	   a	  
negative	  control.	  Twenty-­‐four	  hours	  later,	  cells	  were	  again	  transfected,	  this	  time	  with	  the	  control	  
siRNA,	  R149,	  or	  siP10.	  A	  slight	  attenuation	  of	  psip1	  silencing	  was	  observed	  in	  cells	  where	  levels	  of	  
Ago2	   were	   decreased	   but	   not	   in	   cells	   treated	   with	   the	   Ago1-­‐targeting	   siRNA	   (Figure	   A2.5A),	  
although	  this	  may	  be	  a	  result	  of	  the	  low-­‐level	  of	  Ago1	  mRNA	  suppression	  attained	  (Figure	  A2.5B).	  
However,	  Ago	  mRNA	  suppression	  was	  quantified	  in	  RNA	  extracted	  96	  hours	  post-­‐transfection	  and	  
thus	   is	   probably	   less	   pronounced	   than	   at	   an	   earlier	   time	   point,	   when	   TGS	   induction	  would	   be	  
expected	   to	   take	   place.	   In	   addition,	   the	   Ago2	  mRNA	   suppression	   was	   also	  moderate	   96	   hours	  
post-­‐transfection,	  yet	  sufficient	  to	  have	  an	  effect	  on	  siP10-­‐mediated	  silencing.	  Furthermore,	  Ago1	  
mRNA	   levels	   are	   increased	   when	   Ago2	   is	   suppressed,	   which	   may	   indicate	   a	   mechanism	   to	  
compensate	   for	   the	   loss	   of	   Ago2	   function.	   However,	   despite	   this	   increased	   Ago1,	   there	   is	   still	  
attenuation	  of	  the	  siP10-­‐mediated	  silencing.	  
	  
	  
Figure	  A2.5:	  Ago2	  suppression	  alleviates	  siP10-­‐mediated	  psip1	  silencing.	  A.	  Both	  HEK293T	  cells	  were	  transfected	  with	  
siRNAs	   targeting	  either	  Ago1	  or	  Ago2	  or	   a	   siRNA	   targeting	   the	  HIV-­‐1	   LTR	  as	   a	   control.	   Twenty-­‐four	  hours	   later,	   cells	  
were	   again	   transfected	   with	   promoter-­‐targeting	   or	   control	   siRNAs	   in	   triplicate.	   psip1	  mRNA	   levels	   were	   assessed	  
relative	   to	  gapdh	   by	  qRT-­‐PCR	  on	  RNA	  extracted	  96	  hours	  post-­‐primary	   transfection.	  B.	  As	   (A),	   but	   showing	   levels	   of	  
Argonaute	  mRNA	  levels	  in	  cells	  transfected	  with	  R149.	  *,	  p	  <0.05,	  two-­‐way	  ANOVA	  with	  Bonferroni	  post-­‐tests.	  
	  
Therefore,	   this	   data	   suggests	   that	  Ago2,	   and	  not	  Ago1,	   is	   necessary	   for	   siP10-­‐mediated	  
silencing	  of	  psip1.	  To	  further	  investigate	  whether	  siP10-­‐mediated	  silencing	  is	  via	  classical	  TGS,	  the	  
siRNA	  target	  site	  was	  examined	  for	  epigenetic	  changes.	  
	  
A2.3.5	  siP10	  does	  not	  induce	  significant	  epigenetic	  changes	  at	  the	  siRNA	  target	  site	  
	  
ChIP	   is	   a	   powerful	   technique	   for	   the	   examination	   of	   the	   interaction	   between	   specific	  
proteins	  and	  DNA	  in	  the	  cell.	  Levels	  of	  H3K27me3	  and	  H3K9me2	  were	  assessed	  at	  the	  siP10	  target	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region	  and	  upstream	  as	  a	  control	  (Figure	  A2.4A).	  These	  histone	  modifications	  are	  associated	  with	  
compact	  chromatin	  and,	  thus,	  transcriptionally-­‐silent	  genes.	  
Despite	  a	   trend	   toward	   increased	  H3K27me3	  at	   the	   siRNA	   target	   region	   in	   cells	   treated	  
with	  siP10	  compared	  to	  the	  R149-­‐treated	  control,	  this	  was	  not	  statistically	  significant.	  Further,	  no	  
enrichment	   for	   H3K9me2	   at	   the	   target	   site	   was	   observed.	   The	   lack	   of	   significant	   silent-­‐state	  
histone	  modification	  enrichment	  at	  the	  target	  site	  does	  not	  support	  a	  classical	  TGS	  mechanism.	  
	  
	  
Figure	   A2.6:	   siRNA-­‐mediated	   silencing	   of	   psip1	   is	   not	   accompanied	   by	   epigenetic	   changes	   at	   the	   target	   region.	  
HEK293T	  cells	  transfected	  with	  siRNAs	  were	  analysed	  by	  ChIP	  72	  hours	  later	  in	  duplicate.	  Both	  the	  siRNA	  target	  region	  
and	  an	  upstream	  region	  were	  examined	  for	  changes	  in	  the	  level	  of	  H3K27me3	  and	  H3K9me2,	  two	  histone	  modifications	  
associated	  with	  silent-­‐state	  chromatin.	  Two-­‐way	  ANOVA	  with	  Bonferroni	  post-­‐tests.	  
	  
A2.3.6	  siP10	  does	  not	  alter	  the	  rate	  of	  psip1	  transcription	  
	  
A	   nuclear	   run-­‐on	   experiment	   was	   performed	   to	   discern	   psip1	   transcription	   rates.	   In	  
HEK293T	  cells	  treated	  with	  siP10,	  transcription	  of	  psip1	  was	  unaltered,	  whether	  quantified	  using	  
primers	  that	  amplify	  a	  region	  common	  to	  the	  p52	  and	  p75	  isoforms,	  or	  primers	  specific	  to	  the	  p75	  
isoform	   (Figure	   A2.7).	   This	   result	   strongly	   implicates	   siP10	   functioning	   via	   a	   PTGS,	   not	   a	   TGS,	  
mechanism.	   This	   conclusion	   garners	   further	   support	   from	   the	   previous	   data	   showing	   a	   high	  
abundance	   of	   transcripts	   originating	   from	   the	   target	   region,	   a	   role	   of	   Ago2,	   but	   not	   Ago1,	   in	  
silencing	  and	  no	  accompanying	  epigenetic	  changes	  at	  the	  target	  site.	  Therefore,	  to	  verify	  that	  the	  
target	   sites	   were	   within	   the	   psip1	   promoter,	   an	   alignment	   with	   the	   human	   genome	   was	  
performed.	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Figure	   A2.7:	   psip1	   transcription	   rates	   are	   unaltered	   by	   siRNA-­‐mediated	   silencing.	   A	   nuclear	   run-­‐on	   assay	   was	  
performed	   on	   samples	   72	   hours	   post-­‐transfection	   with	   promoter-­‐targeting	   siRNAs	   in	   triplicate.	   Levels	   of	   psip1	  
transcription	  were	  assessed	  using	  primers	   specific	   to	   the	  p75	   isoform	  and	  common	  to	  both	   the	  p52	  &	  p75	   isoforms.	  
Unpaired,	  two-­‐tailed	  t-­‐tests.	  
	  
All	   siRNAs	   designed	   to	   target	   the	   psip1	   promoter	  were	   in	   fact	   found	   to	   be	   targeting	   a	  
region	   within	   the	   RefSeq	   psip1	   3’	   UTR,	   according	   to	   the	   latest	   human	   genome	   build,	  
hg19/GRCh37.	  It	  is	  unsurprising,	  therefore,	  that	  the	  mode	  of	  siP10-­‐mediated	  silencing	  was	  PTGS.	  
The	  TSS	   listed	   in	   the	  CSH	  TRED,	   from	  which	  promoter	  sequences	  were	  retrieved,	   is	  also	   located	  
within	  the	  3’UTR,	  which	  demonstrates	  that	  TSSs	  listed	  in	  the	  CSH	  TRED	  may	  not	  be	  at	  the	  5’	  end	  
of	  a	  gene.	  Thus,	  promoter	  sequences	  retrieved	  from	  the	  CSH	  TRED,	  in	  the	  absence	  of	  alignments	  
to	  verify	  their	  location,	  are	  an	  unreliable	  data	  source	  from	  which	  to	  design	  TGS	  target	  sites.	  
	  
	  
Figure	  A2.8:	  siRNA	  target	  sites	  do	  not	  align	  to	  the	  psip1	  promoter	  but	  the	  3’UTR.	  siRNA	  target	  sites	  were	  aligned	  to	  
the	  current	  standard	  reference	  assembly	  sequence	  of	  the	  human	  genome,	  build	  hg19/GRCh37,	  and	  found	  to	  map	  to	  the	  
3’UTR	  of	  psip1,	  not	  the	  promoter.	  
	  
A2.3.7	  siRNAs	  do	  not	  induce	  TGS	  of	  ddx3x	  
	  
Similar	   problems	   were	   encountered	   in	   attempting	   to	   induce	   TGS	   of	   ddx3x:	   K.	   Morris	  
designed	   siRNA	   target	   sites	   within	   200	   bp	   of	   the	   TSS	   retrieved	   from	   the	   CSH	   TRED.	   qRT-­‐PCR	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demonstrated	  significant	  mRNA	  knock	  down	  (Figure	  A2.9A),	  although	  this	  was	  not	  accompanied	  
by	   a	   change	   in	   the	  ddx3x	   transcription	   rate	   (Figure	  A2.9B).	  Alignment	  with	   the	  human	  genome	  
placed	  the	  siRNA	  target	  sites	  within	   the	  RefSeq	  ddx3x	  5’	  UTR	   (Figure	  A2.9C)	  and,	   therefore,	   the	  
CSH	  TRED	  within	  the	  5’	  UTR	  also.	  Thus,	  the	  data	  suggests	  that	  the	  siRNAs	  are	  suppressing	  ddx3x	  
mRNA	  expression	  via	  a	  PTGS	  mechanism.	  
	  
	  
Figure	  A2.9:	   siRNAs	   targeting	   the	  CSH	  TRED	  ddx3x	   promoter	  do	  not	   induce	   TGS	  and	  align	   to	   the	   5’UTR.	  A.	   siRNAs	  
designed	  to	  target	  the	  ddx3x	  promoter	  based	  on	  the	  TSS	  retrieved	  from	  the	  CSH	  TRED	  database	  suppress	  ddx3x	  mRNA	  
levels.	  HEK293T	  cells	  were	  transfected	  with	  siRNAs	  in	  triplicate	  and	  qRT-­‐PCR	  performed	  on	  total	  RNA	  extracted	  72	  hours	  
later.	  B.	   A	   nuclear	   run-­‐on	   assay	   was	   performed	   72	   hours	   post-­‐transfection	   with	   siRNAs.	   C.	   siRNA	   target	   sites	   were	  
aligned	  to	  the	  current	  standard	  reference	  assembly	  sequence	  of	  the	  human	  genome,	  build	  hg19/GRCh37,	  and	  found	  to	  
map	  to	  the	  5’UTR	  of	  ddx3x.	  *,	  p	  <0.05,	  one-­‐way	  ANOVA	  with	  Dunnett	  post-­‐tests	  relative	  to	  R149	  and	  unpaired,	   two-­‐
tailed	  t-­‐test.	  
	  
Together,	  the	  data	  demonstrates	  that	  PTGS,	  and	  not	  TGS,	  is	  the	  mechanism	  of	  psip1	  and	  
ddx3x	   siRNA-­‐mediated	   silencing.	   This	   follows	   inadvertently	   targeting	   regions	   within	   the	   coding	  
transcript,	  and	  not	  the	  promoter,	  demonstrating	  that	  the	  CSH	  TRED	  promoter	  sequences	  require	  
an	  alignment	  to	  verify	  their	  location	  prior	  to	  use	  in	  TGS	  target	  site	  design.	  
	  
	   221	  
A2.4	  Discussion	  
	  
The	   approach	   used	   in	   this	   study	   was	   to	   design	   asRNA/siRNA	   target	   sites	   within	   a	   HDF	  
promoter	  in	  the	  hope	  of	  inducing	  TGS.	  Unfortunately,	  TGS	  was	  not	  induced	  at	  either	  the	  htatsf1,	  
psip1	  or	  ddx3x	  genes:	  no	  asRNAs	  or	  siRNAs	  reduced	  htatsf1	  mRNA	  levels	  (Figures	  A2.2	  and	  A2.3)	  
whilst	  siRNAs	  that	  were	  successful	  at	  reducing	  psip1	  and	  dd3x	  mRNA	  levels	  functioned	  by	  a	  PTGS	  
mechanism	   (Figures	  A2.7	  and	  A2.9).	   For	  psip1,	   this	  was	   supported	  by	   several	   lines	  of	   evidence;	  
high	  levels	  of	  target	  region-­‐associated	  transcripts	  (Figure	  A2.4),	  a	  role	  of	  Ago2	  in	  silencing	  (Figure	  
A2.5),	  a	   lack	  of	  silent-­‐state	  histone	  modification	  enrichment	  at	  the	  target	  site	  (Figure	  A2.6)	  and,	  
most	  convincingly,	  unaltered	  transcription	  rates	  (Figure	  A2.7).	  This	  was	  a	  result	  of	  the	  sequences	  
inadvertently	  used	   in	   the	  design	  of	   siRNA	   target	   sites	   aligning	   to	   coding	   transcripts	   rather	   than	  
promoters	  (Figure	  A2.8).	  
The	   CSH	   TRED	   lists	   several	   TSS	   per	   gene,	   and	   it	   is	   unknown	   on	   what	   basis	   K.	   Morris	  
selected	  a	  TSS,	  particularly	  as	  the	  quality	  (where	  lower	  numbers	  reflect	  a	  higher	  quality	  level,	  as	  
determined	  by	  the	  reliability	  of	  the	  supporting	  evidence)	  of	  the	  psip1	  TSS	  retrieved	  was	  only	  ‘3.2:	  
refseq’	  versus	  another	  of	  the	  same	  quality	  and	  one	  of	  higher,	  ie	  ‘	  3.1:	  refseq,	  predicted’,	  the	  latter	  
correlating	  with	  the	  5’	  end	  of	  the	  RefSeq	  gene.	  Nevertheless,	  it	  seems	  peculiar	  that	  this	  database	  
annotates	  a	   region	  within	   the	  psip1	   3’	  UTR	  as	  a	  TSS.	   The	  CSH	  TRED	  claims	   to	  annotate	  human,	  
mouse	   and	   rat	   promoters	   through	   an	   automated	  pipeline	   that	   extracts	   known	  promoters	   from	  
databases,	   including	   Genbank,	   the	   Eukaryotic	   Promoter	   Database	   (EPD)	   and	   the	   Database	   of	  
Transcription	   Start	   Sites	   (DBTSS),	   and	   employs	   a	   promoter-­‐finding	   program,	   Human	   First	   Exon	  
Finder	   (FirstEF),	   combined	   with	   mRNA/EST	   information,	   cross-­‐species	   comparisons	   and	   hand	  
curation	  (Zhao	  et	  al.	  2005).	  However,	  despite	  an	  additional	  modality	  being	  added	  in	  2007	  (Jiang	  et	  
al.	  2007),	  the	  underlying	  CSH	  TRED	  content	  has	  not	  been	  reappraised	  since	  its	  assembly	  in	  2005.	  
Since	  then,	  deep	  sequencing	  CAGE	  technologies,	  such	  as	  those	  used	  in	  the	  FANTOM	  project,	  have	  
increased	   depth	   and	   accuracy	   of	   promoter	   annotation.	   Consultation	   of	   the	   FANTOM	   genome	  
browser	   revealed	   no	   predicted	   promoter	   within	   the	   3’	   UTR	   of	   psip1	  
(http://fantom.gsc.riken.jp/4/gev/gbrowse/hg18/).	  
Given	   that	   the	   TSS	   retrieved	   was	   actually	   in	   the	   3’	   UTR	   of	   the	   psip1	   gene,	   the	   asRNA	  
target	   sites	  were	   also	  within	   the	   3’	   UTR.	   It	   is	   surprising,	   therefore,	   that	   no	   gene	   silencing	  was	  
observed	  with	  the	  asRNA	  expression	  plasmids.	  Although	  it	  is	  possible	  that	  none	  of	  the	  target	  sites	  
were	  appropriate,	  given	  that	  the	  same	  algorithm	  designed	  the	  siRNA	  target	  sites,	  which	  all	  proved	  
effective,	  it	  seems	  unlikely.	  	  
asRNAs	   have	   been	   shown	   to	  mediate	   TGS	   (Weinberg	   et	   al.	   2006)	   and	   can	   even	   recruit	  
Ago1	   to	   the	   target	   site	   (Turner	   et	   al.	   2009).	   However,	   it	   is	   unknown	   whether	   asRNAs	   are	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incorporated	   as	   efficiently	   into	   Ago2-­‐containing	   RISC	   as	   Ago1-­‐containing	   RITS.	   One	   study	   has	  
shown	   that	   incorporation	   of	   siRNAs	   into	   Ago1	   versus	   Ago2	   is	   influenced	   by	   the	   degree	   of	  
complementarity	   between	   strands,	   with	   perfectly-­‐matched	   duplexes	   being	   preferentially	  
incorporated	   into	   Ago2	   and	   bulged	   duplexes	   into	   Ago1	   (Gonzalez	   et	   al.	   2008).	   Moreover,	   an	  
influence	  of	  duplex	  thermodynamics	  on	  the	  associated	  Ago	  protein	  has	  precedence	  in	  Drosophila	  
(Tomari	  et	  al.	  2007).	  One	  can	  envisage	  then	  that	  a	  single-­‐stranded	  asRNA,	  with	  no	  complementary	  
base-­‐pairing,	  may	  be	  inefficiently	  incorporated	  into	  Ago2	  complexes.	  
Of	  the	  three	  TSS	  listed	  on	  the	  CSH	  TRED	  for	  ddx3x,	  K.	  Morris	  did	  retrieve	  the	  TSS	  ranked	  of	  
the	  highest	  quality	  (ie	  ‘2:	  known’),	  which	  corresponds	  to	  the	  promoter	  annotated	  by	  the	  FANTOM	  
project.	   Thus,	   although	   targeting	   downstream	   of	   the	   extreme	   5’	   end	   of	   the	   RefSeq	   gene,	   it	   is	  
possible	   that	   the	   siRNAs	  were	   indeed	   targeting	   the	  ddx3x	   promoter.	   Nevertheless,	   the	   nuclear	  
run-­‐on	   assay	   showed	  no	   change	   in	   transcription	   rates	   supporting	   a	   PTGS	  mechanism.	  Unlike	  S.	  
cerevisiase	   (David	  et	  al.	   2006),	   transcription	  of	  human	  genes	   rarely	   commences	   from	  a	  defined	  
TSS	   but	   rather	   over	   a	   region	   (Juven-­‐Gershon	   et	   al.	   2008),	   with	   the	   size	   of	   this	   region	   varying	  
considerably	   between	   genes	   (Balwierz	   et	   al.	   2009).	   The	   TSS	   can	   also	   vary	   between	   tissues	   and	  
conditions	  and,	  as	  such,	  the	  most	  active	  TSS	  in	  HEK239T	  cells	  could	  differ	  from	  that	  described	  by	  
the	  FANTOM4	  project,	  which	  focused	  on	  a	  differentiating	  macrophage-­‐like	  cancer	  cell	  line,	  THP-­‐1	  
(Kawaji	   et	   al.	   2009).	   It	   is	   possible,	   therefore,	   that	   whilst	   the	   siRNAs	   were	   targeting	   the	   most	  
defined	  promoter	  region,	  this	  same	  region	  could	  be	  part	  of	  a	  coding	  transcript	  in	  HEK293T	  cells.	  
Indeed,	  of	  the	  two	  other	  TSS	  for	  ddx3x	  given	  in	  the	  CSH	  TRED,	  one	  does	  correlate	  with	  the	  5’	  end	  
of	  the	  RefSeq	  gene	  (Promoter	  ID	  43226;	  764	  bp	  upstream	  of	  targeted	  Promoter	  ID	  43224)	  and	  the	  
other	  is	  further	  upstream	  still	  (promoter	  ID	  43225	  –	  543	  bp	  upstream	  of	  Promoter	  ID	  43226	  and	  
the	  5’	  end	  of	  the	  RefSeq	  gene).	  If	  either	  of	  these	  were	  the	  most	  active	  TSS	  in	  HEK239T	  cells,	  the	  
siRNAs	   would	   be	   targeting	   a	   coding	   transcript.	   The	   primary	   TSS	   in	   HEK293T	   cells	   could	   be	  
interrogated	  by	  5’	  RACE.	  
In	  summary,	  before	  designing	  siRNA	  target	  sites,	  5’	  RACE	  data	  for	  the	  cell	  line	  to	  be	  used	  
should	   be	   obtained.	   Alternatively,	   promoters	   should	   be	   retrieved	   from	   recently	   compiled	   data	  
sources,	   such	   as	   those	   available	   through	   the	   FANTOM	  project,	   that	   use	  deep	   sequencing	  CAGE	  
identification	   of	   TSSs	   combined	  with	   transcription	   factor	   binding	   sites,	   predicted	   by	   algorithms	  
and	   experimentally	   determined	   by	   ChIP-­‐Seq,	   to	   annotate	   promoters.	   Although	   TGS	   was	   not	  
successfully	  induced,	  this	  study	  demonstrates	  that	  the	  experiments	  performed	  were	  sufficient	  to	  
discriminate	  PTGS	  from	  TGS.	  Such	  interrogation	  of	  the	  observed	  suppression	  of	  gene	  expression	  is	  
advised	  before	  a	  verdict	  of	  classical	  TGS	  is	  reached.	  
	  
